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Zusammenfassung 
Einführung 
Das pränatale Screening umfasst Untersuchungen zur Entwicklung des Fetus 
und zur Gesundheit der Mutter. Pränatale Diagnostik beinhaltet weiterfüh-
rende bildgebende wie genetische Interventionen, u.a. nach Chromosome-
nanomalien. Das durchschnittliche Risiko für eine Chromosomenanomalie 
beträgt etwa 1:1.000, als Hochrisiko wird 1:300 angenommen. Die Rate von 
allen schweren angeborenen Anomalien liegt bei 3-4%, wovon nur ein Anteil 
Chromosomenanomalien sind. 
Das gängige Ersttrimester-Screening auf Chromosomenanomalien basiert 
auf drei Parametern (Combined Test):  
b dem mütterlichen Alter,  
b einer Ultraschallmessung der Nackentransparenz (der Flüssigkeits-
ansammlung (Ödem) zwischen der Haut und dem Weichteilgewebe 
im Nackenbereich) des ungeborenen Fetus,  
b der Bestimmung der Hormone PAPP-A (Pregnancy-associated Plas-
maprotein A) und Beta-hCG (humanes Choriongonadotropin) im 
mütterlichen Blut.  
Mit Hilfe eines speziellen Computerprogrammes wird schließlich aus den 
Ultraschalldaten gemeinsam mit den biochemischen Werten unter der Be-
rücksichtigung des mütterlichen Altersrisikos ein Gesamtrisiko berechnet. 
Weitere Ultraschalluntersuchung dienen zur Erkennung von Mehrlingen, 
Wachstumsstörungen, maternalen Risken wie Präeklampsie, Anomalien der 
Plazentation und Plazentalokalisation sowie von fetalen Fehlbildungen. 
Seit einigen Jahren sind zahlreiche neue nicht-invasive pränatale Tests 
(NIPTs, auch nicht-invasive pränatale Diagnostik [NIPD]) zur Identifizierung 
von häufigen Chromosomenanomalien erhältlich.  
 
Beschreibung der Technologie und der Komparatoren  
Diese neuen In-Vitro-diagnostischen Tests zur Identifizierung von häufigen 
Chromosomenanomalien basieren auf der Analyse der zellfreien fetalen DNA 
(Cell-free fetal DNA, cffDNA) aus dem Blut von Schwangeren zur Identifizie-
rung von häufigen Chromosomenanomalien (Trisomie 21 [T21], Trisomie 18 
[T18] und Trisomie 13 [T13]) des Fetus. Derzeit werden 21 kommerziell-
erhältliche Tests angeboten. Die häufigsten Anbieter sind  
b Ariosa Diagnostics Inc./Roche Sequencing Solutions Inc.  
(Harmony ®),  
b BGI Diagnostics (NIFTY™),  
b Igenomix (NACE®),  
b LifeCodexx AG (PrenaTest®),  
b Natera (Panorama®),  
b Sequenom Laboratories (MaterniT® 21 PLUS, nur in den USA ver-
marktet) und  
b Illumina (Verifi™).  
Risiko auf 
Chromosomenanomalie 
1:1.000, Hochrisiko 
1:300,  alle  
angeborenen Anomalie: 
3-4% 
herkömmliches 
Ersttrimester-Screening 
auf Trisomien:  
Combined Test 
 
mütterliches Alter 
Nackentransparenz 
Hormone PAPP-A und 
Beta-hCG  
 
 
neue nicht invasive 
Tests am Markt: NIPT 
NIPT:  
T21, T18, T13 
 
 
21 NIPTs am Markt 
angeboten 
Die Techniken von NIPTs sind vielfältig: einige verwenden die Polymerase-
Kettenreaktion (PCR) zur Amplifikation der zellfreien DNA (cfDNA), wäh-
rend andere auf molekularer Karyotypisierung (Chromosomale Microarray-
Analysen, CMA) beruhen. Darüber hinaus unterscheiden sie sich in den tech-
nologischen Verfahren hinsichtlich der Analyse und Interpretation von 
Screening-Ergebnissen, ebenso wie in unterschiedlichen Qualitätsstandards 
und Art der Ergebnisberichte. Unabhängig von den Tests benötigen alle ei-
nen ausreichenden Anteil an cfDNA im mütterlichen Plasma, um zwischen 
dem Status der Mutter und dem des Fetus differenzieren zu können. Nicht al-
le Labore quantifizieren jedoch die fetalen Anteile in einzelnen Proben. Die 
Untersuchung muss ab der 8. bis 10. Schwangerschaftswoche durchgeführt 
werden.  
Die meisten NIPTs werden für T21-, T18- und T13- und Aneuploidien der 
Geschlechtschromosomen angeboten, aber viele Labore haben ihre Analyse-
palette um andere Trisomien und gängige Mikrodeletionen erweitert. Ab-
hängig von den Tests werden sie für Einlings-, Zwillings-, Eizellspende- oder 
In-Vitro-Fertilisationsschwangerschaften angeboten. 
NIPTs können sowohl im primären wie auch im sekundären Screening zum 
Einsatz kommen. In den meisten europäischen Ländern werden NIPTs der-
zeit vor allem durch private Anbieter vermarktet, nicht aber im öffentlichen 
Gesundheitssystem finanziert. In den meisten dieser Länder hat das Scree-
ning auf fetale Aneuploidien als Screening an Frauen mit hohem Risiko an-
schließend an auffällige oder unklare Befunde begonnen, obwohl einige 
Länder auch überlegen, die Tests für alle Schwangeren anzubieten.  
Derzeit eingesetzte und – in klinischen Leitlinien identifizierte – Ver-
gleichsinterventionen für nicht-invasive Screening-Optionen umfassen In-
formationen zum mütterlichen Alter in Kombination mit folgenden Interven-
tionen:  
1. Ersttrimester-Screening (vgl. oben Combined Test: fetale Nackenfalten-
Messung (NT) und fetale Scheitel-Steiß-Länge (CRL), Informationen zum 
mütterlichen Alter und mütterliche Serum-biochemische Marker [PAPP-
A, Beta-hCG]),  
2. Zweittrimester- Screening (Organscreening, Doppler-Ultraschall Triple 
Test [freies Estriol, Beta-hCG, Alpha-Fetoprotein]), oder  
3. Zweistufiges integriertes pränatales Screening: das Serum-Screening im 
ersten und zweiten Trimester mit oder ohne NT (für „Kontingente“ [alle 
Hochrisiko Schwangere] oder sequentiell [erst nach positivem Befund]). 
Die Bestätigung eines positiven Ergebnisses erfordert invasive Tests (Chori-
onzottenbiopsie [CVS] ab der 12. Schwangerschaftswoche oder Amniozente-
se [AC] ab der 16. Schwangerschaftswoche). Beide Verfahren sind mit einem 
Fehlgeburtsrisiko verbunden (2-10 von 1.000 Schwangerschaften).  
Der hauptsächliche Vorteil von NIPT im Vergleich zum konventionellen 
Screening-Ansatz besteht in der Einfachheit der Durchführung und der 
Nicht-Invasivität des Tests sowie in der möglichen Verringerung der falsch-
positiven [FP] Ergebnisse. Es wird erwartet, dass NIPT unnötige invasive 
Verfahren (AC und CVS) vermeidet und das Risiko von Komplikationen, 
Schwangerschaftsverlust und Angstzuständen minimiert. Zudem wird er-
wartet, dass die NIPTs auch eine frühere Testung erlauben, was den Vorteil 
hätte, den Schwangeren bzw. den Eltern mehr Zeit zu geben, Entscheidungen 
für/gegen einen Schwangerschaftsabbruch zu treffen.  
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Das Ziel des vorliegenden EUnetHTA Assessments ist die Bewertung der 
Wirksamkeit und Sicherheit von nicht-invasiven pränatalen Tests (NIPT) für 
das Screening auf fetale Trisomie 21 (T21), Trisomie 18 (T18) und Trisomie 
13 (T13) bei schwangeren Frauen ab der 8. bis 9. Schwangerschaftswoche.  
Für die Bewertung der NIPTs werden fünf Einsatzbereiche berücksichtigt: 
1. NIPT als Primär-Screening-Test als Ersatz für Ersttrimester-
Screening/Combined Test (alle Schwangeren) 
2. NIPT als Ergänzung (Add-on) zu Ersttrimester-
Screening/Combined Test (alle Schwangeren) 
3. NIPT als Ergänzung (Add-on) zu Ersttrimester-
Screening/Combined Test für die Hochrisiko-Population  
4. NIPT als Ergänzung (Add-on) zu Ersttrimester-
Screening/Combined Test für Schwangere mit hohem und mittle-
rem Risiko  
5. NIPT als Ersatz für invasive Tests  
 
Gesundheitsproblematik  
T21 (Down-Syndrom [DS]), T18 (Edwards-Syndrom) und T13 (Pätau-
Syndrom) sind die häufigsten Chromosomenstörungen bei Neugeborenen. In 
Europa liegen die geschätzten Prävalenzen bei 24 (T21), 5,6 (T18) und 2,08 
(T13) pro 10.000 Lebendgeburten. Etwa 68,7% der T21-Fälle, 94,3% der 
T18-Fälle und 93,4% der T13-Fälle werden pränatal diagnostiziert, obwohl 
die Prävalenz je nach Screening-Strategie (<30% bis ≥ 90%) zwischen den 
industrialisierten Ländern erheblich variieren kann.  
In Europa wird geschätzt, dass mehr als 90% der Menschen mit Down-
Syndrom (T21) länger als 20 Jahre leben, und ungefähr 60% sogar ein Alter 
von 60 Jahren erreichen. Es wird geschätzt, dass in der EU jedes Jahr etwa 
5.000 Neugeborene von T21 betroffen sind. Im Gegensatz zu T21 ist die Le-
benserwartung von Kindern mit Pätau-Syndrom (T13) und Edwards-
Syndrom (T18) aufgrund von Fehlbildungen gering. Die meisten Schwanger-
schaften enden mit spontanen Fehlgeburten oder Totgeburten, und wenn die 
Kinder geboren werden, überleben nur wenige mehr als ein Jahr.  
In den meisten europäischen Ländern werden Ersttrimester-
Screenings/Combined Tests für alle schwangeren Frauen in Form von natio-
nalen oder regionalen Schwangeren Screening-Programmen angeboten. In 
Europa liegt die Schwelle für Tests, die häufig zur Definition eines hohen Ri-
sikos verwendet werden, bei 1:250 bis 1:300, obwohl dies von Land zu Land 
unterschiedlich gehandhabt wird. Klinische Leitlinien empfehlen keine wei-
teren Tests für Frauen mit niedrigem Risiko. Wenn eine Kontingent-
Screening-Strategie angeboten wird, werden Schwangere in Hoch-, Mittel- 
und Niedrigrisikogruppen klassifiziert. Die Schwelle für mittleres Risiko ist 
allerdings in den meisten Ländern nicht standardisiert.  
Die NIPTs sind für alle schwangeren Frauen, die sich für ein pränatales 
Screening auf T21, T18 und T13 entscheiden, zugelassen. Dies würde bedeu-
ten, dass etwa 5,1 Millionen Schwangerschaften in der EU-28 (EUROSTAT-
Fertilitätsstatistik) als mögliche Kandidatinnen für ein NIPT-Screening in 
Frage kommen. Die genaue Zielpopulation ist jedoch schwer abzuschätzen, 
da sie sich wesentlich davon unterscheidet, ob eine 1st-line- oder eine 2nd-
line-Screening Strategie geplant ist, und auch wo die Risikoschwelle ange-
setzt wird. 
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Das Assessment wurde im EUnetHTA HTA Core Model® REA Version 4.2 er-
stellt. Eine systematische Suche wurde von Februar bis März 2017 (ohne 
zeitliche Beschränkung) in 5 Datenbanken durchgeführt: 
b MEDLINE (PubMed)  
b Embase (OVID SP)  
b Centre for Reviews and Dissemination (CRD)-Database,  
b ISI Web of Knowledge und  
b Cochrane Library (Wiley)  
Zusätzlich wurden Leitlinien-Register durchsucht, um relevante Leitlinien 
zum Schwangeren-Screening zu identifizieren (nach 2010 veröffentlicht).  
Laufende klinische Studien wurden in…gesucht.  
b ClinicalTrials.gov  
b EU Clinical Trials Register  
b International Clinical Trials Registry Plattform (ICTRP) und  
b UK Clinical Trials Gateway  
Allgemeine Internetsuchen und manuelle Recherchen von Zitaten dienten als 
ergänzende Informationsquellen.  
Die zum Zeitpunkt der Suche identifizierten Hersteller wurden vom LBI-HTA 
kontaktiert, um Informationen bezüglich NIPT CE-Kennzeichnung (Art des 
CE-gekennzeichneten Produkts und Indikationen) und Beschreibungen der 
unterschiedlichen Technologieeigenschaften zu erhalten. Zwei AutorInnen 
von AVALIA-T schlossen relevante Studien nach definierten Kriterien (PICO) 
basierend auf den Scoping-Fragen ein. Studien, die keine Daten zu relevan-
ten Endpunkten lieferten oder von denen angenommen wurde, dass sie ein 
inakzeptables Bias-Risiko haben, wurden ausgeschlossen. Die Gründe für 
den Ausschluss waren folgende:  
b gemischte Populationen mit unklaren Auswahlkriterien;  
b retrospektive Kohorten- oder Fallkontrolldesigns;  
b Mangel an Informationen zum Indextest oder Referenzstandard;  
b fehlende unabhängige Bewertung des Indextests/ Referenzstandards;  
b Ungeeignete Bezugsgrößen hinsichtlich der Mehrheit der Schwange-
ren.  
Nicht nur die Studienselektion, sondern auch Bias-Risiko- wie Qualitätsbeur-
teilung wurde von 2 AutorInnen unabhängig voneinander durchgeführt, und 
Diskrepanzen wurden im Konsens gelöst. Für die Bereiche klinische Wirk-
samkeit und Sicherheit wurden die relevanten Daten extrahiert und in Evi-
denztabellen von einem/r AutorIn von AVALIA-T durchgeführt und von 
dem/ der Ko-AutorIn überprüft.  
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Das QUADAS-2-Tool wurde zur Bewertung (RoB – „Risk of Bias“) der diag-
nostischen Genauigkeits-Studien verwendet. GRADE wurde zur Beurteilung 
der Qualität der Evidenz herangezogen. Für andere Domänen (organisatori-
sche, ethische und soziale Aspekte) wurde kein Tool zur Qualitätsbewertung 
verwendet.  
Statistische Analysen wurden entsprechend den Empfehlungen der 
EUnetHTA-Leitlinie „Meta-Analyse von diagnostischen Genauigkeitsstudien“ 
durchgeführt. Es wurde ein bivariates Random-Effects-Modell verwendet, 
außer wenn das Modell unzuverlässige Parameterschätzungen lieferte. In 
diesem Fall wurden zwei univariate Random-Effects-Modelle verwendet.  
Als Referenztests werden die in klinischen Leitlinien identifizierten Verfah-
ren herangezogen (vgl. oben). Als Referenzstandards werden fetale Karyo-
typisierung (Untersuchung des gesamten Genoms zur Diagnostik kleinster 
genomischer Veränderungen) oder Geburtsergebnisse bestimmt durch klini-
sche Untersuchung oder Follow-Up des Neugeborenen verwendet. 
Die Wirksamkeit der Screening-Verfahren wird ….beurteilt 
b in Bezug auf sekundäre Endpunkte (Sensitivität, Spezifität, positiver 
prädiktiver Wert [PPV] und negativer prädiktiver Wert [NPV]), aber 
auch  
b in Bezug auf primäre Endpunkte, wie die Reduzierung unnötiger in-
vasiver Tests und die Beurteilung der Auswirkungen (Kinder, gebo-
ren mit undiagnostizierten T13, T18 und T21, Reduktion der Fehlge-
burten im Zusammenhang mit invasiven Tests [AC, CVS], etc.) 
Die Sicherheit wird anhand von … beurteilt.  
b Falsch-positive Raten (FP),  
b Falsch-negative Raten (FN), 
b Testfehlern 
b Anstieg der Anzahl von Neugeborenen, die mit anderen pränatal nicht 
nachzuweisenden chromosomalen Anomalien geboren wurden (nicht 
durch pränatales Aneuploidie-Screening identifizierbar) und  
b der Anstieg der elektiven Schwangerschaftsabbrüche bei anderen 
Chromosomenanomalien mit unsicherer Signifikanz.  
Für die Beurteilung der Wirksamkeit und Sicherheit werden randomisierte 
kontrollierte klinische Studien, nicht randomisierte kontrollierte klinische 
Studien und diagnostische Genauigkeitsstudien herangezogen. Darüber hin-
aus werden auch Register für die Beurteilung der Sicherheit herangezogen.  
Qualitative Studien und Konsensdokumente werden für die organisatori-
schen, ethischen und sozialen Aspekte herangezogen.  
 
Ergebnisse: Verfügbare Evidenz 
Direkte Evidenz für die Bewertung der klinischen Wirksamkeit und Sicher-
heit wurde nur für NIPT als primäre Testmethode gefunden (Ersatz des 
Combined Tests). Dazu liegen fünf vergleichende diagnostische Genauig-
keitsstudien und vier nicht-komparative Studien vor, die bei Einlings-
schwangerschaften durchgeführt wurden (vgl. Tabelle 6 in EUnetHTA Be-
richt). Zu patientenrelevanten Endpunkten liegen keine Daten vor.  
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Die Frage nach NIPT als Ergänzung zum Combined Test bei Einlingsschwan-
gerschaften mit hohem Aneuploidierisiko (basierend auf Ergebnissen aus 
Combined Test oder klinischen Informationen) wurde indirekt durch Daten 
aus 26 Studien beantwortet, die NIPT als abgestufte Strategie untersuchten 
(vgl. Tabelle 7 in EUnetHTA Bericht). Die Add-on-Strategie für Schwangere 
mit mittlerem Risiko wurde nur in einer Studie untersucht (vgl. Tabelle 8 in 
EUnetHTA Bericht).  
Sechs Studien lieferten Daten zur Genauigkeit von NIPT für Zwillingspopula-
tionen (vgl. Tabelle A5 in EUnetHTA Bericht).  
Das Szenario des NIPT als Ersatz für invasive Tests wurde nicht berücksich-
tigt, da derzeit keiner dieser Tests für diesen Zweck zugelassen ist.  
 
Ergebnisse: Klinische Wirksamkeit  
Die diagnostische Genauigkeit von NIPT als primäre Testmethode für T21 
wurde auf der Basis von 136.544 schwangeren Frauen (885 Aneuploidien 
und 135.659 Euploidie-Fälle) berechnet. Die Meta-Analyse mit dem bivaria-
ten Random-Effects-Modell ergab eine gepoolte Schätzung der Sensitivität 
von 99,3% (95% Konfidenzintervall (CI) 97,8%-99,8%) und Spezifität von 
99,9% (95% CI, 99,8%-99,9%). Die Ergebnisse unterscheiden sich nicht vom 
univariaten Modell.  
In den vier Vergleichsstudien zeigte NIPT eine höhere Sensitivität im Ver-
gleich zum Standard-Screening (100% vs. 94%, p <0,001). Die Spezifität war 
ebenfalls signifikant höher. Die PPV in den Studien betrug zwischen 80% 
und 100%, außer in einer Studie, die einen PPV von 45,5% berichtet. Der 
NPV betrug in allen in die Bewertung einbezogenen Studien mehr als 99%. 
Die PPV und NPV waren signifikant höher für NIPT als für den Combined 
Test in einer der beiden Studien, die eine statistische vergleichende Analyse 
dieser Ergebnisse (PPV von 80,9% vs. 3,4% und NPV von 100% vs. 99,9%) 
vorlegte. In einer Studie wurde kein Unterschied gefunden.  
Insgesamt war die Qualität der Evidenz (QoE) für T21 - mit GRADE bewertet 
- moderat für die Sensitivität und niedrig für die Spezifität. Die QoE für T18 
und T13 wurde aufgrund der wenigen Fälle, des Bias-Risikos und/ oder der 
Ungenauigkeit der Schätzungen als niedrig und sehr niedrig für Sensitivität 
und Spezifität bewertet.  
Die Studien, die Daten zur Genauigkeit des NIPT als Zweitstufentest lieferten, 
betrafen 1.408 Fälle von Aneuploidie und 99.818 Euploidie-Fälle. Die gepool-
te Sensitivität unter Anwendung der bivariaten Random-Effekt-Modelle be-
trug 99,2% (95% CI, 98,6%-99,6%) und die Spezifität 99,9% (95% CI, 
99,9%-99,9%).  
Somit waren die Testgenauigkeitsergebnisse unabhängig von der Position 
des NIPT innerhalb der Screening-Strategie sehr ähnlich.  
Die Evidenzbasis für Zwillingspopulationen wurde aufgrund der geringen 
Fallzahl, des Verzerrungspotenzials und der Ungenauigkeit der Schätzungen 
als sehr niedrig eingestuft. Die erhobenen Studien umfassten 33 T21-Fälle 
und 1.547 Euploidie-Fälle.  
Die eingeschlossenen Studien lieferten keine Daten zu primären Endpunkten 
wie zur Reduktion invasiver Tests (AC oder CVS).  
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Ergebnisse: Sicherheit  
Die wichtigsten vergleichenden Informationen zur Sicherheit beziehen sich 
auf Ergebnisse zu sekundären Endpunkten (FP- und FN-Raten) und sog. „No-
Call“-Ergebnisse (Testfehler, Proben geringer Qualität, unklare Befunde). 
Für T21 waren die FP- und FN-Raten, die ohne Fehlgeburten und „No-Call“ 
Ergebnisse berechnet wurden, bei Combined Tests höher als bei NIPT. Die 
Studien zeigten auch höhere FP-Raten mit Standard-Screening als mit NIPT 
für T18 und T13, aber waren in Bezug auf FN-Raten inkonsistent. Die FP- 
und FN-Raten stiegen an, wenn die „No-Call“-Ergebnisse (zurückgerufene 
Proben) in die Analyse einbezogen wurden. Der Anteil der Testfehler betrug 
in den Studien zwischen 0,5% und 3%.  
Die FP-Rate, die für T21 und T18 beobachtet wurde, war in der überwiegen-
den Mehrheit der Studien, die NIPT als einen abgestuften (sekundären) Test 
bewerteten, null oder sehr niedrig (<0,5%). Die FN-Rate war in den meisten 
Studien ebenfalls null, obwohl die FN-Rate für T13 und T18 in den wenigen 
Studien, die FN-Fälle berichteten, stark variierte (2,6%-37,5% bzw. 12,5%-
100%). Die bei Zwillingsschwangerschaften beobachteten FP- und FN-Raten 
waren ebenfalls sehr unterschiedlich.  
Nur eine Studie liefert vergleichende Informationen über andere Chromo-
somenanomalien (z. B. andere Trisomien, chromosomale Deletionen oder 
Doppelungen). Diese Studie ergab, dass NIPT allein 8 von 13 Fällen anderer 
Chromosomenaberrationen nicht fand. Die Combined Teststrategie fand nur 
4 dieser 13 Fälle nicht.  
 
Relative Wirksamkeit  
Für drei der fünf Forschungsfragen liegen keine Daten vor:  
b NIPT als Teil von Ersttrimester-Screening für alle Schwangere  
b NIPT als Ergänzung zu Ersttrimester-Screening für die Schwangere 
mit hohem und mittlerem Risiko;  
b NIPT als Ersatz für invasive Tests.  
Für die verbleibenden zwei Fragen 
b NIPT als primäre Screeningmethode als Ersatz für den herkömmli-
chen Combined Test und  
b NIPT als Ergänzung zum Combined Test für die Hochrisikopopulation 
(1 in 300 Cut-off-Punkt)  
liegen ausreichende Daten aus den diagnostischen Genauigkeitsstudien zur 
Bewertung von Sensitivität, Spezifität, PPV, NPV und zur Testausfallrate vor.  
Aufgrund des Mangels an direkten Daten zu primären Endpunkten wurde 
eine Simulationsmodellierung durchgeführt, um die Screening-Strategien 
mit NIPT im Vergleich zur aktuellen Screening-Praxis in Bezug auf Sensitivi-
tät und Spezifität und deren Auswirkung auf die Anzahl der für T21 erfor-
derlichen invasiven Tests zu vergleichen. Schätzungen der Genauigkeit des 
Combined Tests wurden aus einem Cochrane Review übernommen. Die QoE 
für die Sensitivität und Spezifität für T18 und T13 bei Hochrisiko-
Schwangeren wurde als niedrig eingestuft, und eine Modellierung wurde als 
nicht angemessen erachtet.  
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Daten zum Vergleich 
aus Cochrane Review 
Simulationsmodellierung: NIPT als primäre Screening-Methode als Ersatz 
für Ersttrimester-Screening auf T21  
Auf der Grundlage der 2 x 2-Testgenauigkeitsdaten des Cochrane Reviews 
und der Verwendung eines bivariaten metaanalytischen Modells wird die 
gepoolte Sensitivität des Ersttrimester-Screening für das Risikoniveau von 1 
in 300 auf 87,26% (95% CI, 85,18%-89,09%) berechnet. Die gepoolte Spezi-
fität beträgt 95,50% (95% CI, 94,86%-96,05%). Unter der Annahme einer 
Prävalenz von T21 von 24 in 10.000 würde ein pränatales Screening basie-
rend auf primären NIPTs zu einem PPV von 82,6% gegenüber einem PPV 
von 4,4% mit Combined Tests mit einer FN-Rate von Null für NIPT im Ver-
gleich zu 0,03% für Combined Tests führen.  
Simulationsmodellierung: NIPT als Ergänzung zum Ersttrimester-Screening 
für Schwangere mit hohem T21-Risiko  
Auf der Grundlage der 2 x 2-Testgenauigkeitsdaten des Cochrane Reviews 
und der Verwendung eines bivariaten metaanalytischen Modells wird die 
gepoolte Sensitivität des Ersttrimester-Screening für das Risikoniveau von 1 
von 300 auf 87,26% (95% CI, 85,18%-89.09%) berechnet. Die gepoolte Spe-
zifität beträgt 95,50% (95% CI, 94,86%-96,05%). Unter Annahme einer Prä-
valenz von T21 von 24 in 10.000 und unter der Annahme, dass alle Schwan-
geren, die im kombinierten Ersttrimester-Screening positiv getestet wurden, 
NIPT unterzogen werden, würde die berechnete Sensitivität der Add-on-
Strategie (Ersttrimester-Screening plus NIPT) für eine hypothetische Kohor-
te von 10.000 auf der Grundlage der gepoolten Hochrisikodaten 86,8% be-
tragen (95% CI, 82,2%- 90,4%). Die Spezifität wäre 100% (95% CI, 99,9%-
100%). Der PPV wäre 99,1% (95% CI, 96,7%-99,7%%) und der NPV wäre 
100% (95% CI, 99,9%-100%).  
 
Abwägungen bei der Wahl der Screening-Strategie 
Aus den Simulationsmodellen ist es nicht möglich, direkt abzuleiten, wie die 
mögliche Implementierung von NIPT die Identifizierung von Feten mit T21 
und die Inanspruchnahme von invasiven Tests ändern würde. Aus einem 
Vergleich der beiden Modelle der möglichen Verwendung von NIPT (d.h. 
NIPT allein vs. Ergänzung) haben beide Modelle Vor- und Nachteile.  
Die Verwendung von alleiniger NIPT würde die T21 Nichterkennungsraten 
(Anzahl der unentdeckten Feten mit T21) reduzieren, würde im Vergleich 
zum derzeitigen Standard (nur Combined Test), jedoch eine größere Anzahl 
von invasiven Tests erfordern. Kombiniertes Testen (Combined Test + 
NIPT) würde im Gegensatz zu der alleinigen NIPT-Strategie die Anzahl der 
invasiven Tests in höherem Umfang reduzieren.  
  
Erstattung von NIPT 
Derzeit wird NIPT in den meisten europäischen Ländern hauptsächlich 
durch private Anbieter, noch nicht im öffentlichen Gesundheitssystem (au-
ßerhalb des Kontextes von Forschungsstudien) zur Verfügung gestellt.  
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Betrachtung ethischer und organisatorischer Aspekte 
Zu den vier ethischen Grundprinzipien zur Beurteilung von Interventionen 
gehören  
b Respekt vor Autonomie: Es wird angenommen, dass die frühe Ver-
fügbarkeit von Ergebnissen und die erhöhte Genauigkeit des NIPT als 
Screening-Test im Vergleich zum Combined Test die informierte Ent-
scheidung einer schwangeren Frau (sowie ihres Partners/ ihrer Part-
nerin) erleichtert. Informierte Entscheidung erfolgt aber in Abhän-
gigkeit zu vielen Faktoren, einschließlich der Frage, wie die Einwilli-
gung zur Testung und die Beratung zu möglichen Konsequenzen er-
folgt.  
b Nicht-Schaden und Nutzen wie Fürsorge: Die Beurteilung von „non-
maleficence“ und „beneficence“ von NIPT ist komplex, da sie sich auf 
das (individuelle) Werturteil stützt, ob die Früherkennung dieser 
Trisomien schädlich oder nützlich erlebt werden. Im Wesentlichen 
erfordert es eine Abwägung der Vorteile und Schäden nicht nur für 
die schwangere Frau und für ihre PartnerInnen, sondern auch für die 
Familie und andere Beteiligte. Für NIPT können die Vorteile und 
Nachteile je nach Perspektive und Implementierungsansatz (Add-on, 
vollständiger oder teilweiser Ersatz der Combined Tests) erheblich 
variieren. Der Nutzen wird in Studien primär in der Genauigkeit der 
NIPT-Ergebnisse und in der Reduktion des verfahrensbedingten 
Fehlgeburtsrisikos nach invasiver Diagnostik gesehen. Da pränatales 
Screening wegen seiner Assoziation mit Schwangerschaftsabbrüchen 
ein sensibles Thema ist, können die ethischen Implikationen von 
NIPT je nach den für die Gesellschaft und Individuen akzeptablen Zie-
len und Werten in den verschiedenen Ländern und Kulturen sehr un-
terschiedlich sein.  
b Gleichheit und Gerechtigkeit: Um dem Grundsatz der Gleichheit (glei-
cher Zugang) gerecht zu werden, sollte sichergestellt werden, dass 
der NIPT gegenüber dem herkömmlichen Screening kosteneffektiv 
und öffentlich finanziert ist. Verschiedene gesundheitsökonomische 
Modelle ergaben, dass NIPT als „kontingenter“ Test bei Hochrisiko-
Schwangeren mit einem Risiko-Cut-off von mehr als 1 zu 150 kosten-
effektiv ist. Es liegen aber keine Vergleichsstudien zu den verschie-
denen NIPT-Algorithmen vor, die Aussagen zum „Uptake“ nach in-
formierter Entscheidung, zur tatsächlichen Performanz (Reduktion 
von invasiven Tests und Fehlgeburten, Nachweis anderer Anomalien 
usw.) machen und wirft wichtige Fragen zur Implementierung in der 
Praxis auf. Bei privater Finanzierung von NIPT besteht angesichts der 
höheren Genauigkeit von NIPT die Gefahr, das T21/ Down-Syndrom 
ein Problem sozial-benachteiligter Familien wird, was eine soziale 
Stigmatisierung noch verstärken würde.  
Das Ausmaß der Umsetzung des NIPT in verschiedenen Ländern steht 
mit Faktoren wie Bildungsniveau, Einkommen oder Versicherungs-
schutz in Zusammenhang. Daher ist die NIPT-Aufnahme in Ländern 
mit hohem Einkommen wahrscheinlicher als in Ländern mit geringen 
Ressourcen. Diese Ungleichheiten können durch die NIPT-Kosten 
noch verschärft werden, da der Test hauptsächlich in privaten Ein-
richtungen durchgeführt wird.   
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Unter Berücksichtigung des Grundsatzes der Verteilungsgerechtigkeit 
ist zu prüfen, ob es ethisch vertretbar ist, Ressourcen für Technolo-
gien auszugeben, die hinsichtlich ihrer Umsetzung und Ergebnisse 
noch große Unsicherheiten aufweisen.  
 
Nicht-intendierte Auswirkungen 
Wenn NIPT bei allen Schwangeren durchgeführt wird, ist mit einer Erhö-
hung der Nachweisrate von T21, T18 und T13 zu rechnen, was zu einem An-
stieg an Schwangerschaftsabbrüchen führen könnte. Vor diesem Hinter-
grund werden Bedenken geäußert, dass jene Schwangeren/Familien, die 
sich gegen eine pränatale Testung und/oder gegen einen Schwangerschafts-
abbruch entscheiden, stigmatisiert werden und gegebenenfalls sogar der Zu-
gang zu medizinischer Versorgung (Physiotherapie, Ergotherapie oder 
Schulprogramme) reduziert werden könnte.  
Da es sich bei NIPT um einen sicheren und einfachen Test handelt, der auch 
privat verfügbar ist, besteht das Risiko, dass der Test auch für geringe ge-
sundheitliche Beeinträchtigungen oder sogar unerwünschte nicht-
medizinische Merkmale (Geschlechtsselektion) verwendet wird.  
Die Praxis der Abläufe zu Einwilligungen und zu Beratungsgesprächen - insb. 
bei einem einstufigen Screening und der Einführung von NIPT als Routine-
test - wird öffentliche Gesundheitseinrichtungen vor Herausforderungen 
stellen. Es besteht die Befürchtung, dass Frauen – in Ermangelung an ausrei-
chenden Beratungskapazitäten – eine gute informierte Entscheidung vor-
enthalten wird. Umfassende NIPT-Vortest-Beratung zu Vorteilen und Unsi-
cherheiten sowie zum Potenzial zur Entdeckung von Zufallsbefunden könnte 
erschwert zugänglich werden. Das Gentechnikgesetz (GTG 1994, § 69) re-
gelt, dass Schwangere vor einem genetischen pränatalen Test und nach dem 
Vorliegen des Untersuchungsergebnisses zu beraten sind, damit sie zum ei-
nen eine persönliche Entscheidung treffen können, ob sie das Screening ak-
zeptieren oder ablehnen, sowie zum anderen nach einer Beratung, um posi-
tive Ergebnisse mit betroffenen Frauen zu besprechen.  
Da das NIPT-Screening andere Implikationen als das Screening mittels Com-
bined Test hat, sollten klare und genaue Einwilligungsformulare entwickelt 
werden, die den KlinikerInnen Schulungsmaterialien zur Erklärung des 
Zwecks des Testens und der potenziellen Risiken und Vorteile zur Verfügung 
stellen. Im Jahr 2017 wurde das IQWIG mit der Erstellung solcher Materia-
lien für Deutschland beauftragt.  
 
Organisatorische Aspekte  und Kostenbewertungen 
Wie oben erwähnt, können je nach NIPT-Screening-Strategie für die beteilig-
ten Gesundheitsfachkräfte im Ablauf und Aufwand – aufgrund des Bedarfs 
nach zusätzlicher Vor- und Nachtestberatung zur informierten Entschei-
dungsfindung – Veränderungen im Ablauf und Mehraufwand erforderlich 
werden. Im Einklang mit den Ergebnissen einer kürzlich in den USA durch-
geführten Studie sollte auch den Einwilligungsdokumenten besondere Auf-
merksamkeit geschenkt werden, damit den bestehenden psychosozialen 
Abwägungen angemessen Aufmerksamkeit geschenkt wird.  
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Wenn NIPT als Ersatz im Ersttrimester Screening eingesetzt werden soll, ist 
zu erwarten, dass die Arbeitslast in Labors sowie beim Ultraschall deutlich 
abnimmt, wenngleich Tests für andere Gesundheitsbedrohungen (fetale 
Wachstumsbeschränkung oder Präeklampsie) noch erforderlich sind.  
Auch ist die qualitätsgesicherte Handhabung der Proben beim Versand oder 
Transport wie bei der Analyse von Bedeutung. Spezifische, von Herstellern 
unabhängig entwickelte Mindeststandards, Qualitätskontrollen, Laboranfor-
derungen sind für NIPT noch nicht entsprechend entwickelt.  Auch der 
Schutz der Vertraulichkeit von Patientinneninformationen ist einzuhalten.  
In europäischen Ländern (basierend auf Angaben zu Österreich, Deutsch-
land, Großbritannien, Rumänien, Spanien und der Schweiz) belaufen sich die 
Kosten des NIPT auf rund 447 - 992 €.  Verschiedene gesundheitsökonomi-
sche Evaluierungen befassten sich mit der Kosten-Effektivität von NIPT in 
der Diagnostik von T21 in europäischen Ländern (d.h. in den Niederlanden, 
Belgien und Spanien).  
Ein rezentes (August 2017) gesundheitsökonomisches Modell für Österreich 
wurde durch den Hauptverband der Sozialversicherungen (HVB) durchge-
führt (http://bit.ly/2DSvDEp). 3 Screening-Strategien wurden für die End-
punkte Detektionsraten, vermiedene invasive Untersuchungen und Kosten 
modelliert. 
  
Diskussion  
Die hauptsächliche Einschränkung der Aussagekraft der NIPT Studien zu 
T21 in der Allgemeinbevölkerung bezieht sich auf das hohe Verzerrungspo-
tenzial: Das Follow-Up war in den meisten Studien unvollständig, und zwei 
der Studien, die (aufgrund der Stichprobengröße) am meisten zu den Ergeb-
nissen beitragen, zeigen hohe „lost-to-follow-up“ Raten von 16,4% bzw. 
23%. Die Überprüfung negativer NIPT-Fälle wurde in den meisten Studien 
durch Sichtung von Krankenakten, Informationen von Allgemeinmedizine-
rInnen und durch Telefoninterviews durchgeführt, was ebenfalls wichtige 
Bedenken hinsichtlich der Vollständigkeit und Zuverlässigkeit der Spezifi-
tätsdaten aufwirft (GRADE: Low-QoE).  
Die Evidenz für T21 in Hochrisikopopulationen basiert ebenfalls auf Daten 
von mäßiger Qualität. Der Ausschluss von Fällen von Fehlgeburten, Totge-
burten und Fällen ohne oder mit unsicheren Ergebnissen kann zu einer 
Überschätzung der Spezifität und der PPV sowohl in der Allgemeinbevölke-
rung als auch in der Hochrisikopopulation führen. Ein niedriger fetaler An-
teil (in den Proben) oder andere Qualitätsprobleme können auch die aktuel-
len Schätzungen der Sensitivität und Spezifität verändern. Im Allgemeinen 
waren die T18- und T13-Studien aufgrund der geringen Stichprobengröße 
unzureichend aussagekräftig.  
Eine wichtige Einschränkung der Studien ist der Mangel an Informationen 
bezüglich des Nachweises von Neuralrohrdefekten und anderen wichtigen 
chromosomalen Anomalien im Vergleich zum Combined Test. Obwohl NIPT 
eine große Anzahl von größeren Anomalien nicht identifiziert, die zufällig 
durch invasive Tests diagnostiziert werden, ist das Ausmaß dieses Mangels 
an Nachweisen von anderen Anomalien unbekannt. In diesem Sinne scheint 
es wesentlich zu sein, dass Schwangeren, die sich einer cfDNA-Analyse un-
terziehen, auch eine Ultraschalluntersuchung angeboten wird. Unsicherhei-
ten bestehen bezüglich der Implikationen zufälliger Befunde, die nicht im 
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Fokus der NIPT Studien standen (z.B. Aneuploidien der Geschlechtschromo-
somen, Mikrodeletionen).  
Die Beurteilung der Performanz verschiedener Teststrategien in der Praxis 
bedarf der Berücksichtigung aller Auffälligkeiten, Abtreibungen, Fehlgebur-
ten und anderer patientInnenbezogener Ergebnisse. Wichtige Unsicherhei-
ten bestehen bezüglich der besten Screening-Strategie. Wie die EUnetHTA 
Modellierungsergebnisse (aber auch jene vom HVB) zeigen, müssen Ent-
scheidungsträgerInnen eine Abwägung der verschiedenen Ziele des NIPT 
machen:  
b Das Ziel der Erkennung aller T21-Fälle könnte mit einer etwas höhe-
ren Rate invasiver Tests erreicht werden;  
b Das Ziel, die Rate der invasiven Tests zu reduzieren, hat andererseits 
den Nachteil, dass nicht alle Fälle von T21 erfasst werden.  
Dennoch ist das Modell allein keine ausreichende Grundlage für eine Ent-
scheidung, da es auf mehreren Annahmen und Vereinfachungen beruht.  
  
Fazit  
Die vorliegenden Daten belegen, dass die Sensitivität vom NIPT bei T21 sig-
nifikant höher ist als im herkömmlichen Ersttrimester-Screening und dass 
diese Form des Screenings zu einer erheblichen Verringerung unnötiger in-
vasiver Tests führen würde. Aufgrund der nicht ausreichenden Überprüfung 
negativer Ergebnisse bestehen jedoch weiterhin Unsicherheiten hinsichtlich 
der Spezifität der NIPTs. Daten zu den wichtigsten Sicherheitsergebnissen 
fehlen ebenfalls (Zunahme der Anzahl der Neugeborenen, die mit anderen 
Anomalien geboren wurden, elektiver Schwangerschaftsabbruch bei ande-
ren unbestätigten Chromosomenanomalien mit unsicherer Signifikanz usw.).  
b Es liegen keine Daten vor, um die Genauigkeit von NIPT als Teil des 
bisherigen Ersttrimester-Screenings zu beurteilen.  
b Die verfügbaren Daten deuten darauf hin, dass die Verwendung von 
NIPT als Add-on für das Ersttrimester-Screening von T21-
Hochrisikopopulationen zu einer erheblichen Reduzierung von inva-
siven Tests führen könnte, obwohl dies erst mit Versorgungsdaten 
bestätigt werden muss. Die Durchführung des Tests (Testversagen, 
unsichere Ergebnisse) und die Aufnahme wie Akzeptanz (Uptake) 
von NIPT-Screening gehören zu den Faktoren, die dazu beitragen 
könnten, dieses Verhältnis in der realen Praxis zu ändern.  
b Es fehlen Daten, um die Verwendung von NIPT als Ergänzung zum 
Ersttrimester-Screening für Populationen mit hohem und mittlerem 
Risiko zu beurteilen.  
b Die niedrige QoE für T18 und T13 erlaubt keine Rückschlüsse auf die-
se Trisomien für eine der Screening-Strategien.  
b Es gibt keine ausreichenden Nachweise für die Genauigkeit der NIPT 
bei Zwillingsschwangerschaften.  
b Um die Performanz der verschiedenen Teststrategien beurteilen zu 
können, sind entsprechend konzipierte prospektive Vergleichsstu-
dien erforderlich, in denen alle Auffälligkeiten, Aborte, Fehlgeburten 
und andere patientInnenbezogene Ergebnisse erfasst werden.  
b Wichtige Unsicherheiten bestehen bezüglich der besten Screening-
Strategie. 
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SUMMARY OF RELATIVE EFFECTIVENESS OF NONINVASIVE  
PRENATAL TESTING FOR FETAL ANEUPLOIDIES 
Scope 
The aim of this collaborative assessment is to evaluate the relative effectiveness and safety of 
noninvasive prenatal testing (NIPT) for the screening of fetal trisomy 21 (T21), trisomy 18 (T18) and 
trisomy 13 (T13) in pregnant women of at least 8–9 weeks’ gestation. Five screening pathways are 
considered for the purpose of NIPT assessment: 
1. NIPT as a primary screening test (total replacement of first trimester combined testing (FCT)) 
2. NIPT as part of FCT (replacement of serum testing) 
3. NIPT as an add-on to FCT for the high-risk population 
4. NIPT as an add-on to FCT for the high- and intermediate-risk population 
5. NIPT as a replacement for invasive testing 
Specific interventions and population subanalyses are outlined in Section 1. 
The comparator, chosen by application of EUnetHTA criteria [1], is first-trimester serum screening 
(pregnancy-associated plasma protein A (PAPP-A) and β subunit of human chorionic gonadotropin 
(β-hCG)) and/or an ultrasound scan to measure fetal nuchal translucency (NT) or fetal crown-rump 
length (CRL) and maternal age. Fetal karyotyping or birth outcomes determined through clinical 
examination or follow-up of the newborn are considered the reference standards. 
The effectiveness of the screening processes is evaluated in terms of secondary outcomes (sensi-
tivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)) but also in 
terms of primary outcomes, reducing unecessary invasive tests, assessing the impact on children 
born with undiagnosed T13, T18 and T21, natural miscarriages or stillbirths, and miscarriages 
related to invasive testing (amniocentesis or chorionic villus sampling (CVS)). False positive (FP) 
rates, false negative (FN) rates and test failures were chosen as critical safety issues. The increase 
in the number of children born with other major prenatally undetected chromosomal conditions/ 
anomalies (not targeted by prenatal aneuploidy screening) and the increase in elective pregnancy 
termination for other chromosomal anomalies with uncertain significance were considered important 
safety issues. Several organisational, ethical and social outcomes were also considered of rele-
vance (see Section 1). 
Randomised controlled clinical trials, nonrandomised controlled clinical trials and diagnostic test 
accuracy (DTA) studies on the index test, the comparator and the reference standard (cross-
sectional studies) are included for the effectiveness and safety domain. In addition, registries are 
included for the safety domain and qualitative studies and consensus documents are included for 
the organisational, ethical and social domains. 
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Introduction 
Description of technology and comparators 
Noninvasive prenatal tests are in vitro diagnostic tests that use cell-free DNA (cfDNA) from maternal 
blood of pregnant women for the identification of common chromosomal anomalies of the fetus, 
including T21, T18 and T13. Though commonly referred to as cell fetal free DNA, the DNA does 
not derive from the fetus but originates from the cytotrophoblast layer of the chorionic villi (the outer 
placental cell layer) [2].The search identified 21 commercialised assays, although many others 
might exist given the externalisation of the technology. The most common providers are  Ariosa 
Diagnostics Inc./Roche Sequencing Solutions Inc. (Harmony®), BGI Diagnostics Technology Col Ltd. 
(NIFTY™), Igenomix SL (NACE®), LifeCodexx AG (PrenaTest®), Natera® (Panorama®), Sequenom 
Laboratories (MaterniT® 21 PLUS) and Illumina Inc. (Verifi™) . Of these, the MaterniT® 21 PLUS 
test is commercialised only in the USA [3] (B0001).  
The landscape of NIPT is diverse: some tests adopt polymerase chain reaction (PCR) for amplifi-
cation of the cell-free DNA (cfDNA) before next-generation sequencing (NGS), whilst others rely on 
other methods of quantification such as chromosomal microarray analysis. The NGS approach and 
the software for analysis and interpretation of screening results differ between tests, using  these 
different quality standards and reporting results in different ways. Regardless of the tests,  all 
require a sufficient proportion of cfDNA in the maternal plasma to be able to cfDNA-differentiate 
between the status of the mother and the fetus. However, not all laboratories quantify fetal  fraction 
in individual samples. Testing has to be performed from 8 to 10 weeks’ gestation. All assays can 
be confounded by several biological and maternal factors, including confined placental mosaicism, 
maternal copy number variations, and fetal mosaicism [4]. Failure to obtain an NIPT result could 
also be due to different technical/statistical reasons [5, 6] (B0001). 
Currently available prenatal screening options include maternal age combined with one of the follow-
ing: (1) first-trimester screening (NT, maternal age and maternal serum biochemical markers), (2) 
second-trimester serum screening (maternal age and maternal serum biochemical markers), or (3) 
two-step integrated screening, which includes first- and second-trimester serum screening with or 
without NT (integrated prenatal screening, serum integrated prenatal screening, contingent and 
sequential) [7-9]. Confirmation requires invasive testing (amniocentesis or CVS). Both procedures 
are associated with a risk of miscarriage, which seems to differ substantially depending on the 
skills of the operator and the number of procedures performed [10, 11]. 
Most noninvasive prenatal tests are offered for T21, T18 and T13 and sex chromosome aneu-
ploidies but many laboratories have expanded their panels to include other trisomies and common 
microdeletions. Depending on the assays, they can be available for singleton, twin, egg-donor or in 
vitro fertilisation (IVF) pregnancies.The proposed indication is primary or secondary screening (see 
Table 3). In most European countries, noninvasive prenatal tests are delivered mainly through private 
providers, not yet being available in publicly funded antenatal services outside the context of re-
search studies. In most of these countries, screening for fetal aneuploidies has started as contingent 
screening with high-risk women, although some countries have started offering the tests for all 
pregnancies (B0003, B0009, A0021).  
The main claimed benefit of NIPT in relation to conventional screening approaches resides in the 
simplicity and noninvasiveness of the test, as well as in the potential reduction in FP results. It is 
claimed that NIPT avoids unnecessary invasive procedures (amniocentesis and CVS), minimising 
the risk of complications, pregnancy loss and anxiety. It is claimed that the assays might also allow 
earlier testing, which would have the advantage of giving parents more time to make decisions . 
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Reimbursement 
Currently, NIPT is delivered mainly through private providers, not yet being available in publicly 
funded antenatal services outside the context of research studies in most European countries 
(A0021). The information provided by manufacturers on the reimbursement status/recommenda-
tions in Europe can be found in Tables A14–A15 in Appendix 2. 
 
Health problem 
T21 (Down syndrome, DS), T18 (Edwards syndrome) and T13 (Patau syndrome) are the most  
common chromosomal disorders among newborns. In Europe, the estimated prevalences are 24, 
5.6 and 2.08 per 10,000 live births, respectively [12]. Around 68.7% of T21 cases, 94.3% of T18 cases 
and 93.4% of T13 cases are diagnosed prenatally, although prevalence can dif fer substantially 
between countries depending on the uptake of screening programmes (<30% to 90%) (A0002, 
A0003, A0004). 
In Europe, more than 90% of individuals with T21 are expected to survive beyond the age of 20 
years, and approximately 60% reach the age of 60 years [13-16] (A0003). Individuals are charac-
terised by physical growth delay and mental retardation [17, 18], and are commonly affected by 
many comorbidities (congenital heart diseases, hearing and vision problems, neurobehavioural  
and psychiatric disorders, etc.) and premature ageing chronic diseases [19, 20]. Assessment, moni-
toring, prevention and guidance will be required from birth [18, 21]. It is estimated that with the 
current screening approximately 5000 newborns are affected in the EU each year (A0003, A0004, 
A0005, A0006). 
In contrast to T21, T13 and T18 are lethal conditions characterised by major structural malforma-
tions. Most pregnancies will end in spontaneous abortions or stillbirths, and if born, few children 
survive beyond the first year [22]. Most newborns have severe impairments, and although little 
follow-up information exists, it has been reported that mental delay ranges from marked to pro-
found. Most individuals do not achieve expressive language or walk independently (A0005). 
In most European countries, combined testing is offered to all pregnant women in the form of na-
tional or regional population screening programmes, although some countries (e.g., Ireland, Austria 
and Malta) still have no official prenatal screening policies [23]. In Europe, the threshold for testing 
frequently used to define high risk is 1 in 250 to 1 in 300, although this differs between countries. 
Guidelines recommend no further testing for low-risk patients . If contingency screening is available, 
women will be classified into high-, intermediate- and low-risk groups, and the intermediate-risk 
group will be offered second-trimester screening, although the threshold for intermediate risk is not 
standardised in most countries. For explicit information regarding NIPT recommendations, see Table 
A1 in Appendix 1 (A0025).  
As far as authorisation is concerned, the target population is all pregnant women who choose to 
have prenatal screening for T21, T18 and T13. This would mean that around 5.1 million pregnancies 
would be possible candidates for NIPT in the EU-28 (EUROSTAT fertility statistics) [24]. However, 
the precise target population is difficult to estimate because it will differ substantially depending on 
whether will a first-line or a second-line test will be used, and also on the risk threshold used (A0025, 
A0007, A0011). 
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Methods 
The selection of assessment elements was based on the HTA Core Model® for Rapid Relative Effec-
tiveness Assessment version 4.2 [25]. Additional elements were added from the HTA Core Model® 
Application for Diagnostic Technologies version 3.0 and the HTA Core Model® Application for 
Screening Technologies version 3.0 [26]. The checklist for potential ethical, organisational, patient 
and social, and legal aspects was used to establish the relevance for assessment of these domains.  
A systematic search of the scientific literature was performed in February to March 2017 in MED-
LINE (PubMed), Embase (OVID SP), the Centre for Reviews and Dissemination (CRD) database, 
Web of Science and the Cochrane Library (Wiley). Guideline repositories were used to identify 
relevant guidelines published after 2010. No limitations were applied in terms of the timing or type 
of studies for any of the domains. Ongoing clinical trials and research projects were found through 
ClinicalTrials.gov, the EU Clinical Trials Register, the International Clinical Trials Registry Platform 
(ICTRP) and the UK Clinical Trials Gateway. General Internet searches and manual searches of 
citations were complementary sources of information. Detailed tables containing the search strate-
gies can be found in Appendix 1. 
Manufacturers identified at the time of the search were contacted by the Ludwig Boltzmann Institute 
for Health Technology Assessment for information related to NIPT CE mark (type of CE-marked 
product and indications) and technology characteristics. For feasibility reasons, only four manufac-
turers which were identified to have relevant peer-review publications were asked for submission 
files. Additional information related to NIPT CE mark (type of CE-marked product and indications) 
and specific characteristics of the technologies were requested from all manufacturers identified 
during the assessment scoping phase on 23rd December 2016. Manufacturers were also asked if 
their product was commercialised in Europe, if their companies produced other technologies rele-
vant for the assessment and if they were aware of any other relevant CE-marked devices on the 
market for the respective technology and indication. Finally, they were asked to provide additional 
information/data that they considered relevant/differentiating (studies, etc.). In this way, it was 
ensured that no key information was missed. General Internet searches were performed to com-
plement information sent by manufacturers in all cases. 
Two authors from avalia-t reviewed and selected relevant abstracts according to the population, 
intervention, comparison and outcome (PICO) question. The full text of potentially relevant articles 
was read, and studies were included/excluded on the basis of scoping questions. Studies which did 
not provide data on relevant outcomes or were considered to have an unacceptable risk of bias 
or applicability concern were excluded. The reasons chosen for exclusion were as follows: mixed 
populations with unclear patient selection criteria; retrospective cohort or case-control design; lack 
of information on the index test or reference standard; lack of independent assessment of index 
test/reference standard; inappropriate reference standard in most of the population. Selection was 
done independently, and discrepancies between the authors were resolved by consensus. For the 
clinical effectiveness and safety domains, the relevant data were extracted and recorded in evi-
dence tables by one author from avalia-t and reviewed by another. Both of these steps were 
checked by the co-author.  
The QUADAS-2 tool was used to assess the risk of bias of DTA studies [27]. The level of confi-
dence/certainty in the evidence was evaluated with use of the Grading of Recommendations, Assess-
ments, Development and Evaluation (GRADE) system [28]. No quality assessment tool was used 
for other domains. A descriptive analysis of data was provided for all relevant outcomes in these 
domains. Quality evidence assessment was performed by the two authors independently of each 
other. Discrepancies were resolved by consensus. The whole process was reviewed by the co-
author. 
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Statistical analyses were performed according to recommendations described in the European 
Network for Health Technology Assessment (EUnetHTA) guideline “Meta-analysis of Diagnostic 
Test Accuracy Studies” [29]. A bivariate random-effects model was used except when then the 
model failed to converge or provided unreliable parameter estimates, in which case two univariate 
random-effects models were used. 
 
Results 
Characteristics of the available evidence 
Direct evidence for the clinical effectiveness and safety domains was found only for NIPT as a  
primary testing method (total replacement of FCT). This evidence derives from five paired DTA 
comparative studies and four noncomparative studies performed in singleton pregnancies. No data 
exist on patient-relevant outcomes. Characteristics and accuracy results of individual studies are 
provided in Table 6. 
The question regarding NIPT as an add-on to FCT in singleton women with high-risk of aneuploidies 
was answered indirectly from pooled data derived from 26 retrieved studies which assessed the 
performance of NIPT as a second-tier test (Table 7). The add-on strategy for intermediate-risk pa-
tients was addressed in only one study. Six studies provided data on the accuracy of NIPT for twin 
populations (Table 9). No evidence was found regarding the performance of these tests in combi-
nation with and/or NT. The scenario of NIPT as a replacement for invasive testing was not consid-
ered because none of these tests are currently indicated for this purpose. 
 
Test accuracy 
The diagnostic accuracy for T21 NIPT as a primary testing method was calculated on the basis of 
136,544 pregnant women (885 aneuploidy and 135,659 euploidy cases). The meta-analysis using 
the bivariate random-effects model yielded a pooled estimate of sensitivity of 99.3% (95% confi-
dence interval (CI) 97.8%–99.8%) and specificity of 99.9% (95% CI 99.8%–99.9%), which did not 
differ from the univariate model (Figure 8). In the four paired comparative studies, NIPT showed a 
higher sensitivity in comparison with standard screening (100% vs. 94%, respectively, p<0.001). 
The specificity was also significantly higher. The PPV in the studies included ranged from 80% to 
100%, except in the study of Bianchi et al. [30], which reported a PPV of 45.5%. The NPV was 
more than 99% in all studies included in the assessment. The PPV and NPV were significantly 
higher for NIPT than for FCT in one of the two studies which provided a statistical comparative 
analysis of these outcomes (PPV of 80.9% vs. 3.4% and NPV of 100% vs. 99.9%) [31]. No differ-
ence was found in the other study [30]. Overall, the quality of the evidence (QoE) for T21 assessed 
with the GRADE approach was moderate for sensitivity and low for specificity. The QoE for T18 
and T13 was rated to be low and very low for sensitivity and specificity because of the sparse 
cases, risk of bias and/or imprecision of the estimates (D0024).  
The 24 studies which provided data on the accuracy for 21 NIPT as a second-tier test involved 1408 
aneuploidy cases and 99,818 euploidy cases. The pooled sensitivity with application of the bivariate 
random-effect models was 99.21% (95% CI 98.59%–99.56%) and specificity was 99.95% (95% CI 
99.93%–99.96%) (Figure 11). Thus, the test accuracy results were very similar regardless of the 
position of NIPT within the screening strategy. In a similar way to what occurred in general popu-
lation, the QoE for T18 and T13 was rated to be low and very low (D0024). 
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The evidence base for twin populations was also rated to be very low because of the scarce number 
of cases, risk of bias and imprecision of the estimates. Retrieved studies involved 33 T21 cases 
and 1547 euploidy cases. 
The studies included failed to provide data regarding the reduction in invasive testing (amniocen-
tesis or CVS).  
 
Comparative performance 
No data are available to address three of our five research questions: NIPT as part of FCT; NIPT 
as an add-on to FCT for the high- and intermediate-risk population; NIPT as a replacement for 
invasive testing. 
For the remaining two questions – NIPT as a primary screening method as a replacement for FCT 
and NIPT as an add-on to FCT for the high-risk population (1 in 300 cut-off point) – there are suffi-
cient data from diagnostic accuracy studies to assess sensitivity, specificity, PPV, NPV and rate of 
test failures. 
Because of the lack of direct data on primary outcomes, simulation modelling was used to compare 
screening strategies with NIPT versus current screening practice in terms of sensitivity and speci-
ficity and their impact on the number of invasive tests required for T21. Estimates of the combined 
test’s accuracy were provided by Cochrane review. The QoE for the sensitivity and specificity for 
T18 and T13 in high-risk pregnant women was rated to be low, and modelling was not considered 
appropriate (D1002). 
NIPT as a primary screening method as a replacement for FCT for T21 
On the basis of the 2×2 test accuracy data of the Cochrane review and the use of a bivariate meta-
analytic model, the estimated pooled sensitivity of FCT for the risk level of 1 in 300 is estimated to 
be 87.26% (95% CI 85.18%–89.09%). The estimated pooled specificity is 95.50% (95% CI 
94.86%–96.05%). Assuming a prevalence of T21 of 24 in 10,000 (European Surveillance of Con-
genital Anomalies (EUROCAT) data [12], prenatal screening based on primary NIPT would result 
in a PPV of 82.6%% versus a PPV of 4.4% with FCT, with a zero FN rate for NIPT compared with 
0.03% for combined testing. The accuracy measures were calculated based on the hypothetical 
scenarios presented in Figure 16 and Figure 17. 
NIPT as add-on to FCT for the population with high risk of T21  
On the basis of the 2x2 test accuracy data of the Cochrane review and the use of a bivariate meta-
analytic model, the estimated pooled sensitivity of FCT for the risk level of 1 in 300 is estimated to 
be 87.26% (95% CI 85.18%–89.09%). The estimated pooled specificity is 95.50% (95% CI 94.86%–
96.05%). Assuming a prevalence of T21 of 24 in 10,000 (EUROCAT data) [12] and assuming that 
all women testing positive with FCT would undergo NIPT (pooled sensitivity of 99.24%, 95% CI 
98.64%–99.58%, and specificity estimate of 99.95%, 95% CI 99.93%–99.96%), the estimated sen-
sitivity of the add-on strategy (FCT plus NIPT) for a hypothetical cohort of 10,000 estimated on the 
basis of the pooled high-risk data would be 86.8% (95% CI 82.2%–90.4%). Estimated specificity 
would be 100% (95% CI 99.9%–100%). The PPV would be 99.1% (95% CI 96.7%–99.7%%) and 
the NPV would be 100% (95% CI 99.9%–100%). The hypothetical scenario used to estimate sen-
sitivity and specificity of NIPT as an add-on test is shown in Figure 15. 
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Comparison of NIPT screening pathways 
From the simulation models it is not possible to directly estimate how the possible implementation 
of NIPT would change key outcomes, such as T21 detection and invasive testing. From a compar-
ison of the two models of using NIPT (i.e., NIPT only vs. FCT and NIPT), both models have 
advantages and disadvantages. Using only NIPT would reduce the number of undetected cases 
but would require a larger number of invasive tests. FCT would fail to increase the T21 detection 
rate, but would allow – as opposed to the NIPT-only strategy – the number of invasive tests to be 
reduced to a larger degree. These estimations can change if no-call results are included in the 
analysis. Because of the lack of data on the rate of missed cases among no-call results, this mod-
elling could not be done (Figure 16 and Figure 17). 
 
Safety 
The main comparative information relates to intermediate safety outcomes (FP and FN rates) and 
no-call results (test failures, low-quality samples, undeterminate results). For T21, FP and FN rates 
calculated excluding miscarriages and no-call results were higher with combined testing than with 
NIPT (Table 12). Studies also showed higher FP rates with standard screening than with NIPT for 
T18 and T13 but were inconsistent regarding FN rates. FP and FN rates increased when no recall 
cases were included in the analysis. The proportion of no-call results ranged from 0.5% to 3% 
(C0008). 
The FP rate observed for T21 and T18 was zero or very low (<0.5%) in all of the studies which 
assessed NIPT as a second-tier test (Table 13). The FN rate was also zero in most of the studies, 
although the FN rate for T13 and T18 differed widely in the few studies which did report FN cases 
(2.6%–37.5% and 12.5%–100%, respectively). The FP and FN rates observed in twin pregnancies 
were highly variable (Table 14) (C0008). 
Only one study provides comparative information on other chromosomal anomalies (e.g., other  
trisomies, chromosomal deletions or duplications). This study found that NIPT alone missed 8 of  
13 cases of other chromosomal aberrations. FCT missed only 4 of these 13 cases. 
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Table 1: Summary of the available evidence on the performance of noninvasive prenatal testing 
Outcome No. of studies and  
no. of patients 
Study 
design 
Factors that may decrease QoE Perfor-
mance, % 
(95% CI, %) 
Test  
accuracy, 
QoE 
Im-
portance 
Risk of  
bias 
Incon-
sistency 
Indirectness Imprecision Publication 
bias 
GENERAL POPULATION 
Trisomy 21 
Sensitivity 
(TP+FN) 
23 studies 
28,188 pregnant women 
DTA 
studies  
Seriousa Not serious Not serious Not serious Unlikelyb 99.33  
(97.82–99.80) 
⨁⨁⨁◯ 
Moderate 
Critical 
Specificity 
(FP+TN) 
23 studies 
28,188 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikelyb 99.93  
(99.85–99.97) 
⨁⨁◯◯ 
Low 
Critical 
Trisomy 18 
Sensitivity 
(TP+FN) 
20 studies 
25,972 pregnant women 
DTA 
studies 
Seriousa Not serious Not serious Very 
seriousc 
Unlikelyb 97.43  
(94.41–98.84) 
⨁◯◯◯ 
Very low 
Critical  
Specificity 
(FP+TN) 
20 studies 
25,972 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikelyb 99.94  
(99.87–99.97) 
⨁⨁◯◯ 
Low 
Critical  
Trisomy 13 
Sensitivity 
(TP+FN) 
15 studies 
22,650 pregnant women 
DTA 
studies 
Seriousa Not serious Not serious Very 
seriousc 
Unlikelyb 99.81  
(1.14–100) 
⨁◯◯◯ 
Very low 
Critical 
Specificity 
(FP+TN) 
15 studies 
22,650 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikelyb 99.95  
(99.94–99.97) 
⨁⨁◯◯ 
Low 
Critical 
HIGH-RISK PREGNANT POPULATION 
Trisomy 21 
Sensitivity 
(TP+FN) 
23 studies 
28,188 pregnant women 
DTA 
studies  
Seriousa Not serious Not serious Not serious Unlikelyb 99.21  
(98.59–99.56) 
⨁⨁⨁◯ 
Moderate 
Critical  
Specificity 
(FP+TN) 
23 studies 
28,188 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikelyb 99.95  
(99.93–99.96) 
⨁⨁◯◯ 
Low 
Critical  
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Outcome No. of studies and  
no. of patients 
Study 
design 
Factors that may decrease QoE Perfor-
mance, % 
(95% CI, %) 
Test  
accuracy, 
QoE 
Im-
portance 
Risk of  
bias 
Incon-
sistency 
Indirectness Imprecision Publication 
bias 
Trisomy 18 
Sensitivity 
(TP+FN)  
20 studies 
25,972 pregnant women 
DTA 
studies 
Seriousa Not serious Not serious Very 
seriousc 
Unlikelyb 96.86  
(88.35–99.21) 
⨁◯◯◯ 
Very low 
Critical  
Specificity 
(FP+TN) 
20 studies 
25,972 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikelyb 99.97  
(99.93–99.98) 
⨁⨁◯⨁ 
Low 
Critical  
Trisomy 13 
Sensitivity 
(TP+FN) 
15 studies 
22,650 pregnant women 
DTA 
studies 
Seriousa Not serious Not serious Very 
seriousc 
Unlikelyb 97.67  
(59.69–99.91) 
⨁◯◯◯ 
Very low 
Critical 
Specificity 
(FP+TN) 
15 studies 
22,650 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikelyb 99.98  
(99.92–99.99) 
⨁⨁◯◯ 
Low 
Critical 
HIGH- OR INTERMEDIATE-RISK PREGNANT POPULATION 
Trisomy 21 
Sensitivity 
(TP+FN) 
1 study 
3633 pregnant women 
DTA 
study 
Seriousa Not serious Not serious Not serious Unlikely 97.7  
(88.2–99.6) 
⨁⨁⨁◯ 
Moderate  
Critical  
Specificity 
(FP+TN) 
1 study 
3633 pregnant women 
DTA 
study 
Seriousa Not serious Not serious Not serious Unlikely 99.9  
(99.8–100) 
⨁⨁⨁◯ 
Moderate 
Critical  
Trisomy 18 
Sensitivity 
(TP+FN) 
1 study 
3633 pregnant women 
DTA 
study 
Seriousa Not serious Not serious Very 
seriousc 
Unlikely 87.5  
(69.0–95.7) 
⨁⨁◯◯ 
Low  
Critical  
Specificity 
(FP+TN) 
1 study 
3633 pregnant women 
DTA 
study 
Seriousa Not serious Not serious Not serious Unlikely 99.8  
(99.8–100) 
⨁⨁⨁◯ 
Moderate 
Critical 
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Outcome No. of studies and  
no. of patients 
Study 
design 
Factors that may decrease QoE Perfor-
mance, % 
(95% CI, %) 
Test  
accuracy, 
QoE 
Im-
portance 
Risk of  
bias 
Incon-
sistency 
Indirectness Imprecision Publication 
bias 
Trisomy 13 
Sensitivity 
(TP+FN) 
1 study 
3633 pregnant women 
DTA 
study  
Seriousa Not serious Not serious Veryc 
serious 
Unlikely 50  
(15.0–85.0) 
⨁⨁◯◯ 
LOW 
Critical 
Specificity 
(FP+TN) 
1 study 
3633 pregnant women 
DTA 
study  
Seriousa Not serious Not serious Not serious Unlikely 99.8  
(99.7–100) 
⨁⨁⨁◯ 
Moderate 
Critical 
TWIN PREGNANCY POPULATION 
Trisomy 21 
Sensitivity 
(TP+FN) 
6 studies 
1985 pregnant women 
DTA 
studies 
Seriousa Not serious Not serious Very 
seriousC 
Unlikely 99.19  
(44.71–99.99) 
⨁◯◯◯ 
Very low  
Critical 
Specificity 
(FP+TN) 
6 studies 
1985 pregnant women 
DTA 
studies 
Very 
seriousa 
Not serious Not serious Not serious Unlikely 99.75  
(98.97–99.94) 
⨁⨁◯◯ 
Low 
Critical 
Abbreviations: CI=confidence interval; DTA=diagnostic test accuracy; FN=false negative; FP=false positive; QoE=quality of the evidence; TN=true negative; TP=true positive. 
a Many studies presented a high or unclear risk of bias due to the use of an inappropriate reference standard or important follow up losses;  
for sensitivity estimations, risk of bias was very serious for some studies due to the lack of confirmation of negative noninvasive prenatal test cases.  
b Possibility of publication bias not excluded but not considered sufficient to downgrade QoE. 
c Many studies showed wide CIs of sensitivity.  
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Discussion 
The main limitation of general population T21 studies relates to the high risk of bias related to the 
flow and timing and reference standard domains. Follow-up was incomplete in most studies, and 
two of the studies which contribute most to the results given the sample size have losses as high 
as 16.4% and 23%, respectively. The verification of negative NIPT cases was done in most studies 
by review of medical records, general practitioner databases and telephone interviews, raising also 
important concerns regarding the completeness and reliability of the specificity data (low QoE 
GRADE approach).  
The findings for T21 in high-risk populations were also based on moderate-low quality evidence. 
Excluding cases of miscarriages, stillbirths and cases with no or uncertain results could have led to 
an overestimation of the specificity and PPV in both the general population and the high-risk popu-
lation. The low fetal fraction or other quality issues could also change current estimates of  sensi-
tivity and specificity. In general, T18 and T13 studies were insufficiently powered because of the 
small sample size, and this could have greatly contributed to the imprecision observed and could 
also explain why many of the studies failed to show FN or FP cases for any of the three types of 
aneuploidy. 
An important limitation of the studies is the lack of information regarding the detection of neural tube 
defects and other major chromosomal anomalies in relation to FCT screening. Although NIPT will 
miss a large number of major anomalies that are incidentally diagnosed by invasive testing, the 
extent of these losses is relatively unknown. In this sense, it seems to be essential that patients 
who are undergoing cfDNA analysis should be offered maternal serum fetoprotein screening or 
ultrasound evaluation. Uncertainties remain regarding the implications of incidental findings on sex 
chromosomal aneuploidies and other conditions which are not being targeted. 
It is essential to highlight that although paired study designs have advantages over randomised 
controlled trials, given that they may be more feasible and would require fewer patients, they are 
inappropriate for assessing trade-offs between different screening approaches. To determine if 
NIPT would serve as a replacement, triage or add-on requires more information than the accuracy 
of the test. It needs assessment of the performance of the different test strategies, taking into account 
detection of all anomalies, abortions, miscarriages and other patient-related outcomes. Important 
uncertainties remain regarding the best screening pathway. As illustrated by the modelling results, 
however, it is necessary for decision makers to find the right balance between the different aims of 
using NIPT: the aim of detecting all T21 cases might be achieved with a slightly higher rate of 
invasive testing; the aim of reducing the rate of invasive testing, on the other hand, comes with the 
disadvantage of not detecting all cases of T21. Nevertheless, the model alone is an insufficient 
basis for any decision, as it is based on several assumptions and simplifications. 
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Conclusion 
 Existing moderate quality evidence supports that the detection of T21 cases is higher when 
NIPT replaces FCT as a primary screening test and that this replacement would lead to a 
reduction in unnecessary invasive testing. However, important uncertainties remain regarding 
the under-reporting of missed cases given the inappropriate verification of negative results. 
Data regarding key safety outcomes are also lacking (increase in the number of children 
born with major anomalies, elective pregnancy termination for other unconfirmed chromoso-
mal anomalies with uncertain significance, etc.). The generalisability of the PPV and NPV is 
limited by the fact that the prevalence of T21 found in the studies included is not representa-
tive of that found in the general pregnant population. 
 No data exist to assess the accuracy of NIPT offered as part of FCT. 
 Available data suggest that the use of NIPT as an add-on to FCT for screening of the high-
risk T21 population could also lead to substantial reductions in unnecessary invasive testing, 
although this needs to be confirmed with real-world data. The performance of the test (test 
failures, uncertain results) and the uptake of NIPT screening are among the factors that could 
contribute to changing this ratio in real practice.  
 There is a lack of data to assess the use of NIPT as an add-on to FCT for high- and interme-
diate-risk T21 populations. 
 The low QoE for T18 and T13 does not allow conclusions to be drawn on these trisomies for 
any of the screening pathways.  
 There is insufficient evidence to establish the accuracy of NIPT for twin pregnancies. 
 Appropriately designed prospective comparative studies are required to be able to assess the 
performance of the different test strategies, taking into account detection of all anomalies, 
abortions, miscarriages and other patient-related outcomes. Important uncertainties remain 
regarding the best screening pathway.  
 
 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 22 
1 SCOPE 
Description Project scope 
Population  Pregnant women of at least 8–9 weeks’ gestation undergoing routine primary 
screening for fetal aneuploidies. 
Three types of population are considered in this assessment: 
1. Pregnant women classified as at high risk of fetal aneuploidies by FCT or 
assessed as high risk as a result of other risk factors such as family history 
of genetic or chromosomal anomaly, or previous aneuploid pregnancy 
history. The cut-off value for defining high-risk women is 1 in 300. 
2. Pregnant women classified as having intermediate risk of fetal aneuploidies 
by FCT. The threshold cut-off value for defining intermediate risk is 1 in 
300 to 1 in 1000. 
3. General pregnant population without any predefined fetal aneuploidy risk 
factor. 
Singleton and twin populations were analysed independently given the claimed 
differences in performance of NIPT in these populations. 
Rationale: According to guidelines from the National Society of Genetic 
Counselors [9] and the American College of Obstetricians and Gynecologists 
(ACOG) [32] and position statements from the International Society for Prenatal 
Diagnosis [33] and the (ACOG and the Society for Maternal–Fetal Medicine [34], 
NIPT could be offered to pregnant women at high risk of aneuploidy or the 
general obstetric population. The International Society for Prenatal Diagnosis 
considers NIPT could be used as a primary method, offered secondary to a 
high-risk assessment or contingently to women ascertained as having high or 
intermediate risk by conventional screening. NIPT would not be applicable in 
triplet and higher-order pregnancies. 
Target 
condition 
ICD-10 codes: 
 Trisomy 21: ICD-10-CM diagnosis code Q90  
(Q90.0, Q90.1, Q90.2 y Q90.90) 
 Trisomy 18: ICD-10-CM diagnosis code Q91 (Q91.0-3) 
 Trisomy 13: ICD-10-CM diagnosis code Q91 (Q91.4-7) 
MeSH terms: aneuploidy, trisomy 21, trisomy 18, trisomy 13, Down syndrome, 
Edward syndrome and Patau syndrome 
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Intervention  Five types of interventions are assessed: 
1. Prenatal screening based on NIPT to estimate the risk of fetal 
aneuploidies, followed – for women testing at risk – by invasive diagnostic 
tests (NIPT as a primary screening test; total replacement of FCT) 
 
2. Prenatal screening based on NT, NIPT and other clinical information 
(family history of chromosomal anomaly, previous aneuploid pregnancy 
history, etc.) to estimate the risk of major fetal anomalies, followed – for 
women with low risk of aneuploidies – by invasive diagnostic tests (NIPT 
as part of FCT; partial replacement of FCT) 
 
3. Prenatal screening based on the FCT and/or clinical information (family 
history of chromosomal anomaly, previous aneuploid pregnancy history, 
etc.) to estimate the risk of fetal aneuploidies, followed – for women 
estimated to be at high risk – by NIPT, followed – for women having risk 
confirmed by NIPT – by invasive diagnostic tests (NIPT as an add-on to 
FCT and other risk factors) 
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Description Project scope 
 
4. Prenatal screening based on the FCT to estimate the risk of fetal 
aneuploidies, followed — for women testing as having intermediate to 
high risk of aneuploidies – by NIPT, followed – for women having risk 
confirmed by NIPT– by invasive diagnostic tests (NIPT as add-on to FCT 
and/or other factors) 
5. Prenatal screening and diagnosis with NIPT without confirmation by 
invasive diagnostic tests (NIPT as a replacement for invasive diagnostic 
tests) 
Noninvasive prenatal tests are based on the analysis of cfDNA in the maternal 
plasma and are performed with one of the following techniques: 
 Next-generation sequencing: 
o Whole genome sequencing  
o Targeted genome sequencing: chromosome-specific sequencing or 
single nucleotide polymorphism-based method 
 Chromosomal microarray analysis 
Noninvasive prenatal test trademarks identified: Genatal 1, Genatal 2, Genatal 
+, Verifi™ prenatal test, MaterniT® 21 PLUS, MaterniT® GENOME, VisibiliT™, 
Harmony® prenatal test, Panorama® prenatal screening test, IONA® test, 
Vanadis SMART™ NIPT, Prendia START, Prendia EXTEND, VERACITY™, 
BambniTest, NACE®, NACE® amplified, PrenatalSafe®, Prenataltest®, Aurora, 
Clarigo™, PrenaTest® or PraenaTest®, informaSeq™ test, TrisoNIM® Advance, 
Trisonim® Premium, NIFTY™ test. 
MeSH terms: cell-free fetal DNA, massively parallel sequencing, single 
nucleotide polymorphism-based method. 
Intended use of technology: prevention 
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Description Project scope 
Compariso
n 
Routine first-trimester screening for fetal aneuploidies based on the risk 
estimated by the standard FCT and other risk factors, followed – for women 
considered to be at risk – by invasive diagnostic tests.  
The FCT relies on:  
 maternal first-trimester serum screening (pregnancy-associated plasma 
protein A and β subunit of human chorionic gonadotropin); 
 and an ultrasound scan to measure fetal NT or fetal crown–rump length;  
 and maternal age. 
Rationale: comparators were chosen by application of EUnetHTA criteria [1] 
Reference 
standard 
 Fetal karyotype through invasive testing such as amniocentesis or CVS 
 Outcome at birth through clinical examination or follow-up of the newborn 
or by karyotyping in the case of miscarriage or fetal loss 
Outcomes The intervention assessed is prenatal screening (with different positioning of 
NIPT) aimed at informing women about the risk of trisomies 13, 18 and 21.  
The claimed benefit of the tests is to provide information that is more accurate 
than that from currently used screening tests. The effectiveness of the screening 
process is evaluated in terms of accuracy (intermediate outcomes), as invasive 
tests are already a decision based on noninvasive prenatal test results, but also 
in terms of how these screening strategies could change the management of 
prenatal aneuploidies and thereby impact on patient-relevant outcomes.  
 Safety of NIPT for trisomies 13, 18 and 21 
o False negative rate 
o False positive rate 
o Increase in the number of children born with other major prenatally 
undetected chromosomal conditions/anomalies (not targeted by 
prenatal aneuploidy screening) 
o Increase in elective pregnancy termination for other chromosomal 
anomalies with uncertain significance (not targeted by prenatal 
aneuploidy screening) 
o Test performance: test failure rate, uncertain results rate 
 Effectiveness of NIPT for trisomies 13,18 and 21 
o Sensitivity and specificity 
o Positive predictive value 
o Negative predictive value 
 Effectiveness of prenatal screening with NIPT versus screening 
without NIPT with regard to patient-relevant outcomes for the 
different screening strategies 
o Reduction in children born with undiagnosed trisomies 13, 18 and 21  
o Reduction in the number of miscarriages or stillbirth of individuals 
affected by trisomies 13, 18 and 21  
o Reduction in the number of miscarriages related to invasive testing 
(amniocentesis or CVS) 
o Reduction in uptake of invasive testing 
 Organisational, ethical and social issues of aneuploidy screening 
o Completion of the diagnostic pathway by the 15th week of gestation 
o Genetic counselling before and after aneuploidy screening  
o Process-related costs 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 26 
Description Project scope 
 Other important patient outcomes 
o Anxiety 
Rationale: outcomes are identified from the documents mentioned above [9, 
32, 33] based on EUnetHTA guidelines about selection of endpoints for relative 
effectiveness assessment [35]. 
Study 
design 
 Safety of prenatal screening with NIPT: randomised controlled clinical 
trials, nonrandomised controlled clinical trials, DTA studies on the index test, 
comparator and reference standard (cross-sectional studies) and registries 
 Effectiveness of prenatal screening with NIPT: randomised controlled 
clinical trials, nonrandomised controlled clinical trials and DTA studies on 
the index test, comparator and reference standard (cross-sectional studies) 
 Organisational, ethical and legal issues and patient outcomes: 
reviews/consensus documents and qualitative studies. 
Abbreviations: cfDNA=cell-free fetal DNA; CVS=chorionic villus sampling; DTA=diagnostic test accuracy; 
EUnetHTA=European Network of Health Technology Assessment; FCT=first-trimester combined testing;  
ICD-10=International Classification of Diseases, 10th revision; ICM-10-CM=International Classification of Diseases,  
10th revision, clinical modification; MeSH=Medical Subject Headings; NIPT=noninvasive prenatal testing;  
NT=nuchal translucency. 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment team 
The tasks assigned to the agencies were: 
Avalia-t (authors): 
 Developed the first draft of the EUnetHTA project plan 
 Performed the literature search and study selection 
 Conducted the assessment (extraction, analysis, synthesis and interpretation of findings) 
 Sent the first draft to dedicated reviewers, compiled feedback, answered comments and 
performed changes according to reviewers’ comments 
 Sent the second draft to external experts, compiled feedback, provided answers to reviewers 
and were responsible for undertaking corresponding changes 
 Sent the second draft to manufacturers for fact checking, compiled feedback and performed 
changes 
 Prepared the final assessment and wrote a final summary of the assessment 
Regione Emilia-Romagna (co-author): 
 Collaborated in the development of the EUnetHTA project plan 
 Checked and approved all steps (e.g., literature selection, data extraction, assessment of 
risk of bias) and provided methodological support 
 Reviewed the first and second draft assessment, proposed amendments where necessary 
(performed additional hand search when needed) and provided written feedback 
 Collaborated in the elaboration of conclusions, which were discussed and agreed on 
Dedicated reviewers: 
 Reviewed and discussed the EUnetHTA project plan (scoping meeting) 
 Reviewed and provided comments on the first draft assessment, as well as methodological 
support when needed 
 Guaranteed quality assurance 
 Reviewed and agreed on the conclusions 
 
2.2 Scoping phase/patient involvement 
During the scoping phase the assessment team, external experts, manufacturers and a user rep-
resentative (pregnant women from Alvaro Cunqueiro Hospital, Spain, who had undergone NIPT) 
were consulted and asked to provide written feedback regarding the Population, Intervention, Com-
parator and patient related Outcomes (PICO). The assessment team and external experts were 
asked about the threshold used in their respective countries for risk classification. A scoping meeting 
was organised before the start of the assessment to discuss the PICO question where the as-
sessment team, clinicians and geneticists (i.e. external experts) were present. All agreed on the 
PICO as described in the assessment. 
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2.3 Source of assessment elements 
The selection of assessment elements for the description and technical characteristics of technol-
ogy domain, the health problem and current use of the technology domain, the clinical effective -
ness domain and the safety domain was based on the HTA Core Model® for Rapid Relative Effec-
tiveness Assessment version 4.2 [25]. Additional elements were added from the HTA Core Model® 
Application for Diagnostic Technologies version 3.0 and the HTA Core Model® Application for 
Screening Technologies Version 3.0 [26]. The checklist for potential ethical, organisational, patient 
and social, and legal aspects of the HTA Core Model® for Rapid Relative Effectiveness Assess-
ment was used to identify if ethical, organisational, social or legal aspects were deemed relevant 
for assessment. For the purpose of the report, critical issues were chosen from the ethical analysis, 
organisational aspects, and patients and social aspects domains of the HTA Core Model® Application 
for Diagnostic Technologies version 3.0. General questions referring to selected issues were trans-
lated into specific answerable questions, which were answered individually or grouped together.  
 
2.4 Search 
A systematic search of the scientific literature was performed between February and March 2017 
in the following databases: 
 CRD database 
 Cochrane Library Plus 
 MEDLINE (PubMed) 
 Embase (OVID SP) 
 Web of Science 
Specific search strategies were designed for each of the databases to identify studies for the safety 
and clinical effectiveness domains. Additional strategies were defined to recover information for 
relevant ethical, organisational, and patient and social issues. Searches in PubMed, Embase and 
Web of Science were performed for each of the health problem and current use of the technology 
domain issues and the description and technical characteristics of technology domain issues. 
Guideline repositories were used to identify relevant guidelines (Guidelines International Network 
(GIN), National Guideline Clearinghouse, TRIP database, Australian Clinical Practice Guidelines, 
American College of Physicians (ACP) Website, CPG Infobase). As far as the searches were con-
cerned, no limitations were applied in terms of the type of studies for any of the domains. However, 
specific searches of guidelines, reviews/health technology assessment reports and accuracy or 
qualitative studies were limited to the year 2010 when the first studies on NIPT were published. 
General Internet searches and manual searches of citations were complementary sources of infor-
mation for all domains; that is, ongoing clinical trials and research projects were located through Clini-
calTrials.gov, ICTRP and the UK Clinical Trials Gateway. 
Detailed tables containing the search strategies can be found in Appendix 1. 
Manufacturers identified at the time of the search were contacted by the EUnetHTA Joint Action 3 
WP4 project manager (Ludwig Boltzmann Institute for Health Technology Assessment). For feasi-
bility reasons, and given that general information regarding NIPT approaches is common to all  
tests, only four manufacturers who were identified to have peer-reviewed publications were asked 
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for submission files. The short version of the submission files was sent to these manufacturers by 
the EUnetHTA JA3 WP4 project manager on 18 th November 2016. Duly completed submission 
files were received from Illumina Inc., Roche/Ariosa Diagnostic Inc. and Premaitha Health. General 
Internet searches were performed to complement technical information sent by manufacturers. Ad-
ditional information related to NIPT CE mark (type of CE-marked product and indications) and spe-
cific characteristics of the technologies were requested from all manufacturers identified during the 
assessment scoping phase on 23rd December 2016. Manufacturers were asked if their product/s 
had a CE mark certificate or equivalent regulatory approval for the indications under assessment 
and if they did, the manufacturers were asked to provide additional information regarding the type 
of CE mark (research only, etc.) and product for which the CE mark was applicable (software, kit or 
both). Manufacturers were also asked if their product was commercialised in Europe, if their com-
panies produced other technologies relevant for the assessment and if they were aware of any 
other relevant CE-marked devices on the market for the respective technology and indication. Fi-
nally, they were asked to provide additional information/data that they considered relevant/ differ-
entiating (studies, etc.). In this way, it was ensured that no key information was missed.  
 
2.5 Literature selection and data extraction 
Two independent authors from avalia-t selected the relevant abstracts pertaining to the PICO 
question. The two authors read the full text of potentially relevant articles independently and in -
cluded/excluded original studies according to the scope predefined eligibility criteria (inclusion/ 
exclusion). Studies which did not provide data on relevant outcomes, reported on duplicated data 
or were judged a priori to have a high risk of bias or important concerns regarding applicability 
issues because of the following reasons were excluded: 
 Unclear selection criteria and/or indications  
 Case-control design 
 Lack of information on the index test or reference standard  
 Uncertainty regarding independent assessment of the index test/reference standard  
 Inappropriate/no reference standard in more than 80% of cases 
Congress abstracts and studies published in languages other than English, Spanish, French or 
Italian were also excluded. The discrepancies in the study selection process were resolved by 
consensus. Excluded studies and reasons for exclusion can be found in Appendix 1.  
The identification of relevant outcomes was done in accordance with the EUnetHTA guidelines 
about endpoints used in relative effectiveness assessment [35]. The preliminary proposal of out-
come variables developed by the authors and the co-author was discussed with the dedicated re-
viewers and external experts during the scoping phase. The authors and the co-author evaluated 
the relative importance of outcomes according to the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) system [28].  
For the clinical effectiveness and safety domains, the relevant data were extracted and recorded in 
evidence tables by one author from avalia-t and reviewed by another. Both of these steps were 
checked by the co-author. Figure 1 displays the study selection flow chart. 
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Figure 1: Study inclusion flow chart.  
Abbreviations: EFF=clinical effectiveness; SAF=safety; ETH=ethical analysis; ORG=organisational aspects; 
SOC=patients and social aspects; LEG=legal aspects; NIPT=noninvasive prenatal testing, DTA=diagnostic test accuracy 
 
A total of 1654 abstracts of original research articles/guidelines were retrieved from the systematic 
bibliographic searches and 41 additional relevant were publications identified by means of the manual 
search. Overall, 219 were considered potentially relevant and were selected for full-text analysis. 
After elimination of duplicates and studies which did not comply with the eligibility criteria, 41 original 
studies were included for the assessment of clinical effectiveness and safety. Nine guidelines were 
considered for the purpose of the description and technical characteristics of technology and the 
health problem and current use of the technology domains and 34 studies were analysed for the 
ethical analysis, organisational aspects, patients and social aspects, and legal aspects domains. 
Moreover, the search identified five systematics reviews and/or meta-analyses and five health tech-
nology assessment reports.  
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Additional references identified 
through other sources 
(n=41) 
EFF and SAF (n=18) 
ETH, ORG and SOC (n=23) 
Records after duplicates removed 
(n=1193) 
Records screened 
(n=381) 
Records excluded 
(n=150) 
Full-text articles assessed for eligibility 
(n=231) 
10 guidelines or consensus documents 
136 NIPT accuracy studies 
85 studies for ETH, ORG, SOC  
and LEG domains 
Full-text studies excluded for the SAF 
and EFF domains (n=93): 
 Validation studies or retrospective 
cohort studies which present  
≥1 key biases/applicability (n=44) 
 Case-control studies (n=17) 
 Lack of data on relevant outcomes 
(n=11) 
 Unclear selection criteria and/or 
indications (n=6) 
 Duplicated data (n=3)  
 Lack of information regarding  
of reference standard (n=1)  
 Congress abstracts (n=10) 
 Articles in other languages (n=1) 
 Full-text studies for other domains 
excluded (n=57) 
Studies included in quantitative analysis 
of SAF and EFF 
(n=41) 
Comparative DTA studies (n=5) 
Noncomparative DTA studies (n=36) 
Guidelines/consensus documents (n=9) 
Studies included in ETH, ORG, SOC and 
LEG domains (n=34 studies) 
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2.6 Quality rating of studies 
The QUADAS-2 tool was used to assess the risk of bias of DTA studies [27]. Following QUADAS 
group recommendations, “if a study is judged as low on all domains relating to bias or applicability, 
then it is appropriate to have an overall judgment of low risk of bias or low concern regarding ap-
plicability”; and “if a study is judged high or unclear in 1 or more domains, then it may be judged at 
risk of bias or as having concerns regarding applicability” [27]. The level of confidence/certainty in 
the evidence was evaluated with the GRADE system [28].  
No quality assessment tool was used for the description and technical characteristics of technology 
and the health problem and current use of the technology domains. Information from different 
sources (manufacturers, bibliography searches, official Web pages and general Internet searches) 
was compared and contrasted to cross-check it for validity. Information was synthesised in a de-
scriptive manner. A descriptive analysis of data was provided for all relevant outcomes in the other 
domains (i.e., ethical analysis, organisational aspects, patients and social aspects, and legal as-
pects domains).  
The two authors carried out the Quality of evidence assessment for the description and technical 
characteristics of technology and the health problem and current use of the technology domains, 
independently of each other. Discrepancies were resolved by consensus. The whole process was 
reviewed by the co-author. 
 
2.7 Statistical analysis 
Statistical analyses were performed according to recommendations described in the EUnetHTA 
guideline “Meta-analysis of Diagnostic Test Accuracy Studies” [29]. 
Statistical analyses were mainly conducted with use of the metandi command in STATA 13. This 
command fits both hierarchical summary receiver operating characteristics (HSROC) and bivariate 
random-effects models. Forest plots and measures of variability (variances and covariance of logit 
sensitivity and logit specificity across studies) were used to assess between-study heterogeneity. 
A bivariate random-effects model was used to estimate mean sensitivity, specificity, positive likeli-
hood ratio (LR+), negative likelihood ratio (LR–) and diagnostic odds ratios (DORs) with 95% CIs 
for each trisomy to provide aggregate result for all three trisomies. When the bivariate random-
effects model failed to converge or provided unreliable parameter estimates, two univariate random-
effects models were used [36].  
To summarise overall test performance, the HSROC curve was constructed.  
Publication bias was assessed by funnel plots representing DOR versus effective sample size [37]. 
This analysis was performed only when more than 10 studies were available. 
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2.8 Description of the evidence used 
The guidelines/consensus articles considered for the description and technical characteristics of 
technology and the health problem and current use of the technology domains were elaborated by 
different medical colleges or societies from the UK, USA, Australia, etc. (see Appendix 1, Table A1). 
Only one was evidence based [38]. 
The clinical effectiveness and safety were assessed for five screening pathways:  
1. NIPT as a primary screening test as a replacement for FCT 
2. Prenatal screening based on NIPT as part of FCT 
3. NIPT as an add-on to FCT for the high-risk population 
4. NIPT as an add-on to FCT for the high- and intermediate-risk population 
5. NIPT as a replacement for invasive testing 
Direct evidence for the clinical effectiveness and safety domains was found only for the first pathway 
(total replacement of FCT). This evidence derives from five paired comparative studies and four 
noncomparative studies performed in singleton pregnancies. Moreover, two studies on twin preg-
nancies offered NIPT as a primary screening strategy to some of the women included, although 
results were reported jointly with those of women offered NIPT as a second-tier test (high-risk preg-
nancies). The question regarding NIPT as an add-on to FCT in women with high risk of aneu-
ploidies was answered indirectly from pooled data derived from 26 retrieved studies on singleton 
pregnancies which assessed NIPT as a second-tier test in these populations. The add-on strategy 
for intermediate-risk patients was addressed in only one study. Six studies provided data on the 
accuracy of NIPT for twin populations. No evidence was found regarding the performance of these 
tests in combination with FCT and/or NT assessment. The scenario of NIPT as a diagnostic test 
will not be considered as none of the tests are currently indicated for this purpose. No data exist 
regarding patient-relevant outcomes (Table 2). Detailed information about studies included in the 
assessment can be found in Appendix 1 (Tables A2–A5). 
The evidence included in the ethical analysis, organisational aspects, patients and social aspects, 
and legal aspects domains comes from 14 quantitative surveys, questionnaires or interviews and 
two systematic reviews. One of the systematic reviews, which focused on factors affecting the 
clinical use of noninvasive testing, used a mixed method approach to identify key features of the 
studies included. The other used thematic analysis to explore Internet advertising of NIPT. 
Ongoing clinical trials and research projects identified can be found in Appendix 1 (Table A6).  
The search identified five systematics reviews and/or meta-analyses and five health technology 
assessment reports which were not included because they did not comply with the PICO question. 
Detailed information about these documents can be found in Appendix 1 (Table A7).  
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Table 2: Main characteristics of studies included for the clinical effectiveness and safety domains 
Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Sarno et al. [39], 
2016 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
10,698 Index test trademark: Harmony® prenatal test 
Comparator: no intervention 
Reference standard: fetal karyotype (method used 
not specified) 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Comas et al. [40], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21 
333 Index test trademark: Harmony® prenatal test or 
Panorama™ test 
Comparator: no intervention 
Reference standard: CVS or amniocentesis and 
neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Norton et al. [31], 
2015 
Prospective, multicentre comparative 
DTA trial (cross-sectional design) 
NIPT analysis blinded to clinical 
information 
Trisomies 21, 18 and 13 and other an-
euploidies (45,X maker 
chromosomes, unbalanced 
translocations, unbalanced 
translocations, 7p deletion, 5p 
deletion/duplication, 1q41 deletion 
and isochromosome Yp) 
18,955 Index test trademark: Harmony® prenatal test 
Comparator: standard screening (NT and 
biochemical analytes, i.e., PAPP-A and total hCG 
or β-hCG 
Reference standard: CVS, products of conception 
or neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV. 
Effectiveness of prenatal screening with 
NIPT vs. screening without NIPT 
Reduction in children born with 
undiagnosed trisomies 13, 18 and 21 
Reduction in uptake of invasive testing 
Pérez-Pedregosa 
et al. [41], 2015 
Prospective comparative DTA trial 
(cross-sectional design) 
Trisomies 21 and 18 
582 Index test trademark: Harmony® prenatal test 
Comparator: standard screening, i.e., NT with serum 
biochemical assays (PAPP-A and total hcG or β-hCG) 
Reference standard: CVS or amniocentesis and 
neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Effectiveness of prenatal screening with 
NIPT vs. screening without NIPT 
Reduction in uptake of invasive testing 
Quezada et al. 
[42], 2015 
Prospective, comparative DTA trial 
(cross-sectional design) 
Trisomies 21, 18 and 13  
2905 Index test trademark: Harmony® prenatal test 
Comparator: standard screening, i.e., NT and fetal 
CRL with serum biochemical assays (PAPP-A and 
total hCG or β-hCG) 
Reference standard: CVS or amniocentesis and 
neonatal follow-up  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Effectiveness of prenatal screening with 
NIPT vs. screening without NIPT 
Reduction in children born with 
undiagnosed trisomies 13, 18 and 21 
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Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Reduction in uptake of invasive testing  
Zhang et al. [43], 
2015 
Prospective, multicentre DTA trial 
(cross-sectional design) 
Trisomies 21, 18 and 13  
147,314 Index test trademark: NA (Illumina HiSeq200 platform) 
Comparator: no intervention 
Reference standard: CVS or amniocentesis and 
neonatal follow-up  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Bianchi et al. 
[30], 2014 
CARE study 
Prospective, blinded, multicentre 
DTA trial (cross-sectional design) 
NIPT analysis blinded to clinical data 
and outcomes 
Trisomies 21, 18 and 13 
2042 Index test trademark: Verifi™ prenatal test 
Comparator: standard screening, i.e., serum 
biochemical assays in the first trimester (PAPP-A 
and total hCG or β-hCG) or second trimester 
(maternal serum α-fetoprotein, hCG, unconjugated 
oestriol and inhibin A) with or without NT 
Reference standard: CVS or amniocentesis and 
neonatal follow-up  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Effectiveness of prenatal screening with 
NIPT vs. screening without NIPT 
Reduction in children born with 
undiagnosed trisomies 13, 18 and 21 
Reduction in uptake of invasive testing  
Pergament et al. 
[44], 2014 
Prospective DTA trial (cross-
sectional design) 
Trisomies 21, 18 and 13 and 
monosomy X 
1064 Index test trademark: NA (SNPs) 
Comparator: no intervention 
Reference standard: amniocentesis, CVS, 
products of conception or genetic testing of 
umbilical cord blood, buccal sample or saliva 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Song et al. [45], 
2013 
Prospective, comparative DTA trial 
Trisomies 21, 18 and 13 and SCA 
(45,X and 47,XXy syndrome) 
1916 Index test trademark: NA (Illumina HiSeq2000 
platform) 
Comparator: triple serum screening in the second 
trimester (α-fetoprotein, free β-hCG and 
unconjugated oestriol) 
Reference standard: amniocentesis, CVS, 
cordocentesis or neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Effectiveness of prenatal screening with 
NIPT vs. screening without NIPT 
Increase in the number of children born 
with other unconfirmed chromosomal 
anomalies 
Reduction in children born with 
undiagnosed trisomies 13, 18 and 21 
Reduction in the number of 
miscarriages or stillbirths of individuals 
affected by trisomies 13, 18 and 21 
Reduction in uptake of invasive testing  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 35 
Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Kim et al. [46], 
2016 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21 
101 Index test trademark: NA (Ion semiconductor-
based sequencing) 
Comparator: no intervention 
Reference standard: amniocentesis  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Ma et al. [47], 
2016 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
2439 Index test trademark: NA (BGISEQ-1000/ 
combinatorial probe-anchor ligation sequencing-
cPAL platform) 
Comparator: no intervention 
Reference standard: CVS or amniocentesis or 
cordocentesis and neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Oepkes et al. 
[48], 2016 
TRIDENT study 
Prospective multicentre DTA trial 
(cross-sectional design) 
Trisomies 21, 18 and 13  
1390 Index test trademark: NA (Illumina HiSeq2500 
platform or Life Technologies 5500 W SOLID) 
Comparator: no intervention 
Reference standard: CVS or amniocentesis, 
ultrasound data, genetic testing in products of 
conception and neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Persico et al. 
[49], 2016 
Prospective, multicentre DTA trial 
(cross-sectional design) 
Trisomies 21, 18 and 13  
259 Index test trademark: NA (SNPs) 
Comparator: no intervention 
Reference standard: CVS or amniocentesis and/or 
aCGH  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Zhang et al. [50], 
2016 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 and Turner 
syndrome  
87 Index test trademark: Verifi™ Prenatal Test 
Comparator: no intervention 
Reference standard: amniocentesis, neonatal 
blood karyotyping and neonatal follow-up  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Benachi et al. 
[51], 2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
900 Index test trademark: NA (Illumina HiSeq1500 
platform) 
Comparator: no intervention 
Reference standard: CVS or amniocentesis  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
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Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Hernández-
Gómez et al. [52], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 18 and monosomy X 
42 Index test trademark: Harmony® prenatal test 
Comparator: no intervention 
Reference standard: amniocentesis and neonatal 
follow-up  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Ke et al. [53], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
2340 Index test trademark: NA (Illumina HiSeq2000 
platform) 
Comparator: no intervention 
Reference standard: amniocentesis and neonatal 
follow-up  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Lee et al. [54], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
93 Index test trademark: NA (MiSeq and NextSeq 
(Illumina))  
Comparator: no intervention 
Reference standard: amniocentesis, CVS 
cordocentesis, neonatal peripheral blood or 
products of conception 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Sago et al. [55], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
7740 Index test trademark: MaterniT PLUS 
Comparator: no intervention 
Reference standard: amniocentesis or CVS  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Sánchez-
Usabiaga et al. 
[56], 2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
270 Index test trademark: NA (SNPs) 
Comparator: no intervention 
Reference standard: CVS or amniocentesis and 
neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Song et al. [57], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 and SCA 
213 Index test trademark: NA (Illumina HiSeq 2000 
platform) 
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
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Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Wang et al. [58], 
2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21 and 18 
917 Index test trademark: NA (Illumina HiSeq2000 
platform) 
Comparator: no intervention 
Reference standard: standard karyotyping, FISH 
and neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Jeon et al. [59], 
2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21 and 18 
155 Index test trademark: NA (Ion Proton™ system) 
Comparator: no intervention 
Reference standard: amniocentesis 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Korostelev et al. 
[60], 2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13  
1968 Index test trademark: NA (SNPs) 
Comparator: no intervention 
Reference standard: amniocentesis, chromosomal 
microarray analysis or neonatal follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Porreco et al. 
[61], 2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 and SCA 
(Turner syndrome, trisomy X, 
Klinefelter syndrome and 47,XYY 
syndrome) 
4170 Index test trademark: NA (Illumina HiSeq2000 
platform) 
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Stumm et al. 
[62], 2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
522 Index test trademark: NA (Illumina HiSeq2000 
platform) 
Comparator: no intervention 
Reference standard: amniocentesis, CVS or 
cordocentesis  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Willems et al. 
[63], 2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
3000 Index test trademark: Harmony® prenatal test 
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Zhou et al. [64], 
2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13  
7705 Index test trademark: NA 
Comparator: no intervention 
Reference standard: amniocentesis or neonatal 
follow-up 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
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Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Liang et al. [65], 
2013 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18, 13 and 9 and SCA 
(Turner syndrome, XXX, XXY or XYY) 
435 Index test trademark: NA (Illumina HiSeq2000 
platform) 
Comparator: no intervention 
Reference standard: amniocentesis  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Nicolaides et al. 
[66], 2013 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 and Turner 
syndrome 
242 Index test trademark: NA (SNPs) 
Comparator: no intervention 
Reference standard: CVS  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Verweij et al. 
[67], 2013 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21 
595 Index test trademark: NA 
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Lau et al. [68], 
2012 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 and SCA 
(Turner syndrome and Klinefelter 
syndrome) 
108 Index test trademark: Verifi™ prenatal test 
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Norton et al. [69], 
2012 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21 and 18 
4002 Index test trademark: Harmony® prenatal test  
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Ehrich et al. [70], 
2011 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21 
480 Index test trademark: NA (GAIIx sequencer; Illumina)  
Comparator: no intervention 
Reference standard: amniocentesis or CVS  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Gil et al. [71], 
2016 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13  
4012  
(460 classified as 
high risk and 3552 
classified as 
intermediate risk) 
Index test trademark: Harmony® prenatal test  
Comparator: no intervention 
Reference standard: CVS  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
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Authors and year 
or study name 
Study type and target condition Number of 
women enrolled 
Intervention(s) Main endpoints 
Fosler et al. [72], 
2017 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21  
487 Index test trademark: Verifi™ prenatal test 
Comparator: no intervention 
Reference standard: amniocentesis, CVS or 
ultrasound findings  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Sarno et al. [39], 
2016 
This study was 
mentioned for the 
general pregnant 
population 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21, 18 and 13 
467 Index test trademark: Harmony™ prenatal test 
Comparator: no intervention 
Reference standard: fetal karyotype (not specified 
method used) 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Tan et al. [73], 
2016 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21  
565 Index test trademark: NA (MPS) 
Comparator: no intervention 
Reference standard: amniocentesis or CVS 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Bevilacqua et al. 
[74], 2015 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21 
515 Index test trademark: Harmony™ prenatal test 
Comparator: no intervention 
Reference standard: amniocentesis, CVS or 
neonatal blood examination 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Huang et al. [75], 
2014 
Prospective DTA trial  
(cross-sectional design) 
Trisomies 21 and 18 
189 Index test trademark: NA  
Comparator: no intervention 
Reference standard: amniocentesis, CVS or 
cordocentesis 
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV  
Lau et al. [76], 
2013 
Prospective DTA trial  
(cross-sectional design) 
Trisomy 21 
12 Index test trademark: NA 
Comparator: first- or second-trimester screening 
and/or first-trimester ultrasound marker screening 
(NT, fetal nasal bone and Doppler assessment of 
the tricuspid valve and ductus venosus) 
Reference standard: amniocentesis, CVS or 
cordocentesis  
Safety and effectiveness of NIPT: FN, 
FP, test failure rate, S, Sp, PPV, NPV 
Abbreviations: aCGH=microarray-based comparative genomic hybridisation; CARE=Comparison of Aneuploidy Risk Evaluations; CRL=crown–rump length; CVS=chorionic villus sampling; 
DTA=diagnostic test accuracy; FISH=fluorescence in situ hybridisation; FN=false negative; FP=false positive; hCG=human chorionic gonadotropin; β-hCG=β subunit of human chorionic gonadotropin; 
MPS=massive parallel sequencing; NA=not available; NIPT=noninvasive prenatal test; NPV=negative predictive value; NT=nuchal translucency; PAPP-A=pregnancy-associated plasma protein A; 
PPV=positive predictive value; S=sensitivity; SNP=single nucleotide polymorphism; Sp=specificity; TN=true negative; TP=true positive; SCA=sex chromosome aneuploidy. 
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2.9 Deviations from project plan 
 Delay in the deliverable due to the extension of the scoping and assessment phase. 
 Only four manufacturers who had peer-reviewed publications were asked for submission 
files for feasibility reasons. All were contacted to provide information regarding 
reimbursement. 
 The search was restricted to 2010 given that the first noninvasive prenatal test was 
launched in 2011. 
 Studies were restricted to those published in English, Spanish, French, Italian and 
Portuguese. 
 Subgroup analysis could not be performed because of the lack of data and was deleted 
from the project plan. 
 One additional assessment element was identified for the description and technical 
characteristics of technology domain (B0018). 
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
3.1 Research questions  
Element ID Research question 
B0001 What are noninvasive prenatal tests and the comparators? 
B0002 What is the claimed benefit of NIPT in relation to the comparators? 
B0003 What is the phase of development and implementation of NIPT and the 
comparators? 
B0004 Who administers NIPT and the comparators and in what context and at what 
level of care are they provided? 
B0008 What kind of special premises are needed to use NIPT and the comparators? 
B0009 What equipment and supplies are needed to use NIPT and the comparators? 
B0018 Are the reference values or cut-off points clearly established? 
A0020 For which indications has NIPT received marketing authorisation or CE marking? 
A0021 What is the reimbursement status of NIPT in prenatal screening? 
 
3.2 Results 
Features of the technology and comparators 
[B0001] – What are noninvasive prenatal tests and the comparators? 
General characteristics of NIPT 
Noninvasive prenatal tests are in vitro diagnostic products that use cfDNA from maternal blood of 
pregnant women. Though commonly referred to as cell fetal free DNA, the DNA does not derive 
from the fetus but originates from the cytotrophoblast layer of the chorionic villi (the outer placental 
cell layer). It comprises around 10%–15% of the total cfDNA in the maternal circulation during the 
late first and early second trimester [2]. Testing can be performed between 8–10 weeks’ gestation.  
Since the development of the first commercialised NIPT in 2011, which was designed for the de-
tection of T21, T18 and T13, different laboratories have developed different assays, expanding  
the panel of chromosomal anomalies detected to other common chromosomal anomalies. Table 3 
illustrates the features of the commercialised tests which were identified by the search, although 
many laboratory-developed tests with local redesigned workflows also exist given the transfer of 
existing technology to many laboratories worldwide. According to an international survey from 28 
countries performed in 2015, the most common providers of noninvasive prenatal tests are currently 
Ariosa Diagnostics Inc./Roche Sequencing Solutions Inc. (Harmony®), BGI Diagnostics Technology 
Co. Ltd., (NIFTY™ test), Illumina Inc. (Verifi™, VeriSeq NIPT Solution and Serenity (Verifi™ and 
VeriSeq NIPT Solution)), Igenomix (NACE®), LifeCodexx AG (PrenaTest®), Natera (Panorama®) 
and Sequenom (MaterniT 21 PLUS test). Of these, the MaterniT 21 PLUS test is a laboratory-based 
test which is commercialised only in the USA [3].  
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The landscape of NIPT is diverse: some tests adopt PCR for amplification of the cfDNA before 
next-generation sequencing, whilst others rely on other methods of quantification such as chromo-
somal microarrays. All technologies thereafter use proprietary algorithms for chromosomal aneu-
ploidy risk analysis. Regardless of the tests, all require a sufficient proportion of cfDNA in the 
maternal plasma to be able to cfDNA-differentiate between the status of the mother and the fetus. 
Initially many manufacturers established a minimum fetal fraction of 4% for NIPT evaluation, alt-
hough with further development of NIPT technologies and analysis methods, this limit has been 
lowered. It has been highlighted that specimens containing excessive amounts might also affect  
the performance of the test (Harmony submission file) [77]. However, not all laboratories quantify 
fetal fraction in individual samples. Fetal fraction can be influenced by factors such as fetal aneu-
ploidy, gestational age and maternal body mass index and weight, although failure to obtain an 
NIPT result could also be due to different technical/statistical reasons [5, 6]. In cases of a low fetal 
fraction, a redraw can be requested. 
The results of NIPT can be confounded by several biological factors such as confined placental 
mosaicism, maternal copy number variations, maternal mosaicism, fetal partial trisomy or translo-
cations, fetal mosaicism, fetal structural chromosomal anomalies other than trisomy, intrauterine 
fetal demise and disappearing twin [4]. Other factors which are liable to confound results are recent 
maternal transfusions, maternal organ or bone marrow transplants, maternal immunotherapy or 
stem cell therapy or maternal malignancy [77-79]. 
Specific features of the process and tests 
NGS technologies can be broadly categorised as whole genome sequencing (WGS) or targeted 
sequencing (chromosome-specific sequencing and single nucleotide polymorphism (SNP) analy-
sis) [80]: 
 WGS analyses the whole genome and generates DNA sequence reads from all chromo-
somes nonspecifically. This method analyses random sequences and can allow millions of 
short DNA fragments to be sequenced rapidly in a single run. It can allow screening of 
more conditions than T21, T18 and T13 in extended screening programmes. The depth of 
sequencing or coverage (number of reads giving information about a base present at a set 
position in the reference sequence, or the number of times a base is represented within all 
the reads) will determine the resolution achievable; hence more sequencing will increase 
performance and allow the test to be more specific and sensitive. 
 Targeted sequencing as the name indicates targets a subset of genomic regions. This ap-
proach differs from the whole genome approach by selectively amplifying and sequencing 
specific genomic regions, significantly reducing the total number of analysed reads. The re-
gion can include certain chromosomal loci (chromosome-specific sequencing) or SNPs of 
interest. The genome region will be predetermined by the specific test used, and the test 
would need to be modified and validated to provide information about other regions of the 
genome.  
Most existing tests use first-generation quantitative WGS approaches or counting methods (Table 
3) to determine the percentage of cfDNA compared with cell-free maternal DNA. Practically all of 
these use the Illumina platforms (Illumina Inc., San Diego, CA, USA) for multiple parallel sequenc-
ing. Accessing results commonly takes from around 3 to 10 days. The IONA® test (Premaitha 
Health plc, Manchester, UK) uses another platform, the Ion Proton™ ion semiconductor sequencing 
platform (Thermo Fisher Scientific), which is categorised by a total turnaround time, from the start 
of sample processing to a result, of 3 days.  
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Illumina Inc. has developed a new-generation noninvasive prenatal test, the VeriSeq NIPT Solution, 
which has been commercialised with different brand names (Table 3). VeriSeq NIPT Solution uses 
paired end sequencing. This allows the enrichment of a sample for placental cfDNA and as such 
removes the need for presequencing PCR. The turnaround time from sample accessing to results 
for the VeriSeq NIPT Solution is 26 hours. Natera has commercialised an NGS approach which 
specifically targets SNPs to determine ploidy (Panorama®). This second-generation approach, used 
also by other companies such as Imegen-Instituto de Medicina Genómica- (Spain), in comparison 
with other first-generation tests, has the ability to differentiate between cell-free maternal DNA and 
cfDNA, and in addition to identifying T21, T18, T13, monosomy X, and sex chromosome trisomies, 
it can identify the presence of a vanishing twin and maternal duplications. Currently it is being vali-
dated for common microdeletion conditions, including 22q11.2 deletion syndrome, 1p36 deletion 
syndrome, cri du chat syndrome, Prader-Willi syndrome and Angelman syndrome. Several other 
tests such as TrisoNIM and Prendia also target other trisomies and microdeletions. 
The Harmony® test, initially commercialised as a laboratory NGS test based on Illumina technology, 
changed in 2014 to use an alternative microarray sequencing process that operates on the Affy-
metrix technology platform. This targeted amplification process, termed digital analysis of selected 
regions amplifies a set of universal PCR products from genomic intervals on chromosomes 1–13, 
18, 21, X and Y and determines the fetal fraction by also measuring SNPs. These can be analysed 
to distinguish between cfDNA and cell-free maternal DNA. No data have been published regarding 
the Vanadis™ NIPT system, which is an innovative approach based on fluorescence. This system 
has still not been placed on the market in the European Union (EU). 
Existing noninvasive prenatal tests have different software for analysis and interpretation of screening 
results with differentiating features, algorithms and quality standards. For example, not all tests 
measure fetal fraction to ensure adequate DNA analysis, or if done, include it in the analysis of fetal 
risk. VeriSeq NIPT Solution tests use a quality control metric to ensure that samples have sufficient 
coverage to make a confident call, eliminating the need for a set fetal fraction percentage cut-off 
point. The neoBona®, for example, integrates sequencing depth on each chromosome, the percent-
age of fetal fraction and size of the fragments to calculate risks [81]. The Harmony® prenatal test 
establishes standards thresholds for all quality control metrics. This test uses an analysis algorithm 
termed FORTE to compute the probability of trisomies and probability of fetal sex chromosomes. 
The algorithm takes into account the total cfDNA quantification from chromosomes measured with 
digital analysis of selected regions, the amount of fetal DNA in a sample as measured by NIPT, 
maternal age and gestational age-related risk for trisomy in calculating the probability score [82].  
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Table 3: Features of the intervention 
Company Brand name Platform 
provider/ 
technology  
Mechanism 
of action 
Chromosomal anomalies detected Sample and 
reporting 
time (days) 
Indication for use/ 
target population 
Illumina Inc. 
(San Diego, 
CA, USA) 
Verifi™ prenatal test 
(https://www.illumina.com/) 
Illumina 
Verifi™ 
NGS 
(WGS) 
T21, T18, T13 and sex chromosome 
aneuploidies in singleton pregnancies 
T21, T18, T13 and presence of Y for women with 
twins through natural or reproductive methods 
Additional indications: T9, T16 and microdeletions 
( Di George, Prader-Willi/ Angelman, Cri-du-
Chat, Wolf-Hirschhorn and 1p36 deletion) 
3–5 days All pregnant women ≥ 10 weeks 
gestation who have chosen to have 
T13, T18 and T13 prenatal screening 
Not intended to be used in isolation 
from other clinical findings and tests 
results  
Single, twin or egg donor pregnancies 
Illumina Inc. 
(San Diego, 
CA, USA) 
VeriSeq NIPT Solution 
Includes: the VeriSeq NIPT 
Workflow Manager for the 
VeriSeq NIPT Microlab 
STAR, the VeriSeq NIPT 
Sample Prep Kits, and the 
VeriSeq Onsite Server 
with the VeriSeq NIPT 
Assay Software. 
Illumina 
VeriSeq 
NIPT 
Solution 
NGS 
paired end 
(WGS) 
T21, T18, T13 and sex chromosome 
aneuploidies 
1 day  
(26 hours) 
Intended for use in pregnant women 
of at least 10 weeks gestation 
The product must not be used as the 
sole basis for diagnosis or other 
pregnancy management decisions 
Genesis 
Genetics 
(London, 
UK) 
Genesis Serenity  
prenatal test 
(http://genesisgenetics.co.
uk/genesis-serenity/) 
Illumina 
Verifi™ and 
VeriSeq 
NIPT 
Solution 
NGS 
paired end 
(WGS) 
T21, T18, T13 and sex chromosome 
aneuploidies 
— Single or twin pregnancies 
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Company Brand name Platform 
provider/ 
technology  
Mechanism 
of action 
Chromosomal anomalies detected Sample and 
reporting 
time (days) 
Indication for use/ 
target population 
Labco 
Quality 
Diagnostics/ 
Synlab 
International 
GmBH 
(München, 
Germany) 
NeoBona® 
NeoBona® Advanced 
NeoBona® Advanced+ 
(http://www.neobona.es/) 
Illumina 
VeriSeq 
NIPT 
Solution 
NGS 
paired end 
(WGS) 
NeoBona: T21, T18, T13  
NeoBona Advanced: T21, T18, T13 and sex 
chromosome aneuploidies (singleton 
pregnancy only) 
NeoBona Advanced+: T21, T18, T13, T16, 
T9, sex chromosome aneuploidies and 
microdeletions (singleton pregnancy only) 
Prenatal Test Extended Panel: T21, T18, 
T13, sex chromosome aneuplodies and 
microdeletions (DiGeorge, Angelman/Prader -
Willi, 1p36 deletion, Wolf -Hirschhorn y Cri-du-
chat) (singleton pregnancy only) 
Prenatal Test Extended Panel + All 
chromosomes: T21, T18, T13, sex 
chromosome aneuplodies, microdeletions 
(DiGeorge, Angelman/Prader -Willi, 1p36 
deletion, Wolf -Hirschhorn y Cri-du-chat) and 
all chromosome aneuploidies. (singleton 
pregnancy only) 
10 days Can be used in pregnancies  
≥ 10 weeks of gestation 
Single, twin, IVF and egg donor 
pregnancies 
Sequenom 
Laboratorie
s (San 
Diego, CA, 
USA) 
VisibiliT™ 
MaterniT 21® PLUS test 
(previously MaterniT 21) 
MaterniT® GENOME 
(https://www.sequenom.
com/) 
Illumina  NGS 
(WGS) 
VisibiliT™: T21 and T18 
MaterniT® 21 PLUS:T21, T18, T13, sex 
chromosome aneuploidies and 7 microdeletions 
(T21, T18, T13, sex chromosome aneuplodies, 
T16, T22 and microdeletions (Di George, 
Prader-Willi/ Angelman, Cri-du-Chat, Wolf-
Hirschhorn, Jacobsen, Langer-Giedion and 
1p36 deletion) 
MaterniT® GENOME: All chromosomes and 
deletions or duplications of chromosome material 
7 Mb or larger, as well as seven clinically micro-
deletion regions less than 7 Mb in size (Di 
George, Prader-Willi, Cri-du-Chat, Wolf-
Hirschhorn, Jacobsen, Langer-Giedion and 
1p36 deletion) 
5 days Can be utilized in pregnant women  
≥ 10 weeks gestation  
MaterniT21 Plus is relevant for 
pregnancies at increased risk of fetal 
anomalies 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 46 
Company Brand name Platform 
provider/ 
technology  
Mechanism 
of action 
Chromosomal anomalies detected Sample and 
reporting 
time (days) 
Indication for use/ 
target population 
Natera® 
(San Carlos, 
CA, USA) 
Panorama®  
(http://www.panoramatest.
com/) 
Illumina  NGS 
(SNP) 
T21, T18, T13, sex chromosome aneuploidies 
and most common microdeletions, including 
22q11.2 deletion syndrome, 1p36 deletion 
syndrome, cri du chat, Prader-Willi and 
Angelman  
9 days Panorama could be useful for the 
general pregnant population ≥ 9 weeks 
gestation 
Single pregnancies 
Premaitha 
Health PLC 
(London, 
UK) 
Iona® test 
(http://www.premaitha.com
/the-iona-test) 
Thermo 
Fisher 
Scientific 
NGS 
(WGS) 
T21, T18 and T13 3–5 days Suitable for all pregnant women  
≥ 10 weeks of gestation 
Intended to be used by a clinician in 
combination with other risk factors to 
estimate the risk of affected pregnancies 
Single, twin, surrogate or in-vitro 
fertilization pregnancies 
Ariosa 
Diagnostics 
Inc./Roche 
Sequencing 
Solutions Inc. 
(San Jose, 
California, 
USA) 
Harmony® prenatal test Affymetrixa 
F. Hoffman-
La Roche, 
Ltd) 
Chromoso
mal micro-
arrays 
T21, T18, T13, Monosomy X*, sex 
chromosome aneuploidies* and 22q11.2 
deletion syndrome 
*singleton pregnancy only 
≤7 days Intended for use in pregnant women  
≥ 18 years of age, of ≥ 10 weeks´ 
gestation, and with ≤ 2 foetuses 
LifeCodexx 
AG 
(Germany) 
PrenaTest® 
(https://lifecodexx.com/) 
Illumina NGS 
(WGS) 
T21, T18, T13, sex chromosome aneuploidies 
and 22q11.2 deletion syndrome 
A few days Available for pregnant women ≥ 9 weeks 
Primary diagnostic procedures in 
combination with ultrasound in 
pregnant women who are at high risk 
of fetal aneuploidies (≥ 35 years old, 
increased risk based on screening 
methods, ultrasound anomalies, prior 
pregnancies with aneuploidy, family 
risk, other medical reasons)  
Single or twin pregnancies 
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Company Brand name Platform 
provider/ 
technology  
Mechanism 
of action 
Chromosomal anomalies detected Sample and 
reporting 
time (days) 
Indication for use/ 
target population 
Berry Ge-
nomics Co. 
Ltd. (Beijing, 
China) 
BambniTest Illumina NGS 
(WGS) 
— — — 
BGI 
Diagnostics 
Technology 
Co. Ltd. 
(Shenzhen, 
China) 
NIFTY™ test 
(http://www.niftytest.com/) 
Illumina 
and 
Thermo 
Fisher 
Scientific 
NGS 
(WGS) 
T21, T18, T13, sex chromosome aneuploidies 
and most common microdeletions, including 
2q33.1, 1p36, cri du chat, Prader-Willi, 
Angelman, Jacobsen, DiGeorge and  
van der Wonde  
10 days Available for any pregnant women ≥ 
10 weeks gestation but particularly 
suitable for ≥ 35 years, fetal 
ultrasonographic findings indicative of 
increased risk of aneuploidy, 
reassurance following screening 
results, contraindication for invasive 
testing, prior pregnancies with trisomy, 
received In-Vitro Fertilization (IVF) 
treatment or suffered habitual 
abortion 
Single, twin, egg-donor and IVF 
pregnancies 
Igenomix SL 
(Valencia, 
Spain) 
NACE® test 
NACE® amplified test 
(http://nace.igenomix.es/) 
Illumina  NGS 
(WGS) 
NACE®:T21, T18, T13 and sex chromosome 
aneuploidies  
NACE® amplified: additionally T9 and T6 and 
six common microdeletions: 1p36, cri du chat, 
Prader-Willi, Angelman, Wolf-Hirschhorn and 
DiGeorge (singleton pregnancy only) 
NACE®:  
3 days 
NACE® 
amplified: 
15 days 
Available for pregnant women ≥ 10 
weeks of gestation 
Specially indicated for women with 
abnormal 1st trimester test results, 
previous T21 pregnancies or 
suspicious ultrasonographic findings 
Single, twin, egg-donor and IVF 
pregnancies 
Any age, with independence of BMI 
NIM 
Genetics 
(Madrid, 
Spain)  
TrisoNIM® Advance 
TrisoNIM® Premium 
(https://www.nimgenetics.
com/trisonim/) 
Illumina 
and 
Thermo 
Fisher 
Scientific 
(NIFTY™ 
technology) 
NGS 
(WGS) 
Trisomy Advance: T21, T18, T13, sex 
chromosome aneuploidies and 3 microdeletions 
(1p36, 2q 33.1 and cri du chat) 
TrisoNIM Premium: T21, T18, T13, sex 
chromosome aneuploidies, T9, T16, T22 and 7 
microdeletions (1p36, 1q32-q41 (van der Woude), 
2q33.1, 5p (cri du chat), 10p14-p13 (DiGeorge 2), 
11q (Jacobsen) and 16p12.2-p11.2 
5–7 days Can be used in pregnancies ≤ 10 
weeks 
Single, twin, egg-donor pregnancies 
and IVF pregnancies 
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Company Brand name Platform 
provider/ 
technology  
Mechanism 
of action 
Chromosomal anomalies detected Sample and 
reporting 
time (days) 
Indication for use/ 
target population 
Imegen 
Instituto de 
Medicina 
Genómica 
(Valencia, 
Spain) 
Genatal 1 
Genatal + 
Genatal 2 (Genatal Twin 
(https://www.imegen.es/t
est-prenatal-no-
invasivo/) 
Illumina 
Panorama® 
technology 
NGS 
(SNP) 
Genatal 1: T21, T18, T13 and  
sex chromosome aneuploidies 
Genatal +: T21, T18, T13, triploidy,  
sex chromosome aneuploidies and 5 
microdeletions 
Genatal 2 (exclusive for twin or multiple 
pregnancies: T21, T18 and T13) 
7 days Can be used in pregnancies ≥ 9 weeks 
of gestation 
Single, twin, egg donor pregnancies 
and multiple pregnancies (depending 
on the tests) 
Genoma 
Laboratorie
s (Rome 
and Milan, 
Italy) 
PrenatalSafe® 
PrenatalSafe® Kario 
PrenatalSafe® Kario Plus 
PrenatalSafe® 5 
PrenatalSafe® 3 
PrenatalSafe® Plus 
(http://www.prenatalsafe.it/) 
Illumina NGS 
(WGS) 
PrenatalSafe® 3:T21, T18 and T13 
PrenatalSafe® 5: T21, T18, T13 and  
sex chromosome aneuploidies 
PrenatalSafe® Plus: T21, T18, T13, T9, T16 and 
6 microdeletions (1p36, cri du chat, Prader-Willi, 
Angelman, Wolf-Hirschhorn and DiGeorge) 
PrenatalSafe® Kario: All chromosomes of 
fetal karyotype 
PrenatalSafe® Kario Plus: All chromosomes 
of fetal karyotype and 9 microdeletions  
(1p36, cri du chat, Prader-Willi, Angelman, 
Wolf-Hirschhorn, DiGeorge, Jacobsen,  
Langer-Giedion and Smith-Magenis) 
3 days Can be performed in all pregnant 
women ≥ 10 weeks of gestation 
Single, twin, egg-donor pregnancies 
and IVF pregnancies 
Sorgente 
Genetica 
S.r.l. (Milan, 
Italy) 
Aurora 
(http://www.testprenatale
aurora.it/) 
Illumina 
Verifi™ 
NGS 
(WGS) 
T21, T18, T13, sex chromosome aneuploidies, 
T9, T16 and 5 microdeletions (1p36, cri du 
chat, Prader-Willi/Angelman, Wolf-Hirschhorn 
and DiGeorge) 
10 days Can be performed in all pregnant 
women but particularly recommendable 
for maternal age > 35 years, positive 
screening test for the first/second 
quarter, suggestive fetal US findings, 
contraindication for invasive testing, 
personal/family history of 
chromosomal anomalies 
Single, twin, egg-donor pregnancies 
and IVF pregnancies 
Ebios 
Futura S.r.l. 
(Cuneo, Italy) 
Prenataltest® Illumina NGS 
(WGS) 
T21, T18, T13 and sex chromosome 
aneuploidies 
<10 days Can be performed in pregnant women 
≥ 10 weeks gestation 
Single or twin pregnancies 
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Company Brand name Platform 
provider/ 
technology  
Mechanism 
of action 
Chromosomal anomalies detected Sample and 
reporting 
time (days) 
Indication for use/ 
target population 
Multiplicom 
NV, Belgium 
(Agilent 
Technolo-
gies, CA, 
USA) 
ClarigoTM 
(http://www.multiplicom.
com/) 
Illumina NGS 
(targeted 
technology
) 
T21, T18 and T13  6–10 days Can be used in pregnant women  
≥ 8 weeks gestation 
Single pregnancies 
Genesupport, 
FASTERIS, 
Swiss 
Institute  
for Bio-
informatics 
(Switzerland) 
Prendia START 
Prendia EXTEND 
(http://www.prendia.ch/fr/) 
— NGS 
(WGS) 
Prendia START: T21, T18 and T13 
Prendia EXTEND: sex chromosome 
aneuploidies, rare chromosomal anomalies  
(6, 7, 14, 15, 16) and structured chromosomal 
anomalies of other autosomes 
7–14 days Can be performed in pregnant women 
≥ 10 weeks gestation 
Single, twin, egg-donor pregnancies 
and IVF pregnancies 
LabCorp Inc. 
(North Caro-
lina, USA) 
InformaSeqSM 
(https://www.integratedg
enetics.com/)  
Illumina NGS 
(WGS) 
T21, T18, T13 and sex chromosome 
aneuploidies (optional) 
5–7 days Can be performed in pregnant women 
≥ 10 weeks gestation 
Single and twin pregnancies 
Vanadis 
Diagnostics, 
Perker 
Elmer Inc. 
(Sweden) 
Vanadis™ NIPT system 
http://www.vanadisdx.com/ 
— Microplate-
based 
technology  
T21, T18 and T13 2–3 days Vanadis™ NIPT is under development. 
The system does not conform to 
98/79 EC In Vitro Diagnostic Medical 
device directive and cannot beplaced 
on the market or put into service in EU 
until they have been made to comply. 
NIPD 
Genetics 
(Nicosia, 
Cyprus) 
VERACITY™ test 
(https://www.nipd.com/) 
Illumina NGS 
(targeted 
enrichment 
technology) 
T21, T18 and T13 and sex chromosome 
aneuploidies 
A few days Can be performed in pregnant women 
≥ 10 weeks gestation 
Single and twin pregnancies 
Abbreviations: IVF=in vitro fertilisation; NGS=next-generation sequencing; SNP=single nucleotide polymorphism; T6=trisomy 6; T9=trisomy 9; T13=trisomy 13; T16=trisomy 16; T18=trisomy 18; 
T21=trisomy 21; US=ultrasound; WGS=whole genome sequencing. 
a Illumina WGS technology before 2014. 
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Comparators for T13, T18 and T21 screening 
Screening tests 
Multiple prenatal screening strategies exist for first- and second-trimester T21, T18 and T13 prena-
tal screening. The most commonly used approaches involve the measurement of serum proteins 
via a blood draw and ultrasound assessment. The FCT, which uses NT, PAPP-A and beta human 
chorionic gonadotropin (ßhCG) measurements, is the standard of practice in most European 
countries [7-9]. The test is usually performed between 10 weeks and 13 weeks 6 days to provide 
information about risk in early pregnancy. Differences in levels of the proteins have been observed 
in patients carrying a fetus with T21 and certain other chromosomal anomalies. Risk is calculated 
with use of different complex statistical population-derived algorithms which are based on these 
measurements and other maternal factors, such as maternal age, history of aneuploidy, weight, 
race and number of fetuses. NT can be used independently as a risk marker because, measured 
between 11 weeks and 13 weeks 6 days of gestation, it can be associated with other numeric 
chromosomal anomalies and major fetal anomalies, such as cardiac defects and diaphragmatic 
hernia, and a number of single gene disorders [38]. The translucent area disappears after 14 weeks’ 
gestational age, when it becomes more echogenic. A recent Cochrane review established that 
the sensitivity for T21 detection, estimated at a 5% FP rate, was 71% (66%–75%) with the NT and 
maternal age strategy and 87% (86%–89%) with the combined NT, PAPP-A, hCG and maternal 
age strategy. Adding other ultrasound markers (nasal bone, fetal heart rate, frontomaxillary facial 
angle, etc.) increased sensitivity to more than 90% and specificity to more than 95% [83]. The 
detection rate for T18 and T13 has been shown to as high as 97% and 92% in some large studies 
[84]. 
Second-trimester screening for T18 and T21 is also used for women who present at more than 14 
weeks’ gestation [8, 9, 85], as this test can be performed at around 15–20 weeks’ gestation. Women 
can be offered tests which use double, triple or quadruple serum markers. The most recommended 
is the quadruple test, which measures levels of hcG, alpha fetoprotein, dimeric inhibin A and un-
conjugated oestriol, in combination with maternal factors such as age, diabetes and plurality. On 
the basis of existing studies, it is acknowledged to provide an adjusted risk assessment for  T21 
and T18 similar to that of first-trimester screening and in addition identifies the risk of open neural 
defects [38], but delays reassurance and/or restricts women’s options. These markers are not reli-
able for other forms of aneuploidy such as T13 or Klinefelter syndrome. In comparison with first-
trimester tests, they do not require specialised ultrasonographic measurements [7-9].  
The combination of first- and second-trimester ultrasound markers and serum analytes constitutes 
an alternative to one-step screening. With integrated screening, the patient undergoes NT and 
PAPP-A measurements in the first trimester and quadruple screening in the second trimester,  
receiving a single test result in the second trimester. In stepwise sequential screening, patients who 
are stratified into the high-risk group on the basis of the first-trimester screening NT and serum 
markers test are informed of the result and offered diagnostic testing, whilst those estimated to be 
of low risk proceed with the second-trimester quadruple test, being given a risk based on the com-
bined results. Conventional screening via contingency screening is another two-step screening op-
tion, where patients are divided into low-, moderate- and high-risk groups on the basis of FCT. The 
overall detection rate for contingency screening is 91%–92% for T21 and 91%–96% for T18. 
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Diagnostic tests 
Both NIPT and the comparators require confirmatory invasive testing (amniocentesis or CVS). 
Confirmation can be done by either karyotyping or chromosomal microarray, which might provide 
different levels of information. During CVS, a sample of cells is extracted from the placenta by 
either transabdominal CVS, via a needle, or transcervical CVS, using forceps or a catheter inserted 
through the cervix. CVS is usually performed between 10 and 14 weeks of pregnancy. Amniocen-
tesis involves the insertion of a needle through the placenta to extract a sample of amniotic fluid. 
In comparison with CVS, amniocentesis is usually performed after 15 weeks. Both procedures are 
associated with a risk of miscarriage, which seems to differ substantially depending on the skills of 
the operator and the number of procedures performed. Miscarriage risks of up to 1% were reported 
in a Cochrane review [11] of 16 randomised studies but a recent systematic review and meta-anal-
ysis of controlled studies excluding those describing fewer than 1000 procedures showed lower 
added risk of 0.1% for amniocentesis and 0.2% for CVS, suggesting that the risk of miscarriage in 
specialist centres performing a large number of procedures is considerably lower than the figures 
currently given [10]. Results are normally available within 3 days (rapid test for chromosomal 
anomalies) or 10 days (full karyotype of the 23 pairs of chromosomes or array). 
 
[B0002] – What is the claimed benefit of NIPT in relation to the comparators? 
The main claimed benefit for the patient relates to the simplicity and noninvasiveness of the test, 
as well as the increased accuracy and decrease in FP rates in comparison with conventional 
screening. Whilst traditional FCT screening which involves NT, PAPP-A and hCG measurements 
and a maternal age strategy is the standard of care for T21 screening in many countries, it is asso-
ciated with a 5% FP rate and fails to identify an important number of cases. According to a recent 
Cochrane review the estimated sensitivity for T21 was 85% and the specificity was 95% at a cut-
off risk of 1 in 250. Adding other ultrasound markers (nasal bone, fetal heart rate, frontomaxillary 
facial angle, etc.) increased sensitivity to more than 90% and specificity to more than 95% [83] but 
these ultrasound measurements require referral to a skilled specialist to provide an accurate scan, 
and there is variation in the experience of the operators. Integrated screening has also shown de-
tection rates as high as 91%–92% for T21 and 91%–96% for T18 but first-trimester results must be 
withheld until the test has been completed and the patient is not given the option of early diagnostic 
testing [85]. 
The higher accuracy of NIPT as a primary test could increase the confidence in the negative results 
and facilitate the informed consent decision, whilst minimising anxiety related to further testing. With 
the reduction in FP rates, unnecessary invasive procedures (amniocentesis and CVS) would be 
reduced, minimising the risk of complications such as iatrogenic loss of pregnancy, rupture of mem-
branes followed by preterm delivery and fear of fetal trauma, as well reducing the anxiety to the 
[87].The reduction of unnecessary invasive procedures could also have advantages for the system 
as it could result in a reduction in the burden associated with the number of patient visits and re-
works. In comparison with FCT, NIPT measurements can be performed at any time after 8–10 
weeks. In this sense, the assays which allow earlier testing would have the advantage of giving 
women more time to make decisions. 
Another potential benefit of NIPT as a primary test relates to the fact that unlike serum protein  
measurements and ultrasound assessment, which uses indirect and nonspecific markers, NIPT 
can target specific trisomies. This could potentially facilitate genetic counselling because women 
could be given precise information about the condition being screened.  
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When NIPT is used in a contingent approach (add-on to FCT) the same advantages are not appli-
cable. In this case, the potential benefits of NIPT reside in reducing unnecessary invasive testing. 
NIPT could also constitute an alternative for women who are not willing to undertake invasive  
screening but would like to have more information to prepare for childbirth. 
 
[B0003] – What is the phase of development and implementation  
of NIPT and the comparators?  
Traditional first-line screening for T21, which involves the measurement of serum proteins and ultra-
sound assessment, is the current standard of care in most European countries [12]. With regard 
to NIPT, the first test launched, the MaterniT 21 PLUS (Sequenom Inc.), was commercialised in 
China/Hong Kong and the USA in 2011. Soon after, it was available in many countries of western 
Europe, the Middle East, South America, Asia and Africa, with samples from these countries being 
sent to the USA or Hong Kong for testing. Many other companies have commercialised noninvasive 
prenatal tests, which are offered in more than 60 countries throughout world, although a  recent 
market report shows that North America accounts for 64.5% of global NIPT revenue, followed by 
Europe. Sequenom Inc., Natera Inc., Roche Diagnostics, Illumina Inc., BGI Diagnostics, LabCorp, 
LifeCodexx AG and Berry Genomics are the leading companies operating in the global NIPT mar-
ket, although in many European countries, other companies and their distribution partners offer 
many other tests (Table 4). All offer testing for the chromosomal aneuploidies T13, T18 and T21, 
but most have now available many other additional options depending on the tests [88].  
Whilst commercial laboratories have not published official data regarding the actual uptake, the 
estimates for 2016 indicate that more than 3 million pregnancies worldwide were screened by NIPT. 
According to a research market analysis, the market is expect to grow at a rate of 17.44% per year in 
2016–2020 (Research and Markets, Global non-invasive prenatal testing market 2016-2020) [89].  
NIPT is currently available in most of the European countries, though in many only privately (Table 
5). In some countries like UK and Denmark NIPT is offered as contingent screening for women at 
high risk women from FCT, in others like Switzerland and France it is considered for intermediate 
to high risk pregnancies (risk > 1:1000), though only for T21 in this last case. In Belgium and the 
Netherlands NIPT is now accessable for all pregnant women, although in the latter case as part of 
the Trident 2 research study. In Belgium only for the trisomy 21.  
 
[B0004] – Who administers NIPT and the comparators  
and in what context and at what level of care are they provided? 
Prenatal screening tests are designed for administration by healthcare professionals. Both tradi-
tional serum testing and NIPT involve a simple blood sample, which can be obtained during an 
outpatient appointment with no special requirements. Ultrasound assessment usually requires referral 
to a specialist. In both screening approaches, women should be counselled both before and after 
testing to ensure the test, results and limitations are clearly understood. 
 
[B0008] – What kind of special premises are needed to use NIPT and the comparators? 
[B0009] – What equipment and supplies are needed to use NIPT and the comparators? 
Samples for traditional serum testing are analysed in standard biochemistry laboratories. NIPT 
samples are frequently collected locally but shipped to external laboratories, which are equipped to 
handle cfDNA extraction, if not provided in the technology solution. The local implementation  
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would require a laboratory suitable for molecular workflows such as a clinical genetic laboratory. 
General laboratory equipment should be present, such as thermocyclers, a fridge, a freezer, pi -
pettes and an extraction system capable of purifying cfDNA from plasma. PCR-based tests require 
separated areas for pre-PCR and post-PCR work, which must comply with specific requirements 
with regard to temperature (20°C–24°C), humidity (30%–80%), pressure and environmental area 
filtering, water sources and liquid hazardous waste disposal. Both biochemical assays and NIPT 
assays should be handled by trained laboratory personnel working according to manufacturers in-
structions and in line with good laboratory practice.  
Test companies supply the additional equipment, which, depending on the company, can include 
reagent kits and analysis and application software (Table 4). 
 
[B0018] – Are the reference values or cut-off points clearly established? 
Laboratories report cfDNA results in different ways. Some laboratories define a positive or negative 
aneuploidy risk based on a cut-off point (Z score, t score or L score), which is used to determine if 
the percentage of the chromosome considered was increased relative to a reference standard. Others 
report the chance of aneuploidy by calculating the odds ratio for the trisomy considered on the 
basis of cfDNA counts and sample fetal fraction applying a likelihood ratio to the a priori trisomy 
risk based on maternal age and gestational age.  
Submission files provided by manufacturers do not report the Z score or the trisomy odds ratio. The 
Harmony test provides both a qualitative (high probability/low probability) and a quantitative result 
in the form of a probability score. In most studies, a probability score greater than 99% (high prob-
ability) or less than 0.01% (low probability) is reported. Most of the studies that performed NIPT 
using Verifi™ or other noninvasive prenatal tests based on Illumina platforms considered a Z score 
of 3 or greater as high risk for aneuploidies and a Z score of less than 3 as low risk for aneuploidies 
(Z score>2 in one study and Z score>4 in another one). Five studies [54, 59, 61, 62, 65] performed 
on the high-risk population established a specific Z score for each trisomy, and three studies [73, 75, 
76] conducted on the twin pregnancy population fixed two cut-off points (i.e., a t score and an 
L score) for classifying the trisomy risk of samples.  
 
[A0020] – For which indications has NIPT received marketing authorisation or CE marking? 
Noninvasive prenatal tests are most commonly available as laboratory-developed assays, and as 
such are liable only for the laboratory accreditation and quality standards that apply in the different 
countries where they are implemented [88]. Most of the existing tests are offered for screening of 
T21, T18, T13 and sex chromosome trisomies, although several companies offer expanded NIPT 
panels for other rare chromosomal anomalies and microdeletion syndromes (Table 3). Depending 
on the assays, they can be available for singleton, twin, egg-donor or IVF pregnancies, The pro-
posed indication and primary screening protocol proposed for NIPT use differ for the different tests. 
Whilst most of the tests are proposed for use in all pregnant women who have chosen to have 
prenatal screening for T21, T18 and T13, some highlight the special relevance for high-risk preg-
nancies (≥35 years old, increased risk based on screening methods, ultrasound anomalies, prior 
pregnancies with aneuploidy, family risk, other medical reasons) (Table 3). Several assays, among 
these IONA® and Verifi™, specify that these tests are not intended as the sole basis for diagnosis 
[78, 79]. The PrenaTest® indicates that it should be used in combination with ultrasound assess-
ment. 
None of the tests are indicated as diagnostic tests. 
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The following are commonly considered contraindications for the use of NIPT: 
 Women of less than ≤ 8–10 weeks’ pregnancy (depending on the test) 
 Women who have a chromosomal anomaly 
 Recent maternal blood transfusion 
 Maternal organ or bone marrow transplant 
 Maternal surgical procedure 
 Maternal radiotherapy 
 Maternal immunotherapy or stem cell therapy 
In recent years, several companies have commercialised specific reagents, kits or analysis software 
which offer a solution for implementation in local clinical laboratories using standard laboratory 
equipment and most of the current massively parallel sequencing systems. In line with Di rective 
98/70/EC, conformity assessment by the notified body is required only for commercialised products 
designed for evaluating T21 (Annex II list B). The EC declaration can be done by a declaration of 
conformity of full quality assurance (Annex IV) or by EC-type examination (Annex V) couplet with EC 
verification or EC declaration of conformity (production quality assurance) (Annex VI). For all other 
trisomy determinations, companies are required to comply only with the general requirements for 
in vitro medical devices (Annex III).  
Information regarding CE marking is lacking for many of the existing providers or laboratories.  
Table 4 summarises the information on the companies which provided information on this aspect. 
Details of the identified in vitro diagnostic products with CE marking are provided in Table A14 in 
Appendix 2. 
Table 4: Regulatory status of noninvasive prenatal tests 
Company Products with  
CE certificate  
Type of CE certificate  
(if available) 
Organisation 
issuing 
approval 
Year of 
approval 
Illumina Inc.a,b 
(San Diego, CA, 
USA) 
VeriSeq NIPT Solution List II Annex B BSI 2017 
Natera®a  
(San Carlos, CA, 
USA) 
Panorama-specific 
NIPT reagents and 
Constellation software 
EC declaration of conformity — — 
Premaitha  
Health PLCb 
(London,UK) 
IONA® test  
(including software) 
IONA® test HTA 
(including software) 
EC full quality assurance 
system approval certificate: 
design, development and 
manufacture of IVD reagents 
and associated software for 
noninvasive assessment of 
genetic anomalies, including 
trisomy 21 (Annex IV) 
UL 
International 
(UK) 
2015 
Ariosa 
Diagnostics Inc./ 
Roche 
Sequencing 
Solutions Inc.b 
(California,USA) 
Harmony IVD kit 
AcfS software  
EC full quality assurance 
system approval certificate; 
design and manufacture of 
reagents and associated 
software for NIPT of fetal 
chromosome aneuploidy, in-
cluding trisomy 21 (Annex IV) 
UL 
International 
(UK) 
2017 
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Company Products with  
CE certificate  
Type of CE certificate  
(if available) 
Organisation 
issuing 
approval 
Year of 
approval 
LifeCodexx AGb 
(Konstanz,Germ
any) 
PrenaTest® DAP.plus 
software  
EC full quality assurance 
system approved certificate 
for PrenaTest DAP.plus 
(limited to trisomy 21) 
(Annex IV) 
EC declaration of conformity 
for trisomy 13 and trisomy18 
EC full quality assurance 
certification from certification 
body: design, development 
and provision of IVD 
software for the application 
in the field of prenatal 
diagnostics 
TÜV 
Rheinland 
(Germany) 
Renewed 
2017 
Erbios Futura 
S.r.l.b (Italy) 
Prenataltest® kit EC IVD certification — — 
Multiplicon 
(Belgium) 
Clarigo™ test  
 
Clarigo Reporter™ 
software 
EC declaration of conformity 
(Annex III) 
— 2015 
 
2015 
Genesupport 
(Switzerland) 
Prendia software for 
the interpretation of 
sequencing data in the 
prenatal diagnosis of 
trisomy 21 
EC certificate from notified 
body of full quality 
assurance: design and 
manufacture of the Prendia 
software for the 
interpretation of sequencing 
data in the prenatal diagnosis 
of trisomy 21 (Annex IV) 
BSI, UK 2013 
Abbreviations: EC=European Conformity; HTA=health technology assessment; IVD=in vitro diagnostic; 
NIPT=noninvasive prenatal testing. 
a Source: company webpage. 
b Source: submission file/information provided by the company. 
 
[A0021] – What is the reimbursement status of the technology/comparator? 
NIPT is delivered mainly through private providers, not yet being available in many publicly funded 
antenatal services outside the context of research studies in most European countries. According 
to a global survey chromosome aneuploidy a growing number of payers consider NIPT for all preg-
nancies and cover NIPT for all pregnancies in the USA (Anthem Blue Cross and Blue Shield, Blue 
Cross and Blue Shield and Cigna). The information provided by manufacturers on the reimburse-
ment status/recommendations in Europe can be found in Tables A14–A15 in Appendix 2. 
Table 5. Summary of reimbursement recommendations for noninvasive prenatal testing  
in European countries  
Country and issuing 
organisationa 
Status of 
recommendation 
Level of reimbursement 
UK, National Screening 
Committee 
Positive for T21, T13 
and T18  
(contingent screening 
with high-risk women) 
Implementation starting in 2018 for a 2-year 
study. Fully reimbursed on contingent with risk 
greater than 1:150 with FCT) 
Belgium,  
Ministry of Health 
Positive for T21 Full or near full reimbursement for all pregnant 
women (€8 out-of-pocket cost) 
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Country and issuing 
organisationa 
Status of 
recommendation 
Level of reimbursement 
Denmark Positive for T21, T13 
and T18 
Fully reimbursed on contingent for high-risk 
women (risk 1:300 with FCT) 
France, French National 
authority for Health (HAS) 
Positive for T21  Fully reimbursed on contingent with risk 
greater than 1:1000 with FCT 
Germany, Federal Joint 
Committee (GBA) 
Ongoing No reimbursement at present 
Offered privately 
Greece No national programme Private 
Ireland No national programme Private 
Italy,  
National Plan Genomics 
Positive for T21, T13 
and T18 
No reimbursement at present 
Offered privately 
Netherlands,  
Ministry of Health 
Positive for T21, T13 
and T18 
Implementation of government Trident  
2 research study started in 2017 for a 3-year 
study, choice between FCT and primary NIPT 
Fully reimbursed for women with risk greater 
than 1:200 with FCT, €170 out-of-pocket cost 
for risk less than 1:200 
Norway,  
Health Directorate 
Positive for T21, T13 
and T18 
Not yet released 
Poland No national programme Private 
Sweden, Swedish National 
Board of Health and Welfare 
No national programme No reimbursement 
Offered privately 
Spain Ongoing Reimbursed in some regions 
Offered privately 
Switzerland,  
Federal Office of Public 
Health (FOPH/BAG) 
Positive for T21, T13 
and T18 
Full reimbursement on contingent screening 
with risk greater than 1:1000 with FCT with 
NGS-based technologies only (Analysenliste 
1.7.2017 BAG) 
Abbreviations: FCT=first-trimester combined testing; NGS=next-generation sequencing; NIPT=noninvasive prenatal testing. 
a Sources: submission files/information provided by the manufacturers. 
 
3.3 Discussion 
NIPT seems to constitute an apparently simple approach to the screening of fetal chromosomal 
aneuploidies. However, it must be acknowledged that whilst the general method for trisomy assess-
ment is common to all currently marketed noninvasive prenatal tests, these have potentially  dif-
ferentiating characteristics and modes of action. Existing noninvasive prenatal tests differ with re-
gard to many features, including the actual platform used, the depth of read, the quality control 
measures, the statistical algorithms and risk score used for risk calculation and the measurement 
of the fetal fraction. Whilst the different companies claim that some of these innovative features 
could potentially contribute to improve the performance of these tests in relation to other assays 
on the market, there are important uncertainties regarding the real influence of these in practice  
since direct comparison trials have not been performed.  
One of the main limitations of cfDNA resides in the fact that it is derived from trophoblasts and the 
fetal chromosomal constitution and the placental layers are not always correlated, leading to pos-
sible erroneous classification of some women [90]. Moreover, the fact that tests require a minimum 
fetal fraction for test interpretation constitutes a challenge, especially because low fetal fraction can 
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appear for different technical and biological reasons. Low fetal fractions have been associated with 
increased risk of T13, T18 and T21, and this should be further explored and discussed in the light 
of the current findings as they could be liable to have important implications for the accuracy of 
these tests. The resampling of low fetal fraction cases is another issue which should also be further 
evaluated and reflected on, as resampling is not always effective and could contribute to delayed 
diagnosis. 
Especially in the context of assessing NIPT in comparison with FCT, it is important to take into 
account that the benefits of NIPT will differ depending on whether NIPT will be used as a first-line 
screening test (alone or in combination with FCT) or in a contingent model (add-on to FCT). As a 
primary test it is claimed to considerably increase the accuracy for the detection of T13, T18 and 
21, whilst reducing unnecessary invasive testing given the lower FP rates. However, this benefit  
can be realised only in a healthcare setting where most women who participate in first-trimester 
screening undergo invasive testing. It this is not the case, NIPT could actually increase unnecessary 
invasive testing and loss of healthy fetuses. However, if used as a sole screening test, it could be 
liable to miss clinically relevant anomalies which the traditional screening approaches may bring to 
light when screening for T21 [91], on the one hand, because the information from NT assessment 
is essential to detect other major conditions such as cardiovascular defects, and on the other, be-
cause it could miss neural tube defects, ventral wall defects and other atypical chromosomal anom-
alies with phenotypic significance which are detected with serum analytes or ultrasound [92]. In this 
sense, some laboratories recommend the test only for high-risk groups and others highlight the 
importance of using NIPT in combination with other information and/or ultrasound examination. From 
the information provided it can be inferred that there are uncertainties regarding the best way to 
incorporate NIPT into existing screening pathways, as well as inconsistencies regarding the best 
follow-up approach for women with undeterminate or uninterpretable results.  
The potential role of NIPT for screening for fetal anomalies in twin pregnancies or medically as-
sisted pregnancies (IVF or egg donor) is another matter of concern. Although most assays are 
offered for these indications, it has been highlighted that these women could pose certain chal-
lenges for NIPT assessment as they have lower levels of cfDNA [6, 39]. The fact that most tests 
include a fetal sex chromosome complement could also pose certain challenges regarding the 
reporting of results when the screening is not offered for these anomalies. Challenges are also 
expected when noninvasive prenatal tests which have expanded their panels to cover microdele-
tions and other anomalies are used. These new additions are not part of this assessment as they 
currently lack sufficient supportive evidence, it being anticipated that in most cases the PPV would 
be low, undermining the benefits of NIPT to reduce the need for invasive testing [93].  
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY 
4.1 Research questions  
Element ID Research question 
A0002 What are the fetal chromosomal aneuploidies in the scope of this assessment? 
A0003 What are the known risk factors for fetal chromosomal aneuploidies? 
A0004 What is the natural course of fetal chromosomal aneuploidies? 
A0005 What are the symptoms and the burden of disease of chromosomal aneuploidies? 
A0006 What are the consequences of chromosomal aneuploidies for society? 
A0007 Who is the target population for prenatal aneuploidy screening? 
A0011 How much is NIPT used? 
A0023 How many people belong to the target population for prenatal aneuploidy 
screening? 
A0024 How are chromosomal aneuploidies currently screened and diagnosed 
according to published guidelines and practice? 
A0025 How are chromosomal aneuploidy pregnancies currently managed according  
to published guidelines and in practice? 
 
4.2 Results 
Overview of the disease or health condition 
[A0002] – What are the fetal chromosomal aneuploidies in the scope of this assessment? 
Noninvasive prenatal tests are validated for use in pregnant women and are currently applied in 
Europe for the assessment of the fetal chromosomal anomalies T21 (DS), T18 (Edwards syndrome) 
and T13 (Patau syndrome), which are the aneuploidies in the scope of this assessment. The tests 
can also detect sex chromosome aneuploidies and select microdeletions, although the accuracy for 
these is much lower. 
DS (International Classification of Diseases, 10 th revision, code Q90) originates in most cases 
from a cell division error which leads to a full trisomy of chromosome 21 (95%) [94]. This type of 
DS, called trisomy 21 (T21), is the most common chromosomal disorder among newborns. The 
remaining cases are due to either an inherited meiotic nondisjunction (4%) or a mosaicism-mitotic 
nondisjunction of chromosome 21 (1%). Like with other common autosomal trisomies, the number 
of pregnancies affected by T21 has experienced a rising trend in recent decades because of the 
increase in maternal age. However, studies are consistent in claiming that the increasingly wide-
spread use of prenatal screening and termination of pregnancy have counteracted the effect and 
resulted in a relatively stable live birth prevalence for DS [95]. According to EUROCAT [12], which 
is the main source of information on the epidemiology of congenital anomalies in Europe, the total 
and live birth prevalence of DS is 24 and 9.62 per 10 000 births (2010–2014 registry data; covers 
43 registries from 23 countries) [95]. Prevalence rates differ widely among countries, which has 
been explained by the maternal age distribution, except in France and Switzerland, which have  
higher estimates in comparison with other countries [95].  
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The T18 and T13 syndromes (International Classification of Diseases, 10th revision, code Q91),  
also known as Edwards syndrome and Patau syndrome, are the second and fourth most common 
autosomal chromosomal anomalies in Europe. Most T18 and T13 cases originate from maternal 
meiotic nondisjunctions, even though for T13 a minority of cases can be caused by unbalanced 
translocations with a high recurrence rate in parental carriership [97]. Less than 2%–5% are mosa-
icisms [96, 97]. According to EUROCAT data [12], the overall prevalence in 2010–2014 for T18 and 
T13 was 5.6 and 2.08 per 10,000 births, respectively. In a study conducted from a regional UK pop-
ulation-based register, the adjusted live birth prevalence of T18 was 6.8 per 10,000 in mothers aged 
35 years or older and 1.06 per 10,000 in mothers aged less than 35 years [96].  
 
[A0003] – What are the known risk factors for the disease or health condition? 
The causes of the three trisomies are relatively unknown. Advanced age at conception is the strongest 
epidemiological risk factor for all three trisomies. For DS prevalence increases from 0.6 to 4.1 per 
1000 between the age of 15 years and the age of 45 years.  
 
[A0004] – What is the natural course of the fetal chromosomal aneuploidies? 
The outcome of chromosomal anomaly cases has changed very much since the availability of pre-
natal screening. Since then, there has been a continuous increase in the proportion of cases diag-
nosed prenatally, although the uptake of screening programmes differs widely between countries. 
For example, the uptake is 90% or more in France [98] and Denmark [99] and less than 30% in 
Sweden [100]. 
Overall, it can be estimated, on the basis of EUROCAT registry data from 2010–2014 [12], that 
68.7% of DS cases, 94.3% of Patau syndrome cases and 93.4% of Edwards syndrome cases are 
diagnosed prenatally. Prenatally diagnosed cases of fetal chromosomal aneuploidies could result 
in elective termination of pregnancy, miscarriage (20–23 weeks’ gestation age), stillbirth (deaths of 
fetuses delivered at 24 weeks or more) or live birth.  
In Europe, around 55% of DS pregnancies are terminated following prenatal diagnosis, and 3.5% 
result in spontaneous fetal death/stillbirths, although termination rates are also highly variable [12] 
(EUROCAT). More than 90% of the prenatally diagnosed cases recorded in the National Down 
Syndrome Cytogenetic Register (UK) between 1989 and 2000 ended in termination [101]. Overall, 
it is estimated that if DS pregnancies were not terminated, about 32%–40% of fetal losses would 
still occur between CVS and birth and about 23%–25% would still occur between amniocentesis 
and birth [101, 102].  
Several population studies show that more than 90% of DS infants are expected to survive beyond 
the age of 20 years in developed countries [13-16]. In two of these studies, survival was shown to 
be significantly better for children with T21 mosaicism, in comparison with the other two chromoso-
mal errors [15, 16]. Congenital heart defects and respiratory infections were found to be the main 
cause of death among persons with DS who die before the age of 20 years [13, 16, 18]. On the 
basis of existing data sets from Australia and Denmark the survival probabilities at 50 and 60 years 
would be expected to be around 70% and 60%, respectively [13, 16].  
T13 and T18 are lethal conditions characterised by major structural malformations, which can be 
frequently detected by ultrasound examination, as more than 90% of the fetus present sonographic 
anomalies. The most common malformations for T18 are omphalocele, ventricular septal defects, 
abnormal posturing of the hands and megacystis [22]. The most common anomalies found in T13 
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fetuses are cleft lip and/or palate, holoprosencephaly and talipes or rocker bottom feet [103]. On 
the basis of EUROCAT data [12], more than 90% of cases in Europe are diagnosed prenatally. In 
Ireland, where there is no national policy on prenatal screening for fetal aneuploidy, it has been  
documented that only 33% of T13 cases and 65% of T18 cases are diagnosed before birth [103]. 
EUROCAT registries [12] show that overall 77% of affected pregnancies are electively terminated 
following prenatal diagnosis, and that of those T13 and T18 pregnancies which are allowed to  
continue, 6% and 9%, respectively end in spontaneous abortions or stillbirths. In the Irish study,  
almost half of the pregnancies resulted in live-born infants. A UK study shows that the uptake of 
termination can differ by ethnic group, being much lower in Pakistanis in relation to non-Pakistanis 
(58.6% vs. 86.6%) [96]. 
The published literature is consistent regarding the fact that few T18 and T13 live-born infants 
survive beyond the first year [22]. Although the medium survival time for children is less than 15 
days, some recent studies [104, 105] have found longer survival than those previously reported for 
these trisomies (5%–10% at 1 year), consistent with some publications claiming increased survival 
following more aggressive medical interventions. A multistate population-based study from the Na-
tional Birth Defects Prevention Network showed that 9.7% of patients with T13 and 12.3% of pa-
tients with T18 survived beyond 5 years [104]. A retrospective cohort study conducted in Ontario 
reported that the 1-year survival rate was 19.8% for T13 and 12.6% for T18. At 10 years, 12.9% of 
the T13 cohort and 6.4% of the T18 cohort was alive. Overall, 23% of the T13 children and 13.8% 
of the T18 children had undergone surgical procedures [105]. One study reported a 1-year survival 
rate of more than 40% but this was highly biased as it was questionnaire based. On the basis of 
the analysis of data recorded in the National Down Syndrome Cytogenetic Register it was estab-
lished that survival was significantly greater for children with mosaicisms with regard to the full 
trisomies (70%–80% vs. 8%) [106]. 
 
Effects of the disease or health condition 
[A0005] – What are the symptoms and the burden of disease  
of fetal chromosomal aneuploidies? 
Down syndrome 
Although the presentation can differ, the DS population is characterised by mental retardation as-
sociated with physical growth delay and certain physical traits. DS individuals have a variety of phe-
notypic clinical features, including mongoloid faces, protruding tongue, transverse single palmar, 
depressed nasal bridge, small low-set ears, upward-slanted eyes with epicanthic fold, short neck 
and hypotonia. Cognitive impairment frequently ranges from mild to moderate [17, 18], although in 
one study conducted in Italy, 65% of the participants had severe impairment [19]. DS will frequently 
require speech therapy, physical therapy and occupational therapy. Special education and develop-
ment interventions also play an important role in the social integration of these children [21, 107]. 
Congenital heart disease is a common comorbidity recognised in these patients. About half of the 
children are born with congenital heart disease (44%–60%), and this anomaly is a major cause of 
morbidity and death in childhood [20, 108-110]. The most common lesions are atrioventricular septal 
defects (45%), ventricular defects (35%) and patent ductus arteriosus (7%), although many other 
lesions could arise [108, 111, 112]. In many cases, early corrective surgery might be required to 
prevent irreversible damage [108, 110]. In a community study conducted in New York, up to 60% 
of the children with heart disease required surgery [113].  
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DS individuals frequently have vision and hearing problems as well as thyroid dysfunction. Hearing 
problems have been reported in up to 38% and 78% of the DS population [18, 111], which can be 
conductive, sensorineural or mixed. Around 38% of children younger than 12 months and 80% of 
children aged 5–12 years have vision problems, with refractive errors, strabismus and nystagmus 
being the most frequent. Hypothyroidism frequency also increases with age, and it has been shown 
to be as high as 50%–75% in some studies [114].  
In general, children with DS have more neurobehavioural and psychiatric problems than the general 
population. The most frequent problems are disruptive behaviour disorders, such as attention deficit 
hyperactivity disorder, conduct/oppositional disorder, aggressive behaviour and obsessive–com-
pulsive disorders [18, 111]. One recent study showed that the prevalence of attention deficit hyper-
activity disorder can be as high as 43.9% [115]. More than 20% of adults have been found to have 
a psychiatric disorders, most frequently aggressive behaviour or depression disorders [116]. Autism 
or autism spectrum disorders have been noted in DS children (7%) [18]. 
Disorders such as leukaemia and epilepsy also occur more frequently among DS children than in 
the general population. A systematic review found that the pooled estimate for epilepsy was 12.4% 
[117]. Whilst solid tumours are rare, the cumulative risk of leukaemia is 2% by the age of 5 years 
and 2.7% by the age of 30 years [118]. Other related comorbidities include skin disorders, airway 
anomalies, juvenile rheumatoid arthritis, diabetes mellitus and sleep apnoea. 
DS predisposes to premature ageing, and adults are commonly affected with chronic conditions 
resembling those of the geriatric population. Common conditions encountered in adults with DS 
include Alzheimer disease, epilepsy, mood and behavioural disorders, osteoarthritis and autoim-
mune diseases, such as thyroiditis and coeliac disease [19]. Histological changes in the central 
nervous system resemble those of Alzheimer disease, and according to recent data, it is more than 
80% may experience dementia by the age of 65 years [119]. 
Because of the different medical problems, assessment, monitoring, prevention and guidance is 
recommended from birth [18, 21]. The high prevalence of associated disorders requires lifetime 
care and individualised treatment plans for children and adults. 
Edwards syndrome and Patau syndrome 
These two syndromes are characterised by prenatal growth deficiency, special craniofacial features, 
major and minor anomalies and marked psychomotor and cognitive development delay. Most of 
the children have feeding difficulties and require nasogastric/nasojejunal feeding in the neonatal 
period or placement of a gastrostomy tube in older children. Most also have major malformations, 
which can affect different organs. Among 468 live borns with T18 registered in 16 European coun-
tries (2000–2011), 80% had cardiac anomalies, 21% had nervous system anomalies, 8% had 
oesophageal atresia and 10% had an orofacial cleft. Among 240 T13 live-born babies, 57% had a 
cardiac anomaly, 39% had a nervous system anomaly, 30% had an eye anomaly, 44% had poly-
dactyly and 45% had an orofacial cleft [120].  
Although little follow-up information is available, it has been reported that mental delay ranges from 
marked to profound. Most individuals do not achieve expressive language or walk independently. 
Whilst development age in older children is around 6–8 months, older children have some skills of 
older children, including sleeping independently, self-feeding, imitating, using a few words/signs, 
following simple commands and understanding a cause and effect [121]. 
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[A0006] – What are the consequences of chromosomal aneuploidies for society? 
Down syndrome 
DS is an important health issue since those born with this condition have special medical, social 
and educational needs. Taking into account that around 5.1 million children are born in the EU-28 
annually (EUROSTAT fertility statistics), it is be estimated that approximately 5000 DS infants would 
be born each year, assuming a live birth prevalence of 1 per 1000. These infants will require in 
many cases early medical support and surgical interventions during childhood.  
The key role of the parents is recognised in children with special needs and can require a lot of  
parental time and resources. In a longitudinal cohort study performed in the UK, which included 138 
adults with DS, only eight (4.3%) lived independently, 54.3% lived with a family carer and the rest 
had paid carer support [116]. Although information regarding abandonment of children with DS at 
birth is practically nonexistent, a follow-up study conducted in France in 1995 found that 12% of 
children born with DS were placed for adoption [122].  
Edwards syndrome and Patau syndrome 
The rarity and low survival of patients beyond 1 year have resulted in a very low number of affected 
patients.  
 
Current clinical management of the disease or health condition 
[A0024] – How are chromosomal aneuploidies currently screened  
and diagnosed according to published guidelines and in practice? 
Whilst there is consensus that all pregnant women should be offered aneuploidy screening and 
diagnostic testing, recommendations regarding screening tests differ widely, and significant differ-
ences exist regarding the screening and diagnostic strategies adopted among the different Euro-
pean countries. A range of maternal serum biochemical and fetal ultrasound biomarkers are avail-
able for establishing aneuploidy risks, and these are being offered during the first, second and/or 
third trimester with different screening protocols [7, 9].  
Published guidelines propose that NIPT could be offered as a primary method, secondary to a high-
risk value calculated on the basis of combined screening, or contingently to women ascertained as 
having high or intermediate risk by conventional screening. Guidelines highlight the limitations of 
these tests for the detection of other relevant chromosomal aberrations which might be present in 
the fetus. Some guidelines recommend that women who have a no-call result with NIPT should also 
be offered comprehensive ultrasound evaluation and diagnostic testing because of the increased 
risk of aneuploidy [38]. For more explicit information regarding NIPT recommendations, see Table 
A1 in Appendix 1.  
Most countries offer a second-trimester ultrasound examination for dating, growth and detection of 
severe structural defects. Ultrasonographic markers can identify other disorders, and various mark-
ers are also associated with T21, T18 and T13. Prenatal cytogenetic diagnosis (amniocentesis or 
CVS) is recommended for women who have high risk of DS\chromosomal defects, with independ-
ence of the screening tests used to determine this risk. Many countries also offer these tests for 
other indications, including maternal age (range 35–40 years), previous child or fetus with a chro-
mosomal anomaly or a monogenetic disease, family history of DNA anomaly or metabolic disorders, 
fetal major structural anomalies or soft markers detected by prenatal ultrasound examination.  
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[A0025] – How are chromosomal aneuploidy pregnancies  
currently managed according to published guidelines and in practice? 
In most European countries, combined first-trimester screening is offered to all pregnant women in 
the form of national or regional population screening programmes, although there are some coun-
tries, such as Ireland, Austria and Malta, which still have no official prenatal screening policies [23]. 
Screening is a voluntary informed patient choice, with shared decision making. Currently, women 
who test above a predetermined high-risk cut-off value receive genetic counselling and are given 
the choice of no further screening or invasive testing (amniocentesis or CVS). In Europe, the threshold 
frequently used to define high risk is 1 in 250 to 1 in 300, although this might differ between coun-
tries. Guidelines recommend no further testing for low-risk patients. If contingency screening is avail-
able, the moderate-risk group will be offered second-trimester screening, although this threshold is 
not standardised in most countries.  
Women opting to undergo diagnostic invasive testing receive pretest counselling and information 
as there is a risk of miscarriage associated with these procedures. If a chromosomal aneuploidy is 
diagnosed, further counselling is offered and women can opt for termination. In some countries 
termination of pregnancy is illegal.  
 
Target population 
[A0007] – Who is the target population for prenatal aneuploidy screening? 
[A0023] – How many people belong to the target population for prenatal  
aneuploidy screening? 
As far as authorisation is concerned, the target population is all pregnant women who will accept 
prenatal screening for T21, T18 and T13. This would mean that around 5.1 million women would 
be possible candidates for NIPT in the EU-28 (EUROSTAT fertility statistics) [24]. However, the pre-
cise target population is difficult to estimate because it will vary substantially depending on differ-
ent issues, including whether the pregnant women wants to undergo screening, if NIPT will be used 
as a first- or second-tier test or on the risk threshold used. 
 
[A0011] – How much is NIPT used?  
The uptake of NIPT-based prenatal screening is relatively unknown.  
 
4.3 Discussion 
The existing literature shows that the options for prenatal screening differ widely among European 
countries, highlighting that the degree of uptake and use can differ substantially depending on the 
country or even the region. Among the possible factors that could be responsible for these differ-
ences are the availability of resources, the degree of medicalisation, the termination of pregnancy 
laws and social and cultural factors [23, 100]. These factors are viewed to be determinants of how 
screening is offered, perceived and used and should be reflected on when one is analysing the 
potential application of NIPT in different contexts. 
Current guidelines/position statements consider that NIPT is appropriate for T21, T18 and T13 
screening, but there is no common agreement regarding the best clinical care pathway (first- or 
second-tier test), the complementary tests or the threshold of risk used to define which women 
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would undergo NIPT or the management of “no-call” results, among other issues. Most guidelines 
focus on appropriate use of NIPT, but fail to provide firm recommendations on the best alternative 
screening option, highlighting once again the great uncertainties that remain regarding the best  
choice. There is widespread agreement that NIPT is not yet ready to replace invasive diagnostic 
tests because of its limitations. It is also acknowledged that the value of NIPT can be substantially 
different for T21 than for T18 and T13 because the sensitivity and specificity can be lower and these 
last two trisomies can be detected by ultrasonographic findings in more than 90% of fetuses.  
Whilst it is commonly accepted that women should have the opportunity to receive the best possible 
estimate of their personal risk for common chromosomal anomalies so to allow an informed choice 
to be made, there are many ongoing debates regarding the advantages and disadvantages of ex-
isting screening strategies. Currently, robust analyses are lacking regarding the performance and 
outcomes of the different existing approaches. Current reviews and meta-analyses commonly tend 
to focus only on the accuracy of the tests for detecting the specific trisomies, providing insufficient 
documentation of overall effectiveness of the screening, which would be important, especially from 
the point of view of deciding which strategy should be offered as a public health programme. It 
should be taken into account that since prenatal screening is a morally sensitive practice because 
of its connection with abortion [93], establishing the benefits and harms of the different alternatives 
can be highly challenging. It is important to note that countries might weight the aspects differently, 
and that even if most agree with the choices made by the experts of what could constitute potentially 
relevant outcomes not all have the same healthcare priorities. For example, some countries might 
wish to prioritise the whole detection rate, whilst others might only want to prioritise the minimisation 
of the risk of miscarriage [91]. 
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5 CLINICAL EFFECTIVENESS 
5.1 Research questions 
Element ID Research question 
D0024 What is the accuracy of NIPT versus the reference standard? 
D1002 How does NIPT screening compare with other optional screening approaches  
in terms of accuracy measures? 
D1006 Does the test reliably rule in or rule out chromosomal aneuploidies? 
D1007 How does the accuracy of NIPT differ in different settings? 
D0001 What is the expected beneficial effect of prenatal screening with NIPT  
on neonatal mortality? 
D0005 How does prenatal screening with NIPT affect the frequency of newborns  
with aneuploidies? 
D0006 How does prenatal screening with NIPT affect the progression of pregnancy? 
D0012 What is the effect of NIPT on mothers’ health-related quality of life? 
D0030 Does the knowledge of the NIPT results affect the population’s non-health-related 
quality of life? 
D0017 Was the population satisfied with NIPT? 
D0020 Does the use of NIPT lead to improved detection of chromosomal aneuploidies? 
D0021 How does NIPT change physicians’ management decisions? 
D0022 Does NIPT detect other potential health conditions that can impact the 
subsequent management decisions? 
D0010 How does the technology modify the need for hospitalisation? 
D0029 What are the overall benefits and harms of NIPT in terms of health outcomes? 
 
5.2 Included studies 
5.2.1 NIPT as a primary screening test for the general singleton pregnancy population 
(total replacement of FCT) 
Study characteristics 
The systematic review retrieved eight studies which assessed prenatal screening based on NIPT 
as a primary testing method in the general singleton population (five comparative studies, i.e., NIPT 
vs. combined serum screening, and four DTA studies). One study considered only women whose 
health records were available [30], another included only women with known results [43] and an-
other restricted NIPT to samples verified by invasive testing [44]. Zhang et al. [43] included cases 
where NIPT had been offered either as primary or as secondary screening. Comas et al. [40] also 
included a small percentage of patients who had already been defined as high risk by FCT (16.5%). 
Song et al. [45] included only women younger than 35 years. The sample size of the eligible studies 
ranged from 324 to 146,958 women. 
The mean gestational age of the women ranged from around 12 weeks to 20.3 weeks. Five of the 
studies included patients screened during the first or second trimester. Only one enrolled women 
exclusively undergoing FCT. All but two exclusively assessed singleton pregnancies. In these studies 
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[43, 44] only 0.2%–0.36% of the included women had twin pregnancies. The studies included nat-
urally conceived pregnancies and pregnancies conceived by assisted reproductive technology 
(ART), with these ranging from 0.8% to 17% in the studies included. Norton et al. [31] and Per-
gament et al. [44] excluded IVF with user donor oocytes. 
Of the nine studies included, four used the Harmony® prenatal test (Ariosa Diagnostics Inc., San 
Jose, CA, USA) (SNP), one used the Panorama test (Natera, San Carlos, CA, USA), one used the 
Harmony® test and the Panorama test, one used Verifi™ (Illumina Inc. San Diego, CA, USA), one 
used the NIFTYTM test (BGI Diagnostics, China) and one used BambniTest (Berry Genomics, 
China). Three of the studies indicated that they performed a blinded analysis of the index test and 
reference standard [30, 31, 44]. Confirmation of outcomes was done by invasive testing (amniocen-
tesis or CVS), telephone contact, clinical history or neonatal examination. Only one of the studies 
verified miscarriages, terminations and stillbirths [44]. Three offered verification data for test failures, 
although this was not taken into account for diagnostic accuracy assessment.  
The comparators in the five general population studies differed widely, as did the cut -off points 
used to consider patients at high risk. The comparator in three studies was FCT [31, 41, 42], in one 
study it was first and second serum biochemical assays with or without NT assessment [30] and in 
the final study it was triple serum screening in the second trimester [45]. The cut-off point used by 
Norton et al. [31] to define high risk was 1 in 270 for T21 and 1 in 150 for T18 and T13. In the other 
two studies, patients were classified as high risk if the estimated risk was 1 in 100 [41, 42].  
In one of the studies the comparator was FCT, quadruple screening or combined first- and second-
trimester screening (serum integrated, sequential combined screening) [30].  
 
Risk of bias and QoE 
All of the studies which assessed NIPT as a primary testing method were judged “at risk of bias” 
and/or as having “concerns regarding applicability”. Eight of the nine the studies (88.9%) were  
judged to have a high risk of bias for the flow and timing domain because of the great number of 
women excluded from the analysis (no-call results or lack of reference standard results). The refer-
ence standard used for verification of negative cases was also considered to have an unclear or 
high risk of bias in eight of the nine studies (i.e., databases, telephone contact). The index test risk 
of bias was unclear because of nonblinded interpretation of NIPT and/or nonreporting of NIPT anal-
ysis (33%; three of the nine studies).  
High or unclear concern regarding the applicability in the patient selection was identified in seven 
of the nine studies (77.8%) because of the restricted enrolment of patients. Almost all studies had 
a low concern regarding applicability for the index test and reference standard domain (Figure 2 
and Figure 3). 
Evidence assessment of individual studies can be reviewed in Appendix 1 (Table A8).  
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Figure 2: Risk of bias assessed by the QUADAS-2 tool for noninvasive prenatal testing  
as a primary testing method in singleton pregnancies 
 
Figure 3: Concern regarding applicability of the use of the QUADAS-2 tool for noninvasive 
prenatal testing as a primary testing method in singleton pregnancies 
According to the GRADE approach, the DTA studies provide moderate QoE for T21 sensitivity  
and low-quality evidence for specificity because of the serious risk of bias in the reference standard 
and flow and timing domain of most studies. The QoE for T18 and T13 was low/very low for 
sensitivity and specificity because of the sparse cases, high risk of bias and/or imprecision of the 
estimates. Tables of GRADE assessment can be found in Appendix 1 (Tables A9–A12). 
 
5.2.2 NIPT as an add-on to FCT for the high risk singleton pregnancy population 
Study characteristics 
None of the studies included fulfilled the inclusion criteria but 26 studies which assessed the per-
formance of NIPT in the high-risk singleton pregnancy population were retrieved for indirect assess-
ment of outcomes. The population in these 26 DTA studies (cross-sectional design) ranged be-
tween 41 and 7740 patients. Two studies included singleton and twin pregnancies but twin preg-
nancies accounted for less than 2% of the patients included in these studies [54, 58]. All studies 
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included women who had been screened during the first and second trimesters. The mean gesta-
tional age of the enrolled women ranged from around 11 to 21 weeks. The mean maternal age 
ranged from 31 to 37 years. 
The high-risk classification was done on the basis of first- and second-trimester screening and/or 
other individual risk factors, including abnormal serum screening findings, advanced maternal age, 
family history of chromosomal anomaly, previous aneuploid pregnancy, sonographic markers or 
ultrasound anomalies. Advanced maternal age was the main or only indication for NIPT in seven 
studies [46, 52, 57, 61-63, 70]. NIPT was predominantly indicated on the basis of FCT results in 
five studies [48, 49, 60, 66]. The threshold for high-risk classification in these studies ranged from 
1 in 200 to 1 in 300. Several studies included women with anxiety, not suitable for invasive tests, or 
who just wished to have NIPT for other reasons [50, 52, 60-63, 67, 68, 70]. The proportion of women 
with no risk indication was 15% or less in all studies. 
Four of the 25 studies used the Harmony® prenatal test (Ariosa Diagnostics Inc., San Jose, CA, 
USA) [52, 63, 67, 69].  The rest of studies used the WGS method. Four specified using the Pano-
rama test or sending samples to Natera (San Carlos, CA, USA) [49, 56, 60, 66], one offered Pano-
rama and Prendia (Genesupport, Switzerland) [123], two reported usuing MaterniT 21 or sending 
samples to Sequenom Laboratories [55, 70], two used the Verifi™ test (Illumina Inc., San Diego, 
CA, USA) [50, 68], one sent samples to LifeCodexx [62], three sent samplers to Berry Genomics 
[57, 58, 65] and two sent samples to BGI Laboratories in China [47, 64]. Eight other studies per-
formed in-house testing using WGS methods; five used Illumina sequencing platforms [48, 50, 61] 
and two used the Ion PGM and the Torrent™ Personal Genome Machine™ (PGM) System (Life 
Technologies, CA, USA) [46, 59]. Three other NIPT-based studies reported that NIPT was per-
formed by Berry Genomics, China [57, 58, 65], and one study sent samples to LabGenomics Clin-
ical Laboratory (Korea) [54]. Three studies failed to report the testing method [53, 64, 67]. Twelve 
studies reported that NIPT was blinded to reference standard results [46, 50, 54, 57, 61, 62, 64, 65, 
68-70]. 
The reference standard (full karyotyping results obtained with CVS or amniocentesis) was per-
formed in all pregnancies in 18 of the 27 studies [46-49, 54, 57, 59, 61, 62, 65-70, 123].  In the rest, 
invasive testing was used only for verification of positive cases; negative cases were verified by 
follow-up.  
 
Risk of bias and QoE 
All but two of the studies [68, 70] on the high-risk pregnant population were judged “at risk of bias” 
and/or as having “concerns regarding applicability” (one or more domains were judged as “high” or 
“unclear”). Twenty of the 25 studies (80%) had a high or uncertain risk of bias in the flow and timing 
domain. With respect to the reference standard, 11 of the 25 studies (36%) had an unclear or high 
risk of bias. The proportion of studies with uncertain/high risk of bias in the index domain rose to 
approximately 16% (4 of 25). Twenty-one studies had an unclear or high risk of bias with respect to 
the patient selection domain (Figure 4).  
With regard to applicability, almost all studies had a low concern for the index test and reference 
standard domains. However, 19 of the 25 studies (76%) had an unclear/high concern regarding 
applicability for the patient selection domain because of of the uncertainties regarding patient en-
rolment (Figure 5).  
Evidence assessment of individual studies can be reviewed in Appendix 1 (Table A8).  
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Figure 4: Risk of bias assessed by the QUADAS-2 tool for noninvasive prenatal testing  
in women with high-risk singleton pregnancies 
 
Figure 5: Concern regarding applicability of the use of the QUADAS-2 tool for noninvasive 
prenatal testing in women with high-risk singleton pregnancies 
According to the GRADE approach, the QoE of NIPT accuracy for T21 was moderate for sensitivity 
and low for specificity as all studies were judged “at risk of bias” or as having “concerns regarding 
of applicability”. However, for T18 and T13, the QoE was low or even very low because of the 
presence of risk of bias, publication bias and/or imprecision of sensitivity estimations. Tables of 
GRADE assessment can be found in Appendix 1 (Tables A9–A12). 
 
5.2.3 NIPT as an add-on to FCT for the high-and intermediate-risk  
singleton pregnancy population 
The only DTA study [71] which focused on high-and intermediate-risk population (risk of 1 in 2500) 
reported on 4012 women with singleton pregnancies who had undergone contingent NIPT (com-
bined serum screening during 11–13 weeks’ gestation followed by NIPT). The risk of 1 in 100 or 
greater was selected to define the high-risk group. This group was offered the options of CVS, NIPT 
or no testing. The risk of 1 in 2500 was chosen to select patients who would be offered the options 
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of NIPT or no testing. Following combined testing, 3552 cases were classified as high and interme-
diate risk and 460 as high risk. NIPT was done with the Harmony® prenatal test (Ariosa Diagnostics 
Inc., San Jose, CA, USA) in 3698 cases (i.e., 3246 high risk and 276 intermediate risk). Invasive 
testing was performed in 2.7% of the study population. The median maternal age of high- and in-
termediate-risk women was 36.1 and 34.8 years, respectively. 
 
Risk of bias and QoE 
This study had a high risk of bias for the flow and timing domain. Regarding applicability, low con-
cern was identified in the index test and reference standard domains. Evidence assessment of  
individual studies can be found in Appendix 1 (Table A8). 
According to the GRADE approach, the only DTA study performed in the high- or intermediate-risk 
pregnant population showed a moderate QoE of NIPT sensitivity and specificity for T21. The QoE 
of NIPT for T18 and T13 sensitivity was low because of high imprecision of pooled sensitivity, whilst 
NIPT specificity was moderate for these trisomies. Tables of GRADE assessment can be found in 
Appendix 1 (Tables A9–A12).  
 
5.2.4 NIPT as an add-on to FCT for the high risk population twin pregnancy population 
The six DTA studies (cross-sectional design) which reported on twin pregnancies had samples 
size which ranged from 12 to 565 patients. Sarno et al. [39] included singleton and twin pregnan-
cies, but only twin pregnancies are taken into account in this section. One of the studies enrolled 
pregnant women from the general population, with or without prior screening results, who were 
prospectively tested by NIPT after ART treatment [73] and the other four assessed women for whom 
NIPT was indicated because of high risk. The indication for screening in this last group was based 
on advanced age, abnormal ultrasound findings, previous affected pregnancy or positive  serum 
screening (n=1) [72]; abnormal serum screening, sonographic markers or anxiety (n=1) [75]; prior 
first- and second-trimester combined screening or ultrasound examination (n=1) [74]; and positive 
traditional screening results and decision not to have invasive testing (n=1) [76]. In two of the studies 
[74, 75] 53%–58% of the patients had also undergone ART treatment. In the four studies which 
reported on chorionicity, more than 80% of twins were dichorionic diamniotic. 
The median maternal age of enrolled women ranged from 29.8 to 36.8 years. Although all of the 
studies included first- and second-trimester pregnancies, the median gestational age was around 
12–13 weeks in all but one of the studies [75], indicating that most of the patients were analysed 
during the first trimester. 
One of the studies used the Harmony® prenatal test (Ariosa Diagnostics Inc., San Jose, CA, USA) 
[74]. The rest were based on WGS; three used BGI technology [73, 75, 76] and one used the 
Verifi™ test (Illumina Inc., San Diego, CA, USA) [72]. 
Huang et al. [75] confirmed all results with karyotyping. Tan et al. [73] used karyotyping to confirm 
positive cases and obtained clinical outcomes of negative cases from telephone interview 1 month 
after delivery. The rest confirmed cases by invasive diagnostic procedures and newborn testing/ 
physical examinations. Fosler et al. [72] also considered ultrasound evaluations for verification pur-
poses. 
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Risk of bias and QoE  
All studies but one performed in the twin pregnancy population were judged “at risk of bias” and/or 
as having “concerns regarding applicability” (one or more domains were judged “high” or “unclear”) 
[75]. As can be observed in Figure 6, five of the six studies (83%) had a low risk of bias for the index 
test. Four studies (66.7%) showed a high or unclear risk of bias due to the reference standard 
domain as neonatal examination was used as the reference standard in negative NIPT cases and 
ultrasound findings were used as the reference standard for all NIPT cases. Most of the studies 
included had high risk of bias due to flow and timing, mainly due to cases excluded from the analy-
sis.  
All studies had a low concern regarding applicability for the reference standard and index test. With 
respect to the patient selection domain, three studies had high concern for different reasons; that 
is, 100% of pregnant women included had a pregnancy by ART, opted to have invasive testing 
included or NIPT indications do not match the review question (Figure 7).  
Evidence assessment of individual studies can be found in Appendix 1 (Table A8). 
 
Figure 6: Risk of bias assessed by the QUADAS-2 tool for noninvasive prenatal testing in 
women with high-risk twin pregnancies 
 
Figure 7: Concern regarding applicability of the use of the QUADAS-2 tool for twin 
pregnancy population studies 
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According to the GRADE approach, the DTA studies performed in the twin pregnancy population 
showed a low QoE of NIPT specificity for T21 because of scarce data and the presence of the risk 
of bias. The QoE of NIPT sensitivity was very low because of high imprecision of pooled sensitivity. 
Tables of GRADE assessment can be found in Appendix 1 (Tables A9–A12).  
 
5.3 Test accuracy 
[D0024] – What is the accuracy of NIPT versus the reference standard? 
As described already, the accuracy of NIPT was evaluated through sensitivity, specificity, PPV and 
NPV of the test for each trisomy. NIPT accuracy was analysed separately for each type of interven-
tion considered in the assessment. Whenever possible, a meta-analysis was performed by risk 
group for each type of aneuploidy and for all three types of aneuploidy together.  
 
5.3.1 NIPT as a primary screening test for the general singleton pregnancy population 
5.3.1.1 NIPT accuracy for T21 
Sensitivity and specificity values 
The DTA for NIPT as a primary testing method for T21 was based on eight studies (five comparative 
studies, i.e., NIPT vs. combined serum screening, and three DTA studies) involving 136,544 preg-
nant women (885 aneuploidy and 135,659 euploidy cases). The sensitivity and specificity provided, 
excluding miscarriages, fetal losses and no-call results, was more than 99.9% in all studies included 
(Table 6). Three of the studies [31, 42, 44] provided data on no-call results, showing eight missed 
cases (among 85 cases), two missed cases (among 51 cases) and three missed cases (among 488 
cases) among these women. The sensitivity and specificity were recalculated in these three studies 
on the basis of two hypotheses: (1) considering no result cases as positive cases or (2) considering 
no result cases as negative cases. Under the first hypothesis, sensitivity did not change and thus 
remained at 100% but the specificity decreased from 99.9%–100% to around 92%–97%. Under 
the second scenario, specificity was unchanged but sensitivity decrease from 100% to around 
89%–94%. 
The meta-analysis of DTA, excluding miscarriages, fetal losses and no-call results, computed with 
a bivariate random-effect model yielded a pooled estimate of sensitivity of 99.3% (95% CI 97.8%–
99.8%) and specificity of 99.9% (95% CI 99.8%–99.9%) (Figure 8). Because the model was unsta-
ble because of the low variability in sensitivity and specificity (studies reporting 100% sensitivity and 
specificity) caused by the great number of zeros in the contingency tables, two independent uni-
variate random-effects meta-analyses were applied to support the results obtained with the bivariate 
model, showing similar results. The sensitivity and specificity found with the univariate model were 
99.3% (95% CI 98.4%–99.7%) and 99.9% (95% CI 99.8%–99.9%), respectively. The prediction 
ellipses of the HSROC curves provided no information because all studies generated estimates in 
the upper left corner. The HSROC curves and other endpoints of interest obtained with bivariate 
meta-analysis (i.e., DOR, LR+, and LR–) can be found in Appendix 4 (Table A16 and Figure A1).  
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Figure 8: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing  
for trisomy 21 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
PPV and NPV 
The PPV in the studies included ranged between 80% to 100%, except in the study of Bianchi et 
al. [30], which reported a PPV of 45.5%. The NPV was more than 99% in all studies included in 
the assessment when no-call results were excluded. When no result cases were considered as 
positive, the NPV remained unchanged but the PPV decreased from 80.9% to 7.66% in the study 
of Norton et al. In the studies of Quezada et al. [42] and Pergament et al. [44] the PPV would be 
lowered from 96.9% to 40.7% and from 100% to 46%, respectively. If no results were classified as 
low risk, the PPV would not be altered in the study of Pergament et al [44] but would vary from 
100% to 99.2% in the second case. 
5.3.1.2 NIPT accuracy for T18 
Sensitivity and specificity values 
Seven of the studies included (five comparative studies, i.e., NIPT vs. combined screening, and two 
DTA studies) which assessed the general population evaluated T18 (234 T18 cases and 135,405 
euploidy cases). The sensitivity found in these individual studies, excluding miscarriages, follow-up 
losses and no-call results, ranged from 89.1% to 100% (Table 6). Specificity ranged from 99.8% to 
100%. Two [31, 44] of the three [31, 42, 44] studies which performed a confirmation of aneuploidy 
states for pregnancies with no-call results found missed cases in 5.9% (5/85) and 0.2% (1/488) of 
the no-recall samples, respectively. The rate of missed cases in these no-call result samples was 
5.6% (5/8) and 0.2% (1/488), respectively. When sensitivity and specificity were recalculated in 
these two studies taking into account these missed cases and assuming that no-call results would 
be treated as negative cases, sensitivity would decrease from 90% to 81.8% and from 96% to 
75.7%, respectively. Specificity would not be influenced under this scenario. If no-call results were 
considered as positive cases, sensitivity would remain unchanged but specificity would decrease 
from 100% to 97% and from 99.9% to 92.2%, respectively.  
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The meta-analysis pooled estimate of sensitivity, excluding miscarriages, fetal losses and no-call 
results, calculated on the basis of the bivariate random-effects model was 97.4% (95% CI 94.4%–
98.8%) and the specificity was 99.90% (95% CI 99.87%–99.97%) (Figure 9). However, the model 
gave unreliable parameter estimates because of sparse data and the low number of trisomy cases 
in comparison with nontrisomy cases. The correlation parameter between sensitivity and specificity 
logits was 0.009 (standard error 9.45, 95% CI –1 to 1). Similar results were observed when the 
univariate random-effects model was applied. Other endpoints of interest obtained with bivariate 
meta-analysis (i.e., DOR, LR+, LR– and HSROC curves) can be found in Appendix 4 (Table A16 
and Figure A1).  
 
Figure 9: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing  
for trisomy 18 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
PPV and NPV 
The PPV reported in individual studies ranged from 40% to 100%. The NPV of NIPT for T18 was 
more than 99.9% in all of the studies. The PPV in the study of Norton et al. [31] would decrease 
from 90% to 2% if it was recalculated taking into account no-call results as positive cases. In the 
study of Pergament et al. [44] it would decrease from 96.1% to 28.8%. The NPV would remain more 
than 99% in all studies. 
5.3.1.3 NIPT accuracy for T13 
Sensitivity and specificity 
Six studies (four comparative studies, i.e., NIPT vs. combined screening, and two DTA studies) 
which reported on 43 cases of T13 and 130,160 euploidy cases were included for assessment  
purposes. The sensitivity and specificity in these individual studies, calculated excluding no-call 
results and patients with no follow-up data, ranged form 40% to 100% and from 99.9% to 100%, 
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respectively. Two studies [31, 44] found missed cases of T13 among no-call results (2.3% and 
0.4%, respectively). Specificity would decrease in these studies from 100% to 95.8% and from 
100% to 91.9% if test accuracy was recalculated assuming that no-call results were treated as 
positive cases. If no-call results were to be considered as negative cases, sensitivity would de-
crease from 100% to 50% and 85%, respectively. 
When the bivariate random-effects model was applied, pooled sensitivity was estimated to be 
98.8% (95% CI 1.41%–100%) and specificity was 99.9% (95% CI 99.94%–99.97%) (Figure 10). 
The model was unstable because of the lack of variability between sensitivity and specificity and 
the great number of zeros in the accuracy contingency tables. The correlation parameter between 
logits of sensitivity and specificity approximated 1 and standard error CIs estimates could not be 
estimated. A univariate random-effects meta-analysis, performed to support the results obtained, 
equally showed great imprecision (sensitivity of 99.8%, 95% CI 3.49%–100%, and a pooled speci-
ficity of 99.9%, 95% CI 99.94%–99.97%). Other endpoints obtained with bivariate meta-analysis 
(i.e., DOR, LR+, LR– and HSROC curves) can be found in Appendix 4 (Table A16 and Figure A1).  
 
Figure 10: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing 
for trisomy 13 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
PPV and NPV 
The PPV calculated from the study results ranged between 32.8% and 50%, except in two studies 
[44, 45], which reported a rate of 100%. The NPV was more than 99% in all studies. The recalcu-
lated PPV considering no results as positive samples was 0.8% in the study of Norton et al. [31] 
and 14.4% in the study of Pergament et al. [44].The NPV was more than 99.8% in all cases. 
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Table 6: Characteristics and noninvasive prenatal testing accuracy results of individual studies retrieved for noninvasive prenatal testing  
as a primary testing method for the general singleton pregnancy population 
Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population 
characteristics 
Index test/ 
cut-off point 
Reference test(s) Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Sarno et al. [39], 
2016, UK 
Prospective DTA study 
Oct 2012–Aug 2015 
Singleton or twin 
pregnancy women at  
11 weeks’ gestation to 13 
weeks 6 days who received 
NIPT as an option following 
FCT or as part of routine 
screening 
10,530 Median maternal age 
(years): 36.3  
(33.2–39.3) 
Median GA (weeks): 
11.9 (10.6–12.9) 
Index test: 
Harmony 
prenatal test 
Cut-off point: 
>99% or 
<0.01% 
Overall: 100%  
(fetal karyotype) 
S=98.7 S=89.1 S=53.3 
Comas et al. [40], 
2015, Spain 
Prospective DTA study 
Jan–Dec 2013 
All singleton pregnancy 
women were offered NIPT 
in addition to FCT 
Exclusion criteria: cases 
with US anomalies or 
those at high risk for other 
conditions 
324 Median age (years): 
37 (21–46) 
Mean GA (weeks): 
14.6 (9.5–23.5) 
Mean BMI: 22.9 
(17.1–42.5) 
Index test: 
Panorama 
prenatal test 
Cut-off point: 
not reported 
Fetal karyotyping (n=5) 
and follow-up (n=310) 
S=100 (51–100) 
Sp=99.6 (98.3–99) 
PPV=80 (37.6–96.4) 
NPV=100 (98.8–100) 
— — 
Norton et al. [31], 
2015, USA, Canada, 
Sweden, Belgium, 
Netherlands and 
Italy  
Multicentre 
comparative 
prospective blinded 
DTA study 
Women aged>18 years. 
with a singleton pregnancy 
(10–14 weeks) 
Exclusion criteria: outside 
GA window, no standard 
screening result, maternal 
aneuploidy or cancer, 
donor oocyte conception, 
twin pregnancies or an 
empty gestational sac 
15,841 Median maternal age 
(years): 31 (18–48) 
Mean GA (weeks): 
12.5 (10.0–14.3) 
Pregnancy by ART: 
3.0% 
Index test: 
Harmony 
prenatal test 
Cut-off point: 
>1/100 
Genetic testing 
(amniocentesis,  
CVS or products of 
conception or newborn) 
(3.9% or 625/15,481) 
S=100 (90.7–100) 
Sp=99.9 (99.9–100) 
PPV=80.9 (66.7–90.9) 
NPV=100 (99.9–100) 
S=90.0 (55.5–99.7) 
Sp=100 (99.9–100) 
PPV=90.0 (55.5–99.7) 
NPV=100 (99.9–100) 
S=100 (15.8–100) 
Sp=100 (99.9–100) 
PPV=50 (6.8–93.2) 
NPV=100 (99.9–100) 
Pérez-Pedregosa et 
al. [41], 2015, Spain 
Comparative 
prospective DTA 
study 
Data collection period 
not reported 
Women with a singleton 
pregnancy of at least 10 
weeks’ gestation 
579 Median maternal age 
(years): 36.5 (22–47) 
Median GA (weeks): 
not reported 
Index test: 
Harmony 
prenatal test 
Cut-off point: 
>99% or 
<0.01% 
Overall: 100% 
Fetal karyotype 
(amniocentesis, CVS) 
in population with high-
risk 
Telephone contact in 
the rest of women 
S=100 (73.2–100) 
Sp=100 (99.1–100) 
PPV=100 (73.2–100) 
NPV=100 (99.1–100) 
S=100 (30.9–100) 
Sp=100 (99.1–100) 
PPV=100 (30.9–100) 
NPV=100 (99.1–100) 
— 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population 
characteristics 
Index test/ 
cut-off point 
Reference test(s) Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Quezada et al. [42], 
2015, UK 
Comparative 
prospective DTA study 
Oct 2012–Jan 2014 
Women with a singleton 
pregnancy and a live fetus 
2851 Median maternal age 
(years): 36.9  
(20.4–51.9) 
Median GA: 10 weeks 
4 days (10 weeks to 
11 weeks 6 days) 
Index test: 
Harmony 
prenatal test 
Cut-off point: 
>99% or 
<1/10,000 
Overall: 100% (n=2857) 
Fetal karyotype 
(amniocentesis, CVS  
or neonate blood) or 
neonate phenotype 
examination 
S=100 (89.3–100) 
Sp=99.9 (99.8–100) 
PPV=96.9 (84.7–99.5) 
NPV=100 (99.9–100) 
S=90.0 (59.6–98.2) 
Sp=99.8 (99.6–99.91) 
PPV=64.3 (38.3–83.7) 
NPV=99.9 (99.8–100) 
S=40.0 (11.8–76.9) 
Sp=99.9 (99.7–100) 
PPV=50.0 (15.0–85) 
NPV=99.9 (99.7–100) 
Zhang et al. [43], 
2015, China 
Multicentre prospective 
DTA study 
Jan 2012–Aug 2013 
Women aged>18 years 
with a singleton or twin 
pregnancy of at least  
9 weeks’ gestation 
112669 Median age (years): 
30.9 (18–46) 
Mean GA (weeks): 
18.7 (9–36) 
Index test: 
HiSeq2000 
(Illumina) 
Cut-off point: 
not reported 
Fetal karyotyping (68%, 
or 1055) and clinical 
follow-up (111,605) 
S=99.17 (98.52–99.83) 
Sp=99.95 (99.93–99.95) 
PPV=92.19 (90.31–94.07) 
NPV=99.9 (99.9–100) 
S=98.24 (94.93–99.63) 
Sp=99.95 (99.94–99.97) 
PPV=76.61 (70.99–82.23) 
NPV=100 (99.99–100) 
S=100 (84.56–100) 
Sp=99.96 (99.95–99.97) 
PPV=32.84 (21.59–44.08) 
NPV=100 (99.99–100) 
Bianchi et al. [30], 
2014, USA 
Multicentre com-
parative prospective 
blinded DTA study 
Jul 2012–Jan 2013 
Women aged>18 years 
with a singleton pregnancy 
of at least 8 weeks’ gesta-
tion who had planned to 
undergo or completed 
standard serum screening 
for fetal aneuploidies 
1952 Mean age (years): 
29.6±5.54 
Mean GA (weeks): 
20.3±8.6 
Index test: 
Verifi™ 
prenatal test 
Cut-off point: 
≥4.0 high risk; 
≤3.0 low risk 
Fetal karyotyping 
(amniocentesis, CVS, 
testing of products of 
conception and post-
natal evaluation) (n=57) 
Newborn physical 
examination (n=1857) 
S=100 (47.8–100) 
Sp=99.7 (99.3–99.9) 
PPV=45.5 (16.7–76.6) 
NPV=100 (99.8–100) 
S=100 (15.8–100) 
Sp=99.8 (99.6–100) 
PPV=40.0 (5.3–85.3) 
NPV=100 (99.8–100) 
S=100 (20.7–100) 
Sp=99.8 (99.5–99.9) 
PPV=25 (4.6–69.9) 
NPV=100 (99.8–100) 
Pergament et al. 
[44], 2014, USA 
Prospective DTA study 
Data collection period 
not reported 
Women aged>18 years with 
a singleton pregnancy of 
7weeks’ gestation and who 
provided signed consent 
Exclusion criteria: sex 
chromosome anomaly, 
triploid or fetal mosaicism 
966 Median age (years): 
30.0 (18–47) 
Mean GA (weeks): 
14.3 (7.6–40.6) 
Index test: 
NS (SNPs) 
Cut-off point: 
not reported 
Fetal karyotyping 
(amniocentesis, CVS or 
products of conception) 
or genetic testing of 
umbilical cord blood, 
buccal sample, saliva 
S=100 (93.8–100) 
Sp=100 (99.6–100) 
PPV=100 (93.8–100) 
NPV=100 (99.6–100) 
S=96 (79.7–99.9) 
Sp=99.9 (99.4–100) 
PPV=96.1 (79.7–99.9) 
NPV=99.9 (99.4–100) 
S=100 (75.7–100) 
Sp=100 (99.6–100) 
PPV=100 (75.7–100) 
NPV=100 (99.6–100) 
Song et al. [45], 
2013, China  
Comparative 
prospective DTA 
study 
Apr 2011–Dec 2011 
Pregnant women  
aged<35 years 
1741 Mean age (years): 
29.03±2.70 
Mean GA (weeks): 
16.57±1.56 
Pregnancy by ART: 
0.8% 
Index test: 
HiSeq2000 
(Illumina) 
Cut-off point: 
Z score≥3 
Fetal karyotyping 
(amniocentesis, CVS or 
cordocentesis(n=2017) 
Neonatal follow-up 
(n=1805) 
S=100 (59.8–100) 
Sp=100 (99.7–100) 
PPV=100 (59.8–100) 
NPV=100 (99.7–100) 
S=100 (19.79–100) 
Sp=99.9 (99.6–99.9) 
PPV=66.7 (20.8–93.1) 
NPV=100 (99.8–100) 
S=100 (5.5–100) 
Sp=100 (99.7–100) 
PPV=100 (5.5–100) 
NPV=100 (99.7–100) 
Abbreviations: ART=assisted reproductive technology; BMI=body mass index; CI=confidence interval; CVS=chorionic villus sampling; DTA=diagnostic test accuracy; FCT=first-trimester combined testing; 
GA=gestational age; NIPT=noninvasive prenatal testing; NPV=negative predictive value; NS=not specified; PPV=positive predictive value; S=sensitivity; SNP=single nucleotide polymorphism; 
Sp=specificity; US=ultrasound. 
a Number of samples with NIPT and reference standard results. 
b Calculations provided/based on study results (exclusion of low fetal fraction, uncertain results, test failures and miscarriages). 
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5.3.2 NIPT as an add-on to FCT for the high risk singleton pregnancy population 
There is lack of direct data regarding the accuracy of the prenatal strategy which includes NIPT as 
an add-on to the FCT. However, 27 DTA studies which assessed the performance of NIPT as a 
second-tier test in singleton women who had been classified as high risk of aneuploidy were in-
cluded to assess NIPT accuracy for indirect inferences and modelling. The individual characteristics 
and results of these individual studies are displayed in Table 7. 
5.3.2.1 Accuracy of NIPT for T21 as a second-tier test 
Sensitivity and specificity values 
The 24 studies which provided data on sensitivity and specificity involved 1408 aneuploidy cases 
and 99,818 euploidy cases. The reported sensitivity in these individual studies, excluding miscar-
riages, follow-up losses and no-call results, was 100% in all but five of the studies (94.2% in all 
cases). Specificity ranged from 99.7% to 100% (Table 7). One of the studies [49] which reported 
the trisomy status of cases among no-call results (n=10) found two missed cases (20%). If these 
cases were included in the analysis and no-call results were treated as positive samples, sensitivity 
would remain unchanged but specificity would decrease from 100% to 95.9%. If no results were 
considered as negative samples, specificity would be maintained but sensitivity would be reduced 
from 97.2% to 94.6%.  
The pooled sensitivity obtained when the bivariate random-effects model was applied was 99.2% 
(95% CI 98.59%–99.56%) and specificity reached 99.95% (95% CI 99.93%–99.96%). The model 
failed to converge because of the lack of variation between studies, and therefore two independent 
univariate random-effects meta-analyses were applied. The meta-analysis results showed a 
pooled sensitivity of 99.24% (95% CI 98.64%–99.58%) and a pooled specificity of 99.95% (95% CI 
99.93%–99.96%) (Figure 11).  
 
Figure 11: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing 
for trisomy 21 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
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The HSROC curves did not provide any information because once more all studies generated esti-
mates in the upper left corner. HSROC curves and other endpoints of interest obtained with bivari-
ate meta-analysis (i.e., DOR, LR+ and LR–) can be found in Appendix 4 (Table A16 and Figure 
A2). 
PPV and NPV 
Similarly to the results reported for the general population, in all studies in the population at high 
risk of aneuploidies, NIPT showed an NPV of more than 99%. When no-result studies were included 
and classified as negative cases, the calculated NPV in the study of Persico et al. [49] was 99.1%. 
The PPV was 100%, except in six studies, where it ranged from 93.5% to 98.8% [48, 51, 55, 61, 
64, 69]. The value recalculated in the study of Persico et al. [49] was 80%. 
5.3.2.2 NIPT accuracy for T18  
Sensitivity and specificity values 
The evidence for T18 was derived from 21 DTA studies on high-risk women which reported on 211 
T18 cases and 26,636 euploidy cases. The sensitivity calculated, excluding women with no-call 
results and follow-up losses ranged from 80% to 100% in all but one of the studies (40%). Specificity 
was 99.8% or greater in all studies (Table 7). Only one study [49] reported the trisomy status of 
cases with no test results, and the recalculation of diagnostic accuracy showed a reduction of spec-
ificity from 100% to 96.7% when these no-call results were considered positive; sensitivity did not 
change in this scenario. Specificity remained unchanged but sensitivity was 86.7% if the no-call 
results were considered negative.  
When the bivariate random-effects model was applied, pooled sensitivity was estimated to be 96.86% 
(95% CI 88.35%–99.21%) and pooled specificity was 99.97% (95% CI 99.93%–99.98%) (Figure 12).  
 
Figure 12: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing 
for trisomy 18 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
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The model was unreliable because of the lack of variability in the specificity and the great number 
of cells with zero values. Although the model did converge, the correlation parameter between sensi-
tivity and specificity logits was –1, and standard error and CIs could not be estimated. Therefore 
two independent univariate random-effects meta-analyses were performed to support the results 
obtained with the bivariate model. The pooled sensitivity was 96.6% (95% CI 88.35%–99.24%) 
and the pooled specificity was 99.97% (95% CI 99.94%–99.98%). Other endpoints of interest 
obtained with bivariate meta-analysis (i.e., DOR, LR+, LR– and HSROC curves) can be found in 
Appendix 4 (Table A16 and Figure A2).  
PPV and NPV 
NIPT showed an NPV for women with high risk of aneuploidies of more than 99%, except in the 
study of Lau et al. [68], where it was reported to be 94.2%. The PPV was 100% in most studies, 
although in seven studies it ranged between 66.7% and 95.6% [48, 51, 55, 57, 58, 62, 64, 69]. In 
the study of Persico et al. [49], the PPV decreased from 100% to 65.2% when no results were 
included as positive cases. Assuming the contrary, the NPV decreased from 100% to 99.2%. 
5.3.2.3 NIPT accuracy for T13 
Sensitivity and specificity values 
Sixteen DTA studies (63 T13 cases and 23,468 euploidy cases) provided sensitivity and specificity 
data. The sensitivity calculated, excluding women with no-call results, miscarriages and follow-up 
losses, ranged from 75% to 100%; 13 studies showed a sensitivity of 100%. In one study sensitivity 
was 0% because of the lack of positive cases [68] (Table 7). Specificity was 99.8% or greater in all 
studies (Table 7). Only one study [49] reported the trisomy status of cases with no test results, and 
the recalculation of diagnostic accuracy showed a reduction of specificity from 100% to 96.4% when 
these two missed cases were considered positive; sensitivity did not change under this assumption. 
The sensitivity reached 83.3% if the two missed cases were considered negative; there were no 
changes in specificity under this scenario. 
The bivariate random-effects model showed a pooled sensitivity of 97.67% (95% CI 59.68%–
99.91%) and a pooled specificity of 99.98% (95% CI 99.92%–99.99%) (Figure 13). The model 
was again relatively unstable, showing a correlation parameter between logits of sensitivity and 
specificity of –1. The pooled sensitivity estimated with the univariate random-effects model was 
95.81% (95% CI 47.59%–99.82%) and the pooled specificity was 99.98% (95% CI 99.91%–
99.99%). Other endpoints of interest obtained with bivariate meta-analysis (i.e., DOR, LR+, LR– 
and HSROC curves) can be found in Appendix 4 (Table A16 and Figure A2).  
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Figure 13: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing 
for trisomy 13 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
PPV and NPV 
The NPV of NIPT for T13 screening was more than 99% in all studies. The PPV differed substan-
tially between studies (50%–100%) (Table 7). The PPV was 0% in one study because of the lack 
of positive cases [68]. In the study of Persico et al. [49], the PPV would be reduced from 100% to 
40% if no-call results were included in the analysis as positive cases; the NPV would remain the 
same under this assumption. The NPV would decrease from 100% to 99.6% if no-call results were 
classified as negative cases; the PPV would not change.  
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Table 7: Characteristics and noninvasive prenatal testing accuracy of individual studies performed in the high-risk singleton pregnancy population 
Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population characteristics Index test/  
cut-off point 
Reference 
test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Kim et al. [46], 
2016, Korea 
Prospective DTA 
study 
Dec 2014–Apr 2015 
High-risk pregnant women  101 Mean maternal age (years.): 
35.5±3.63 
GA (weeks): 11–13 (69.3%), 
14–18 (30.7%) 
Indication: high risk by first-
trimester combined FTS tests 
or second-trimester quadruple 
screening 
Ion Torrent 
PGM 
Z score>2.07 
Proton 
platform 
(PGM) 
Z score>2.10 
Overall: 100% 
(IT) 
S=100 (47.8–100) 
Sp=100 (96.2–100) 
PPV=100 (47.8–100) 
NPV=100 (96.2–100) 
— — 
Ma et al. [47], 
2016, China 
Prospective DTA 
study (18 centres) 
Feb–May 2014 
Prospective samples of 
high-risk pregnant women 
Exclusion criteria: organ 
donation history or maternal 
chromosome anomaly 
2425 Median maternal age (years): 32 
Median GA (weeks): 19 (10–35) 
Indication: positive serum 
screening (49%); family history 
(4.74%), US markers (5.5%), 
other risk factors (29%), 
without risk (12%) 
BGI  
Z score>3 
Overall: 100% 
(karyotyping 
results) 
S=100 (90.8–100) 
Sp=99.8 (99.4–100) 
PPV=100 (90.8–100) 
NPV=100 (99.4–100) 
S=100 (60.3–100) 
Sp=100 (99.9–100) 
PPV=100 (60.3–100) 
NPV=100 (99.9–100) 
S=100 (2.5–100) 
Sp=100 (99.9–100) 
PPV=100 (2.5–100) 
NPV=100 (99.9–100) 
Oepkes et al. [48], 
2016, Netherlands 
Prospective DTA 
study, multicentre 
(8 centres) 
TRIDENT 
Apr–Sep 2014 
All high-risk pregnant 
women (FCT or medical 
history) 
Exclusion criteria: multiple 
pregnancies, vanishing 
twins, NT≥3.5mm, other 
structural or chromosome 
anomalies, GA<10 weeks, 
age<18 years 
1390 Mean maternal age (years): 
>36 (43%); >36 (51%); 
unknown (6%) 
GA (weeks): NS 
Indication: high risk by first-
trimester combined FTS risk 
(≥1:200) (87.1%); medical 
history (19.9%) 
Test: NS 
WGS (Illumina 
platform) 
Z score>3 or 
WISECONDOR 
algorithm 
Overall: 100%  
IT (80.9% 
positive cases); 
questionnaire 
after 
pregnancy/ 
birth (rest)  
S=96.7 (83.3–99.4) 
Sp=99.9 (99.5–100) 
PPV=93.5 (79.3–98.2) 
NPV=99.9 (99.6–100) 
S=100 (51–100) 
Sp=99.9 (99.6–100) 
PPV=80 (37.6–96.4) 
NPV=100 (99.7–100) 
S=100 (51–100) 
Sp=99.9 (99.5–100) 
PPV=66.7 (30–90.3) 
NPV=100 (99.7–100) 
Persico et al. [49], 
2016, Italy 
Prospective DTA 
study, multicentre 
(4 centres), blinded 
to IT results 
Consecutive pregnancies 
after first-trimester 
screening (11–13 weeks) 
with risk≥1:250 
249 Median maternal age (years): 
36 (20–46) 
GA (weeks): NS 
Indication: women defined as 
high risk by first trimester 
combined FTS tests (risk≥1:250) 
Panorama 
NATERA 
Cut-off: >100 
(genotypic 
information 
included) 
Overall: 100% 
(IT and US 
examination 
with additional 
genetic testing 
if required) 
S=97.2 (65.8–99.5) 
Sp=100 (98.2–100) 
PPV=100 (90.1–100) 
NPV=99.5 (97.4–99.9) 
S=100 (77.2–100) 
Sp=100 (98.4–100) 
PPV=100 (77.2–100) 
NPV=100 (98.4–100) 
S=100 (56.6–100) 
Sp=100 (98.4–100) 
PPV=100 (56.6–100) 
NPV=100 (98.4–100) 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population characteristics Index test/  
cut-off point 
Reference 
test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Zhang et al. [50], 
2016, China  
Prospective DTA 
study 
Jan 2012–Dec 
2013 
Inclusion criteria: age≥35 
years, singleton pregnancy, 
high risk of DS, elevated 
NT; structural anomalies 
in second-trimester 
screening, not suitable for 
IT, GA<12 weeks 
87 Mean maternal age (years): 
37.5±2.17 
Median GA (weeks): 19.0 
(12.4–32.5) 
Indication: serological positive 
screening (45.2%); sonography 
positive screening (16%) 
Test: NS 
WGS (Illumina 
platform) 
Z score>3 
Amniocentesis 
(24.1%), 
neonatal blood 
karyotyping 
(42.3%); 
follow-up 
examination 
of newborn 
(33.6%) 
S=100 (43.8–100) 
Sp=100 (95.6–100) 
PPV=100 (43.8–100) 
NPV=100 (95.6–100) 
S=100 (20.7–100) 
Sp=100 (95.7–100) 
PPV=100 (20.7–100) 
NPV=100 (95.7–100) 
— 
Benachi et al. 
[51], 2015, France 
Multicentre 
prospective DTA 
study 
Dec 2012–Oct 2013 
Singleton or twin pregnancy 
women aged>38 years, 
≥10 weeks’ gestation, 
family history of trisomy  
or positive FCT 
892 Mean maternal age (years): 35 
(30–39) 
Mean GA (weeks): 15.1  
(10.2–34.5) 
HiSeq1500 
Cut-off point: 
T21 3; T18 
and T13 3.95 
Overall: 100% 
(amniocentesis 
or CVS) 
S=100 (95.3–100) 
Sp=99.9 (99.3–100) 
PPV=98.7 (93.0–99.8) 
NPV=100 (99.5–100) 
S=88.0 (68.8–97.5) 
Sp=99.9 (99.4–100) 
PPV=95.6 (79.0–99.2) 
NPV=99.6 (99.0–99.9) 
S=100 (73.5–100) 
Sp=99.9 (99.4–100) 
PPV=92.3 (66.7–98.6) 
NPV=100 (99.6–100) 
Hernandez-
Gomez et al. [52] 
2015, Mexico 
Prospective, DTA 
study  
Aug 2013–Jan 
2015 
Women who requested 
testing 
Exclusion of women with 
US markers of 
chromosomepathy 
42 Mean age (years): 37.1 (23–46) 
Mean GA (weeks): 13.3  
(10–18.6) 
Indications: advanced maternal 
age, positive serum screening 
(71.4%), clinician’s decision 
(14%), positive FCT (7%), 
anxiety due to fetal loss or 
chromosome X (7%) 
Harmony 
prenatal test 
(DANSR® and 
FORTE) 
>99% or 
<0.01% 
IT (50% of 
positive cases 
Results 
confirmed at 
birth (100%  
of negative 
cases) 
S=100 (34.2–100) 
Sp=100 (90.6–100) 
PPV=100 (34.2–100) 
NPV=100 (90.6–100) 
— — 
Ke et al. [53], 
2015, China 
Prospective DTA 
study 
Mar 2012–May 2013 
Singleton pregnancy 
women with high risk of 
aneuploidies, i.e., aged 
≥35 years, aneuploidy 
history or abnormal serum 
screening or abnormal US 
findings 
2340 Maternal age (years): 2061 
women 35 and 279 women 
≥35 
GA (weeks): 80 women at  
12–14, 2239 women at 15–20 
and 21 women at 24 
Indications: advanced maternal 
age (n=147), abnormal 
screening results or history of 
aneuploidies (n=1189) and 
abnormal US findings (n=74) 
Test: NS 
Cut-off point: 
not reported 
Karyotyping 
(24 positive 
NIPT cases) 
Neonatal 
follow-up 
(2316 negative 
NIPT cases) 
S=100 (81.6–100) 
Sp=100 (99.8–100) 
PPV=100 (81.6–100) 
NPV=100 (99.8–100) 
S=100 (61–100) 
Sp=100 (99.8–100) 
PPV=100 (61.0–100) 
NPV=100 (99.8–100) 
S=100 (20.7–100) 
Sp=100 (99.8–100) 
PPV=100 (20.7–100) 
NPV=100 (99.8–100) 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population characteristics Index test/  
cut-off point 
Reference 
test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Lee et al. [54], 
2015, Korea 
Prospective DTA 
study 
Aug 2014–Feb 2015 
Singleton or twin pregnancy 
women of at least 8 weeks’ 
gestation, aged≥35 years, 
positive serum screening/ 
US findings or history of 
aneuploidies  
92 Median maternal age (years): 32 
(21–43) 
Median GA (weeks): 21.2  
(8.2–31.1) 
Test: NS 
(LabGenomics 
Clinical 
Laboratory) 
Overall: 100% 
(amniocentesis, 
CVS,  
cordocentesis, 
neonatal pe-
ripheral blood 
or products of 
conception) 
S=100 (47.95–100) 
Sp=100 (95.8–100) 
PPV=100 
NPV=100 
S=100 (19.29–100) 
Sp=100 (95.94–100) 
PPV=100 
NPV=100 
S=100 
Sp=100 
PPV=100 
NPV=100 
Sago et al. [55], 
2015, Japan 
Prospective, 
multicentre DTA 
study (23 centres) 
Apr 2013–Mar 2014 
Women who requested 
NIPT, including those 
aged>35 years, US or 
positive serum screening 
findings, family history or 
parent Robertsonian 
translocation 
7740 Mean age (years): 38.3 (21–48) 
Mean GA (weeks): 13.3  
(10.0–19.9) 
MaterniT 
PLUS 
Karyotyping 
(88.7% of 
positive NIPT 
cases) 
Follow up 
(21.5% of neg-
ative cases) 
PPV=95.9 (70/73)  
for patients with IT 
PPV=81 (34/42)  
for patients with IT 
PPV=81.8 (9/11)  
for patients with IT 
Sánchez-
Usabiaga et al. 
[56], 2015, Mexico  
Prospective DTA 
study 
Mar 2013–Feb 
2015 
Singleton pregnancy 
woman aged≥35 years 
with maternal anxiety or 
positive FCT  
Exclusion criteria: multiple 
pregnancies by donor 
oocytes or surrogate 
mother, previous bone 
transplant or did not give 
consent informed 
266 Mean maternal age (years): 35 
(21–45) 
Mean GA (weeks): 11.85  
(9–26.3) 
Indications: advanced maternal 
age (n=114), maternal anxiety 
(n=84) and positive FCT 
(n=72) 
Test: NS 
SNPs 
Cut-off point: 
not reported 
Karyotyping 
(CVS or 
amniocentesis, 
6 positive 
NIPT cases) 
or neonatal 
examination at 
birth (78% of 
NIPT negative 
cases)  
S=100 (51.0–100) 
Sp=100 (98.5–100) 
PPV=100 (51.0–100) 
NPV=100 (98.5–100) 
S=100 (20.7–100) 
Sp=100 (98.5–100) 
PPV=100 (20.7–100) 
NPV=100 (98.5–100) 
S=100 (20.7–100) 
Sp=100 (98.5–100) 
PPV=100 (20.7–100) 
NPV=100 (98.5–100) 
Song et al. [57], 
2015, China 
Prospective DTA 
study, double blind 
May 2012–Aug 
2013 
Women arbitrarily 
presenting for NIPT 
Inclusion criteria:  
Age ≥35 years, singleton 
pregnancies, GA 8 weeks 
to 12 weeks 6 days 
212 Median maternal age (years): 
37.25 (35–45) 
Median GA: 9 weeks 6 days  
(8 weeks to 12 weeks 6 days) 
Pregnancy by ART: 6% 
Berry 
Genomics 
Z score>3 
Overall: 100% 
(karyotyping 
84%; clinical 
assessment 
26%) 
S=100 (19.79–100) 
Sp=100 (97.35–100) 
PPV=100 (19.79–100) 
NPV=100 (97.35–100) 
S=100 (5.46–100) 
Sp=100 (97.35–100) 
PPV=100 (5.46–100) 
NPV=100 (97.35–100) 
S=100 (5.46–100) 
Sp=100 (97.35–100) 
PPV=100 (5.46–100) 
NPV=100 (97.35–
100) 
Wang et al. [58], 
2015, China 
Prospective  
DTA study 
Jan 2013–Dec 
2013 
Women with abnormal 
results on FCT (56.8%), 
aged≥35 years (32.7%), 
adverse pregnancy history/ 
abnormal amniotic fluid 
volume (9.8%) or abnormal 
US findings (0.65%)  
917 Maternal age range (years): 
18–46 
GA range (weeks): 14–26 
Illumina 
HiSeq2000 
Cut-off point: 
not reported 
Overall: 100% 
(conventional 
karyotyping 
analysis or 
FISH and 
neonatal 
follow-up) 
S=100 (86.2–100) 
Sp=100 (99.6–100) 
PPV=100 (86.2–100) 
NPV=100 (99.6–100) 
S=100 (43.8–100) 
Sp=99.8 (99.4–100) 
PPV=75 (30.1–95.4) 
NPV=100 (99.6–100) 
— 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population characteristics Index test/  
cut-off point 
Reference 
test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Jeon et al. [59], 
2014, China  
Prospective  
DTA study 
Mar 2012–Oct 2013 
High-risk pregnant women 
scheduled for IT (aged≥19 
years, singleton 
pregnancy, ≥12 weeks’ 
gestation) 
155 Mean age (years): 30.7±4.99 
GA range (weeks): 12–16 (18%), 
17–21 (55.5%), ≥22 (26.5) 
Indications: high risk by first-
trimester combined FTS tests or 
second-trimester serum values 
alone or in combination with 
FTS 
Ion Proton™ 
system 
Cut-off point: 
T21 2.459; 
T18 2.566 
Overall: 100% 
(IT) 
S=100 (71.5–100)  
Sp=100 (97.5–100) 
PPV=100 (71.5–100) 
NPV=100 (97.5–100) 
S=100 (47.8–100) 
Sp=100 (97.6–100) 
PPV=100 (47.8–100) 
NPV=100 (97.6–100 
— 
Korostelev et al. 
[60], 2014, Russia  
Prospective,  
DTA study  
2012–2014 
Sample of women from 
private clinics who 
underwent NIPT. All were 
subjected to first-trimester 
screening (n=1728) 
682 Mean age (years): 34.4 (26–45) 
Mean GA (weeks): 14 (9–33) 
Indications: FCT risk<1:250 
(53.8%), advanced maternal 
age (27.9%), personal wish 
(11%), bad reproductive history 
(3.6%), or IVF procedure 
(2.4%) 
Natera 
(NATUS 
algorithm) 
Cut-off point: 
NS 
IT (241; 100% 
of positive 
cases) 
Birth follow-up 
(negative 
cases) 
S=100 (92.4–100) 
Sp=100 (99.4–100) 
PPV=100 (92.4–100) 
NPV=100 (99.4–100) 
S=100 (34.2–100) 
Sp=100 (99.4–100) 
PPV=100 (34.2–100) 
NPV=100 (99.4–100) 
S=75 (30.1–95.4) 
Sp=100 (99.4–100) 
PPV=100 (43.8–100) 
NPV=99.9 (99.2–100) 
Porreco et al. 
[61], 2014, USA 
Prospective 
multicentre blinded 
DTA study  
(31 centres) 
Sep 2009–Apr 2011 
Women who were judged 
to be at risk and made the 
decision to undergo IT 
Inclusion criteria: age≥35 
years, high risk at first- or 
second-trimester screening; 
US anomalies or family 
history 
Exclusion criteria: no 
consent, multiple or fetal 
demise 
3322 Mean age (years)): 35.1  
(SD 5.6) 
Mean GA (weeks): 16.3  
(SD 3.5)  
Test: NS 
WGS (HiSeq 
2000, Illumina 
Inc.) 
Z score3 
(T21); 3.95 
(T18 and 13) 
IT (100% of 
samples) 
S=100 (97.34–100) 
Sp=99.9 (99.72–99.98) 
PPV=97.9 (93.8–99.56) 
NPV=100 (99.98–100) 
S=92.3 (79.13–98.38) 
Sp=100 (99.89–100) 
PPV=100 (90.26–100) 
NPV=99.9 (99.73–99.9) 
S=87.5 (61.65–98.45) 
Sp=100 (99.89–100) 
PPV=100 (76.84–100) 
NPV=99.9 (99.78–99.9) 
Stumm et al. [62], 
2014, Germany 
and Switzerland 
Prospective, 
multicentre  
blinded DTA study 
(5 centres) 
Consecutive enrolled 
women 
Inclusion criteria: signed 
informed consent, age18 
years, high-risk pregnancy, 
performance of IT, blood 
drawn before IT 
472 Mean age (years): 36.0 (19–47) 
Mean GA (weeks): 15.6  
Indications: age35 years, 
(n=363), positive serum 
markers (n=58), US anomaly 
(n=205), family history (n=11), 
parental chromosomal aberration 
(n=2) or other risk factors (n=78) 
LifeCodexx 
Cut off point: 
Z score≥3 (T21); 
3.9 (T18);  
3.2 (T13) 
IT (100% of 
samples) 
S=95.2 (84.2–95.7) 
Sp=100 (99.1–100) 
PPV=100 (91.2–100) 
NPV=99.5 (98.3–99.9) 
S=100 (67.6–100) 
Sp=99.8 (98.8–100) 
PPV=88.9 (56.5–98) 
NPV=100 (99.2–100) 
S=100 (56.6–100) 
Sp=100 (99.2–100) 
PPV=100 (56.6–100) 
NPV=100 (99.2–100) 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population characteristics Index test/  
cut-off point 
Reference 
test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Willems et al. 
[63], 2014, 
Belgium 
Prospective DTA 
study 
Mar–Dec 2013 
Women with NIPT 
indication 
Inclusion criteria: positive 
FCT (>1:200 in Netherlands 
and >1:300 in Belgium), 
maternal age>37 years, 
family history of 
aneuploidies or none of 
the previous indications 
2968 Mean maternal age (years): 
36±3 
Mean GA (weeks): 13±2 
Indications: advanced maternal 
age (40.06%), none of the 
fixed indications (34.73%), 
positive FCT (22%) and family 
history of aneuploidies (3.27%) 
Harmony 
prenatal test 
Cut-off point: 
not reported 
Karyotyping 
(amniocentesis 
or CVS) 
(n=47) 
S=98 (89.9–99.7) 
Sp=100 (99.9–100) 
PPV=100 (93.0–100) 
NPV=99.9 (99.8–100) 
S=80 (37.6–96.4) 
Sp=100 (99.9–100) 
PPV=100 (51.0–100) 
NPV=99.9 (99.8–100) 
S=100 (43.8–100) 
Sp=100 (99.9–100) 
PPV=100 (51.0–100) 
NPV=100 (99.8–100) 
Zhou et al. [64], 
2014, China 
Prospective DTA 
study 
Sep–Jun 2013 
Pregnant women of 12–14 
weeks’ gestation  
Inclusion criteria: advanced 
maternal age, DS risk based 
on serum or abnormal US 
findings or women without 
previous screening 
7701 Maternal age (years): 40.4%  
of women 35 and 59.6% of 
women 35 
GA (weeks): NS 
Indications: high risk of DS 
based on serum or US findings 
(32.1%) and without previous 
screening (56.6%) 
Test: NS (BGI 
Laboratory) 
Cut-off point: 
not reported 
Karyotyping 
(54 samples) 
and neonatal 
follow-up 
(n=3894) 
S=100 (72.2–100) 
Sp=99.9 (99.8–100) 
PPV=94.7 (82.7–98.5) 
NPV=100 (99.9–100) 
S=100 (72.1–100) 
Sp=99.9 (99.8–100) 
PPV=83.3 (55.2–95.3) 
NPV=100 (99.9–100) 
S=100 (34.2–100) 
Sp=99.9 (99.8–100) 
PPV=50.0 (15.0–100) 
NPV=100 (99.9–100) 
Liang et al. [65], 
2013, China 
Prospective DTA 
study 
Mar 2009–Jun 2011 
Women with indication for IT 
Inclusion criteria: positive 
serum screening, 
advanced maternal age, 
US anomaly or more than 
one indication 
412 Mean maternal age (years): 
31±5.9 
Median GA: 21 weeks 3 days 
(11 weeks 3 days to 39 weeks 
3 days) 
HiSeq200 
(Illumina) 
Cut-off point: 
T21 3; T18 5.91; 
T13 5.72;  
T9 7.45; SCA: 
–2.91 to 2.91 
Overall: 100% 
(amniocentesis) 
S=100 (91.2–100) 
Sp=100 (99.0–100) 
PPV=100 (91.2–100) 
NPV=100 (99.9–100) 
S=100 (78.5–100) 
Sp=100 (99.0–100) 
PPV=100 (78.5–100) 
NPV=100 (99.0–100) 
S=100 (51.0–100) 
Sp=99.75 (98.6–100) 
PPV=80 (37.6–96.4) 
NPV=100 (99.1–100) 
Nicolaides et al. 
[66], 2013, UK  
Prospective DTA 
study 
Data collection 
period not reported 
Women at 11–13 weeks’ 
gestation who underwent IT 
Inclusion criteria: positive 
FCT, previous aneuploidy 
pregnancy, advanced 
maternal age or presence 
of sickle cell disease 
229 Median maternal age (years): 
35.7 (18.5–46.5) 
Median GA (weeks): 13.1 
(11.3–13.9) 
Indications: positive FCT (n=227), 
previous aneuploidy (n=6) and 
advanced maternal age (n=5) 
Test: NS 
(SNPs, NATUS 
algorithm) 
Overall: 100% 
(CVS) 
S=100 (86.7–100) 
Sp=100 (98.2–100) 
PPV=100 (86.7–100) 
NPV=100 (98.2–100) 
S=100 (43.8–100) 
Sp=100 (98.3–100) 
PPV=100 (43.8–100) 
NPV=100 (98.3–100) 
S=100 (20.7–100) 
Sp=100 (98.3–100) 
PPV=100 (20.7–100) 
NPV=100 (98.3–100) 
Verweij et al. [67], 
2013, Norway, 
Sweden and 
Netherlands 
Prospective DTA 
study 
High-risk women (based 
on FCT) scheduled for IT 
because of US anomalies 
or anxiety 
 
504 Median maternal age (years): 
36.4 (20–47) 
Median GA (weeks): 14.0  
(10–28) 
Harmony® 
prenatal test 
(samples were 
analysed by 
Ariosa 
Diagnostic) 
Overall: 100% 
of population 
included 
(n=520) 
 
S=94.4 (72.7–99.9) 
Sp=100 (99.4–100) 
PPV=100 (81.6–100) 
NPV=99.8 (99.8–100) 
— — 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Na Population characteristics Index test/  
cut-off point 
Reference 
test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
May 2011–Mar 
2012 
Exclusion criteria: >1 fetus, 
IT prior to blood sampling, 
history or active malignancy 
or language restriction to 
understand study information 
Cut-off point: 
1:100 (1%) 
(amniocentesis 
in 240 samples 
and CVS in 
280 samples) 
Lau et al. [68], 
2012, Japan 
Prospective 
blinded DTA study 
Data collection 
period not reported 
Women with indication for IT 
Inclusion criteria: positive 
FCT or first-trimester US 
markers, other structural 
anomalies, maternal anxiety 
or previous trisomy 
108 Mean maternal age (years): 
37±4.3 
Median GA: 12 weeks 5 days 
(11 weeks 4 days to 28 weeks) 
Verifi™ 
prenatal test 
(Illumina) 
Cut-off point: 
Z score>3 
Overall: 100% 
(94.4% CVS 
and 5.6% 
amniocentesis) 
S=100 (20.7–100) 
Sp=100 (96.2–100) 
PPV=100 (20.7–100) 
NPV=100 (96.2–100) 
S=62.5 (38.6–81.5) 
Sp=100 (96.2–100) 
PPV=100 (72.2–100) 
NPV=94.2 (88.0–97.3) 
S=0 
Sp=100 
PPV=0 
NPV=98.1 
Norton et al. [69], 
2012, USA, 
Netherlands and 
Sweden 
Prospective 
blinded DTA study 
Aug 2010–Nov 
2011 
Women with a singleton 
pregnancy who planned  
to undergo IT for any 
indication 
Exclusion criteria: >fetus, 
presence of known 
aneuploidy, history or 
active malignancy or 
women who received IT 
3080 Median maternal age (years): 
34.3 (18–50) 
Median GA (weeks): 16.9 
(10.0–38.7) 
Harmony® 
prenatal test 
(DANRS and 
FORTE 
analysis 
algorithm) 
Cut-off point: 
1:100 (1%) 
Overall: 100% 
(n=3080) 
(amniocentesis 
in 74.7% and 
CVS in 25.3%) 
S=100 (95.5–100) 
Sp=99.97 (99.8–99.99) 
PPV=98.8 (93.4–99.8) 
NPV=100 (99.9–100) 
For other cut-off point 
(1:1000 (0.1%), 1:300 
(0.33%) and 1:10 (10%)) 
Sp=99.90 
S not changed 
S=97.4 (86.5–99.9) 
Sp=99.9 (99.7–99.9) 
PPV=94.9 (83.1–96.6) 
NPV=99.9 (99.8–100) 
For cut-off point 1:1000 
(0.1%) 
Sp=99.79 
For cut-off point 1:300 
(0.33%) 
Sp=99.86 
For cut-off point 1:10 (10%) 
S=94.7 
— 
Ehrich et al. [70], 
2011, USA 
Prospective DTA 
study, double 
blinded 
From May 2009 
Women classified as 
having high risk for DS 
scheduled for IT  
(singleton pregnancies) 
449 Median maternal age (years): 
37 (8–36) 
Mean GA (weeks): 16 (8–36) 
Indications: high serum levels 
(30.1%), age≥35 years (68.3%), 
US anomalies (13.9%), family 
history (5.2%), other (10.2%) 
Sequenom 
(Qiagen kit) 
Cut off-point: 
Z score 2.5 
Overall: 100% 
(fetal 
karyotyping) 
S=100 (89–100) 
Sp=99.7 (98.5–100) 
PPV=100 (87.1–99.6) 
NPV=100 (99.1–100) 
— — 
Abbreviations: ART=assisted reproductive technology; CI=confidence interval; CVS=chorionic villus sampling; DS=Down syndrome; DTA=diagnostic test accuracy; FCT=first-trimester combined testing; 
FISH=fluorescence in situ hybridisation; FTS=; GA=gestational age; IT=invasive testing; IVF=in vitro fertilisation; NIPT=noninvasive prenatal testing; NPV=negative predictive value; NS=not specified; 
NT=nuchal translucency; PPV=positive predictive value; S=sensitivity; SCA=sex chromosome aneuploidy; SD=standard deviation; SNP=single nucleotide polymorphism; Sp=specificity; T9=trisomy 9; 
T13=trisomy 13; T18=trisomy 18; T21=trisomy 21; US=ultrasound; WGS=whole genome sequencing. 
a Number of samples with NIPT and follow-up results. 
b Calculations provided/based on study results (exclusion of low fetal fraction, uncertain results, test failures and miscarriages). 
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5.3.3 NIPT as an add-on to FCT for the high- and intermediate-risk  
singleton pregnancy population 
The only study included which assessed this screening strategy showed a sensitivity for T21, T18 
and T13, excluding no results, of 97.7%, 87.5% and 50%, respectively. The specificity was 99.9% 
for all three trisomies. The PPV was 97.7% for T21, 84% for T18 and 33.3% for T13. The NPV 
was 99.9%, 100% and 99.9%, respectively. Three T18 cases (12.5%) were not detected because 
the test did not provide a result [71] (Table 8).  
Table 8: Characteristics and noninvasive prenatal testing accuracy of individual studies 
performed in the high- and intermediate-risk singleton pregnancy population  
Authors, year, 
country, study 
characteristics 
Eligibility 
criteria 
Population 
characteristics 
Na Index test, cut-
off point, 
reference test(s) 
Performance resultsb, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Gil et al. [71], 
2016, UK  
Prospective 
DTA study 
Oct 2013–Feb 
2015 
Women with  
a singleton 
pregnancy 
between 11 
and 13 weeks’ 
gestation 
classified as of 
high (≥1:100) 
or intermediate 
(1:2500) risk of 
aneuploidies 
by FCT  
Median maternal 
age (years): high risk 
36.1 (32.1–39.5); 
intermediate risk 
34.8 (30.8–38.4); 
low risk 29.9  
(25.8–33.2) 
Median GA:  
not reported 
Pregnancy by ART 
(n): high risk 16 
(3.5%); Intermediate 
risk 135 (3.8%);  
low risk 172 (2.2%) 
Indications: high or 
intermediate risk, 
3633 samples; low 
risk, 7680 samples 
3633 Harmony 
prenatal test 
Cut-off point not 
reported 
Overall: 100% 
(CVS) 
S=97.7 
(88.2–99.6) 
Sp=99.9 
(99.8–100) 
PPV=97.7 
(88.2–99.6) 
NPV=99.9 
(99.8–100) 
S=87.5 
(69.0–95.7) 
Sp=99.8 
(99.7–100) 
PPV=84 
84.0 (65.3–
93.6) 
NPV=100 
(99.9–100) 
S=50 
(15.0–85.0) 
Sp=99.8 
(99.7–100) 
PPV=33.3 
(9.7–70.0) 
NPV=99.9 
(99.8–100) 
Abbreviations: ART=assisted reproductive technology; CI=confidence interval; CVS=chorionic villus sampling; 
DTA=diagnostic test accuracy; FCT=first-trimester combined testing; GA=gestational age; NPV=negative predictive value; 
PPV=positive predictive value; S=sensitivity; Sp=specificity. 
a Number of samples with noninvasive prenatal testing and reference standard results. 
b Calculations provided/based on study results  
(exclusion of low fetal fraction, uncertain results, test failures and miscarriages). 
 
5.3.4 NIPT as an add-on to FCT for the high-risk twin pregnancy population 
5.3.4.1 NIPT accuracy for T21 
Sensitivity and specificity 
Five DTA studies reported results on high-risk twin pregnancy populations. These included 33 T21 
cases and 1547 euploidy cases), which were included in the analysis. When the bivariate random-
effects model was applied, pooled sensitivity was 99.2% (95% CI 27.1%–99.9%) and pooled speci-
ficity was 99.8% (95% CI 98.5%–99.9%) (Figure 14). The correlation parameter between sensitivity 
and specificity was 1, showing instability in the model. Therefore, two independent univariate 
random-effects meta-analyses were performed to support the results obtained with the bivariate 
model. The results obtained with the univariate random-effects model were similar for specificity 
(99.8%, 95% CI 98.5%–99.9%) but sensitivity was lower (96.9%, 95% CI 81.3%–99.5%). Only 
Sarno et al. [39] provided data on NIPT sensitivity, which reached 100%. Other endpoints of interest 
obtained with bivariate meta-analysis (i.e., DOR, LR+, LR– and HSROC curves) can be found in 
Appendix 4 (Table A16 and Figure A3). 
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Figure 14: Paired forest plot of sensitivity and specificity of noninvasive prenatal testing 
for trisomy 21 
Abbreviations: CI=confidence interval; FN=false negatives; FP=false positives; TN=true negatives; TP=true positives. 
PPV and NPV 
According to the retrieved studies, the NPV of NIPT was more than 99% and PPV was 100% in 
three studies. Fosler et al. [72] and Bevilacqua et al. [74] found PPVs of 75% and 85%, respectively. 
In the study of Tan et al. [73] the PPV would decrease from 100% to 44.4% if test failures are consid-
ered to be cases. The NPV and PPV would remain unaltered if they are treated as negative. 
5.3.4.2 NIPT accuracy for T18 
Sensitivity and specificity 
Only three DTA studies assessed T18. The results of these studies are discordant. Whereas 
Bevilacqua et al. [74] found a sensitivity of 100%, it reached 75% in the study of Sarno et al. [39], 
and Huang et al. [75] reported a value of 50%. The specificity observed in the retrieved studies 
[74, 75] was 96%–100%. None of the studies provided data on no-call results. 
PPV and NPV 
Similarly to the evidence mentioned previously, the NPV of NIPT for T18 was more than 99%. For 
the PPV, Huang et al. [75] found a value of 100% and it reached 29.4% in the study of Bevilacqua 
et al. [74]. None of the studies provided data on no-call results. 
NIPT accuracy data in the twin pregnancy population reported in individual studies can be found in 
Table 9.  
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Table 9: Characteristics and noninvasive prenatal testing accuracy of individual studies performed in the high risk twin pregnancy population  
Authors, year, 
countries, study 
characteristics 
Eligibility criteria Population characteristics Na Index test/comparator  
cut-off point 
Reference 
test(s) 
Performance results, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Fosler et al. [72], 
2017, USA  
Prospective DTA 
study (only cohort B 
included) 
Data collection 
period not reported 
Women aged>18 years 
of at least 8 weeks’ 
gestation who had 
advanced maternal 
age, abnormal US 
findings, previous 
affected pregnancy or 
positive serum 
screening 
Mean maternal age (years): 
35.5±4.9 
Mean GA (weeks): 13.7±3.9 
Pregnancy by ART:  
not reported 
Chorionicity: not reported 
479 Verifi™ prenatal test 
Cut-off point: not reported 
Karyotyping in 
171 samples 
(CVS or 
amniocentesis) 
S=100 (61.0–100) 
Sp=99.7 (99.8–100) 
PPV=85.7 (48.7–97.4) 
NPV=100 (99.2–100) 
— — 
Sarno et al. [39], 
2016, UK 
Prospective DTA 
study (only reported 
twin pregnancy 
results) 
Oct 2012–Aug 2015 
Singleton or twin 
pregnancies at 11 
weeks’ gestation to 13 
weeks 6 days who 
received NIPT following 
FCT or as part of 
routine screening 
Median maternal age (years): 
37.3 (34.6–40.0) 
Median GA (weeks): 11.7 
(10.4–12.9) 
Pregnancy by ART (n): 246 
(56.2%) 
Chorionicity: 373 (85.2%) were 
dichorionic and 65 (14.8%) 
were monochorionic 
Median BMI (kg/m2): 23.5 
(21.0–26.9)  
417 Harmony prenatal test 
Cut-off point: >99% or <0.01% 
Overall: 100% 
(fetal 
karyotyping) 
All trisomies 
S=84.6 (57.8–95.7) 
Sp=99.7 (98.6–100) 
PPV=91.7 (64.6–98.5) 
NPV=99.5 (98.2–99.9) 
Tan et al. [73], 
2016, China  
Prospective DTA 
study 
Jan 2012–Dec 2013 
Women with a twin 
pregnancy after use of 
ART, aged>18 years, 
>10 weeks’ gestation, 
with or without prior DS 
screening result, for 
one- to two-embryo 
transfer, confirmation of 
live twin pregnancy by 
US examination and for 
three-embryo transfer 
confirmation of live twin 
pregnancy and no 
demise fetus by US 
examination 
Median maternal age (years): 
31 (20–43) 
Median GA (weeks): 12  
(11–28) 
Pregnancy by ART: 100% 
Chorionicity: 96.3% 
dichorionic diamniotic,  
1.9% monochorionic 
diamniotic and  
1.2% monochorionic 
monoamniotic 
560 Index test: not reported (MPS) 
Cut-off point: t score>2.5 and 
L score>1 were considered as 
high risk; t score>2.5 or 
L score>1 was considered as in 
the “warning zone”; t score<2.5 
and L score<1 were considered 
as low risk 
Overall: 100% 
Fetal 
karyotyping 
(3.1%, positive 
NIPT result) 
Follow-up 
(96.9%, 
negative NIPT 
result) 
S=100 (51.0–100) 
Sp=100 (99.3–100) 
PPV=100 (51–100) 
NPV=100 (99.3–100) 
— — 
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Authors, year, 
countries, study 
characteristics 
Eligibility criteria Population characteristics Na Index test/comparator  
cut-off point 
Reference 
test(s) 
Performance results, % (95% CI, %) 
Trisomy 21 Trisomy 18 Trisomy 13 
Bevilacqua et al. 
[74], 2015, 
Belgium, UK and 
Spain 
Prospective DTA 
study 
May 2013–Sep 2014 
Women with twin 
pregnancies at 10–28 
weeks’ gestation who 
underwent cfDNA testing 
because of prior high risk 
of aneuploidies (first- or 
second-trimester serum 
screening or US 
examination) 
Median maternal age (years): 
36.8 (19.0–50.3) 
Median GA (weeks.): 13.6 
(10.0–34.7) 
Pregnancy by ART: 52.8% 
Chorionicity: not reported 
340 Harmony prenatal test 
Cut-off point: >99% or <0.01% 
Overall: 351 
samples 
Fetal 
karyotyping 
(amniocentesis, 
CVS) 
Neonatal blood  
Neonatal 
examination 
S=92.3 (66.7–98.6) 
Sp=98.7 (96.9–99.5) 
PPV=75.0 (50.5–89.8) 
NPV=99.6 (98.3–99.9) 
S=100 (56.6–100) 
Sp=96.4 (93.8–97.9) 
PPV=29.4 (13.3–53.1) 
NPV=100 (98.8–100) 
— 
Huang et al.[75], 
2014, China  
Prospective DTA 
study 
Data collection 
period not reported 
Women with twin 
pregnancies who 
required IT because of 
abnormal serum 
screening or US findings 
or maternal anxiety 
Exclusion criteria: 
women with intrauterine 
fetal demise at the time 
of sampling or without 
fetal karyotype results 
Median maternal age (years): 
31 (22–44) 
Median GA (weeks): 19 (11–36) 
Pregnancy by ART: 59.8% 
Chorionicity: 80.4% dichorionic 
diamniotic, 16.4% mono-
chorionic diamniotic, 1.1% 
monochorionic monoamniotic 
and 2.1% unknown  
189 Index test: not reported 
Cut-off point: t score>2.5 and 
L score>1 were considered as 
high risk; t score>2.5 or 
L score>1 was considered as in 
the “warning zone”; t score<2.5 
and L score<1 were considered 
as low risk 
Overall: 100% 
Fetal 
karyotyping: 
amniocentesis 
(94.2%),  
CVS (2.1%) or 
cordocentesis 
(3.7%) 
S=100 (70.1–100) 
Sp=100 (97.9–100) 
PPV=100 (70.1–100) 
NPV=100 (97.9–100) 
S=50 (9.5–90.5) 
Sp=100 (98.0–100) 
PPV=100 (20.7–100) 
NPV=99.4 (97.0–99.9) 
— 
Lau et al. [76], 
2013, China  
Comparative 
prospective DTA 
study 
Aug 2011–Apr 2012 
Women with a twin 
pregnancy who have 
rejected IT on the basis 
of standard screening 
results 
Mean maternal age (years): 
36.5 (28–41)  
Median GA: 13 weeks 1 day 
(11 weeks 6 days to 20 
weeks 1 day) 
Pregnancy by ART: 66.7% 
Chorionicity: 83.3% 
dichorionic and 16.7% 
monochorionic 
12 Index test: NIFTY test 
Cut-off point: t score>2.5 and 
L score>1 were considered as 
high risk; t score>2.5 or 
L score>1 were considered as in 
the “warning zone”; t score<2.5 
and L score<1 was considered as 
low risk 
Comparator: first- or second-
trimester serum screening or US 
examination (NT, fetal nasal bone 
or Doppler assessment of the 
tricuspid valve or ductus venosus) 
Overall: 100% 
Fetal 
karyotyping  
or clinical 
examination of 
the newborn 
S=100 (20.7–100) 
Sp=100 (52.3–94.9) 
PPV=33.3 (6.1–79.2) 
NPV=100 (70.1–100) 
— — 
Abbreviations: ART=assisted reproductive technology; cfDNA=cell-free DNA; CI=confidence interval; CVS=chorionic villus sampling; DS=Down syndrome; DTA=diagnostic test accuracy;  
FCT=first-trimester combined testing; GA=gestational age: IT=invasive testing; NIPT=noninvasive prenatal testing; NPV=negative predictive value; NT=nuchal translucency; PPV=positive predictive value; 
S=sensitivity; Sp=specificity; US=ultrasound. 
a Number of samples with NIPT and reference standard results. 
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5.4 Comparative performance 
[D1002] – How does NIPT screening compare with other optional  
screening approaches in terms of accuracy measures? 
5.4.1 NIPT as a primary screening test for the singleton pregnancy population  
in comparison with FCT 
Sensitivity and specificity for T21, T18 and T13 
Information available for T21 and T13 comes from four included studies. In one of these studies, 
NIPT accuracy was compaired against first- or second-trimester serum screening combined or not 
combined with ultrasonographic findings. T13 was assessed in only three of these studies. 
Stratified analysis for each trisomy was performed by independent univariate random-effects meta-
analysis because the bivariate random-effects model failed to converge. According to these studies, 
NIPT achieved a significantly higher specificity than combined screening for T21, T18 and T13. The 
sensitivity was similar between both screening methods for T13 and T18; however, NIPT showed 
a higher sensitivity for T21 compared with standard screening (100% vs. 94%, p<0.001 respec-
tively; 2) (Table 10).  
PPV and NPV for T21, T18 and T13 
With respect to PPV and NPV, only two studies provided statistical analysis between both screening 
tests. Norton et al. [31] found the PPV and NPV for T21 were higher with NIPT than with combined 
screening (PPV of 80.9% vs. 3.4% and NPV of 100% vs. 99.9%), Bianchi et al. [30] did not find any 
difference. Regarding the other two trisomies assessed, only Norton et al. [31] reported the PPV for 
T18 was higher with NIPT than with combined screening (90.0% vs. 14.0%) and there were no 
differences in the NPV for T18 or the PPV or NPV for T13. 
Table 10: Noninvasive prenatal testing versus combined screening test accuracy  
for each trisomy 
 No. of 
studies 
Nº TP/Nº diseased 
Nº TN/Nº 
nondiseased 
Combined 
screening 
% (95% CI, %) 
TP/diseased 
TN/nondiseased 
NIPT 
% (95% CI, %) 
P value 
Trisomy 13 
Sensitivity 
Specificity 
3  
7/8 
14,710/14,912 
 
0.88 (0.46, 0.98) 
0.99 (0.98, 0.99) 
 
5/8 
15,821/15,828 
 
0.62 (0.28, 0.87) 
1.00 (1.00, 1.00) 
 
0.20 
<0.0001 
Trisomy 18 
Sensitivity 
Specificity 
4  
22/24 
20,913/21,141 
 
0.92 (0.72, 0.98) 
0.99 (0.99, 0.99) 
 
23/25 
21,083/21,092 
 
0.92 (0.73, 0.98) 
1.00 (1.00, 1.00) 
 
0.97 
<0.0001  
Trisomy 21 
Sensitivity 
Specificity 
4  
79/89 
19,981/21,081 
 
0.94 (0.87, 0.99) 
0.95 (0.94, 0.95) 
 
89/89 
21,050/21,046 
 
1.00 (0.99, 1.00) 
1.00 (1.00, 1.00) 
 
<0.001 
<0.0001 
Abbreviations: NIPT=noninvasive prenatal testing; TN=true negatives; TP=true positives.  
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5.4.2 NIPT as an add-on test to FCT for the high-risk singleton pregnancy population  
in comparison with FCT  
There is lack of data regarding the comparison of these two screening strategies. On the basis of 
the 2×2 test accuracy data of the Cochrane review [127] and with the use of a bivariate meta-
analytic model, the estimated pooled sensitivity of FCT for the risk level of 1 in 300 is estimated to 
be 87.26% (95% CI 85.18%–89.09%). The estimated pooled specificity is 95.50% (95% CI 94.86%–
96.05%). Assuming a prevalence of T21 of 24 in 10,000 (EUROCAT data) [12] and assuming that 
all women testing positive with FCT would undergo NIPT (pooled sensitivity estimate of 99.24%, 
95% CI 98.64%–99.58%, and pooled specificity estimate of 99.95%, 95% CI 99.93%–99.96%), the 
estimated sensitivity of the add-on strategy (FCT plus NIPT) for a hypothetical cohort of 10,000 
estimated on the basis of the pooled high-risk data would be 86.8% (95% CI 82.2%–90.4%). Esti-
mated specificity would be 100% (95% CI 99.9%–100%). The PPV would be 99.1% (95% CI 
96.7%–99.7%%) and the NPV would be 100% (95% CI 99.9%–100%). The hypotherical scenario 
used to estimate sensitivity and specificity of NIPT as an add-on test is shown in Figure 15. 
 
Figure 15: Diagnostic test results in a hypothetical scenario of NIPT as an add-on test 
Abbreviations: FCT=first-trimester combined testing; FN=false negatives; FP=false positives; NIPT=noninvasive prenatal 
testing; TN=true negatives; TP=true positives. 
* The results displayed appear incorrect because the calculation of the postive and negative values for the add-on 
strategy (FCT and NIPT) was done using all decimal places in order to avoid round-off errors). 
 
General population: 
100,000 pregnant women 
FCT  
(1:300 level) 
Sensitivity: 87.26% 
Specificity: 95.50% 
TN=95,265 FN=31 
(Total=95,296) 
TP=209            FP=4495 
(Total=4704) 
Negative Positive 
NIPT 
Sensitivity: 99.24% 
Specificity: 99.95% 
TN=4492 FN=2 
(Total=4494) 
TP*=208 FP*=2 
(Total=210) 
Negative Positive 
TN=95,758* FN=32* 
(Total=99,790) 
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5.4.3 NIPT as an add-on to FCT for the high- and intermediate-risk singleton  
pregnancy population in comparison with FCT 
The available data are inappropriate for estimations. 
 
5.4.4 NIPT as part of FCT for singleton pregnancy population 
The available data are inappropriate for estimations. 
 
[D1006] – Does the test reliably rule in or rule out chromosomal aneuploidies? 
NIPT is not indicated as a diagnostic test as its sensitivity and specificity does not reach 100%. 
Currently, it is considered a prenatal screening method aimed at determining the risk of fetal aneu-
ploidy. 
 
[D1007] – How does the accuracy of NIPT differ in different settings? 
Existing data do not allow stratified analysis to be performed. 
 
5.5 Relative effectiveness 
5.5.1 Mortality 
[D0001] – What is the expected beneficial effect of prenatal screening  
with NIPT on neonatal mortality? 
Two outcomes were considered relevant to assess the expected beneficial effect of NIPT on neo-
natal mortality (i.e., reduction of miscarriages or stillbirths of individuals affected by T13, T18 and 
T21 and miscarriages) related to invasive testing with NIPT compared with standard screening.  
None of the studies included provided data on these outcomes.  
 
5.5.2 Morbidity 
[D0005] – How does prenatal screening with NIPT affect the frequency  
of newborns with aneuploidies? 
Given the sensitive nature of prenatal screening, because of its association with abortion, the fre-
quency of newborns with T13, T18 and T21 was not considered a relevant endpoint. The outcome 
considered relevant to this end was the influence of NIPT on the reduction in the number of children 
born with undiagnosed T13, T18 and T21, but none of the studies provided appropriate data to 
assess this outcome. 
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[D0006] – How does prenatal screening with NIPT affect the progression of pregnancy?  
The studies included did not provide data regarding the reduction in invasive testing (amniocentesis 
or CVS). Estimations for T21 in singleton pregnancies were made on the basis of simulation models. 
Modelling was not considered for the other two trisomies (T18 and T13) given the low QoE. 
 
5.5.3 Simulation modelling for NIPT as an add-on test to combined screening  
in the high- and intermediate-risk singleton population in comparison with FCT 
On the basis of the simulation model shown in Figure 15, the combined test strategy would result 
in a total of 32 FN test results and a total of two FP test results. Assuming that all women who  
tested positive in NIPT would undergo invasive testing, 210 women would have to undergo invasive 
testing so as to confirm the T21 status of their unborn child after NIPT (0.002%) in comparison with 
4704 after FCT (4.7%). This would result in a 95.5% reduction of invasive tests in comparison with 
combined testing. 
 
5.5.4 Simulation modelling for NIPT without FCT (NIPT-only strategy) 
The second scenario was developed to estimate test results for a strategy of using only NIPT. This 
model is based on the same prevalence estimate and the same test accuracy data for NIPT as the 
previous model for the combined strategy.  
 
Figure 16: Diagnostic test results in a hypothetical scenario of NIPT only 
Abbreviations: FN=false negatives; FP=false positives; NIPT=noninvasive prenatal testing; TN=true negatives;  
TP=true positives. 
 
1. Comparison of simulation models 
From the simulation models, it is not possible to directly estimate how the possible implementation 
of NIPT would change key outcomes, such as T21 detection and invasive testing. This is because 
there are no data available for Europe to estimate which results are being achieved with the cur-
rently available tests (i.e., only FCT without NIPT). Specifically, the proportion and the risk spectrum 
of women undergoing FCT and subsequent invasive testing are largely unknown.  
General population: 
100,000 pregnant women 
NIPT 
Sensitivity: 99.24% 
Specificity: 99.95% 
TN=99,710  FN=2 
(Total=99,712) 
TP=238             FP=50 
(Total=288) 
Negative  
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In an extreme scenario of using only NIPT versus FCT with the 1 in 300 threshold, it could be ex-
pected that the detection rate would increase slightly (29 excess cases detected in 100,000 preg-
nant woman) and that NIPT would reduce invasive testing, because the specificity of FCT (95.5%) 
is much lower than that of NIPT. Although it is unrealistic to assume that all 4704 women would 
accept invasive testing, this scenario is able to show that the introduction of NIPT would most likely 
reduce the number of invasive tests. Even if only a small proportion of women tested positive by 
FCT would receive NIPT, the number of invasive tests in both scenarios using NIPT is much smaller. 
 
Figure 17: Diagnostic test results in a hypothetical scenario of first-trimester combined 
testing (first-trimester combined testing only) 
Abbreviations: FCT=first-trimester combined test; FN=false negatives; FP=false positives;  
NIPT=noninvasive prenatal testing; TN=true negatives; TP=true positives. 
In the comparison of the two strategies for using NIPT (i.e., NIPT only vs. FCT and NIPT), both 
models show advantages and disadvantages. Using only NIPT reduces the number of undetected 
T21 cases to two (Table 11) but requires a larger number of invasive tests (288). Combined testing 
fails to increase the T21 detection rate (with 32 undetected cases) but allows – as opposed to the 
NIPT-only strategy – the number of invasive tests offered to pregnant women to be reduced to a 
larger degree. In essence, the aim of detecting 30 extra cases of T21 (i.e., 32 vs. 2) has to be 
weighed against an increase in invasive testing offered (i.e., 288 vs. 210). These estimations can 
change if no-call results are included in the analysis. Given the lack of data on the rate of missed 
cases among no-call results, this modelling could not be done. 
Table 11: Comparison of simulation modelling results  
(all based on a general population of 100,000 pregnant women) 
 FCT only NIPT only Combined testing  
(FCT and NIPT) 
Total no. of FCTs applied 
(% of all women) 
100,000 
(100) 
— 100,000 
(100) 
Total no. of NIPTs applied 
(% of all women) 
— 100,000 
(100%) 
4704 
(4.7%) 
No. of detected T21 cases  
(% of all T21 cases) 
209 of 240 
(87.3) 
238 of 240 
(99.2) 
208 of 240 
(86.6) 
No. of undetected T21 cases  
(% of all T21 cases) 
31 
(12.7) 
2 
(0.8) 
32 
(13.4) 
General population: 
100,000 pregnant women 
FCT  
(1:300 level) 
Sensitivity: 87.26% 
Specificity: 95.50% 
TN=95,265  FN=31 
(Total=95,296) 
TP=209          FP=4495 
(Total=4704) 
Negative  Positive 
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 FCT only NIPT only Combined testing  
(FCT and NIPT) 
No. of women undergoing invasive 
testing to confirm T21  
(% of all women) 
4704a 
(4.7) 
288 
(0.3) 
210 
(0.2) 
Abbreviations: FCT=first-trimester combined test; NIPT=noninvasive prenatal test; T21=trisomy 21. 
a It is highly unlikely that all 4704 will women undergo invasive testing because the pretest probability of a fetus with T21 
is very low (i.e., <5%). 
 
[D0012] – What is the effect of NIPT on mothers’ health-related quality of life? 
Studies retrieved in the bibliographic search did not provide information for us to analyse how NIPT 
influenced health-related quality of life. 
[D0030] – Does the knowledge of the NIPT results affect the population’s  
non-health-related quality of life? 
None of the studies included reported on the population’s non-health-related quality of life. 
[D0017] – Was the population satisfied with NIPT? 
None of the studies included which met the eligibility criteria provided information on satisfaction.  
[D0020] – Does the use of NIPT lead to improved detection of chromosomal aneuploidies? 
Randomised controlled trials are required to be able to determine if NIPT screening pathways will 
improve the detection of chromosomal aneuploidies in comparison with conventional approaches 
[128, 129]. Currently, there is no information regarding comparison of the different screening ap-
proaches. 
[D0021] – How does NIPT change physicians’ management decisions? 
The available evidence is inappropriate to assess how NIPT changes physicians’ management  
decisions. 
[D0022] – Does NIPT detect other potential health conditions that can impact  
the subsequent management decisions? 
The information provided in the studies was insufficient to establish the impact of NIPT on other  
potential health conditions identified by NIPT. 
[D0010] – How does the technology modify the need for hospitalisation? 
The retrieved evidence did not provide information for us to analyse the effect of prenatal screening 
with NIPT in management decisions or modify the need for hospitalisation.  
[D0029] – What are the overall benefits and harms of NIPT in terms of health outcomes? 
The overall benefits and harms of NIPT cannot be assessed with the available evidence. 
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5.5.5 Discussion 
Existing evidence comes from prospective cohort studies which are aimed at evaluating the perfor-
mance of NIPT for the detection of the three targeted aneuploidies (T21, T18 and T13) in the gen-
eral population and the high-risk population. Four of the eight studies included for the general pop-
ulation are paired designs which provide a comparison of the accuracy of NIPT versus that of com-
bined testing. No randomised comparative trials comparing NIPT pathways and conventional path-
ways were identified. 
Given that the performance of NIPT can differ substantially between aneuploidies, results have  
been provided for each of these aneuploidies and an aggregate analysis was performed to esti-
mate the overall detection of these three chromosomal anomalies in the different clinical settings/ 
subgroups. With regard to the use of NIPT as a replacement for FCT for screening of the general 
population, the meta-analysis for T21 shows a pooled sensitivity of 99.4% (95% CI 96.1%–99.9%) 
and a pooled specificity of 99.9% (95% CI 99.8%–99.9%), suggesting that NIPT could be highly 
sensitive and specific for the detection of T21 as a primary test compared with combined serum 
screening. The pooled sensitivity for T18 and T13 was also high (97.4%, 95% CI 94.4%–98.8%; 
98.8%, 95% CI 4.2%–100%), although the models were judged to be unreliable because of the 
sparse data and the low number of trisomy cases in comparison with nontrisomy cases. The few 
existing paired trials which compare NIPT with combined testing found significantly higher sensitiv-
ity with NIPT than with FCT. Furthermore, the PPV for T21 seems to be also markedly higher 
(≥80 in all studies), which could suggest that these tests might have the potential to reduce unnec-
essary invasive testing in comparison with combined approaches, which PPV below 24% although 
with a wide range (3.4%–24%). On the basis of the simulation model of using only NIPT versus 
FCT with the 1 in 300 threshold, it could be expected that the detection rate for T21 would increase 
slightly and that NIPT would lead to a substantial reduction in invasive testing, although these re-
sults should be analysed with care given the uncertainties that exist regarding the number of women 
who would undergo invasive testing subsequent to FCT or how NIPT adoption might change current 
screening adoption rates. 
In general terms, drawing solid conclusions regarding the accuracy of NIPT as a primary test for 
general population screening of T21 is not possible because of the lack of evidence on primary 
outcomes and the low QoE for the specificity outcome as assessed by GRADE. Follow-up was 
incomplete in most studies, and two of the studies which contribute most to the results, given the 
sample size (Norton et al. [31] and Zhang et al. [43]), present losses as high as 16.4% and 23%, 
respectively. The verification of negative NIPT cases was done in most studies by review of medical 
records, general practitioner databases and telephone interviews, raising also important concerns 
regarding the completeness and reliability of this information. Information is also lacking in most of 
the paired comparative studies regarding the verification of standard screening positive  cases. 
Similarly to what was found in the general population, the meta-analysis for high-risk singleton 
pregnancy women showed a very high pooled sensitivity and specificity for T21 (sensitivity 99.2%, 
95% CI 98.6%–99.5%; specificity 99.9% 95% CI 99.9%–99.9%), with NPVs and PPVs close to or 
equal to 100%. The pooled estimates were also similar for T18 (98.01%, 95% CI 89.38%–99.65%), 
although the PPV was significantly higher (66.7%–100%). Likewise, we observed great imprecision 
in the T13 estimates. The fact that most of the studies were insufficiently powered because of the 
small sample size could have greatly contributed to this imprecision and could also explain why 
many of the studies failed to show FN or FP cases for these aneuploidies. FN cases could have 
been missed because of the lack of verification of all negative cases with invasive testing. On the 
other hand, excluding cases of miscarriages, stillbirths and cases with no or uncertain results could 
have led to an overestimation of the PPV in both the general population and the high-risk population. 
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No valid statement can be made regarding the sensitivity for estimates for twin pregnancies be-
cause of the small size of the populations and the imprecision of the estimates. 
The proportion of samples not returning a result because of a low fetal fraction or other quality 
issues ranged from 0.09% to 8.1% in the general population and from 0.02% to 6.3% in the high-
risk population. The ACOG and the Society for Maternal-Fetal Medicine recommend that women 
whose cfDNA screening results are not reported, are undeterminate, or uninterpretable should re-
ceive counselling and be offered comprehensive ultrasound evaluation and diagnostic testing be-
cause of increased risk of aneuploidy. The few existing studies which provide information regarding 
no results (three studies in the general population, one study in the high-risk pregnant population 
and one study in in twin pregnancy population) support this increased risk of aneuploidy. In the 
study of Norton et al. [31], the prevalence of aneuploidies was 2.7% in the group with no results 
versus 0.4% in the overall general population cohort. Pergament et al. [44] found that no-call sam-
ples were six times more likely to be abnormal than samples with fetal fractions greater than 3.4%. 
Likewise, Persico et al. [49] showed a significantly higher risk of aneuploidies in high-risk patients 
with no result rates in comparison with patients with NIPT results (8.5% vs. 2.1%). When we reas-
sessed NIPT performance including these no results as positive cases, we observed substantial 
reductions in the specificity for T21, T18 and T13 for several studies. On the other hand, reductions 
in sensitivity were found if these no results were classified as negative, highlighting the great un-
certainties that remain regarding the best approach for these cases. Pergament et al. [44] propose 
that these patients cannot be automatically classified as either high or low risk, and that a modified 
risk score should be determined in light of other factors (gestational age, high-resolution ultrasound 
findings, modified risk if available and other indications). Some authors [2, 31] propose that obesity 
and gestational age could be associated with lower fetal fractions but further research is required 
to verify these findings and optimise the screening approach.  
The generalisability of the studies included is another matter of concern. Even though most of the 
studies which assess NIPT in the general population include the average-risk population, the preva-
lence of aneuploidies is above that estimated in most European countries. In three of the studies 
[41, 42, 44] the prevalence of T21 was similar to that found in high-risk studies, suggesting that 
these populations might not be representative of the use of NIPT as a primary test in routine settings 
given the influence of the prevalence on the PPV and NPV. These studies also differ substantially 
regarding factors such as maternal age, gestational age and maternal weight. The influence of 
these factors on accuracy measures could not be analysed in the current analysis given the low 
number of general population studies and the wide variability of the spectrum of pregnant women 
included in the high-risk population.  
We observed that the prevalence of aneuploidies also varied widely in the studies of high-risk single-
ton pregnancies, ranging from 0.4% to 50% for T21. Likewise, studies differed substantially regarding 
the criteria used for the classification of high-risk patients. We found that the vast majority of studies 
included patients screened during the first and second trimester and did not provide an FCT cut-off 
point for high risk, offering these tests for multiple indications, including elevated levels of serum 
markers, advanced maternal age (range 35–40 years), abnormal ultrasound findings, sonographic 
anomalies, previous child or fetus with a chromosomal anomaly and family history of DNA anomaly 
and anxiety. It would be important to have unbiased information regarding how these different indi-
cations would influence test accuracy and patient outcomes, particularly in the case of T18 and 
T13, since these trisomies are commonly characterised by malformations which can easily be de-
tected by first-trimester ultrasound examination. Although envisioned, the existing data did not allow 
a stratified analysis to be performed. 
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The lack of information concerning key outcomes such as the reduction in invasive testing and 
miscarriages constitutes an important limitation for ascertaining the consequences of NIPT imple-
mentation. Assuming that all high-risk patients would opt for invasive testing, we could estimate that 
offering NIPT as a primary test would increase the detection rate slightly and would contribute to 
reduce invasive testing although this reduction would be increased with combined testing (FCT and 
NIPT). However, these results could be highly misleading because the percentage of women who 
will take up invasive screening for confirmation of positive results can vary widely depending on 
many different factors. The two routine care studies performed in the UK highlight very well this 
phenomenon. In the UK RAPID study, the number of women who opted for invasive testing confir-
mation because of a high-risk result increased with the availability of NIPT (54%–80%), and this led 
to an only modest decrease in the rate of invasive testing [130]. In the other NHS study, which 
assessed the implementation of contingent NIPT screening for intermediate-risk to high-risk women, 
invasive testing of high-risk patients was reduced by 43% in comparison with the previous 1-year 
rate but the overall rate was similar (2.6%) [71]. These figures could differ substantially if invasive 
testing were done in patients with no results from NIPT. For example, in the study by Norton et al. 
[31] we could hypothesise that invasive testing for T21 would still be reduced by 2.2% but could 
increase for T18 (2.75%) and T13 (4%) if no test results were considered as high risk. Large popu-
lation studies assessing these and other patient-relevant outcomes are necessary to determine the 
real clinical implications derived from NIPT implementation. 
It is important to highlight that whilst paired study designs have advantages over randomised con-
trolled trials to establish diagnostic accuracy, given that they may be more feasible and would require 
fewer patients, they are inappropriate for assessing trade-offs between different approaches. To 
determine if NIPT would serve as a replacement, triage or add-on requires more information than 
the accuracy of the test. It needs assessment of the performance of the different test strategies, 
taking into account detection of all anomalies, abortions, miscarriages and other patient-related 
outcomes. To date, important uncertainties remain regarding the best screening pathway. As illus-
trated by the modelling results, however, it is important for decision makers to find the right balance 
between the different aims of using NIPT: the aim of detecting all T21 cases might be achieved 
only with a slightly higher rate of invasive testing; the aim of reducing invasive testing, on the other 
hand, comes with the disadvantage of not detecting all cases of T21. Nevertheless, the model alone 
is an insufficient basis for any decision, as it is based on several assumptions and simplifications. 
 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 101 
6 SAFETY 
6.1 Research questions  
Element ID Research question 
C0008 How safe is NIPT in relation to the comparators? 
C0006 What are the consequences of false positives, false negatives and incidental 
findings generated by use of the technology from the point of view of patient 
safety? 
B0010 What kind of data/records and/or registry is needed to monitor the use of NIPT 
and the comparators? 
 
6.2 Included studies 
Study characteristics and QoE 
For the assessment of safety, all 41 primary studies were considered. The main characteristics of 
individual studies as well as the risk of bias and the QoE of the studies retrieved can be found in 
the clinical effectiveness domain.  
Detailed information on the studies retrieved can be found in the evidence tables in Appendix 1 
(Tables A2–A5). 
 
6.3 Safety outcomes 
[C0008] – How safe is NIPT in relation to the comparators? 
The only existing comparative information relates to safety measures (FP and FN rates) and no-
call results (test failures, low-quality samples, undeterminate results). These outcomes were ana-
lysed separately for each of the three types of aneuploidy, providing individual results for general, 
high and high and intermediate risk of aneuploidies (see the definition earlier) given the different 
disease prevalence. Twin pregnancies were also assessed individually given that NIPT can have a 
different performance in these patients.  
 
6.3.1 NIPT as a primary screening test for the general singleton pregnancy population 
Nine studies reported on safety outcomes for NIPT as a primary testing method: seven provided 
data on T21 (n=135,957 women), six on T21, T18 and T13 individually (n=135,378) and one on the 
three trisomies combined (n=106,898) (Table 12). Overall, the studies showed 78 FPs for T21 
(0.06%), 62 FPs for T18 (0.04%) and 52 FPs for T13 (0.05%). The total number of FNs found was 
six for T21 (0.004%), six for T18 (0.004%) and three for T13 (0.02%). 
Four of the paired accuracy studies included provided a comparative analysis of NIPT versus com-
bined screening [30, 31, 41, 42] for T21 (Table 11). All showed higher FP rates for combined testing 
in comparison with NIPT. The FP rate ranged from 3.6% to 6.7% for combined testing and was 
below 0.3% for NIPT in all retrieved studies. Three of these studies [31, 41, 42] showed a zero or 
near zero FP rate. The FN rate obtained with combined testing was higher than that for NIPT in  
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two studies [31, 41]: 14.3% and 21% versus 0%. In the other two studies [30, 42], the FN rate was 
zero with both testing methods.  
The proportion of no-call results in the comparative studies ranged from 0.5% to 3%. Two of these 
studies provided the incidence of aneuploidies in these samples [31, 42], and we estimated the FP 
and FN rates which would result from considering these pregnancies as either high risk or low risk. 
Under the first assumption, the FP rate would increase to 1.79% and 3% in the corresponding stud-
ies. Under the second assumption, the FN rate would increase to 5.88% and 7.3%, respectively. In 
the study of Quezada et al. [42] the estimated FN rate for NIPT would exceed that of combined 
screening (5.88% vs. 0%). 
The four comparative DTA studies reported higher FP rates with standard screening (0.3%–5.8%) 
than with NIPT for T18 (0.006%–0.2%). The FN rate was zero in two studies for both approaches 
[30, 41]. In the study of Norton et al. [31] the FN rate was higher for standard screening than for 
NIPT (20% vs. 10%). In contrast, Quezada et al. [42] reported a higher FN rate with NIPT (10% 
vs. 0%). 
When we reanalysed the results of Norton et al. [31] considering the no NIPT results as high-risk 
cases, the FP rate increased to 2.19% versus the 0.3% obtained with combined screening. The 
FN rate rose to 18.2% when these cases were considered as low risk, the FN rate being 20% with 
combined testing. Bianchi et al. [30] did not observe any T18 among the no-result cases. 
The FP rate obtained for T13 was also lower with NIPT than with combined testing in the three 
paired comparative studies [30, 31, 42], although in two studies it was less than 1% with both ap-
proaches [30, 31]. In the study of Quezada et al. [42] the FP rate was 5.9% for combined testing 
versus 0.07% for NIPT. The FN rate achieved with NIPT was lower in the study of Norton et al. 
(0% vs. 50%) and higher in the study of Quezada et al. [42] (60% vs. 0%). The FN rate was 0% for 
both testing options in the study of Bianchi et al. [30]. 
When we recalculated these values for the study of Norton et al. [31] including no-result cases, we 
observed an FP rate of 4%. The FN rate was 50% if we considered these results as negative. No 
T13 cases were found among no-result samples. 
Mainly, the four remaining noncomparative studies showed rates of NIPT FP, FN and test failures 
similar to those reported by comparative studies (Table 11). Only Sarno et al. [39] found a higher 
FN rate for T18 and T13 (10.8% and 46.7%, respectively), and Pergament et al. [44] reported an 
NIPT failure rate of around 8%.  
Table 12: NIPT safety results of individual studies performed in the general  
singleton pregnancy population 
Authors, year, 
countries  
Safety, no. or rate Final test failure 
rate  
Failure rate at 
first attempt 
Trisomy 21 Trisomy 18 Trisomy 13 
Sarno et al. [39], 2016, 
UK 
FN rate 1.26% FN rate 10.8% FN rate 46.7% 1.5% (n=168) 2.9% (n=316) 
Comas et al. [40], 
2015, Spain 
FP=1 (0.3%) 
FN=0 
— — 1.2% (n=4) 2.8% (n=9) 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 103 
Authors, year, 
countries  
Safety, no. or rate Final test failure 
rate  
Failure rate at 
first attempt 
Trisomy 21 Trisomy 18 Trisomy 13 
Norton et al. [31], 
2015, USA, Canada, 
Sweden, Belgium, 
Netherlands and Italy  
cfDNA 
FP=9 (0.06%) 
FN=0 
Standard 
screening 
FP=854 (5.4%) 
FN=8 (21%) 
cfDNA 
FP=1 (0.01%) 
FN=1 (10%) 
Standard 
screening 
FP=49 (0.3%) 
FN=2 (20%) 
cfDNA 
FP=2 (0.018%) 
FN=0 
Standard 
screening 
FP=28 (0.25%) 
FN=1 (50%) 
3% (n=488)  
(absence of cfDNA 
result) 
3% (n=488) 
Pérez-Pedregosa et al. 
[41], 2015, Spain 
cfDNA 
FP=0 
FN=0 
Standard 
screening 
FP=38 (6.7%) 
FN=2 (14.3%) 
cfDNA 
FP=0 
FN=0 
Standard 
screening 
FP=5 (0.86%) 
FN=0 
— 0.5% (n=3) 0.5% (n=3) 
Quezada et al. [42], 
2015, UK  
cfDNA 
FP=1 (0.04%) 
FN=0 
Standard 
screening 
FP=139 (4.96%) 
FN=0 
cfDNA 
FP=5 (0.18%) 
FN=1 (10%) 
Standard 
screening 
FP=163 (5.8%) 
FN=0 
cfDNA 
FP=2 (0.07%) 
FN=3 (60%) 
Standard 
screening 
FP=168 (5.9%) 
FN=0 
1.9% (n=54)  
(low FF or assay 
failure) 
4.25 (n=122) 
Zhang et al. [43], 2015, 
China 
FP=61 (0.05%) 
FN=6 (0.83%) 
FP=51 (0.05%) 
FN=3 (1.77%) 
FP=45 (0.04%) 
FN=0 
0.098% (n=145) 
(inappropriate 
samples: 0.14%  
or n=211;  
uncertain results: 
0.2% or n=326) 
0.098% 
(n=145) 
Bianchi et al. [30], 
2014, USA  
cfDNA 
FP=6 (0.3%) 
FN=0 
Standard 
screening 
FP=69 (3.6%) 
FN=0 
cfDNA 
FP=3 (0.2%) 
FN=0 
Standard 
screening 
FP=11 (0.6%) 
FN=0 
cfDNA 
FP=3 (0.16%) 
FN=0 
Standard 
screening 
FP=6 (0.67%) 
FN=0 
0.9% (n=18) 0.9% (n=18) 
Pergament et al. [44], 
2014, USA 
Prospective DTA study 
Data collection period 
not reported 
FP=0 
FN=0 
FP=1 (0.1%) 
FN=1 (3.84%) 
FP=0 
FN=0 
8.1% (n=85/1051) 8.1% (n=85) 
Song et al. [45], 2013, 
China 
Comparative 
prospective DTA study 
Apr 2011–Dec 2011 
FP=0 
FN=0 
FP=1 (0.06%) 
FN=0 
FP=0 
FN=0 
3.8% (n=73) 3.8% (n=73) 
Abbreviations: cfDNA=cell-free DNA; DTA=diagnostic test accuracy; FF=fetal fraction; FN=false negative(s);  
FP=false positive(s). 
* Number of samples with noninvasive prenatal testing and reference standard results. 
 
6.3.2 NIPT as an add-on to FCT for the high-risk singleton pregnancy population 
There is lack of direct data regarding the safety of the prenatal strategy which includes NIPT as an 
add-on to the combined test. However, 26 DTA studies which assessed the performance of NIPT in 
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singleton women who had been classified as having high risk of aneuploidy were included for indi-
rect inferences and modelling. The individual characteristics and results of these individual studies 
are displayed in Table 13. 
Only six of the 24 studies included which provided T21 accuracy data showed FP cases when verified 
against invasive testing and/or pregnancy follow-up [48, 49, 51, 61, 64, 69, 70]. The FP rate was 
less than 0.5% in all these studies. The overall mean rate of FPs in the whole population was 0.03% 
(10/28,591). The proportion of reported no-call/test failures/undeterminate results ranged from 
0.002% to 6.3%. Only one of the studies provided aneuploidy findings for these no-result samples. 
The recalculated FP considering these no-call samples as positive would be 4% [49]. FN cases 
were reported in only five studies [48, 49, 62, 63, 67]. The FN rate in these studies ranged from 1.92% 
to 5.6%. The mean rate was 0.017% (2/28,591). When recalculated in the study of Persico et al. 
[49], with no results classified as negative, it would increase to 5.4%. 
A total of 21 studies analysed NIPT in T18 (n=27,999 women). Six reported FP cases, showing FP 
rates between 0.05% and 0.21% [48, 51, 58, 62, 64, 69]. Overall, the mean rate of FP cases in the 
studied population was 0.028% (8/2799). The FP rate including no-call data in the study of Persico 
et al. [49] was 3.28%. Five studies reported FN cases, with FN rates from 0.33% to 37.5% [51, 61, 
63, 68, 69] (overall mean rate 0.05%). The recalculated FN rate in the study of Persico et al. [49] 
was 13.3%. 
Seventeen studies reported on NIPT T13 detection (n=23,760 participants). Of these, only five 
(29%) reported on FP cases. The FP rate observed in the studies ranged between 0.02% and 
0.24% [48, 51, 64, 65] (overall mean rate 0.02%). When recalculated, the FP rate in the study of 
Persico et al. [49] rose to 3.55%. Three studies [60, 61, 68] identified FN cases, and the FN rate 
ranged in these studies from 12.5% to 100%. The mean value was 0.021% (5/23,760) 
Table 13: Noninvasive prenatal testing safety results of individual studies performed  
in the high-risk singleton pregnancy population 
Authors, year, 
countries  
Safety, no. or rate Final test failure 
rate 
Failure rate at 
first attempt 
Trisomy 21 Trisomy 18 Trisomy 13 
Kim et al. [46], 2016, 
Korea 
FP=0 
FN=0 
— — NS 
Low FF: 0% 
NS 
Ma et al. [47], 2016, 
China  
FP=0 
FN=0 
FP=0 
FN=0 
FP=0 
FN=0 
0.06%  0.06% 
Oepkes et al. [48], 
2016, Netherlands 
FP=2 (0.15%) 
FN=1 (3.33%) 
FP=1 (0.07%) 
FN=0 
FP=2 (0.14%) 
FN=0 
0.3% (low FF 0.2%) 0.3% (n=3) 
Persico et al. [49], 
2016, Italy 
FP=0 
FN=1 (2.8%) 
FP=0 
FN=0 
FP=0 
FN=0  
3.8%  
(Low FF: 3%) 
3.8%  
Zhang et al. [50], 2016, 
China  
FP=0 
FN=0 
FP=0 
FN=0 
— NS NS 
Benachi et al. [51], 
2015, France  
FP=1 (0.11%) 
FN=0 
FP=1 (0.11%) 
FN=3 (0.33%) 
FP=1 
FN=0 
0.7% (n=7)  0.7% (n=7) 
Hernandez-Gomez et 
al. [52], 2015, Mexico  
FP=0 
FN=0 
— — 2.8% (n=1) 2.8% (n=1) 
Ke et al. [53], 2015, 
China  
FP=0 
FN=0 
FP=0 
FN=0 
FP=0 
FN=0 
0% 0% 
Lee et al. [54], 2015, 
Korea  
FP=0 
FN=0 
FP=0 
FN=0 
FP=0 
FN=0 
1.07% (n=1) 1.07% (n=1) 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 105 
Authors, year, 
countries  
Safety, no. or rate Final test failure 
rate 
Failure rate at 
first attempt 
Trisomy 21 Trisomy 18 Trisomy 13 
Sago et al. [55], 2015, 
Japan  
— — — 0.05% 0.05% 
Sánchez-Usabiaga et 
al. [56], 2015, Mexico  
FP=0 
FN=0 
FP=0 
FN=0 
FP=0 
FN=0 
1% (n=4)  
Low FF: 0.5% (n=2) 
1% (n=4)  
Song et al. [57], 2015, 
China 
FP=0 
FN=0 
FP=0 
FN=0 
FP=0 
FN=0 
0.5% (n=1) 0.5% (n=1) 
Wang et al. [58], 2015, 
China  
FP=0 
FN=0 
FP=1 (0.11%) 
FN=0 
— NS NS 
Jeon et al. [59], 2014, 
China  
FP=0 
FN=0 
FP=0 
FN=0 
— 0% 0% 
Korostelev et al. [60], 
2014, Russia 
FP=0 
FN=0 
FP=0 
FN=0 
FP=0 
FN=1 (25%) 
0% 0% 
Porreco et al. [61], 
2014, USA 
FP=3 (0.09%) 
FN=0 
FP=0 
FN=3 (7.7%) 
FP=0 
FN=2 (12.5%) 
1.3% (n=54) 1.3% (n=54) 
Stumm et al. [62], 
2014, Germany and 
Switzerland 
FP=0 
FN=2 (4.8%) 
FP=1 (0.21%) 
FN=0 
FP=0 
FN=0 
6.3% (n=32) 6.3% (n=32) 
Willems et al. [63], 
2014, Belgium 
FP=0 
FN=1 (1.92%) 
FP=0 
FN=1 (20%) 
FP=0 
FN=0 
1.06% (32 samples) 1.8% (n=55) 
Zhou et al [64], 2014, 
China  
FP=2 (0.05% 
(0.02%–0.10%)) 
FN=0 
FP=2 (0.05% 
(0.02%–0.10%)) 
FN=0 
FP=2 (0.05% 
(0.02%–0.10%)) 
FN=0 
0.05% (n=4) 
(absence of cfDNA 
result) 
0.05% (n=4) 
Liang et al. [65], 2013, 
China  
FP=0 
FN=0 
FP=0 
FN=0 
FP=1 (0.24%) 
FN=0 
2.76% (n=12)  
(failed sequencing 
quality control) 
2.76% (n=12) 
Nicolaides et al. [66], 
2013, UK  
FP=0 
FN=NS 
FP=0 
FN=0 
FP=0 
FN=0 
5.4% (n=13) 5.4% (n=13) 
Verweij et al. [67], 
2013, Norway, Sweden 
and Netherlands  
FP=0 
FN=1 (5.6%) 
— — 3.07% (n=16) 9.8% (n=51) 
Lau et al. [68], 2012, 
Japan  
FP=0 
FN=0 
FP=0 
FN=6 (37.5%) 
FP=0 
FN=2 (100%) 
0% 0% 
Norton et al. [69], 
2012, USA, 
Netherlands and 
Sweden  
FP=1 (0.03% 
(0.002%–
0.20%)) 
FN=0 
FP=2 (0.07% 
(0.02%–0.25%)) 
FN=1 (2.6%) 
— 4.8% (n=148) 4.8% (n=148) 
Ehrich et al. [70], 
2011, USA 
FP=1 (0.24%) 
FN=0 
— — 4% (n=18) 
(processing error or 
quality control) 
4.3% (n=20) 
Abbreviations: cfDNA=cell-free DNA; FF=fetal fraction; FN=false negatives; FP=false positives; NS=not specified. 
 
6.3.3 NIPT as an add-on to FCT for the high- and intermediate-risk  
singleton pregnancy population 
Only one study retrieved assessed NIPT safety in the high- and intermediate-risk population. The 
FP rate for T21, T18 and T13 excluding no-result cases was 0.027%, 0.11% and 0.11%, respec-
tively. The corresponding FN rates were 2.3%, 0% and 50% [71] (Table 14). 
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Table 14: Characteristics and noninvasive prenatal testing safety results of individual 
studies performed in the high- and intermediate-risk pregnant population 
Author, year, country Safety, no. or rate Final test failure 
rate 
Failure rate at 
first attempt 
Trisomy 21 Trisomy 18 Trisomy 13 
Gil et al. [71], 2016,  
UK  
FP=1 (0.03%) 
FN=1 (2.3%) 
FP=4 (0.11%) 
FN=3 (12.5%) 
FP=4 (0.11%) 
FN=2 (50%) 
1.75% (n=65) 2.8% (n=99) 
Abbreviations: FN=false negatives; FP=false positives. 
 
6.3.4 NIPT as an add-on to FCT for the high-risk twin pregnancy population 
Taking to account the lack of comparative studies for assessing NIPT safety, assumptions on safety 
outcomes are based on the results reported by noncomparative DTA studies performed in the twin 
pregnancy population (Table 15). Two of the six studies on twin pregnancies reported FP rates for 
T21 ranging from 0.20% to 1.22% [72, 74]. Only one study observed FNs (FN rate 7.7%) [74]. This 
last study reported an FP rate for 3.58% for T18. The rate of FN for T18 ranged from 25% to 50% 
[39, 75]. Only one study assessed T13 in twin pregnancies, and found an FN rate of 100% (FP 
rate was not specified) [39].  
Sarno et al. [39] reported a test failure rate of 4.8%. The failure rate in the study performed by Tan 
et al. [73] was 0.9%. Two of the studies did not indicate the number of no-call results [75, 76].  
Table 15: Characteristics and noninvasive prenatal testing safety results of individual 
studies performed in the twin pregnancy population 
Authors, year, 
countries 
Safety, no. or rate Final test failure 
rare 
Failure rate at 
first attempt 
Trisomy 21 Trisomy 18 Trisomy 13 
Fosler et al. [72], 2017, 
USA  
Only cohort B included 
FP=1 (0.20%) 
FN=0 
— — 0% 0% 
Sarno et al. [39], 2016, 
UK  
Reported only twin 
pregnancy results 
FP=NS 
FN=0 
FP=NS 
FN=25% 
FP=NS 
FN=100% 
4.8% (n=21) 9.4% (n=41) 
Tan et al. [73], 2016, 
China  
FP=0 (0-.70) 
FN=0 
— — 0.9% (n=5) 0.9% (n=5) 
Bevilacqua et al. [74], 
2015, Belgium, UK 
and Spain  
FP=4 (1.22%) 
FN=1 (7.7%) 
FP=12 (3.58%) 
FN=0 
— 3.1% (n=16) 
(low FF) 
3.1% (n=16) 
Huang et al. [75], 
2014, China  
FP=0 
FN=0 
FP=0 
FN=1 (50%) 
— Not reported  Not reported  
Lau et al. [76], 2013, 
China  
cfDNA 
FP=0 
FN=0 
Comparator 
FP=2 (18.2%) 
FN=0 
— — Not reported Not reported  
Abbreviations: cfDNA=cell-free DNA; FF=fetal fraction; FN=false negatives; FP=false positives; NS=not specified. 
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6.4 Additional safety outcomes 
No evidence was found to answer the question regarding the comparison of NIPT and combined 
testing in relation to the number of children born with other major unconfirmed chromosomal con-
ditions/anomalies (not targeted by prenatal aneuploidy screening) or the increase in elective preg-
nancy termination for other unconfirmed chromosomal anomalies with uncertain significance (not 
targeted by prenatal aneuploidy screening).  
The only comparative information available relating to missed chromosomal conditions comes from 
the findings of the study of Norton et al. [31] on no-call samples and the study of Persico et al. [49], 
which reports on the results of karyotyping for cases which were not targeted by NIPT. The study 
of Norton et al. [31] established that apart from T21, T18 and T13, NIPT missed four cases of 
triploidy, one of case trisomy 16 cases of mosaicism, one case of 11p deletion and one case of a 
structurally abnormal chromosome which may have been detected by standard combined screen-
ing. Persico et al. [49] reported on eight cases of chromosomal defects identified by fetal karyotype 
which are not targeted by NIPT (one case of 47XX4, one case of 47XX22, four cases of 46XY, 
one case of 46XX and one case of Mos45 X0/46XY). Pergament et al. [44] found three T21 cases, 
four T18 cases, two T13 cases and one monosomy X case in samples with no NIPT results, alt-
hough this study, where NIPT was performed as a primary test, did not provide results on combined 
testing.  
Several of the high-risk studies provided data on sex chromosome anomalies (monosomy X, tri-
somy X, Turner syndrome (45,X) or Klinefelter syndrome (47,XXY)). The FN rates for these ranged 
from 0% to 100% in the studies included.  
 
[C0006] – What are the consequences of false positives, false negatives and incidental 
findings generated by use of the technology from the point of view of patient safety? 
Since the studies were not outcome based, there is no information regarding the consequence of 
FPs, FNs or incidental findings generated by the technology. Incidental findings were not reported 
in any of the studies.  
 
6.5 Safety risk management 
[B0010] – What kind of data/records and/or registry is needed to monitor  
the use of NIPT and the comparators? 
Important uncertainties exist regarding the performance of the different NIPT screening pathways 
in real-life scenarios. Data records and/or registries could provide information regarding the real  
uptake of NIPT screening when implemented in routine practice, as well as information on the rate 
of invasive testing, detection of all major anomalies, abortions, miscarriages, and other patient-
relevant outcomes. This information is critical to determine the real implications of implementing 
NIPT as a public health screening programme. 
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6.6 Discussion 
No evidence exists regarding the adverse consequences derived from NIPT screening in terms of 
patient outcomes. The only information available, derived from 41 prospective diagnostic accuracy 
studies, relates to the reporting of FPs and FNs and no-recall cases. 
In this respect, the few comparative studies on the general population which were found are con-
sistent with the finding that NIPT would lead to a reduction in the FP rate for all three trisomies in 
comparison with combined testing if used as a primary test. The studies also support that the FN 
rate could also be lower for T21, with only minor differences being observed for T18 and inconsistent 
results being observed for T13. However, as previously mentioned, all studies included are limited 
by important methodological shortcomings. General population studies frequently have important 
follow-up losses and lack in most cases verification of negative cases, miscarriages, abortions and 
no-recall cases. When we reanalysed the data including no-recall cases we observed that depend-
ing on how we classified cases, the FP rate and FN rate could be higher than those observed with 
combined testing. No-call results constitute an important challenge and should be assessed further.  
The studies included were not explicitly designed for the comparison of FP and FN rates between 
FCT and NIPT screening, contingent on the high or high and intermediate results of FCT. On the 
basis of the 27 high-risk studies and the one study on intermediate and high risk, which assessed 
NIPT performance, it is estimated that NIPT would contribute to reduce the FP rate for all three 
types of aneuploidy (<1%), highlighting the potential contribution of these tests to reduce anxiety 
and invasive testing complications. However, given the sample size, the number of trisomic preg-
nancies was too small for valid conclusions to be drawn. Although it has not been not investigated 
in current studies, positive NIPT results could result from different biological and nonbiological  
causes, including confined maternal mosaicisms, maternal aneuploidy, maternal copy number vari-
ants, maternal malignancy or a co-twin demise. Therefore confirmation of positive cases with diag-
nostic testing is always required. 
The eligible studies also seem to support that NIPT would lead to few missing cases, but these 
results should also be analysed with caution, particularly with regard to T18 and T13, since the FN 
rate for these trisomies was very high in some of the studies included [61, 63, 71, 76]. In the study 
of Gil et al. [71], NIPT would have missed 12.5% of T18 cases (3/24) and 50% of T13 cases (2/4) 
but these cases were all detected with the contingent screening approach, highlighting the possible 
role of invasive testing for very high risk patients with ultrasound anomalies. As previously pointed 
out, the limited sample size of the studies, considering the number of pregnancies available in clin-
ical practice, could have greatly contributed to the heterogeneity observed. Only one of the high-risk 
studies reported on individuals with no results, and this is an important drawback given the possible 
implications of these no-call results in real-life practice.  
Another important limitation of the studies is the lack of information regarding the detection of neural 
tube defects and other major chromosomal anomalies in relation to combined screening [91, 131]. 
Whilst it is acknowledged that NIPT will miss a large number of major anomalies that are inci-
dentally diagnosed by invasive testing [132], the extent of these losses is relatively unknown. Accord-
ing to two retrospective population-based analyses conducted in California and Denmark, up to 
17%–23% of clinically significant anomalies could be missed by NIPT [91, 133]. A retrospective 
cohort study established that NIPT as the sole method might miss 95% of the fetal findings detected 
with ultrasound examination [134]. The role of NT and biochemical markers needs to be evaluated 
in appropriately designed studies so as to establish the best option for T21, T18 and T13 screening. 
Uncertainty also exists regarding the implications of incidental findings on sex chromosome aneu-
ploidies and other conditions which are not being targeted [135, 136]. 
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7 POTENTIAL ETHICAL, ORGANISATIONAL, PATIENT AND SOCIAL, 
AND LEGAL ASPECTS 
7.1 Research questions 
Element ID Research question 
F0010 What are the known and estimated benefits and harms for pregnant women 
when NIPT is implemented or not implemented? 
F0011 What are the benefits and harms of NIPT for relatives, other patients, 
organisations, commercial entities, societies, etc.? 
F003 Are there any other hidden or unintended consequences of NIPT and its 
applications for pregnant women, relatives, other patients, organisations, 
commercial entities, society, etc.? 
F004 Does the implementation or use of NIPT affect the pregnant woman’s capability 
and possibility to exercise autonomy? 
F006 Is there a need for any specific interventions or supportive actions concerning 
information so as to respect the pregnant woman’s autonomy when the 
technology is used? 
F0101 Does NIPT invade the sphere of the pregnant woman/user? 
F0012 How does implementation or withdrawal of the technology affect the distribution 
of resources? 
F0017 What are the ethical consequences of the choice of endpoints, cut-off values  
and comparators/controls in the assessment? 
G0001 How does NIPT affect the current work processes? 
G0100 What kind of pregnant woman/participation flow is associated with the new 
technology? 
G0002 What kind of involvement has to be mobilised for pregnant women/participants 
and important others and/or carers? 
G0003 What kind of process ensures proper education and training of staff? 
G0004 What kind of cooperation and communication of activities has to mobilised? 
G0012 In what way is the quality assurance and monitoring system of NIPT organised? 
G0005 How do decentralisation or centralisation requirements influence the 
implementation of NIPT? 
G0006 What are the costs of processes related to acquisition and setting up of NIPT? 
G0023 How does NIPT modify the need for other technologies and use of other 
resources? 
G0007 What is the likely budget impact of implementing the technologies being 
compared? 
G0008 What management problems and opportunities are attached to NIPT? 
G0009 Who decides which pregnant women are eligible for NIPT and on what basis? 
G0010 How is NIPT accepted? 
H0100 What expectations and wishes do pregnant women have with regard to NIPT 
and what do they expect to gain from the technology? 
H0006 How do pregnant women perceive NIPT? 
H0002 What is the burden on carers? 
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H0012 Are there factors that could prevent a group or person from gaining access to 
NIPT? 
H0202 How are screening options explained to pregnant women? 
H0203 What specific issues may need to be communicated to pregnant women to 
increase acceptance of NIPT? 
 
7.2 Included studies 
The systematic review retrieved 34 studies which assessed ethical, legal, organisational or social 
issues related to NIPT implementation in a routine prenatal care (Table 16). The studies were mainly 
performed in the USA and the UK (10 in each country), and the remaining studies were from Bel-
gium, Spain, Sweden, the Netherlands, Australia, and Canada; only two studies were multicentre 
studies. Most of documents were questionnaire-based or interview-based surveys focusing on an-
alysing attitudes or preferences towards to NIPT of pregnant women/parents or health profession-
als (n=13) or studies aimed at assessing the costs and benefits or cost-effectiveness of NIPT used 
in different screening strategies (n=10). The questionnaire-based survey were administered in writ-
ing, by telephone, or online mainly. Six full cost-effectiveness analysis determined the cost of NIPT 
as a contingent or primary strategy compared with the conventional screening pathway in a hypo-
thetical cohort of pregnant women or a sample of those recruited from a routine prenatal care set-
ting. Moreover, five reviews (two of them systematic), three HTA reports and three position state-
ments were taken into account to analyse ethical and/or organisational issues related to NIPT imple-
mentation. 
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Table 16: Main characteristics of studies included in the ethical analysis, organisational aspects and patients and social aspects domains 
Authors, year, 
countries 
Study characteristics Objective Study participant characteristics Outcomes assessed Assessment 
element 
Oxenford et al. [137], 
2017, UK 
Research study 
Mixed method approach (quantitative 
questionnaires at three points and 
posttraining qualitative interviews) 
To develop and evaluate a training 
package for health professionals to 
support the introduction of NIPT into 
clinical practice 
Midwives and other health 
professionals 
n=381 (follow-up in 151 and 
interviews in 35 attendees) 
Self-perceived confidence and 
knowledge 
Organisational 
Bayón Yusta et al. 
[138], 2016, Spain 
Full HTA report (clinical effectiveness 
and economic evaluation) 
See Appendix 1, Table A7 See Appendix 1, Table A7 See Appendix 1, Table A7 Organisational 
Chitty et al. [139], 
2016, UK 
Cost–benefit analysis To investigate the benefits and costs 
of implementation of NIPT  
All pregnant women with a T21 risk  
of at least 1:1000 
n=3175 
NIPT performance results (uptake 
rate, number of T21 cases detected, 
invasive test performed and 
miscarriages avoided)  
Cost of NIPT 
Ethical 
Gregg et al. [140], 
2016, USA 
Position statement of the American 
College of Medical Genetics and 
Genomics 
See Appendix 1, Table A1 See Appendix 1, Table A1 See Appendix 1, Table A1 Ethical 
Lewis et al. [141], 
2016, UK 
Cross-sectional survey and semi-
structured interviews (face-to-face 
counselling and written information) 
To assess women’s experience of 
being offered NIPT using validated 
measures of decisional conflict, 
decisional regret and anxiety 
Pregnant women with a T21 
risk>1:1000 based on FCT  
n=582 
Preferences and anxiety of pregnant 
women 
Ethical 
Patient and social 
Lewis et al. [142], 
2016, UK 
Telephone interview-based survey 
December 2013 to September 2014 
To explore women’s attitudes 
towards NIPT and determine factors 
influencing their decisions around 
uptake of NIPT 
Pregnant women with a standard T21 
screening risk>1:1000 were offered 
NIPT as a contingent test method 
n=45 (87% accepted NIPT) 
Attitudes and preferences  
of pregnant women 
Ethical 
Lewis et al. [130], 
2016, UK 
Validation study (MMIC) 
Questionnaires and semi-structured 
interviews at two time points 
To validate a modified MMIC 
instrument for NIPT and measure 
informed choice among women 
offered NIPT following T21 screening 
All singleton pregnant women 
ages>16 years who accepted T21 
screening as part of routine care 
n=585 questionnaires and n=45 
interviews 
Attitudes and preferences  
of pregnant women 
Ethical 
Maxwell et al. [143], 
2016, Australia 
Cost–benefit analysis To establish the benefits and cost of 
different FCT cut-off points for NIPT 
as a contingent screening method 
All pregnant women attending for FCT 
n=115,648 
Screen positive rate 
Detection rate 
NIPT fee at different FCT cut-off points 
Ethical 
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Authors, year, 
countries 
Study characteristics Objective Study participant characteristics Outcomes assessed Assessment 
element 
Michie et al. [144], 
2016, USA 
Qualitative review To assess the information provided to 
patients in written patient education 
and consent documents 
n=32  
Informed consent documents 
designed by laboratories and clinics 
Information about test performance, 
screened conditions, test counselling 
and psychosocial issues and other 
test considerations 
Organisational 
Sahlin et al. [145], 
2016, Sweden 
Questionnaire-based survey 
January to June 2015 
To evaluate pregnant women’s 
awareness, attitudes, preferences for 
risk information and decision making 
regarding NIPT 
Pregnant women in any week of 
gestation recruited in waiting rooms 
of nine different maternity clinics 
n=1003 
Attitudes and preferences  
of pregnant women 
Ethical 
Patient and social 
Van Schendel et al. 
[146], 2016, 
Netherlands 
Questionnaire-based survey 
(administered by writing or online 
after genetic counselling) 
To evaluate preferences and decision 
making among high-risk pregnant 
women  
Pregnant women with an increased 
risk for fetal trisomies 21, 18 and 13 
(cut-off risk≥1:200)  
n=1091 
Preferences of pregnant women Ethical 
Patient and social 
Allyse et al. [88], 
2015, USA 
Narrative review Review international implementation 
and challenges of NIPT in high- and 
low-income countries 
NA Clinical, ethical, legal and regulatory 
issues  
Ethical 
Organisational 
Benn et al. [33], 
2015, USA, Spain, 
Hong Kong, 
Netherlands, 
Canada, Israel, UK 
Position statement of the International 
Society for Prenatal Diagnosis 
See Appendix 1, Table A1 See Appendix 1, Table A1 See Appendix 1, Table A1 Ethical  
Organisational 
Beulen et al. [147], 
2015, Netherlands 
Discrete choice experiment Web 
questionnaire-based survey (including 
minimal gestational age, time to wait 
for test results, level of information, 
detection rate, FP rate, miscarriage 
risk and cost of prenatal test) 
To evaluate pregnant women’s and 
healthcare professionals’ preferences 
regarding specific prenatal screening 
and diagnostic test characteristics 
Pregnant women (n=596) 
Healthcare professionals (n=297) 
Attitudes and preferences of 
pregnant women and healthcare 
professionals 
Ethical 
Patient and social 
Evans et al. [148], 
2015, USA 
Cost-effectiveness analysis 
Decision tree analysis 
To determine the cost-effectiveness 
of NIPT as a primary strategy, as a 
contingent strategy and as a hybrid 
strategy (all women aged≥35 years 
and women <35 years who were 
high-risk on FCT) 
NA Cost per patient 
Marginal cost per additional case 
Ethical 
Farrell et al. [149], 
2015, USA and 
Australia 
Questionnaire-based survey 
(administered by investigator) 
September to December 2012 
To assess Latina pregnant women’s 
understanding of NIPT and identify 
what factors influence uptake/refusal 
of NIPT to adapt counselling to the 
needs and interests of this population 
Latina pregnant women aged≥18 
years were referred to genetic 
counselling and offered NIPT  
n=63 (22 women elected to have 
NIPT and 41 women declined NIPT) 
Preferences of pregnant women Ethical 
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Authors, year, 
countries 
Study characteristics Objective Study participant characteristics Outcomes assessed Assessment 
element 
Skirton et al. [150], 
2015, UK 
Systematic review  
Websites advertising NIPT for 
aneuploidies by two Internet search 
engines (Google UK and Bing) 
To investigate the way commercial 
companies and private health 
providers are currently marketing 
NIPT to patients 
NA Attitudes and preferences of 
pregnant women  
Ethical 
Tamminga et al. 
[151], 2015, 
Netherlands 
Discrete choice experiment 
questionnaire-based survey 
November 2013 to July 2014 
To investigate health professionals’ 
opinions towards offering NIPT as a 
primary screening test method 
Obstetric health professionals 
received in-service NIPT training 
n=240 
Preferences of health professionals Ethical 
Patient and social 
Walker et al. [152], 
2015, USA 
Cost-effectiveness analysis 
Monte Carlo simulation with one-way 
and probabilistic sensitivity analysis 
To determine the cost-effectiveness 
of cfDNA as a replacement for 
integrated screening using a societal 
cost perspective 
Hypothetical cohort of 1,000,000 
pregnant women of at least 10 weeks’ 
gestation 
ICER Organisational 
Walker et al. [153], 
2015, USA 
Cost-effectiveness analysis from 
societal, governmental and payer 
perspectives 
Decision-analytic model using 
microsimulation and probabilistic 
sensitivity analysis 
To determine the cost-effectiveness 
of contingent and universal NIPT 
compared with conventional 
screening 
Hypothetical cohort of 1,000,000 
pregnant women of at least 12 weeks’ 
gestation 
ICER Organisational 
Benn et al. [154], 
2014, USA 
Questionnaire-based survey  
March to August 2012 
To assess the opinions of fellows of 
the ACOG on expanded carrier 
testing and NIPT 
Obstetrician-gynaecologists 
n=222  
Preferences of prenatal healthcare 
professionals 
Ethical 
Patient and social 
Beulen et al. [155], 
2014, Netherlands 
Cost-effectiveness analysis 
Decision-analytic model 
To determine the cost-effectiveness 
of NIPT as add-on to FCT and as 
primary screening compared with 
FCT alone 
Theoretical cohort of 180,000 
pregnant women 
Total and relative costs 
ICER 
Organisational 
Chandrasekharan  
et al. [156], 2014, 
USA 
Narrative review To analyse factors affecting NIPT 
implementation in low- and middle-
income countries 
NA Regulatory, ethical issues 
Costs and access 
Informed decision-making 
Organisational 
Hulstaert et al. [157], 
2014, Belgium 
HTA report See Appendix 1, Table A7 See Appendix 1, Table A7 See Appendix 1, Table A7 Organisational  
Institute of Health 
Economic [158], 
2014, Canada 
Full HTA report (clinical effectiveness 
and economic evaluation) 
See Appendix 1, Table A7 See Appendix 1, Table A7 See Appendix 1, Table A7 Organisational 
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Authors, year, 
countries 
Study characteristics Objective Study participant characteristics Outcomes assessed Assessment 
element 
Kellog et al. [159], 
2014, USA 
Online questionnaire-based survey 
(17 questions that included 
demographic and Likert-scale format 
attitudinal) 
October to December 2012 
To assess attitudes towards NIPT 
and what impact would have 
increased use of NIPT in the future  
n=73 
Mothers of children with T21 
Attitudes of mothers of children  
with T21  
Ethical 
Lewis et al. [160], 
2014, UK 
Cross-sectional questionnaire-based 
survey (designed by health 
professionals using a modified  
Delphi technique) 
To assess the views and likely 
uptake of NIPT for trisomy 21 among 
potential service users in the UK 
n=1131 
Women and partners aged>18 years 
recruited from antenatal clinics and 
websites  
Preferences of pregnant 
women/parents 
Patient and social 
Morris et al. [161], 
2014, UK 
Cost analysis 
Decision-analytic model 
To determine the costs and outcomes 
of NIPT for T21 as a contingent 
strategy and as a primary strategy 
compared with current DS screening 
Hypothetical cohort of pregnant 
women 
n=10,000 
Number of cases of T21 detected, 
procedure-related miscarriages  
Total cost 
Ethical 
Neyt et al. [162], 
2014, Belgium 
Cost-consequences analysis  
(time-dependent multistage transition 
probability model) 
Short-term time horizon was applied 
and no discount rate was applied 
To estimate the consequences of 
introducing NIPT for the detection  
of trisomy 21 
All singleton pregnancies  
n=129,199 
Short-term screening costs per case 
of trisomy 21 diagnosed 
Incremental cost per extra case of 
T21 diagnosed 
Organisational 
Okun et al. [163], 
2014, Canada 
Cost analysis 
Scenario modelling  
To examine the cost and 
performance of NIPT in eight distinct 
scenarios or screening strategies 
Population based on a cohort of 
pregnant women observed for a 
single year 
n=144,570 
Total programme cost 
Cost per woman screened, per 
prenatally diagnosed pregnancy  
with T21, per additional prenatally 
diagnosed pregnancy with T21 
Ethical 
O’Leary et al. [164], 
2013, Australia 
Cost-effectiveness analysis 
Decision tree analysis 
To analyse the cost-effectiveness 
and performance of NIPT for high-
risk pregnancies following FCT 
compared with current practice 
Singleton pregnant women 
n=32,478 
Diagnostic test uptake 
Cost of testing pathway, screening, 
invasive diagnostic testing and NIPT 
Cost per trisomy 21 case confirmed 
ICER 
Ethical 
Sayres et al. [165], 
2014, USA 
Online questionnaire-based survey 
(two versions of 25 questions) 
To assess expected interest in cfDNA 
screening for trisomies 13, 18 and 21 
among the general public  
n=3164 
Adults aged≥18 years 
Attitudes of pregnant women Ethical 
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Authors, year, 
countries 
Study characteristics Objective Study participant characteristics Outcomes assessed Assessment 
element 
Skirton et al. [166], 
2014,UK 
Consensus document (guideline) 
Expert group of health professionals 
on prenatal diagnosis (n=13) from  
11 European countries (Belgium, 
Czech Republic, Denmark, Finland, 
Greece, Italy, Netherlands, Spain, 
Sweden and UK) 
To provide prenatal diagnostic testing 
services that enable families to make 
informed choices, consistent with 
their individual needs and values 
Women and/or their partners known 
to genetic services before pregnancy 
because of significant family history, 
fetus at risk of genetic condition or 
abnormal US findings, particularly 
where the fetal karyotype is normal 
NA Patient and social 
Skirton et al. [167], 
2013, UK 
Systematic review (November 2012) 
Six relevant electronic databases 
(CINAHL, MEDLINE, SocIndex, 
PsycARTICLES, PsycLIT and Web  
of Science) and hand searching 
To investigate factors influencing the 
clinical use of NIPT 
NA Attitudes and experience of  
pregnant women 
Economic analysis 
Regulation, practice and ethical 
issues 
Ethical 
Abbreviations: ACOG=American College of Obstetricians and Gynecologists; cfDNA=cell-free DNA, DS=Down syndrome; FCT=first-trimester combined testing; FP=false positive;  
HTA=health technology assessment; ICER=incremental cost-effectiveness ratio; MMIC=multidimensional measure of informed choice; NA, not available; NIPT=noninvasive prenatal testing; 
US=ultrasound.  
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7.3 Ethical assessment elements 
[F0010] – What are the known and estimated benefits and harms  
for pregnant women when NIPT is implemented or not implemented? 
The four basic principles of healthcare ethics include autonomy, nonmaleficence, beneficence and 
justice. In terms of autonomy, the early availability of results and the increased accuracy of NIPT 
as a screening test for T21, in comparison with the combined test, is presumed to facilitate a preg-
nant woman’s and her partner’s informed choice, which is generally regarded as the main objective 
of prenatal screening. A study from the UK looking at the introduction of NIPT in the NHS (RAPID 
study), which used a formal measure of informed choice, found very high rates of informed consent 
(89%) in 587 women offered NIPT [130]. Around half of the 240 obstetricians surveyed in the Neth-
erlands (47%) were of the opinion that the replacement of FCT by NIPT could simplify counselling, 
and 64% considered the procedure of the test easier to explain [151]. The vast majority felt that 
more women would use NIPT, but 49% considered that there could be a risk that pregnant women 
agreed to screening without fully thinking about their decisions. Further assessments are needed 
to understand in depth the implications for informed choice, as this can vary depending on many 
factors, including how the consent and counselling occur.  
Establishing the nonmaleficence and beneficence of NIPT is a complex issue because it relies on 
the value judgement of whether preventing these trisomies could be harmful or good. In essence, 
it requires weighing of the benefits and harms not only for the pregnant woman and her partner, 
but also for the family and other involved parties. For NIPT, the benefits and harms can vary sub-
stantially depending on the perspective and implementation approach (add-on, total or partial re-
placement). In general terms, NIPT is liable to lead to more ethical problems when used as a pri-
mary test rather than a second-tier test. A systematic review analysing the factors affecting NIPT 
uptake highlights that the positive aspects perceived by service users are the greater safety for 
the fetus, earlier information about fetal status and general ease of sample taking [167]. When NIPT 
is offered as a second-tier test, these benefits have to be weighed against the risk of missing mo-
saicisms and the nonidentification of other clinically relevant chromosomal anomalies, which could 
have been detected during the verification of the FCT high-risk results with invasive technologies. 
Whilst invasive testing can put women at a higher risk than NIPT, recent comparative studies highlight 
that the additional risk posed by amniocentesis or CVS could be lower than previously estimated, 
and all this information must be taken into account when ones is informing decision making.  
Available evidence supports that the implementation of NIPT as a primary test could increase the 
detection of T21, T18 and T13 and reduce the number of FP cases in comparison with combined 
screening, contributing to reduce unnecessary anxiety and procedure-related miscarriages in preg-
nant women who have tested positive. In a survey performed as part of the implementation study 
in the UK NHS, women were very much in favour of a test which was safe, accurate and reduced 
the need for invasive testing, identifying T21 cases which might otherwise be missed [141]. Against 
this claimed benefit, great uncertainties remain regarding the possibility of missing some of the 
trisomies because of mosaicisms or technical reasons. Assay failure could also be a potential 
matter of concern or worry because of the possible association of null results with a higher risk of 
chromosomal anomalies, as could the loss of information regarding other major defects and other 
major complications, especially if NIPT replaces NT assessment. In the Swedish survey the positive 
attitude of women to NIPT or FCT did not reach that of ultrasound examination [145]. In this study, 
the women who stated that they would not use NIPT were more interested in knowing about other, 
severer chromosomal anomalies than T21. The questionnaires in the Netherlands also reflected 
that pregnant women were willing to accept a less accurate test to obtain more information on fetal 
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chromosomal status or to exclude the risk of procedure risk miscarriage, whilst health professionals 
put more emphasis on the accuracy of the tests [147]. Around half of the health professionals who 
were trained to offer NIPT the Netherlands preferred to continue using NT measurements [151]. 
To comply with the principle of distribution of justice, it should be ensured that NIPT is cost-effective 
in relation to conventional approaches. The RAPID nonevaluation study performed in the UK, which 
was based on actual clinical data, established that NIPT as a contingent test, with a risk cut-off point 
greater than 1 in 150, could improve quality of care, choices for women and overall performance 
without increasing costs [139]. This and other economic analyses, which establish the cost-effec-
tiveness of NIPT for high-risk women, are based on decision analysis economic modelling, which 
are known not to be representative of real practice. To date, there are no appropriate real-world 
comparative studies to establish how the different NIPT algorithms differ with regard to standard 
approaches in relation to uptake, informed consent, performance or health outcomes (invasive test-
ing performed, miscarriage reduction, detection of other relevant fetal anomalies, etc.), raising im-
portant questions regarding the implementation of these technologies in real practice.  Taking into 
account the principle of distribution of justice it should be assessed if it would be ethical to spend 
resources on technologies which have important uncertainties regarding their implementation, 
adoption and outcomes. Screening being a morally sensitive issue, because of its association with 
abortion, the ethical implications of NIPT may differ in different countries, depending on the goals 
and values acceptable to the society.  
When discussing the principle of justice one should also keep in mind that the access to NIPT 
depends directly on the access to FCT if NIPT is to be used as a second-tier test. In this sense, 
NIPT will be available only to women who can afford FCT, which widens the gap between high- 
and low-income settings. Given the higher accuracy of NIPT it could happen that T21 would be-
come largely a problem of poor families, which would increase social stigmatisation. When reim-
bursement of NIPT as an add-on test is introduced, it is therefore essential to establish general 
reimbursement for FCT. 
 
[F0011] – What are the benefits and harms of NIPT for relatives, other patients, 
organisations, commercial entities, societies, etc.? 
[F003] – Are there any other hidden or unintended consequences of NIPT and its 
applications for pregnant women, relatives, other patients, organisations, commercial 
entities, society, etc.? 
[F004] – Does the implementation or use of NIPT affect the pregnant woman’s capability 
and possibility to exercise autonomy? 
If NIPT is implemented in the general pregnant population, an increase in the rate of detection of 
T21, T18 and T13 is expected, and this could lead to an increase in the number of affected fetuses 
aborted. In this sense, several studies have highlighted concerns regarding the possibility that NIPT 
could be seen to send a message of stigmatisation to families who live with these conditions and 
also reduce the availability of services such as medical care, physical therapy, occupational  ther-
apy or school programmes [167]. According to an anonymous online survey conducted in the USA, 
most mothers of children with T21 perceive that NIPT could lead to increased terminations (88%), 
increased social stigma (57%) and reduced availability of services for T21 individuals (64%) [159]. 
Because it is a safe and easy test, which is privately available, there is a risk that the test could 
also be used for minor conditions or even undesired nonmedical traits. This could lead to women 
deciding to terminate pregnancies for trivial reasons, such as sex selection. In a survey conducted 
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in the USA, 73% of the obstetricians interviewed believed that NIPT would increase pregnancy 
terminations for mild diseases [154]. If it is offered directly, it could also happen that women are 
not appropriately informed and reproductive choices following prenatal screening are made without 
their really understanding the results. The results of a systematic review showed that the infor-
mation provided by commercial companies and private health providers is not equally balanced and 
the need for an invasive test to diagnose aneuploidy is not always underlined [150]. 
Concerns have also been raised regarding how the informed consent and counselling process will 
occur in clinical practice, especially if NIPT is to be used as a one-step screening test. Respondents 
in several studies have cited fears that given the noninvasiveness of the test, it might end up being 
offered as a routine procedure, depriving women of a well-informed option, not giving them the real 
chance to decide if they truly desire this information [167].  
 
[F006] – Is there a need for any specific interventions or supportive actions concerning 
information so as to respect a pregnant woman’s autonomy when the technology is used? 
Comprehensive NIPT pretest counselling could be complicated by emerging information about the 
benefits and uncertainties related to this procedure, as well as the potential to detect incidental 
findings. Professional societies recommend that a trained provider, such as a genetic counsellor, 
an obstetrician or a maternal-fetal medicine specialist [140], give the posttest counselling. Since 
NIPT screening has implications different from those of combined screening, clear and accurate 
consent forms should be developed, providing clinicians with educational materials for explaining, 
in a neutral manner, the purpose of testing and the potential risks and benefits. In 2017, the Institute 
for Quality and Efficiency in Health Care was commissioned to prepare such educational materials 
for Germany. 
Different position statements recommend that counselling should be given both before screening, 
so as to allow women to make a personal decision to accept or decline screening, and after coun-
selling, to discuss positive findings with affected women. This is supported by the findings of a UK 
study, which established that this multistep process would facilitate informed decision making [142]. 
In this study, as well as the Dutch implementation study (Trident study), women were given written 
information in addition to oral counselling [146]. The questionnaire completed by 1091 women who 
participated in this study revealed that women who made an informed choice (78%) had signifi-
cantly higher educational levels and adequate health literacy. Women with inadequate health literacy 
experienced higher posttest result anxiety, highlighting that they might benefit from extra infor-
mation and/or special counselling aids. A study conducted in the USA among Latina women also 
found that women who declined NIPT had a lower educational level, suggesting that culturally tai-
lored information could be useful for women to make informed choices [149]. 
 
[F0101] – Does NIPT invade the sphere of the pregnant woman/user? 
Because of the cytotrophophast origin, NIPT may result in an incidental identification of clinically 
significant maternal or fetal constitutional chromosomal anomalies or acquired cytogenetic anomalies, 
including associated malignancies, which might require genetic counselling [33]. 
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[F0012] – How does implementation or withdrawal of the technology  
affect the distribution of resources? 
Some assessments aimed at evaluating the costs of implementing NIPT for T21 performed in different 
countries (UK, Canada, USA and Australia) show inconsistent results. Whilst some estimate that 
adding NIPT to current screening programmes would lead to increased costs, others estimate that 
costs would remain unchanged a result of the reduction in the number of invasive diagnostic tests 
performed [139, 143, 148, 161, 163, 164]. To date, there are no appropriate studies to assess the 
real impact of NIPT, leaving important uncertainties regarding the human and financial resources 
needed to implementation NIPT in a prenatal care programme.  
 
[F0017] – What are the ethical consequences of the choice of endpoints,  
cut-off values and comparators/controls in the assessment? 
[H0012] – Are there factors that could prevent a group or person from gaining  
access to NIPT? 
The level of NIPT implementation in different countries seems to be associated with factors such 
as the level of education, incomes or insurance coverage. Therefore NIPT uptake is more likely in 
high-income settings than in countries with low resources. These inequalities may be exacerbated 
by the NIPT cost, the test being provided mainly in private settings. The availability of genetic labor-
atories or the viability for transportation of samples to external laboratories might be other factors 
which could interfere with the access of NIPT, especially in populations from low- and middle-in-
come countries [88, 165]. 
 
7.4 Organisational assessment elements 
[G0001] – How does the technology affect the current work processes? 
[G0100] – What kind of pregnant woman/participation flow is associated  
with the new technology? 
[G0002] – What kind of involvement has to be mobilised for pregnant women/participants 
and important others and/or carers? 
[G0003] – What kind of process ensures proper education and training of staff? 
[G0004] – What kind of cooperation and communication of activities has to be mobilised? 
[G0012] – In what way is the quality assurance and monitoring system of NIPT organised? 
The implementation of NIPT would not require significant changes in the patient workflow or the 
health professionals involved. However, the current work process of the professionals responsible 
for screening could change substantially as these might be required to provide additional pretest 
counselling to inform decision making. To date, little information exists regarding the education and 
training given to these professionals. The only information comes from the UK RAPID study [137]. 
This study supports that providing professionals with face-to-face training (lesson plan and Power-
Point presentation) and written factsheets improves confidence and perceived knowledge. Nonethe-
less 65% of attendees interviewed still had little understanding regarding certain knowledge in spe-
cific areas (test turnaround time, FP rates, cfDNA originating from placenta and cell concentration 
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increases with gestation) [137]. In line with the results of a recent US study, special attention should 
also be paid to consent documents because it is acknowledged that many of the existing ones do 
not appropriately reflect psychosocial considerations [144].  
In the same way as combined screening, NIPT requires close collaboration and cooperation be-
tween all actors involved in the screening process (screening unit, laboratory, manufacturers, hos-
pital, pregnant woman and partner). Samples should be handled and shipped according to manu-
facturers’ instructions and according to good laboratory practices. Training might also be required 
if the system is to be implemented in standard laboratories. Specific independently developed mini-
mum standards, quality control, proficiency testing and inspection requirements have not yet been 
developed for NIPT. However, laboratories must adhere to specific standards for laboratory proce-
dures and the protection of patient information confidentiality [33].  
 
[G0005] – How do decentralisation or centralisation requirements  
influence the implementation of NIPT? 
[G0006] – What are the costs of processes related to acquisition and setting up of NIPT? 
[G0023] – How does NIPT modify the need for other technologies and  
use of other resources? 
[G0007] – What is the likely budget impact of implementing the technologies  
being compared? 
[G0008] – What management problems and opportunities are attached to NIPT? 
Although currently most samples are analysed externally, NIPT could be done in most of the labor-
atories which are already perform molecular-diagnostic assays. Standard laboratory equipment, in 
addition to specific equipment and software, would be required in this case.  
No information is available regarding costs related to acquisition and setting up of NIPT, and great 
uncertainty surrounds the actual costs of external testing, as these can differ greatly between labor-
atories, depending on the specific test and country. According to two narrative reviews in North 
American countries (USA and Canada) prices range from $795 to $3000 (approximately €665–
€2511). In European countries (only provided information regarding Austria, Germany, the UK,  
Romania, Spain and Switzerland) the cost of NIPT is around €447–€992, with the most expensive 
test being sold in the UK and the cheapest one being sold in Romania. A noninvasive prenatal test 
is sold for US$457–US$587 (approximately €382–€491) in China and for US$1492–US$1600 
(approximately €1248–1339) in South American countries such as Brazil and Argentina. No infor-
mation is available about NIPT costs in many low- or middle-income countries [88, 156]. 
Six full economic evaluations reported on the cost-effectiveness of NIPT for diagnosis of T21 per-
formed in European countries (i.e., the Netherlands, Belgium and Spain). These reports showed a 
higher incremental cost-effectiveness ratio of NIPT as primary testing than NIPT as a contingent 
strategy or second-tier testing (cut-off point for NIPT indication between 1 in 200 and 1 in 1000) 
compared with standard serum screening [138, 155, 157]. In line with these reports, other eco-
nomic assessment performed by the Institute of Health Economics (reported a lower incremental 
cost-effectiveness ratio of serum integrated prenatal screening (first- and second-trimester serum 
markers) plus NIPT or first-trimester quadruple serum screening with NT measurement plus NIPT 
than NIPT alone for diagnosis of T21 [158]. The remaining two assessments found from a societal 
perspective that universal NIPT (serum screening is offered to patients in whom NIPT failed and 
invasive testing is offered to patients with positive NIPT or serum screening results) was a cost-
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effective alternative to conventional serum screening (FCT or serum integrated screening); how-
ever, from a government or payer perspective, contingent NIPT was a cost-effective alternative to 
conventional serum screening and less costly than universal NIPT [152, 153]. 
The opportunities attached to NIPT mainly relate to the alleviation of workload for some profession-
als. If NIPT totally replaces FCT, it would be expected that biochemistry serum clinical laboratories 
and cytogenetic and molecular genetics laboratories would receive significantly fewer samples to 
analyse, although some of the conventional tests might still be required to detect other conditions, 
such as fetal growth restriction or preeclampsia. The burden of specialists in NT and obstetricians 
responsible for invasive testing could also be alleviated. Experienced sonographers are limited in 
number or are unavailable in many rural areas. 
 
[G0009] – Who decides which pregnant women are eligible for NIPT and on what basis? 
In principle, all pregnant women would be eligible for NIPT except in those cases where the use of 
a noninvasive test is not recommended; that is, women of less than 8 or 10 weeks’ pregnancy 
(depending on the test), women who have a chromosomal anomaly, low fetal fraction (<4%) and 
other clinical situations (see all NIPT contraindications in page 51) in which NIPT accuracy may be 
reduced. Moreover, some consensus documents and guidelines reported cfDNA screening is not 
recommended for women with multiple gestations and/or donor oocytes or for diagnosis of micro-
deletions.  
NIPT should be offered by a medical healthcare professional (i.e., obstetrician-gynaecologists, ma-
ternal-fetal medicine specialist or other obstetric care providers) following the recommendations  
mentioned earlier and using a standard approach for genetic counselling that includes information 
about available options for screening and diagnosing aneuploidies, all this integrated and coordi-
nated in a prenatal screening programme. It should not be offered independently as a direct -to-
consumer test by laboratories [33, 38].  
 
7.5 Patient and social assessment elements 
[G0010] – How is NIPT accepted? 
[H0006] – How do pregnant women perceive NIPT? 
[H0100] – What expectations and wishes do pregnant women have with regard  
to NIPT and what do they expect to gain from the technology? 
In general terms, psychosocial research exploring women’s and health professionals’ attitudes show 
a general positive view towards NIPT [146, 151, 160], although the available literature points to 
possible differences in acceptability, which might depend on cultural, social or other factors. Most 
Swedish (n=1003) and British (n=1131) pregnant women recruited in maternity clinics indicated  
that they would like to use NIPT (73% and 88%, respectively) [145, 160], in comparison with only 
51% in Denmark. These studies support that women’s preference regarding NIPT is mainly asso-
ciated with the early results, the elimination of the procedure-related miscarriage risk and the accu-
racy of the results, although in the Netherlands a discrete choice experiment reflected a preference 
for safety over accuracy [147]. The existing literature supports that women and professionals would 
be very much in favour of replacing FCT and broadening the scope of NIPT to test for all severe 
disabilities, irrespective of their cause and depending on the woman’s and couple’s choices [145, 
147, 154, 168]. 
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All of the women interviewed in the UK RAPID study expressed their wish that NIPT be publically 
adopted and offered as a first-line test because they expected NIPT results would be easier to 
interpret in comparison with FCT results. Having the two sets of results seemed to create some 
confusion [142]. Ninety-six per cent of women in the nationwide Dutch TRIDENT trial were also 
glad to be offered NIPT, and 68% were satisfied [146]. 
 
[H0002] – What is the burden on carers? 
No information was found regarding the burden that NIPT use may cause to carers. However, no 
additional burden is anticipated.  
 
[H0202] – How are screening options explained to pregnant women? 
[H0203] – What specific issues may need to be communicated to pregnant women  
to increase acceptance of NIPT? 
Throughout any prenatal screening programme, screening and diagnostic testing for fetal anoma-
lies available should be offered by pretest and posttest counselling and an informed consent dis-
cussion in which the benefits and risks of each option are explained in detail. Skirton et al. [166] 
suggested that prenatal counselling should take into account beliefs and values related to cultural 
norms as people from countries with different cultural backgrounds may respond in an uneven 
way to similar information. To ensure that each woman or all parents receive prenatal counselling 
adapted to their needs, Skirton et al. [166] produced a set of best practice guidelines for offering 
genetic testing by a group of experts in prenatal diagnosis from nine European countries (Belgium, 
Czech Republic, Denmark, Finland, Italy, the Netherlands, Spain, Sweden and the UK). This study 
concluded that the information should be provided by an appropriately trained health professional in 
both verbal and written forms, always bearing in mind the local ethical and legal guidelines and 
including information about the condition (genetic cause, phenotypic features or risk of aneuploidies, 
etc.), the test (accuracy, limitations, etc.), practical aspects and psychosocial issues. Finally, they 
recommended that women or parents be given the opportunity to use the information provided on 
the basis of their personal beliefs. 
In the literature retrieved it was not reported if specific issues should be communicated to patients 
to increase acceptance of NIPT. 
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8 CONCLUSION 
 Existing moderate quality evidence supports that the detection of T21 cases is higher when 
NIPT replaces FCT as a primary screening test and that this replacement would lead to a 
reduction in unnecessary invasive testing. However, important uncertainties remain regard-
ing the under-reporting of missed cases given the inappropriate verification of negative re-
sults. Data regarding key safety outcomes are also lacking (increase in the number of chil-
dren born with major anomalies, elective pregnancy termination for other unconfirmed chromo-
somal anomalies with uncertain significance, etc.). The generalisability of the PPV and NPV 
is limited by the fact that the prevalence of T21 found in the studies included is not repre-
sentative of that found in the general pregnant population. 
 No data exist to assess the accuracy of NIPT offered as part of the first-trimester fetal  
combined test. 
 The available data suggest that the use of NIPT as an add-on to combined testing for high-
risk T21 population screening could also lead to substantial reductions in unnecessary inva-
sive testing, although this needs to be confirmed with real-world data. The performance of 
the test (test failures, uncertain results) and the uptake of NIPT screening are among the 
factors that could contribute to change this ratio in real practice.  
 There is lack of data to assess the use of NIPT as an add-on to combined testing for  
high- and intermediate-risk T21 populations. 
 The low QoE for T18 and T13 does not allow conclusions to be drawn on these trisomies 
for any of the screening pathways.  
 There is insufficient evidence to establish the accuracy of NIPT for twin pregnancies. 
 Appropriately designed studies are required so as to be able to assess the performance of 
the different test strategies, taking into account detection of all anomalies, abortions, miscar-
riages and other patient-related outcomes. Important uncertainties remain regarding the best 
screening pathway.  
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Search strategy for identification of clinical guidelines or consensus documents 
Search strategy for GIN, Trip database, National Guideline Clearinghouse, Australian Clinical 
practice guidelines, ACP on line and CPGinfobase on 21th February 2017 
 
#1. Aneuploid* 
#2. “Trisomy screening” 
#3. "Down syndrome" screening 
#4. "Edward syndrome" 
#5. "Patau syndrome" 
 
Search strategy for Medline on 21th February 2017 
 
#1. ((((((("screen"[TW] OR "Screening"[TW] OR "Screened"[TW] OR "Test"[TW] OR 
"Tested"[TW] OR "Di-agnostic"[TW] OR "Diagnosis"[TW] OR "Sequencing"[TW] OR 
"Sequence"[TW])) AND ("Prenatal"[TW] OR "Antenatal")) AND ("aneuploidy"[TW] OR 
"aneuploidies"[TW] OR "Trisomy"[TW] OR "Trisomies"[TW] OR "Triso-mic"[TW] OR "Down 
syndrome"[TW] OR "Edward syndrome"[TW] OR "Patau syndrome"[TW])) AND 
(("Chromosome"[TW] OR "Chromosomal"[TW] OR "DNA"[TW] OR "Cell-free fetal DNA"[TW] OR 
"cfDNA"[TW] OR "Massively parallel sequencing"[TW] OR "MPS"[TW] OR "Single nucleotide 
polymorphisms"[TW] OR "SNPs"[TW]) AND ("NIPT"[TW] OR "Non-invasive prenatal testing"[TW] 
OR "Non-invasive"[TW] OR "Noninvasive"[TW] OR "Blood"[TW] OR "Plasma"[TW]))) AND 
("Position statement"[Text Word] OR "Position statements"[Text Word])) AND (Guideline[ptyp] OR 
Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR systematic[sb])) AND "2010/01/01"[PDat]: 
"3000/12/31"[PDat] 
 
Search strategy for Embase on 21th February 2017 
 
#1 (screen or Screening or Screened or Test or Tested or Diagnostic or Diagnosis or 
Sequencing or Sequence).ti,sh,hw,ab,kw,tw.  
#2 (Prenatal or Antenatal).ti,sh,hw,ab,kw,tw. 
#3 1 and 2  
#4 (aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome").ti,sh,hw,ab,kw,tw. 
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#5 (Chromosome or Chromosomal or DNA or "Cell-free fetal DNA" or ""cfDNA or "Massively 
parallel sequencing" or "MPS" or "Single nucleotide polymorphisms" or "SNPs").ti,sh,hw,ab,kw,tw.  
#6 3 and 4 
#7 ("NIPT" or "Non-invasive prenatal testing" or "Non-invasive" or Noninvasive or Blood or 
Plasma).ti,sh,hw,ab,kw,tw. 
#8 5 and 7  
#9 6 and 8  
#10 limit 9 to yr="2010 -Current"  
#11 limit 10 to consensus development  
#12 limit 10 to "conference review"  
#13 11 or 12  
  
Search strategy for Web of Science on 21th February 2017 
 
# 1 TI=(aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome") OR TI=(aneuploidy or aneuploidies or Trisomy or 
Trisomies or Trisomic or "Down syndrome" or "Edward syndrome" or "Patau syndrome")  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 2 TS=(screen or Screening or Screened or Test or Tested or Diagnostic or Diagnosis or 
Sequencing or Sequence) OR TI=(screen or Screening or Screened or Test or Tested or 
Diagnostic or Diagnosis or Sequencing or Sequence)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 3 TS=(Prenatal or Antenatal) OR TI=(Prenatal or Antenatal)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 4 #3 AND #2  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 5 #4 AND #1  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 6 TITLE: ("clinical Practice guideline" OR "clinical guideline" OR consens* OR "position 
statement" OR "position statments") OR TOPIC: ("clinical Practice guideline" OR "clinical 
guideline" OR consens* OR "position statement" OR "position statments") 
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Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 7 #6 AND #5  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
 
Search strategy for Google on 21th February 2017 
 
#1. Aneuploid* "clinical guideline" filetype:pdf 
#2. Aneuploid* "clinical practice guideline" filetype:pdf 
 
Search strategy for identification of NIPT systematic reviews or HTA reports 
Search strategy for CRD databases on 20th July 2017 
#1. (aneuploid* OR trisom):TI AND (screen*):TI FROM 2010 TO 2017 
#2. ("Down syndrome"):TI AND (screen*):TI FROM 2010 TO 2017 
#3. ("Edward syndrome"):TI AND (screen*):TI FROM 2010 TO 2017 
Search strategy for INAHTA 
#1. aneuploid* OR trisomy OR "Down syndrome" OR "Edward syndrome" OR “Patau syndrome" 
 
Search strategy for identification of NIPT test accuracy studies 
Search strategy for Medline on 10th March 2017  
 
#1. ((((((((((((((("screen"[TW] OR "Screening"[TW] OR "Screened"[TW] OR "Test"[TW] OR 
"Tested"[TW] OR "Diagnostic"[TW] OR "Diagnosis"[TW] OR "Sequencing"[TW] OR 
"Sequence"[TW]))) AND ((("Prenatal"[TW] OR "Antenatal"[TW])) AND ( "2012/01/01"[PDat] : 
"3000/12/31"[PDat] ))) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND 
((("aneuploidy"[TW] OR "aneuploidies"[TW] OR "Trisomy"[TW] OR "Trisomies"[TW] OR 
"Trisomic"[TW] OR "Down syndrome"[TW] OR "Edward syndrome"[TW] OR "Patau 
syndrome"[TW])) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( "2012/01/01"[PDat] : 
"3000/12/31"[PDat] ))) AND ((("Chromosome"[TW] OR "Chromosomal"[TW] OR "DNA"[TW] OR 
"Cell-free fetal DNA"[TW] OR "cfDNA"[TW] OR "Massively parallel sequencing"[TW] OR 
"MPS"[TW] OR "Single nucleotide polymorphisms"[TW] OR "SNPs"[TW]) AND ("NIPT"[TW] OR 
"Non-invasive prenatal testing"[TW] OR "Non-invasive"[TW] OR "Noninvasive"[TW] OR 
"Blood"[TW] OR "Plasma"[TW])) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( 
"2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ((("Sensitivity and Specificity"[MeSH Terms] OR 
accuracy[TIAB] OR Sensitivity[TIAB] OR specificity[TIAB] OR “false positive”[TIAB] OR “false 
negative”[TIAB])) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( "2012/01/01"[PDat] : 
"3000/12/31"[PDat] ))) NOT ((((((((((((((((("screen"[TW] OR "Screening"[TW] OR "Screened"[TW] 
OR "Test"[TW] OR "Tested"[TW] OR "Diagnostic"[TW] OR "Diagnosis"[TW] OR 
"Sequencing"[TW] OR "Sequence"[TW]))) AND ((("Prenatal"[TW] OR "Antenatal"[TW])) AND ( 
"2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) 
AND ((("aneuploidy"[TW] OR "aneuploidies"[TW] OR "Trisomy"[TW] OR "Trisomies"[TW] OR 
"Trisomic"[TW] OR "Down syndrome"[TW] OR "Edward syndrome"[TW] OR "Patau 
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syndrome"[TW])) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ("2012/01/01"[PDat] : 
"3000/12/31"[PDat] ))) AND ((("Chromosome"[TW] OR "Chromosomal"[TW] OR "DNA"[TW] OR 
"Cell-free fetal DNA"[TW] OR "cfDNA"[TW] OR "Massively parallel sequencing"[TW] OR 
"MPS"[TW] OR "Single nucleotide polymorphisms"[TW] OR "SNPs"[TW]) AND ("NIPT"[TW] OR 
"Non-invasive prenatal testing"[TW] OR "Non-invasive"[TW] OR "Noninvasive"[TW] OR 
"Blood"[TW] OR "Plasma"[TW])) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( 
"2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ((("Sensitivity and Specificity"[MeSH Terms] OR 
accuracy[TIAB] OR Sensitivity[TIAB] OR specificity[TIAB] OR “false positive”[TIAB] OR “false 
negative”[TIAB])) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( "2012/01/01"[PDat] : 
"3000/12/31"[PDat] ))) AND (((Addresses[ptyp] OR Autobiography[ptyp] OR Bibliography[ptyp] 
OR Biography[ptyp] OR Comment[sb] OR Congresses[ptyp] OR Editorial[ptyp] OR Interview[ptyp] 
OR Lectures[ptyp] OR Legal Cases[ptyp] OR Legislation[ptyp] OR Letter[ptyp])) AND ( 
"2012/01/01"[PDat] : "3000/12/31"[PDat] ))) AND ( "2012/01/01"[PDat] : "3000/12/31"[PDat] )) 
Filters: Publication date from 2012/01/01 
 
Search strategy for Embase on 10th March 2017  
 
#1 (screen or Screening or Screened or Test or Tested or Diagnostic or Diagnosis or 
Sequencing or Sequence).ti,sh,hw,ab,kw,tw.  
#2 (Prenatal or Antenatal).ti,sh,hw,ab,kw,tw.  
#3 1 and 2  
#4 (aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome").ti,sh,hw,ab,kw,tw.  
#5 (Chromosome or Chromosomal or DNA or "Cell-free fetal DNA" or "cfDNA" or "Massively 
parallel sequencing" or "MPS" or "Single nucleotide polymorphisms" or 
"SNPs").ti,sh,hw,ab,kw,tw.  
#6 3 and 4  
#7 ("NIPT" or "Non-invasive prenatal testing" or "Non-invasive" or Noninvasive or Blood or 
Plasma).ti,sh,hw,ab,kw,tw.  
#8 5 and 7  
#9 6 and 8  
#10 *sensitivity analysis/or *"sensitivity and specificity"/ 
#11 (accuracy or Sensitivity or specificity or false positive or false negative).ab,kw,sh,ti.  
#12 10 or 11  
#13 9 and 12  
#14 limit 13 to (embase and yr="2012 -Current")  
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Search strategy for Web of Science on 10th March 2017  
 
# 1 TI=(aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome") OR TI=(aneuploidy or aneuploidies or Trisomy or 
Trisomies or Trisomic or "Down syndrome" or "Edward syndrome" or "Patau syndrome")  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 2 TS=(screen or Screening or Screened or Test or Tested or Diagnostic or Diagnosis or 
Sequencing or Sequence) OR TI=(screen or Screening or Screened or Test or Tested or 
Diagnostic or Diagnosis or Sequencing or Sequence)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 3 TS=(Prenatal or Antenatal) OR TI=(Prenatal or Antenatal)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 4 #3 AND #2  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 5 #4 AND #1  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 6 TS=(accuracy OR Sensitivity OR specificity OR false positive OR false negative) OR 
TI=(accuracy OR Sensitivity OR specificity OR false positive OR false negative)  
# 7 #5 AND #6  
Refined by: [excluding] DOCUMENT TYPES: (PROCEEDINGS PAPER OR MEETING 
ABSTRACT OR LETTER OR EDITORIAL MATERIAL) Timespan=2012-2017 
 
Search strategy for Cochrane Library on 10th March 2017 
  
#1 screen or Screening or Screened or "Massively parallel sequencing" or MPS or "Single 
nucleotide polymorphisms" or SNPs:ti,ab,kw (Word variations have been searched)  
#2 Prenatal or Antenatal:ti,ab,kw (Word variations have been searched)  
#3 #1 and #2   
#4 NIPT or "Non-invasive prenatal testing":ti,ab,kw (Word variations have been searched)  
#5 #3 or #4   
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#6 DNA or "Cell-free fetal DNA" or cfDNA:ti,ab,kw (Word variations have been searched)  
#7 #5 and #6   
#8 Blood or Plasma:ti,ab,kw (Word variations have been searched)  
#9 #7 and #8   
#10 aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome":ti,ab,kw (Word variations have been searched)  
#11 #9 and #10   
#12 accuracy or Sensitivity or specificity OR false positive OR false negative:ti,ab,kw (Word 
variations have been searched)  
#13 #11 and #12   
#14 MeSH descriptor: [Sensitivity and Specificity] explode all trees  
#15 #11 and #14  
#16 #13 or #15  
 
Search strategy for identification of qualitative studies 
Search strategy for Medline on 10th February 2017 
 
 #1. ((((("screen"[TW] OR "Screening"[TW] OR "Screened"[TW] OR "Test"[TW] OR 
"Tested"[TW] OR "Di-agnostic"[TW] OR "Diagnosis"[TW] OR "Sequencing"[TW] OR 
"Sequence"[TW])) AND ("Prenatal"[TW] OR "Antenatal"[TW])) AND ("aneuploidy"[TW] OR 
"aneuploidies"[TW] OR "Trisomy"[TW] OR "Trisomies"[TW] OR "Triso-mic"[TW] OR "Down 
syndrome"[TW] OR "Edward syndrome"[TW] OR "Patau syndrome"[TW])) AND 
(("Chromosome"[TW] OR "Chromosomal"[TW] OR "DNA"[TW] OR "Cell-free fetal DNA"[TW] 
OR "cfDNA"[TW] OR "Massively parallel sequencing"[TW] OR "MPS"[TW] OR "Single 
nucleotide polymorphisms"[TW] OR "SNPs"[TW]) AND ("NIPT"[TW] OR "Non-invasive prenatal 
testing"[TW] OR "Non-invasive"[TW] OR "Noninvasive"[TW] OR "Blood"[TW] OR 
"Plasma"[TW]))) AND (anxiety[Title/Abstract] OR attitudes[Title/Abstract] OR 
choice[Title/Abstract] OR "clinical imple-mentation"[Title/Abstract] OR Decision-
making[Title/Abstract] OR "Decision mak-ing"[Title/Abstract] OR experience*[Title/Abstract] OR 
"Focus Groups"[Title/Abstract] OR "Fo-cus Group"[Title/Abstract] OR Motivation[Title/Abstract] 
OR interview*[Title/Abstract] OR "Pa-tient Acceptance of Health Care"[Title/Abstract] OR 
testimon*[Title/Abstract] OR story-tell*[Title/Abstract] OR (story[TIAB] tell*[TIAB]) OR Patient 
Education as Topic OR Qualitative Research OR Health Knowledge, Attitudes, Practice OR 
Health Care Surveys OR "Focus Groups" OR "Interviews as Topic" OR narration[MeSH Terms] 
OR qualitative[Title/Abstract] OR Views[Title/Abstract] OR "Health Personnel"[Mesh] OR "Health 
Care Providers"[TIAB] OR "Health Care Provider"[TIAB] OR"Healthcare Providers"[TIAB] OR 
"Healthcare Provider"[TIAB]) Sort by: PublicationDate Filters: Publication date from 2012/01/01 
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Search strategy for Embase on 10th February 2017 
 
#1 (screen or Screening or Screened or Test or Tested or Diagnostic or Diagnosis or Sequencing 
or Sequence).ti,sh,hw,ab,kw,tw.  
#2 (Prenatal or Antenatal).ti,sh,hw,ab,kw,tw.  
#3 1 and 2  
#4 (aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome").ti,sh,hw,ab,kw,tw.  
#5 (Chromosome or Chromosomal or DNA or "Cell-free fetal DNA" or "cfDNA" or "Massively 
parallel sequencing" or "MPS" or "Single nucleotide polymorphisms" or "SNPs").ti,sh,hw,ab,kw,tw.  
#6 3 and 4  
#7 ("NIPT" or "Non-invasive prenatal testing" or "Non-invasive" or Noninvasive or Blood or 
Plasma).ti,sh,hw,ab,kw,tw.  
#8 5 and 7  
#9 6 and 8  
#10 (anxiety or attitudes or choice or "clinical implementation" or Decision-making or "Decision 
making" or experience* or "Focus Groups" or "Focus Group" or Motivation or interview* or "Patient 
Acceptance of Health Care" or testimon* or storytell* or story tell* or Patient Education as Topic or 
Qualitative Research or Health Knowledge, Attitudes, Practice or Health Care Surveys or "Focus 
Groups" or Interview* or narration or qualitative or Views or "Health Personnel" or "Health Care 
Providers" or "Health Care Provider" or "Healthcare Providers" or "Healthcare Provider").ab,sh,ti.  
#11 exp health education/or exp patient education/ 
#12 exp qualitative research/ 
#13 exp interview/ 
#14 exp health care personnel/ 
#15 OR/10-14  
#16 9 AND 15 limit to (embase and yr="2012 -Current")  
 
Search strategy for Web of Science on 10th February 2017 
 
# 1 TI=(aneuploidy or aneuploidies or Trisomy or Trisomies or Trisomic or "Down syndrome" or 
"Edward syndrome" or "Patau syndrome") OR TI=(aneuploidy or aneuploidies or Trisomy or 
Trisomies or Trisomic or "Down syndrome" or "Edward syndrome" or "Patau syndrome")  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
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# 2 TS=(screen or Screening or Screened or Test or Tested or Diagnostic or Diagnosis or 
Sequencing or Sequence) OR TI=(screen or Screening or Screened or Test or Tested or 
Diagnostic or Diagnosis or Sequencing or Sequence)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 3 TS=(Prenatal or Antenatal) OR TI=(Prenatal or Antenatal)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 4 #3 AND #2  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 5 #4 AND #1  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2010-2017 
# 6 TOPIC: (anxiety or attitudes or choice or "clinical implementation" or Decision-making or 
"Decision making" or experience* or "Focus Groups" or "Focus Group" or Motivation or 
interview* or "Patient Acceptance of Health Care" or testimon* or storytell* or story tell* or 
Patient Education as Topic or Qualitative Research or Health Knowledge, Attitudes, Practice or 
Health Care Surveys or "Focus Groups" or Interview* or narration or qualitative or Views or 
"Health Personnel" or "Health Care Providers" or "Health Care Provider" or "Healthcare 
Providers" or "Healthcare Provider") OR TITLE: (anxiety or attitudes or choice or "clinical 
implementation" or Decision-making or "Decision making" or experience* or "Focus Groups" or 
"Focus Group" or Motivation or interview* or "Patient Acceptance of Health Care" or testimon* 
or storytell* or story tell* or Patient Education as Topic or Qualitative Research or Health 
Knowledge, Attitudes, Practice or Health Care Surveys or "Focus Groups" or Interview* or 
narration or qualitative or Views or "Health Personnel" or "Health Care Providers" or "Health 
Care Provider" or "Healthcare Providers" or "Healthcare Provider")  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI, CCR-EXPANDED, IC 
Timespan=2012-2017 
# 7 #5 AND #6 
 
Search strategy for identification of ongoing studies 
Search strategy for ongoing studies databases on 14th July 2017  
 
ClinicalTrials.gov; ICTRP (OMS); EU Clinical Trials Register; UK clinical Trials gateway 
 
#1 aneuploidy OR aneuploidies OR Trisomy OR Trisomies OR Trisomic OR Down syndrome OR 
Edward syndrome OR Patau syndrome |  
#2 Screen* 
#3 #1 AND #2 
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Full-text articles excluded according to selection criteria  
References Reason of exclusion 
Cirigliano V, Ordoñez E, Rueda L, Syngelaki A, Nicolaides KH. 
Performance of the neoBona test: a new paired-end massively 
parallel shotgun sequencing approach for cell-free DNA-based 
aneuploidy screening. Ultrasound Obstet Gynecol. 2017; 49(4): 460-
464. 
Case-control study 
Gerundino F, Giachini C, Contini E, Benelli M, Marseglia G, Giuliani 
C, Marin F, Nannetti G, Lisi E, Sbernini F, Periti E, Cordisco A, Colosi 
E, D'ambrosio V, Mazzi M, Rossi M, Staderini L, Minuti B, Pelo E, 
Cicatiello R, Maruotti GM, Sglavo G, Conti A, Frusconi S, Pescucci 
C, Torricelli F. Validation of a method for noninvasive prenatal testing 
for fetal aneuploidies risk and considerations for its introduction in the 
Public Health System. J Matern Fetal Neonatal Med. 2017; 30(6): 
710-716. 
Proof of principle study 
Unclear selection criteria and/or 
indication 
Xu C, Wang T, Liu C, Li H, Chen X, Zhu H, Chen S, Xin Q, Tao J, 
Huang L, Jiang Z. Noninvasive Prenatal Screening of Fetal 
Aneuploidy without Massively Parallel Sequencing. Clin Chem. 2017; 
63(4): 861-869. 
Proof of principle study 
Unclear selection criteria and/or 
indication 
Pescia G, Guex N, Iseli C, Brennan L, Osteras M, Xenarios I, 
Farinelli L, Conrad B. Cell-free DNA testing of an extended range of 
chromosomal anomalies: clinical experience with 6,388 consecutive 
cases. Genet Med. 2017; 19(2): 169-175. 
Validation study  
Unclear selection criteria and/or 
indication 
Crea F, Forman M, Hulme R, Old RW, Ryan D, Mazey R, Risley MD. 
The IONA® Test: Development of an Automated Cell-Free DNA-
Based Screening Test for Fetal Trisomies 13, 18, and 21 That 
Employs the Ion Proton Semiconductor Sequencing Platform. Fetal 
Diagn Ther. 2017 Feb 8. 
Validation study 
Unclear selection criteria and/or 
indication 
Taneja PA, Prosen TL, de Feo E, Kruglyak KM, Halks-Miller M, 
Curnow KJ, Bhatt S. Fetal aneuploidy screening with cell-free DNA in 
late gestation. J Matern Fetal Neonatal Med. 2017 Feb; 30(3): 338-
342. Epub 2016 Apr 28. 
Retrospective study 
Unclear selection criteria and/or 
indication 
Qi G, Yi J, Han B, Liu H, Guo W, Shi C, et al. Noninvasive prenatal 
testing in routine clinical practice for a high-risk population: 
Experience from a center. Medicine. 2016;95(41):e5126. 
Retrospective study 
Lack of information regarding 
index test and reference standard  
Manotaya S, Xu H, Uerpairojkit B, Chen F, Charoenvidhya D, Liu H, 
Petcharaburanin N, Liu Y, Tang S, Wang X, Dansakul S, Thomsopa 
T, Gao Y, Zhang H, Xu H, Jiang H. Clinical experience from Thailand: 
noninvasive prenatal testing as screening tests for trisomies 21, 18 
and 13 in 4736 pregnancies. Prenat Diagn. 2016 Mar; 36(3):224-31. 
Unclear selection criteria and/or 
indication 
No appropriate reference 
standard in negative cases  
Togneri F, Court S, Parks M, Clokie S, Hamilton S, Bibb N, et al. 
Noninvasive prenatal testing (NIPT) for fetal aneuploidy: The 
experience of an NHS Regional Genetics Laboratory. BJOG: An 
International Journal of Obstetrics and Gynaecology. 2016; 123(5).  
Congress abstract 
Neveling K, Tjwan Thung D, Beulen L, van Rens-Buijsman W, 
Gomes I, van den Heuvel S, Mieloo H, Derks-Prinsen I, Kater-Baats 
E, Faas BH. Validation of two-channel sequencing-by-synthesis for 
noninvasive prenatal testing of fetal whole and partial chromosome 
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Fetal Aneuploidies. Fetal Diagn Ther. 2016; 40(3):219-223. 
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KH. IONA test for first-trimester detection of trisomies 21, 18 and 13. 
Ultrasound Obstet Gynecol. 2016; 47(2): 184-7. 
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LL, Currier RJ. Cell-free DNA vs sequential screening for the 
detection of fetal chromosomal anomalies. Am J Obstet Gynecol. 
2016; 214(6): 727.e1-6.  
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Clinical performance of non-invasive prenatal testing (NIPT) using 
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35(11): 1154. 
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chromosomal anomalies. Fetal Diagn Ther. 2014; 35(3): 174-84. 
Retrospective study 
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33(6): 569-74. 
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prenatal diagnosis methodology for fetal autosomal and sex 
chromosomal aneuploidies. BMC medical genomics. 2012;5. 
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Unclear selection criteria and/or 
indication 
Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun 
FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, 
Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, 
Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM. Non-invasive 
prenatal assessment of trisomy 21 by multiplexed maternal plasma 
DNA sequencing: large scale validity study. BMJ. 2011; 342: c7401. 
Validation study (archived 
maternal samples from euploid 
and aneuploid cases) sampling 
Lack of data on relevant 
outcomes 
Chen EZ, Chiu RW, Sun H, Akolekar R, Chan KC, Leung TY, Jiang 
P, Zheng YW, Lun FM, Chan LY, Jin Y, Go AT, Lau ET, To WW, 
Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van 
Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, 
Nicolaides KH, Lo YM. Noninvasive prenatal diagnosis of fetal 
trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. 
PLoS One. 2011; 6(7): e21791. 
Case-control study 
Tong YK, Jin S, Chiu RW, Ding C, Chan KC, Leung TY, Yu L, Lau 
TK, Lo YM.Noninvasive prenatal detection of trisomy 21 by an 
epigenetic-genetic chromosome-dosage approach. Clin Chem. 2010; 
56(1): 90-8. 
Technical validation study (both 
selected euploid and aneuploid 
samples) 
Lack of data on relevant 
outcomes  
Ghanta S, Mitchell ME, Ames M, Hidestrand M, Simpson P, Goetsch 
M, Thilly WG, Struble CA, Tomita-Mitchell A. Non-invasive prenatal 
detection of trisomy 21 using tandem single nucleotide 
polymorphisms. PLoS One. 2010; 5(10): e13184. 
Validation study (both selected 
euploid and aneuploid samples) 
Lack of data on relevant 
outcomes 
Alberry MS, Maddocks DG, Hadi MA, Metawi H, Hunt LP, Abdel-
Fattah SA, Avent ND, Soothill PW. Quantification of cell free fetal 
DNA in maternal plasma in normal pregnancies and in pregnancies 
with placental dysfunction. Am J Obstet Gynecol. 2009; 200(1): 
98.e1-6. 
Lack of data on relevant 
outcomes 
Chiu RW, Chan KC, Gao Y, Lau VY, Zheng W, Leung TY, Foo CH, 
Xie B, Tsui NB, Lun FM, Zee BC, Lau TK, Cantor CR, Lo YM. 
Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by 
massively parallel genomic sequencing of DNA in maternal plasma. 
Proc Natl Acad Sci U S A. 2008; 105(51): 20458-63. 
Proof of principle study (both 
selected aneuploid and euploid 
samples)  
Lack of data on relevant 
outcomes 
Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. 
Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing 
DNA from maternal blood. Proc Natl Acad Sci U S A. 2008; 105(42): 
16266-71.  
Proof of principle study (both 
selected aneuploid and euploid 
samples)  
Lack of data on relevant 
outcomes 
Dhallan R, Guo X, Emche S, Damewood M, Bayliss P, Cronin M, 
Barry J, Betz J, Franz K, Gold K, Vallecillo B, Varney J. A non-
invasive test for prenatal diagnosis based on fetal DNA present in 
maternal blood: a preliminary study. Lancet. 2007; 369(9560): 474-
81.  
Proof or principle study 
Lack of information on elegibility 
criteria/indication 
Uncertainty regarding the 
independent assessment of index 
test/reference standard 
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DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A1: Overview of guidelines 
Name of society/ 
organisation issuing 
guidance 
Date of 
issue 
Country/ies to 
which 
applicable 
Summary of recommendations related to NIPT Level of 
evidence 
The American College of 
Medical Genetics and 
Genomics (ACGM) 
Noninvasive prenatal 
screening for fetal aneuploidy 
2016 update: a position 
Statement of the ACGM  
July 2016 USA ACGM recommends: 
Allowing patients to select diagnostic or screening approaches for the detection of fetal 
aneuploidy and/or genomic changes that are consistent with their personal goals and 
preferences. 
Informing all women that diagnostic testing (CVS or amniocentesis) is an option for the detection 
of chromosome anomalies and clinically significant selected copy variants. 
Informing all pregnant women that NIPS is the most sensitive option for traditionally screened 
aneuploides (T21, T18 and T13). 
Referring patients to a trained genetics professional when an increased risk of aneuploidy is 
reported after NIPT. 
Offering diagnostic testing when a positive screening test result is reported after NIPS 
Laboratories should not offer screening for autosomal aneuploidies other than those involving 
chromosomes 13, 18 and 21. 
Offering diagnostic testing for a no-call NIPS result due to low fetal fraction if maternal blood for 
NIPS was drawn at an appropriate gestational age. A repeat blood draw is not considered 
appropriate. 
Offering aneuploidy screening other than NIPT in cases of significant obesity. 
Informing patients that a no-call result may be due to long stretches of homozygosity, which 
could be due to either uniparental disomy or parental consanguinity is received. 
Offering diagnostic testing with chromosomic microarrays when a no-call result is obtained. 
In pregnancies with multiple gestations and/or donor oocyts, testing laboratories should be 
contacted regarding the validity of NIPT before it is offered. 
 
The American College of 
Obstetricians and 
May 2016 USA Because cfDNA is a screening test with the potential for false positive and false negative results, 
such testing should not be used as a substitute for diagnostic testing. 
A 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 154 
Name of society/ 
organisation issuing 
guidance 
Date of 
issue 
Country/ies to 
which 
applicable 
Summary of recommendations related to NIPT Level of 
evidence 
Gynecologists (ACOG) and 
Society for Maternal-Fetal 
Medicine (SMFM) 
“Practice Bullletin Number 163: 
Clinical Management 
Guidelines for obstetrician-
gynecologists. Screening for 
fetal aneuploidy” 
All women with a positive NIPT result should have a diagnostic procedure before any irreversible 
action, such as pregnancy termination. 
A 
Women whose cfDNA screening are not reported, are undeterminate, or uninterpretable should 
receive councelling and be offered comprehensive ultrasound evaluation and diagnostic testing 
because of increase risk of aneuploidy. 
A 
NIPT for microdeletions have not been validated clinically and are not recommended at this time. B 
Some women who receive a positive test result from traditional screening may prefer to have 
NIPT screening rather than undergoe definitive testing. This approach may delay definitive 
diagnosis and management and may fail to identify some foetuses with aneuploidy. 
C 
The ACOG and SMFM 
“Committee Opinion Number 
640:cell free DNA screening 
for fetal Aneuploidy” 
September 
2015 
USA A discussion of risks, benefits and alternatives of various methods of prenatal screening and 
diagnostic testing, including the option of no testing should occur with all patients 
Although patients may choose cfDNA analysis regardless of her risk status, they should 
understand limitations and benefits in the context of alternative options. 
Given the risk for inaccurate results, a diagnostic test should be recommended for a patient who 
has a positive cfDNA test result. 
Parallel or simultaneous screening is not cost-effective and should not be performed. However, 
use of cfDNA screening as a follow up test for patients with a positive traditional screening result 
is reasonable for patients who want to avoid a diagnostic test. 
Management decisions, including termination of pregnancy should not be based on cfDNA 
screening alone. 
Patients whose results are not reported, indeterminate or uninterpretable should receive further 
counselling and should be offered comprehensive ultrasound evaluation and diagnostic testing. 
If a fetal structural anomaly is identified on ultrasound examination, diagnostic testing should be 
offered. 
Patients should be counselled that a negative cfDNA test result does not ensure unaffected 
pregnancy. 
CfDNA screening does not assess risk of fetal anomalies such as neural tube defects or ventral 
wall defects; patients who are undergoing cfDNA should be offered maternal serum-fetoprotein 
screening or ultrasound evaluation. 
Before offering NIPT family history should be reviewed in order to determine if the patient should 
be offered other forms of screening 
Conclusion statement 
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Name of society/ 
organisation issuing 
guidance 
Date of 
issue 
Country/ies to 
which 
applicable 
Summary of recommendations related to NIPT Level of 
evidence 
A discussion of risks, benefits and alternatives of various methods of prenatal screening and 
diagnostic testing, including the option of no testing, should occur with all patients. Such a 
discussion should include the advisability and applicability of cell-free DNA and other screening 
tests and the interpretation of test results, based on patient risk stratification. 
European Society of Human 
Genetics (ESHG) and 
American Society of Human 
Genetics (ASHG) 
Position document on prenatal 
screening 
October 
2015 
USA and Europe The main options for using NIPT in practice are: 
1) NIPT as a second test after combined first trimester screening using the current high 
risk cut off point. 
2) NIPT as a replacement for combined first trimester screening. 
3) NIPT as a second test after adapted risk cut off points (intermediate risk). 
 
Austrian Society of Obstetrics 
and Gynecology, Austrian 
Society of Ultrasound in 
Medicine, Austrian Society of 
Pre-and Perinatal Medicine, 
ASHG, German Society of 
Ultrasound in Medicine, 
Fetal Medicine Foundation 
Germany, Swiss Society of 
Ultrasound in Medicine 
“Cell-Free DNA testing for fetal 
chromosomal anomalies in 
clinical practice: Austrian 
German-Swiss 
Recommendations for NIPT 
October 
2015 
Austria 
Germany 
Switzerland 
CfDNA testing should be offered only after, or in conjunction with, a qualified ultrasound and 
following appropriate counselling about the nature, scope and significance of the test. 
CfDNA tests are sceening tests. A high-risk cfDNA testing result should always be confirmed by 
an invasive diagnostic test before a clinical consequence is drawn from the findings 
CfDNA tests can be used as secondary screening test for trisomy 21 (DS) for the reduction of 
invasive procedures after a high or intermediate risk result from first trimester combined tes (1 in 
1,000 or >1:500). It should be noted that, even when cfDNA testing is used as a secondary 
screening, invasive testing is still the method of choice when the adjusted risk for trisomy 21 after 
combined test is >1:10 or the fetal nuchal translucency thickness is >3.5 mm or a fetal 
malformation is present. 
CfDNA can also be used as a primary screening method for fetal trisomy 21 in pregnant women 
of every age and risk group 
In general, it should be noted that the performance of cfDNA screening for trisomy 18 and 
trisomy 13 is lower than that for trisomy 21 
 
The ISPD 
“Position Statement from the 
chromosome anomaly 
screening Committee on behalf 
of the Board of the ISPD 
April 2015 International The following protocol options are currently considered appropriate:  
1. CfDNA screening as a primary test offered to all pregnant women. 
2. CfDNA secondary to a high risk assessment based on serum and ultrasound and 
screening protocols. 
3. CfDNA contingently offered to a broader group of women ascertained as having high 
or intermediate risks by conventional screening. Contingent provision could also 
include a protocol in which women with very high risks are offered invasive diagnosis, 
while those with intermediate risk cfDNA. 
4. Ultrasound at 11 to 13 completed weeks combined with serum markers at 9 to 13 
weeks´ gestation. 
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Name of society/ 
organisation issuing 
guidance 
Date of 
issue 
Country/ies to 
which 
applicable 
Summary of recommendations related to NIPT Level of 
evidence 
5. Extending option 4 to include other trimester serum or sonographic markers 
6. A contingent test whereby women with borderline risks from option 4 have option 5 at 
a specialist centre. 
7. Four maternal markers (quadruple test) at 15 to 19 weeks, for women who first attend 
after 13 weeks 6 days gestation. 
8. Combining options 4 and 7 in either stepwise or contingent protocol, provided all 
markers are included in final risk assessment. Integrated screening can be offered 
when CVS is not available. 
9. Contingent second trimester ultrasound to modify risks for aneuploidy for women 
having options 4, 7 or 8. 
Italian Ministry of Health-
Higher Health Council of 
Italy  
(Consiglio Superiori de Sanita) 
May 2015 Italy NIPT is not a diagnostic test. NIPT investigates the probability of a foetus being affected by the 
most common aneuploidies, with specificity and sensitivity, which are significantly higher than 
combined testing. 
NIPT defines the presence of the specific fetal disease on a probability basis. Therefore, any 
positive results must be confirmed by invasive technique (chorionic villus 
sampling/amniocentesis 
NIPT should be preceded by ultrasound and pre-test counceling. 
Results are reliable if obtained from a percentage of free fetal DNA that is not less than 4% of 
total free DNA present in maternal plasma. 
The investigation is currently targeted and validated for major autosomal aneuoploides (T21, 
T18, T13). The chromosomal anomalies investigated concern only a portion, although relevant 
(50-70%) of the chromosome aberrations which might be present in the foetus. 
NIPT can be performed in twin pregnancies, even after gamete donation. 
Generally, results indicative of a “low risk of trisomy” should be considered reassuring for the 
mother. However, the results of the screening could refer to genetic characteristics of the 
cytotrophoblast (placenta), that in rare cases may be inconsistent with those of the foetus (feto-
placental discrepancy) 
Since NIPT represents the most sensitive non-invasive test for prenatal diagnosis, it is necessary 
that its introduction-as first or second-choice test for the detection of major autosomal 
aneuploidies must be set up at central and regional level 
It is necessary to provide information campaigns to the public and training to prefessionals, to 
ensure equity in access. Currently, NIPT-based screening has no reason to be extended to 
diseases other than T21, T18 and T13 
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Name of society/ 
organisation issuing 
guidance 
Date of 
issue 
Country/ies to 
which 
applicable 
Summary of recommendations related to NIPT Level of 
evidence 
The International Society of 
Ultrasound in Obstetrics and 
Gynecology (ISUOG) 
ISUOG consensus statement 
on the impact of NIPT on 
prenatal ultrasound practice 
2014 International All women should be offered a first-trimester ultrasound scan, regardless of their intention to 
undergo NIPT. 
Pre-test counselling is essential. Various options should be explained clearly to women, 
discussing the pros and cos of each, including the expected performance and adverse effects. 
Following a normal early pregnancy scan, three options should be considered for women who 
wish to have further risk assessment for T21 and, to a lesser extent, T13 and T18. 
1) Screening strategies based on individual risk calculated from maternal age and nuchal 
translucency and/or maternal markers and/or other ultrasound markers in the first 
trimester. At this moment, ISUOG endorsed this strategy. 
2) Invasive testing based on background risk (including for example, maternal age and 
history of aneuploidy), with no other individual calculation or risk 
3) NIPT as first-line screening test. 
NIPT is not a diagnostic test and confirmatory invasive testing is required 
NIPT has not been evaluated extensively in low risk populations 
First-trimester risk estimates for T21, T18 and T13 based on nuchal translucency 
measurements and maternal biochemistry should not be computed in a woman who 
has already received a normal NIPT results. 
NIPT may be discussed as an alternative to invasive testing following an abnormal 
result on combined screening or offered to patients who are not sufficiently reassured 
by an intermediate result. 
The role of NIPT as an alternative to standard invasive testing in women considered to 
be at very high risk (>1:10) after combined screening but with no ultrasound anomaly 
should be evaluated in prospective studies. Expert opinion suggests that NIPT should 
not replace invasive testing. 
In the presence of a fetal structural anomaly, the indications for fetal karyotyping and/or 
microarray testing should not be modified by an normal NIPT result. 
Accuracy of NIPT in twin pregnancies should be investigated further. 
Variations in NIPT performance by different providers should be investigated further. 
The so called “genetic sonogram” which includes looking for soft markers of trisomy 21 
should not be performed in women with normal NIPT results due to its high false 
positive rate and poor positive predictive value. 
Prospective, publicly funded studies assessing the cost-effectiveness of various 
screening strategies should be performed as a matter of urgency. 
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Name of society/ 
organisation issuing 
guidance 
Date of 
issue 
Country/ies to 
which 
applicable 
Summary of recommendations related to NIPT Level of 
evidence 
BeSHG (Belgium Society for 
Human Genetics), approved 
by College of Medical 
Genetics 
December 
2014 
Belgium The use of NIPT for prenatal screening in a general Belgian obstetric population results in the 
smallest number of missed diagnoses of fetal trisomy 21. Morever the number of invasive tests 
that will have to be performed as a result of a positive screening test will be much lower than in 
the current situation using the combined first trimester screening as the primary screening 
instrument. Therefore, NIPT is currently the best choice as a first tier prenatal screening tool for 
trisomy 13, 18 and 21. 
Good clinical practice with NIPT: 
NIPT is the first tier screening tool for prenatal screening for fetal trisomy 13, 18 and 21 
Pre-test counselling with information about the different screening options and their possibilities 
and limitations is required. 
Informed consent has to be obtained. 
NIPT does not replace the first trimester fetal ultrasound for measurement of the nuchal 
translucency and identification of fetal malformations; fetal ultrasound should be performed 
before NIPT screening to ascertain whether there is an indication for another prenatal test or 
additional genetic counselling. 
In case of ultrasound anomalies, including NT> 95 percentile, invasive techniques are indicated. 
Acquiring pre-NIPT family history by means of pedigree information is standard of practice to 
make sure no other prenatal test is indicated. 
Referral of a patient with positive NIPT for invasive testing, preferably amniocentesis is 
necessary. 
Accreditation of genetic labs offering NIPT and regular peer revie on an national level is required. 
NIPT should be performed with caution in case of an increased in maternal BMI (>30) and in 
case of multiple pregnancy. 
NIPT is not indicated in the patient has undergone any of the following treatments in the past 3 
months: blood transfusions, immunotherapy, stem cell transplant or organ transplantation. 
 
Abbreviations: CVS-chorionic villus sampling, T21-trisomy 21, T18-trisomy 18, T13-trisomy 13, NIPS-non-invasive prenatal screening, NIPT-non-invasive prenatal testing, cfDNA-cell free DNA, NT-
nuchal translucency, BMI-body mass index 
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Evidence tables of individual studies included for clinical effectiveness and safety domains 
 
Table A2: Characteristics of included studies on general pregnant population 
Author(s): Sarno et al [39] 
Study 
characteristics 
Study design: prospective DTA trial 
Year of publication: 2016 
Study’s registration number in clinical trial database: not reported  
Country/ies of recruitment: UK 
Setting: routine prenatal screening 
Data collection period: October 2012 to August 2015 
Target population: high-risk pregnant population (singleton or twin pregnancies).  
Target condition prevalence in the enrolled population:  
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): Harmony™ Prenatal Test/CSS 
Country where samples were analysed: USA  
Cut off for NIPT: risk score for T21, 18 and T13 was ranged between >99% to <0.01% 
Population 
characteristics 
Maternal age in years (median [169]): 36.3 [33.2-39.3] 
Gestational age in weeks (median [169]): 11.9 [10.6-12.9] 
BMI in Kg/m2 (median [169]): 23.3 [21.2-26.5] 
Pregnancy by ART (no [% pts]): 1015 (9.5%) 
Inclusion criteria: singleton or twin pregnant women at 11+0 to 13+6 weeks’ gestation who received NIPT as an option following FCT or as part of routine 
screening. All pregnant women had undergone FCT.  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 10698 
Population excluded: 0 
Population included: 10698 
-with NIPT result: 10530 
-with comparator result: no intervention 
-with reference standard result: not reported 
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Reference standard (% pts): fetal karyotype (not specified method used) 
Sample processing protocol 
Maternal blood samples were collected at enrolment centres and sent to laboratory for its analysis. 
Outcomes Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 316 samples (2.9%) in the first analysis. In 235 samples cfDNA testing was repeated and this provided results in 148 cases 
(test failure after 2nd NIPT testing: 1.5% or 168/10698). 
-Uncertain results rate (% samples): NA 
Diagnostic accuracy measures for all trisomies in pregnancies with outcome data, excluding women with low fetal fractions, test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA 
TP 205 
TN 10288 
FP 23 (FP rate= 0.22%) 
FN* 14 (FN rate= 6.4%) 
S* 93.6 (89.6-96.2) 
Sp 99.8 (99.7-99.9) 
PPV 89.9 (85.3-93.2) 
NPV 99.9 (99.8-99.9) 
*FN rate T21=1.26%, FN rate T18= 10.8% and FN rate T13= 46.7%; S T21= 98.7%, S T18= 89.1% and S T13= 53.3%. 
Additional population relevant outcomes 
Safety 
-Increase in the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies of uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing cfDNA vs. standard screening):NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Norton et al [31] 
Study 
characteristics 
Non-invasive Examination of Trisomy-NEXT study 
Study design: prospective, blinded, multicentre comparative DTA trial  
Year of publication: 2015 
Study’s registration number in clinical trial database: NCT01511458 
Country/ies of recruitment: USA, Canada, Sweden, Belgium, Netherland, Italy  
Setting: routine prenatal-screening 
Data collection period: March 2012- April 2013 
Target population: unselected general pregnancy population  
Target condition prevalence in the enrolled population (n=15841 pts): 1/417 for T21, 1/1584 for T18, 1/2640 for T13 and 1/5280 or lower for other aneuploidies 
i.e. 45,X, marker chromosomes, unbalanced translocations, balanced translocations, deletion 7p, deletion/duplication 5p, 1q41 deletion and isochromosome 
Yp. 
Comparator: standard screening (measurement of nuchal translucency and biochemical analytes i.e. serum pregnancy-associated plasma protein A and total 
or free beta submit of human chorionic gonadotropin) 
Cut off point comparator: mid-trimester risk of at least 1/270 for T21 and at least 1/150 for T18 and T13 
Index test (trademark/technique type): Harmony Prenatal Test/CSS  
Country where samples were analysed: USA (Ariosa Clinical Laboratory) 
Cut off for NIPT: 1/100 or higher was clasificated as high risk 
Population 
characteristics 
Maternal age in years (mean [169]): 31 [18-28] 
Gestational age in weeks (median [169]): 12.5 [10.0-14.3] 
Maternal weight (median [169]: 65.8 [31.8-172.4] 
Pregnancy by assisted reproductive techniques (% pts): 3.0 
Inclusion criteria: populations were at least 18 years of age and had a singleton pregnancy between 10.0 and 14.3 weeks of gestation (mean gestational age: 
12.5) 
Exclusion criteria: populationsoutside the gestational-age window, no standard screening result, known maternal aneuploidy or cancer, donor oocytes 
conception, twin pregnancies or an empty gestational sac identified on ultrasonography 
Study protocol Population enrollment flow 
Population enrolled: 18955 
Population excluded: 3114 
Reasons for exclusion: 
-did not meet the eligibility criteria or meet exclusion criteria (n: 445) 
-blood-collection or labeling error (n: 384) 
-absence of a result on standard screening (n: 308)  
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-absence of a result on cfDNA (n: 488)  
-were lost to follow-up (n: 1489) 
Population included: 15841 
-with NIPT result: 15841 
-with comparator result: 15841 
-with reference standard results: 625/15481 (3.9 %) 
Reference standard (% pts): CVS (21.6), amniocentesis (67.5), products of conception (2.6) and newborn (8.3)  
Sample processing protocol 
Blood samples were collected into cell-free DNA BCT tubes (Streck), sent to sponsor (Ariosa Diagnostic) and analysed at 7 days after collection. The analyses 
and interpretation of cfDNA data were performed in a blinded fashion with respect to result of ultrasonographic and standard screening. 
Outcomes Performance of NIPT test for T21, T18 and T13 
-Test failure (% samples): 3% (488/16329) 
-Uncertain results rate (% samples): NA 
Diagnostic accuracy measures for T21 in pregnancies with outcome data, 
excluding women with low fetal fractions, test failures and miscarriages 
(calculated based on study results) 
 
 
Variable  Standard screening cfDNA test1,2 
TP 30 38 
TN 14,949 15,794 
FP 854 (FPrate: 5.4%) 9 (FPrate: 0.06%) 
FN 8 (FN rate: 21%) 0 
S 78.9 (62.7-90.4) 100 (90.7-100)* 
Sp 94.6 (94.2-94.9) 99.9 (99.9-100)** 
PPV 3.4 (2.3-4.8) 80.9 (66.7-90.9)** 
NPV 99.9 (99.9-100) 100 (99.9-100)*** 
AUC 0.958 0.999** 
1In low risk population (n=14,957), there were 8 TP cases, 8 FP cases, no FN 
cases, S=100% [63.1-100], Sp=99.9% [99.9-99.94], PPV=50.0% [24.7-75.3] and 
NPV= 100% [99.9-100] 
2In women with maternal age < 35 yrs (n=11,994), there were 19 TP cases, 6 FP 
cases, no FN cases, S=100% [82.4-100], Sp=99.9% [99.9-99.94], PPV=76.0% 
[54.9-90.6] and NPV= 100% [99.9-100]; 
*p=0.008, **p<0.001, ***p=0.005 
Diagnostic accuracy measures for T21 in pregnancies with outcome data, 
including women with low fetal fractions and test failures (calculated based on 
study results) 
Considering cases with no NIPT test 
results as high-risk of aneuploidies 
Variable  cfDNA test 
TP 41  
TN 15794 
FP 494 (FP rate: 3%) 
FN 0 
S 100 (91.4-100) 
Sp 97.0 (96.7-97.2) 
PPV 7.7 (5.7-10.2) 
NPV 100 (100-100) 
 
Considering cases with no NIPT test 
results as low-risk of aneuploidies  
Variable  cfDNA test 
TP 38 
TN 16279  
FP 9 (FPrate: 0.05%) 
FN 3 (FNrate: 7.3%) 
S 92.7 (80.6-97.5) 
Sp 99.9 (99-100) 
PPV 80.8 (67.5-89.6) 
NPV 100 (99.9-100) 
 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 163 
Diagnostic accuracy measures for T18, for pregnancies with outcome 
data, excluding women with low fetal fraction, test failures and 
miscarriages (calculated based on study results) 
 
 
Variable  Standard screening cfDNA Testing 
TP 8 9 
TN 15,782 15,830 
FP 49 (FP rate: 0.3%) 1 (FP rate: 0.006%) 
FN 2 (FN rate: 20%) 1 (FN rate: 10%) 
S 80.0 (44.4-97.5) 90.0 (55.5-99.7) 
Sp 99.7 (99.6-99.8) 100 (99.9-100)* 
PPV 14.0 (6.2-25.8) 90.0 (55.5-99.7)* 
NPV 100 (99.9-100) 100 (99.9-100) 
*p<0.001 
Diagnostic accuracy measures for T18 in pregnancies with outcome data, 
including women with low fetal fraction and test failures (calculated based on 
study results) 
Considering cases with no NIPT test 
results as high-risk of aneuploidies  
Variable  cfDNA 
TP 10 
TN 15830 
FP 489 (FP rate: 2.9%) 
FN 1 (FN rate: 9%) 
S 90.9 (62.3-98.4) 
Sp 97.0 (96.7-97.3) 
PPV 2.0 (1.1-3.6) 
NPV 100 (100-100) 
 
Considering cases with no NIPT test 
results as low-risk of aneuploidies  
Variable  cfDNA 
TP 9 
TN 16319  
FP 1 (FP rate: 0.006%) 
FN 2 (FN rate: 18.2%) 
S 81.8 (52.3-94.9) 
Sp 99.9 (99.9-100) 
PPV 90.0 (59.6-98.2) 
NPV 100 (100-100) 
 
Diagnostic accuracy measures for T13, for pregnancies with outcome 
data, excluding women with low fetal fraction, test failures and 
miscarriages (calculated based on study results) 
 
 
Variable  Standard screening cfDNA Testing 
TP 1 2 
TN 11,155 11,181 
FP 28 (FP rate:0.25%) 2 (FP rate: 0.018%) 
FN 1 (FN rate: 50%) 0 
S 50.0 (1.2-98.7) 100 (15.8-100) 
Sp 99.7 (99.6-99.8) 100 (99.9-100)* 
PPV 3.4 (0.1-17.8) 50.0 (6.8-93.2) 
NPV 100 (99.9-100) 100 (99.9-100) 
*p<0.001 
Diagnostic accuracy measures for T13 in pregnancies with outcome data, 
including women with low fetal fraction and test failures (calculated based on 
study results 
Considering cases with no NIPT test 
results as high-risk of aneuploidies  
Variable  cfDNA 
TP 4 
TN 11181 
FP 490 (FP rate: 4.2%) 
FN 0 
S 100 (51.0-100) 
Sp 95.8 (95.4-96.2) 
PPV 0.8 (0.3-2.1) 
NPV 100 (100-100) 
 
Considering cases with no NIPT test 
results as low-risk of aneuploidies  
Variable  cfDNA 
TP 2 
TN 11667 
FP 2 (FP rate: 0.02%) 
FN 2 (FN rate: 50%) 
S 50.0 (15.0-85.09 
Sp 100 (99.9-100) 
PPV 50.0 (15.0-85.0) 
NPV 100 (99.9-100) 
 
Additional population relevant outcomes 
Safety 
-Increase in the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies of uncertain significance: NA 
Effectiveness 
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-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NIPT diagnosed 8 more cases of T18, 1 more case of T18 and 1 more case of T13 
than first trimester standard screening. It is unknown if these cases would have been diagnosed during the progression of the pregnancy or i f they were 
livebirths. 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing cfDNA vs. standard screening):NA 
Estimations assuming all high risk patients would undergoe Invasive testing: 5.3 for T21, 0.3 for T18 and 0.16 for T13. 
-Change in uptake of prenatal screening: NA 
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Author(s): Pérez-Pedregosa et al [41]  
Study 
characteristics 
Study design: Comparative prospective observational DTA trial, one centre (cross-sectional design) 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: Spain  
Setting: routine prenatal screening 
Data collection period: not reported 
Target population: general pregnancy population 
Target condition prevalence in the enrolled population: 1/41 for T21 and 1/193 for T18 
Comparator: standard screening that includes serum biochemical assays (PAPP-A and free β-hCG) with NT 
Cut off point comparator: high-risk>1/100 and low-risk=1/101 to 1/1000 (PRISCA 4.0 Typolog software) 
Index test (trademark/technique type): Harmony™ Prenatal Test/CSS 
Country where samples were analysed: USA (Ariosa Diagnostic) 
Cut off for NIPT: high-risk score>99% and low-risk score<0.01% (Fetal –Fraction) Optimized Risk of Trisomy Evaluation-FORTE algorithm) 
Population 
characterisitics 
Maternal age in years (mean [169]): 36.5 [22-47]  
Gestational age in weeks (median [169]): not reported 
Maternal weight (median [169]: not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: women with singleton pregnancy and a gestational age at least 10 weeks 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 582 
Population excluded: 3 (test failure) 
Population included: 579 
-with NIPT result: 579 
-with comparator result: 581 
-with reference standard result: not reported 
With reference standard results: 100% (CVS or amniocentesis in population with high risk for any chromosopathy and neonatal examination or telephone 
contact in the rest of women). 
Sample processing protocol 
Maternal blood was collected in enrollment center and sent to Ariosa Diagnostics.  
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Outcomes 
 
Performance of NIPT for T21 and T18  
-Test failure (% samples): 0.5 (3 samples) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in all included cases 
(exclusion of miscarriages) 
Variable Standard screening1 cfDNA 
TP 12 14 
TN 529 565 
FP 38 (FP rate: 6.7%) 0 
FN 2 (FN rate: 14.3%) 0 
S 85.7 (56.1-97.4) 100 (73.2-100) 
Sp 93.2 (90.7-95.1) 100 (99.1-100) 
PPV 24 (13.5-38.4) 100 (73.2-100) 
NPV 99.6 100 (99.1-100) 
1581 population included; 2 579 included population  
Diagnostic accuracy measures for Trisomy 18 in all included cases 
(exclusion of miscarriages) 
Variable  Standard screening cfDNA 
TP 3 3 
TN 574 576 
FP 5 (FP rate: 0.86%) 0 
FN 0 0 
S 100 (43.8-100) 100 (43.8-100) 
Sp 99.1 (98.0-99.6) 100 (99.3-100) 
PPV 37.5 (13.7-69.4) 100 (43.8-100) 
NPV 100 (99.3-100) 100 (99.1-100) 
*Calculated based on data provided (Sp noted in study=98.9 [97.6-99.5] 
Diagnostic accuracy measures for Trisomy 13 
No data provided for T13 
Additional population relevant outcomes 
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing: NA (calculated from highr risk cfDNA vs. standard screening, %): 1.4% for T21 and 0.85% for T18 
-Change in uptake of prenatal screening: NA 
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Author(s): Quezada et al [42] 
Study 
characteristics 
Study design: prospective, comparative DTA trial (cross-sectional design) 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: United Kingdom (UK) 
Setting: routine prenatal-screening 
Data collection period: October 2012-January 2014 
Target population: general pregnancy population 
Target condition prevalence in the enrolled population: 1/85 for T21, 1/290 for T18 and 1/581 for T13 
Comparator: standard screening that includes serum biochemical assays (PAPP-A and free β-hCG), NT and fetal CRL. It was performed at 11-13 week’s 
gestation 
Cut off point comparator: population was classified as high risk at estimated risk≥1/100 (cut-off recommendation by the UK National Screening Committee 
for invasive testing)  
Index test (trademark/technique type): Harmony™ Prenatal Test/CSS 
Country where samples were analysed: USA (Ariosa Diagnostics) 
Cut off for NIPT: risk score for trisomy>99% or <1/10000 
Population 
characteristics 
Maternal age in years (mean [169]): 36.9 [20.4-51.9] 
Gestational age in weeks (median [169]): 10+4 [10+0-11+6] 
Maternal weight (median [169]): 62.8 [40.5-137.7]  
Pregnancy by assisted reproductive techniques (% pts): 16.1 
Inclusion criteria: women with singleton pregnancies and a live foetus 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Populations enrolled: 2905 
Populations excluded: 0 
Populations included: 2905 
-with NIPT result: 2851 
-with comparator result: 2863 
-with reference standard result: 2857 
Reference standard (% pts): invasive fetal karyotyping (CVS, amniocentesis or neonate blood) or neonate phenotype examination 
No fetal tissue karyotyping available for pregnancies resulting in miscarriage or stillbirth  
Sample processing protocol 
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Maternal blood was collected in Streck cell-free DNA BCT™ tubes and sent to the Ariosa Diagnostics. Invasive testing results were obtained from laboratories 
and pregnancy outcomes were obtained from obstetricians, general practitioners or the population. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (%, n samples): 1.9 (54 samples) (38 cases with fetal fraction<4% and 15 cases of assays failure) 
-Uncertain results rate (%, n samples): not reported 
Diagnostic accuracy measures for T21 in pregnancies with 
outcome data, excluding test failures and miscarriages (calculated 
based on study results) 
 
 
Variable Standard combined test1  cfDNA2 
TP 34 32 
TN 2663 2734 
FP 139 (FP rate: 4.96%) 1 (FP rate: 0.04%) 
FN 0 0 
S 100 (89.8-100) 100 (89.3-100) 
Sp 95.0 (94.2-95.8) 99.9 (99.8-100) 
PPV 19.7 (14.4-26.2) 96.9 (84.7-99.5) 
NPV 100 (99.9-100) 100 (99.9-100) 
1Trisomic status unknown in 69 samples (52 with low-risk, 5 with high-risk 
and 12 with no results)  
 2Trisomic status unknown in 69 samples (65 with low-risk, 1 with high-risk 
and 3 with no results)  
Diagnostic accuracy measures for T21 in pregnancies with outcome data, including 
test failures (calculated based on study results) 
Considering cases with no NIPT test 
results as high-risk of aneuploidies  
Variable  cfDNA 
TP 34  
TN 2734 
FP 50 (FP rate: 1.79%) 
FN 0 
S 100 (89.8-100) 
Sp 98.2 (97.6-98.6) 
PPV 40.5 (80.6-51.2) 
NPV 100 (99.9-100) 
 
Considering cases with no NIPT test 
results as low-risk of aneuploidies  
Variable  cfDNA 
TP 32 
TN 2783 
FP 1 (FP rate: 0.035%) 
FN 2 (FN rate: 5.88%) 
S 94.1 (80.9-98.4) 
Sp 99.9 (99.8-100) 
PPV 96.9 (84.7-99.5) 
NPV 99.9 (99.7-100) 
 
Diagnostic accuracy measures for T18 in pregnancies with 
outcome data, excluding test failures and miscarriages (calculated 
based on study results) 
Variable  Standard screening cfDNA 
TP 10 9 
TN 2663 2730 
FP 163 (FP rate: 5.8%) 5 (FP rate: 0.18%) 
FN 0 1 (FN rate: 10%) 
S 100 (72.2-100) 90.0 (59.6-98.2) 
Sp 94.2 (93.3-95) 99.8 (99.6-99.91) 
PPV 5.8 (3.2-10.3) 64.3 (38.3-83.7) 
NPV 100 (99.9-100) 99.9 (99.8-100) 
 
Diagnostic accuracy measures for T13 in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated based on study results) 
Variable  Standard screening cfDNA 
TP 5 2 
TN 2663 2730 
FP 168 (FP rate: 5.9%) 2 (FP rate: 0.07%) 
FN 0 3 (FN rate: 60%) 
S 100 (56.6-100) 40.0 (11.8-76.9) 
Sp 94.1 (93.1-94.9) 99.9 (99.7-100) 
PPV 2.9 (1.2-6.6) 50.0 (15.0-85) 
NPV 100 (99.9-100) 99.9 (99.7-100) 
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Additional population relevant outcomes  
Safety 
-Increase in the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies of uncertain significance: NA 
Effectiveness 
- Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NIPT detected four less cases of aneuploidies (one case of T18 and 3 cases of T13), 
although it is unknown if these were live births 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages related to invasive testing: NA 
-Reduction in uptake of invasive testing: NA 
Estimations based on high risk cfDNA vs. standard screening, %): 4.13 for T21, 4.16 for T18 and 4.10 for T13 
-Change in uptake of prenatal screening: NA 
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Author(s): Zhang et al [43] 
Study 
characteristics 
Study design: propective, multicentre DTA study (cross-sectional design) 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China 
Setting: routine prenatal care 
Data collection period: January 2012- August 2013 
Target population: high-risk pregnant population 
Target condition prevalence in the enrolled population: 1/205 for T21, 1/882 for T18 and 1/6696 for T13 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): BGI laboratories; Illumina HiSeq2000 platforms with The Fetal Copy-number Analysis through Maternal Plasma 
Sequencing (FCAPS) algorithm/MPS 
Country where samples were analysed: laboratories of BGI-Health, China 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 30.9 [18-46] 
Gestational age in weeks (median [169]): 18.7 [9-36] 
94.13% samples were collected during the second trimester  
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: women at least 18 years old with singleton or twin pregnancy at ≥9 weeks’ gestation  
Population with NIPT testing result were classified into high or low-risk group attending to the following criteria: 
High-risk group: advanced maternal age >35 years of age, positive conventional Down syndrome screening test result (cut-off 1/270 or 1/300, depending 
on hospital’s criteria), abnormal sonographic findings, family history of aneuploidy or previous pregnancy with a trisomic foetus (n= 72382). 
Low-risk group: none of high-risk factors mentioned above (n=40287) 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Populations enrolled: 147314 (802 twin pregnancy and 146156 singleton pregnancy) 
Populations excluded: 356 
Reasons for exclusion: 
-absence of a result on cfDNA (testing failure): 145 
-inappropriate sample (inadequate volume, contamination, obtained before 9 week’ gestation or improper labeling): 211 
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Populations included: 146958 
-with NIPT result: 146958 
-with reference standard result: 112669 
Reference standard (% pts): karyotyping (1055, 66.8% positive NIPT results) or clinical follow-up (111605) 
Sample processing protocol 
Maternal blood samples were collected into EDTA tubes at each enrolment center and sent to laboratories of BGI-Health for its analysis 
Outcomes Diagnostic performance of NIPT for T21, T18 and T13 
-Test failure (% samples): (145 samples (0.098%) 
-Inappropriate sample (n,%): (211, 0.14%) 
-Uncertain results rate (% samples): 326 (0.2%) 
Diagnostic accuracy measures for T21 in pregnancies with outcome 
data, excluding test failures, uncertain results and miscarriages 
Variable  cfDNA testing1,2,3 
TP 720 
TN* 111594 
FP 61 (FP rate: 0.05%) 
FN 6 (FN rate: 0.83%) 
S 99.2 (98.5-99.8) 
Sp 99.9 (99.9-99.9) 
PPV 92.2 (90.3-94.1) 
NPV 100 (99.9-100) 
1 Karyotyping or follow-up confirmation was not available for 34289 samples 
due to follow up loss, elective termination or pregnancy loss (512 samples 
from positive NIPT results cohort and 33777 samples from negative NIPT 
result cohort).  
2In twin pregnancies (n=404), there were 5 TP cases, 2 FP cases, no FN 
cases, S=100 [47.82-100], Sp=99.50 [98.20-99.94], PPV=71.43 [29.04-96.33] 
and NPV= 100 [99.08-100]. 
3 If underteminate results are considered as FP: PPV would be 65,04 
*4605 birth defects irrelevant to trisomy (facial anomalies, cardiac anomalies, 
hearing impairment, heel blood testing anomalies and physical examination 
anomalies).  
Comparison NIPT accuracy for T21 high-risk vs. low-risk pregnancies 
Variable  cfDNA testing 
High-risk Low-risk 
TP 624 96 
TN NA NA 
FP 39 22 
FN 5 1 
S 99.2 (98.5-99.9) 98.9 (94.4-100) 
Sp 99.95 (99.9-99.9) 99.9 (99.9-100) 
PPV* 94.12 (92.3-95.9) 81.4 (74.3-88.4) 
NPV 100 (99.9-100) 100 (99.9-100) 
NA: not available; *p<0.00001 
Diagnostic accuracy measures for T18 in pregnancies with outcome 
data, excluding test failures, uncertain results and miscarriages 
Diagnostic accuracy measures for T13 in pregnancies with outcome data, excluding 
test failures, uncertain results and miscarriages 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 172 
Variable cfDNA testing 
TP 167 
TN 111594  
FP 51 (FP rate: 0.05%) 
FN 3 (FN rate: 1.77%) 
S 98.24 (94.93-99.63) 
Sp 99.95 (99.94-99.97) 
PPV 76.61 (70.99-82.23) 
NPV 100 (99.99-100) 
  
Variable cfDNA Testing 
TP 22 
TN 111594 
FP 45 (FP rate: 0.04%) 
FN 0 
S 100 (84.56-100) 
Sp 99.9 (99.95-99.97) 
NPV 32.8 (21.59-44.08) 
NPV 100 (99.99-100) 
 
Additional population relevant outcomes  
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: Na 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Bianchi et al [30] 
Study 
characteristics 
Comparison of Aneuploidy Risk Evaluations (CARE) study 
Study design: prospective, blinded, multicentre comparative DTA study (cross sectional design) 
Year of publication: 2014 
Study’s registration number in clinical trial database: NCT01663350 
Country/ies of recruitment: United States (21 medical centers) 
Setting: routine prenatal-screening 
Data collection period: July 2012- January 2013 
Target population: general pregnancy population 
Target condition prevalence in the enrolled population (n: 1914 pts): 1/383 for T21, 1/957 for T18 and 1/1914 for T13 
Comparator: standard screening that included serum biochemical assays at first trimester (PAPP-A and hCG) or second trimester (maternal serum alpha-
fetoprotein, hCG, unconjugated estriol and inhibin A) with or without NT 
Cut off point comparator: the risk classification was determined on the basis on first or second-trimester results. Cut of point was not reported.  
Index test (trademark/technique type): Verifi™Prenatal Test (Illumina HiSeq 2000 instruments)  
Country where samples were analysed: USA (Verinata Health) 
Cut off for NIPT: Samples with a normalized chromosome value ≥4.0 were classified as affected and samples with value≤3.0 were classified as unaffected. 
Population 
characteristics 
Maternal age in years (mean [SD]): 29.6±5.54 
Gestational age in weeks (median [SD]): 20.3±8.6 
Body-mass index (median [SD]: 28.7±6.96  
Pregnancy by assisted reproductive techniques (% pts): 3.4 
Inclusion criteria: pregnant women had to be at least 18 years of age and had to be carrying a foetus with a gestational age of at least 8 weeks. All populations 
had planned to undergo or had completed standard prenatal serum screening for fetal aneuploidies. 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Populations recruited: 2042 (ineligible due to maternal age < 18 years (n=1), withdraw consent (n=1) and insufficient blood volume or late receipt (n=8).  
Populations enrolled: 2042 
-Populations excluded: 128 
Reasons for exclusion: 
-no clinical outcome: 72 
-no live birth, no karyotype: 24 
-no result on cfDNA testing: 17 
-no result on standard screening: 39 
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Populations included: 1914 
Reference standard (% pts): newborn physical examination (1857) and karyotype (57)(CVS in 10, amniocentesis in 38, testing of products of conception in 3 
and postnatal evaluation in 6) 
Sample processing protocol 
Blood samples were collected in a cfDNA blood collection tube (Streck) in enrolment sites and sent to Verinata Health. A sample was eligible for analysis if it 
was received within 5 days after the sample was obtained and contained at least 7 ml of blood. All personnel were unaware of clinical data and outcomes.  
All cytogenetic reports were generated in accredited laboratories and reviewed by independent, board-certified cytogeneticist who were unaware of the results 
of cfDNA testing. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 0.9 (18/2042) 
-Uncertain results are (% samples): not reported 
Diagnostic accuracy measures for T21 in 
pregnancies with outcome data, excluding women 
with absence or uncertain screening results, 
cfDNA test failures and miscarriages (n=1952) 
Variable  Standard2 screening cfDNA Testing1 
TP 3 5 
TN 1840 1941 
FP 69 (FP rate: 3.6%) 6 (FP rate: 0.3)* 
FN 0 0 
S 100 (29.2-100) 100 (47.8-100) 
Sp 96.4 (95.4-97.2) 99.7 (99.3-99.9) 
PPV 4.2 (0.9-11.7) 45.5 (16.7-76.6) 
NPV 100 (99.8-100) 100 (99.8-100) 
1 1952 analysed for cfDNA test performance; 28% of 
results obtained in 3rd trimester 
2 1912 analysed for standard screening test performance 
*p<0.001 
Diagnostic accuracy measures for T18 in 
pregnancies with outcome data, excluding 
women with absence or uncertain screening 
results, cfDNA test failure and miscarriages 
Variable  Standard 
screening2 
cfDNA Testing1 
TP 1 2 
TN 1894 1947 
FP 11 (FP rate: 0.6%) 3 (FP rate: 0.2%)* 
FN 0 0 
S 100 (2.5-100) 100 (15.8-100) 
Sp 99.4 (99.0-99.7) 99.8 (99.6-100)  
PPV 8.3 (0.2-38.5) 40.0 (5.3-85.3) 
NPV 100 (99.8-100) 100 (99.8-100) 
1 1952 analysed for cfDNA test performance; 28% of 
results obtained in 3rd trimester 
2 1906 analysed for standard screening test  
*p=0.03 
Diagnostic accuracy measures for T13 in 
pregnancies with outcome data, excluding 
women with absence or uncertain screening 
results, cfDNA test failures and miscarriages 
Variable  Standard screening cfDNA Testing 
TP 1 1 
TN 892 1910 
FP 6 (FP rate: 0.67%) 3 (FP rate: 0.16%) 
FN 0 0 
S 100 100 (20.7-100) 
Sp 99.3 99.8 (99.5-99.9) 
PPV 14 25 (4.6-69.9) 
NPV 100 100 (99.8-100) 
1914 analysed for cfDNA test performance; 28% of 
results obtained in 3rd trimester 
2 analysed for standard screening test performance 
*p=0.059 
Additional patient relevant outcomes 
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies:NA  
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: 0 
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-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing: NA 
Estimations based on high risk cfDNA vs. standard screening, (%): 3.46 for T21 and 0.42 for T18.  
-Change in uptake of prenatal screening: NA 
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Author(s): Comas et al [40] 
Study 
characteristics 
Study design: prospective, unicentre, DTA study (cross sectional design) 
Year of publication: 2015 
Country/ies of recruitment: Spain 
Setting: routine prenatal-screening 
Data collection period: January to December 2013 
Target population: general pregnancy population  
Prevalence of T21 in the enrolled population: 4/333 (1.2%) 
Index test (trademark/technique type): Panorama™ Prenatal Test (Natera Inc.) or HarmonyTM (Ariosa diagnostics) 
Country where samples were analysed: Natera and Ariosa laboratories 
Cut off for NIPT: NA 
Population 
characteristics 
Maternal age in years (mean [SD]): 37 (21-46) 
Gestational age in weeks (mean): 14.6 (9.5-23.5) 
Body-mass index (mean: 22.9 (17-1-42.4)  
Pregnancy by assisted reproductive techniques (% pts): NA 
Inclusion criteria: All singleton pregnant women were offered NIPT in addition to FCT 
Exclusion criteria: cases with ultrasound anomalies or those at high risk for other conditions 
Study protocol 
 
Population enrollment flow 
Patients included: 333 (83.5% considered of low risk (referred for anxiety) and 16.5% high risk pregnancies 
With NIPT result: 324 
With reference standard result: 315 (94.5% pts) 
Reference standard: karyotyping for all high risk patients (n=5); follow up rest (n=310)  
Sample processing protocol 
Maternal blood samples were collected into bcttm tubes at each enrolment center and sent to laboratories the same day 
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Outcomes Performance of NIPT for T21 
-Test failure: 1.2% 
Diagnostic accuracy measures for T21 in pregnancies with outcome data, women with absence or uncertain screening results, cfDNA test failures and 
miscarriages (n=329) 
 Variable  
Test cfDNA TP TN FP FN S Sp PPV NPV 
Harmony™ 0 116 1 0 0 99.1 0 100 
Panorama™ 4 203 0 0 100 100 100  
Total 4 319 1 (FP rate: 0.3%) 0 100 (51-100) 99.6 (98.3-99) 80 (37.6-96.4) 100 
Harmony (n=117); Panorama (n=207) 
Additional patient relevant outcomes 
Safety 
-Increase the number of children born with other relevant unconfirmed chromosomal anomalies:NA  
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: 0 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing: NA 
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Author(s): Song et al [45] 
Study 
characteristics 
Study design: Comparative DTA study (prospective cohort) 
Year of publication: 2013 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China (Peking Union Medical College) 
Setting: routine prenatal care 
Data collection period: April 2011-December 2011 
Target population: general pregnant population 
Target condition prevalence in the enrolled population: 1/239 for T21, 1/958 for T18, 1/1916 for T13, 1/958 for 45,X and no cases for 47,XXY 
Comparator: triple serum screening in the second trimester (α-fetoprotein, free β-hCG and unconjugated estriol) 
Cut off point comparator: 1/270 
Index test (trademark/technique type): Berry Genomics laboratories, HiSeq2000, Illumina/MSP 
Country where samples were analysed: Berry Genomics Co, Ltd, China 
Cut off for NIPT: sample with Z-score≥3 was classified as aneuploidy. GC corrected normalized chromosome representation NCRgc value was also used to 
classify sample trisomy status. 
Population 
characteristics 
Maternal age in years (mean [SD]): 29.03±2.70  
Gestational age in weeks (mean [SD]): 16.57±1.56  
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): 0.8 
Inclusion criteria: pregnant women < 35 years 
Exclusion criteria: not reported. 
Study protocol Population enrollment flow 
Population enrolled: 1916 
Population excluded: 175 
Reason for exclusion: missed follow up and failures with no follow up information 
-absence of a result on cfDNA and no birth follow up (64) 
-No birth outcome information (111)  
Population included: 1741 
-with NIPT result: 1741 
-with comparator result: 1741 
-with reference standard result: 217 by invasive testing and 1805 by neonatal follow-up.  
Reference standard (n or % pts): amniocentesis (190), CVS (10), cordocentesis (2) or birth follow-up including physical details on neonates.  
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Sample processing protocol 
Blood samples were collected into EDTA tubes at each enrolment institution and sent to Berry Genomics Co, Ltd. for its analysis. Plasma DNA was 
extracted using the QIAamp Circulating Nucleic Acid Kit from Qiagen.  
Results analysis was performed in a blinded fashion. 
Outcomes Performance of NIPT for T21, T18, T13, 45,X syndrome and 47, XXY syndrome  
-Test failure (% samples): 73 samples (3.8%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 8 
TN 1733 
FP 0 
FN 0 
S 100 (59.8-100) 
Sp 100 (99.7-100) 
PPV 100 (59.8-100) 
NPV 100 (99.7-100) 
 
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 2 
TN 1738 
FP 1 (FP rate: 0.06%) 
FN 0 
S 100 (19.79-100) 
Sp 99.9 (99.6-99.99) 
PPV 66.7 (20.8-93.1) 
NPV 100 (99.8-100) 
 
Diagnostic accuracy measures for Trisomy 13 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on study 
results)  
Variable cfDNA Testing 
TP 1 
TN 1740 
FP 0 
FN 0 
S 100 (5.5-100) 
Sp 100 (99.7-100) 
PPV 100 (5.5-100) 
NPV 100 (99.7-100) 
  
Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: serum screening false negative rate for all of these trisomies reached 45.45% in 
comparison to 0% of NIPT testing (5 FN cases by serum screening vs. 0 FN cases by NIPT)  
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: According to number of TP or PPV for 13,18 and 21 
trisomies, NIPT identified the most of aneuploid cases and therefore it could avoid unnecessary miscarriages or still birth of affected foetuses 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): FP cfDNA for 13,18 and 21 trisomies was 0.06% vs. 14% 
for serum screening. Aneuploidies screening by NIPT, it was needed 237 invasive testing less than by serum screening (reduction of 3.07%)  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Pergament et al [44] 
Study 
characteristics 
Study design: DTA study (prospective cohort) 
Year of publication: 2014 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: USA (36 prenatal care centers) 
Setting: routine prenatal-screening 
Data collection period: not reported 
Target population: general pregnancy population (high and low risk) 
Target condition prevalence in the enrolled population: 1/17 for T21, 1/39 for T18, 1/80 for T13 and 1/97 for monosomy X 
Comparator: no intervention  
Cut off point comparator: no intervention 
Index test (trademark/technique type): The Next-generation Aneuploidy Test Using SNPs (Natera Inc.) 
Country where samples were analysed: USA 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (median [169]): 30.0 [18-47] 
Gestational age in weeks (median [169]): 14.3 [7.6-40.6] 
Maternal weight (median [169]: not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: women were ≥18 years of age with a singleton pregnancy of at least 7 weeks of gestation and signed an informed consent 
NIPT indication (% pts): 
-High risk (defined after positive serum screen, ultrasound anomaly and/or maternal age≥35 years): 51.0 
-Low risk (defined as maternal age<35 years and lacking any reported high-risk indications): 49.0  
Exclusion criteria: confirmed sex chromosome anomaly (47,XXX/XXY/XYY), confirmed triplody or confirmed fetal mosaicism 
Study protocol Patient enrollment flow 
Patient enrolled: 1,064 (543 with high-risk and 521 with low-risk) 
Patient excluded: 13 
Reason for exclusion: 
-not meet the eligibility criteria or met exclusion criteria: confirmed triploidy (6), fetal mosaic (3), 47,XXY (2), 47,XXX (1) and 47,XYY (1) 
Patient included: 1,051 
-with NIPT result: 966 (85 samples were excluded for non-fulfillment of quality control named “no-calls” for the following reasons: low fetal fraction, low amount 
of input cel-free DNA, contamination, the presence of regions of loss of heterozygosity (LOH) in maternal DNA exceeding 25% of the chromosome or poor fit 
of the data to the model)  
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-with reference standard result: 1064 
Reference standard (% pts): amniocentesis/CVS (44.1), products of conception (42.8) or genetic testing of cord blood, buccal sample, saliva (13.2).  
Sample processing protocol 
Cell-free DNA analysis was blinded to sample karyotype. 
Outcomes Performance of NIPT for T21, T18, T13 and monosomy X 
Test failure (% samples): 8.1 (85/1051 samples) 
Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for T21 in pregnancies with 
outcome data, excluding test failures (calculated based on 
study results) 
Variable  cfDNA Testing 
TP 58 
TN 905 
FP 0 
FN 0 
S 100 (93.8-100) 
Sp 100 (99.6-100)  
PPV 100 (93.8-100) 
NPV 100 (99.6-100) 
  
Diagnostic accuracy measures for T21 in pregnancies with outcome data, including test 
failures (calculated based on study results) 
Considering cases with no NIPT test 
results as high-risk of aneuploidies  
Variable  cfDNA Testing 
TP 66 
TN 905 
FP 77 (FP rate: 7.8%) 
FN 0 
S 100 (94.5-100) 
Sp 92.2 (90.3-93.7) 
PPV 46.2 (38.2-54.3) 
NPV 100 (99.6-100) 
 
Considering cases with no NIPT test results 
as low-risk of aneuploidies  
Variable  cfDNA Testing 
TP 58 
TN 982 
FP 0 
FN 8 (FN rate: 12.1%) 
S 87.9 (77.9-93.7)  
Sp 100 (99.6-100) 
PPV 100 (93.8-100) 
NPV 99.2 (98.4-99.6) 
 
Diagnostic accuracy measures for Trisomy 18 in pregnancies 
with outcome data, excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA Testing 
TP 25 
TN 939 
FP 1 (FP rate: 0.1%) 
FN 1 (FN rate: 3.84%) 
S 96 (79.7-99.9) 
Sp 99.9 (99.4-100] 
PPV 96.1 (79.7-99.9) 
NPV 99.9 (99.4-100) 
. 
Diagnostic accuracy measures for Trisomy 18 in pregnancies with outcome data, 
including test failures and miscarriages (calculated based on study results) 
Considering cases with no NIPT test 
results as high-risk of aneuploidies  
Variable  cfDNA Testing 
TP 32 
TN 939 
FP 79 (FP rate: 7.7%) 
FN 1 (FN rate: 3.03%) 
S 97.0 (84.7-99.59 
Sp 92.2 (90.4-93.7) 
PPV 28.8 (21.2-37.9) 
NPV 99.9 (99.4-100) 
 
Considering cases with no NIPT test results 
as low-risk of aneuploidies  
Variable  cfDNA Testing 
TP 25 
TN 1017 
FP 1 (FP rate: 0.098%) 
FN 8 (FN rate: 24.2%) 
S 75.8 (59.0-87.2) 
Sp 99.9 (99.4-100) 
PPV 96.1 (81.1-99.3) 
NPV 99.2 (98.5-99.6) 
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Diagnostic accuracy measures for Trisomy 13 in pregnancies 
with outcome data, excluding test failures and miscarriages 
(calculated based on study results)  
Variable cfDNA Testing 
TP 12 
TN 953 
FP 0 
FN 0 
S 100 (75.7-100) 
Sp 100 (99.6-100) 
PPV 100 (75.7-100) 
NPV 100 (99.6-100) 
 
Diagnostic accuracy measures for Trisomy 13 in pregnancies with outcome data, 
including test failures and miscarriages (calculated based on study results) 
Considering cases with no NIPT test 
results as high-risk of aneuploidies  
Variable  cfDNA Testing 
TP 14 
TN 953 
FP 83 (FP rate: 8%) 
FN 0 
S 100 (78.5-100) 
Sp 92.0 (90.2-93.5) 
PPV 14.4 (8.8-22.8) 
NPV 100 (99.6-100) 
  
Considering cases with no NIPT test results 
as low-risk of aneuploidies  
Variable  cfDNA Testing 
TP 12 
TN 1036 
FP 0 
FN 2 (FN rate: 14.28%) 
S 85.7 (60.1-96.0) 
Sp 100 (99.6-100) 
PPV 100 (75.7-100) 
NPV 99.8 (99.3-99.9) 
 
Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Change in uptake of prenatal screening: NA 
Abbreviations: NA: not available; S: sensitivity; Sp: specificity; TP: true positive; TN: true negative; FP: false positive; FN: false negative; PPV: positive predictive value; NPV: negative predictive value. 
FPR: false positive rate and FNR: false negative rate. 
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Table A3: Characteristics of included studies on high-risk pregnant population  
Author(s): Persico et al [49] 
Study 
characteristics 
Study design: multicentre prospective DTA study  
Year of publication: 2016 
Study’s registration number in clinical trial database: not reported  
Country/ies of recruitment: Italy 
Setting: routine prenatal screening 
Data collection period: March to December 2014 
Target population: high-risk pregnant population  
Target condition prevalence in the enrolled population (including cases with no result for cfDNA test): 1/7 for T21, 1/17 for T18 and 1/43 for T13  
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): not reported/SNPs 
Country where samples were analysed: USA 
Cut off for NIPT: >1/100 
Population 
characteristics 
Maternal age in years (median [169]): 36 [20-46]  
Gestational age in weeks (median [169]): not reported 
Maternal weight in Kg (median [169]): not reported 
Pregnancy by assisted reproductive techniques (no [% pts]): not reported  
Inclusion criteria: women with singleton pregnancies and an estimated risk for trisomies 21, 18 or 13 after first-trimester combined screening ≥1/250 
(combination of maternal age, fetal NT thickness, fetal heart rate and maternal serum free β-hCG and pregnancy-associated plasma protein-A at 11-13 
weeks’ gestation). 
Exclusion criteria: not reported. 
Study protocol Population enrollment flow 
Population enrolled: 259 
Population excluded: 0 
Population included: 259 
-with NIPT result: 249  
-with comparator result: no intervention 
-with reference standard result: 259 
Reference standard (% pts): amniocentesis, CVS. Microarray- CGH analysis was performed in selected cases (based on clinician’s decision, including NT 
thickness≥3.5 mm and/or evidence of a major structural defect on ultrasound)(n=32) 
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Sample processing protocol 
Maternal blood samples were collected into Cell-Free DNA BCT tubes at enrolment centres and sent to Natera, Inc. where sequencing analysis was performed.  
It was not reported if karyotyping and sequencing analysis were performed in a blinded fashion. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 10 samples (3.9%)(fetal fraction <4% in 8 cases and failed internal quality control in 2). 
-Uncertain results rate (% samples): NA 
Diagnostic accuracy measures for T21 in pregnancies with 
outcome data, excluding test failures and miscarriages 
(calculated based on study results) 
 
Variable  cfDNA testing 
TP 35 
TN 213 
FP 0 
FN 1 (FN rate: 2.8%) 
S 97.2 (65.8-99.5) 
Sp 100 (98.2-100) 
PPV 100 (90.1-100) 
NPV 99.5 (97.4-99.9) 
 
Diagnostic accuracy measures for T21 in pregnancies with outcome data, including test 
failures (calculated based on study results)  
Considering no results cfDNA test cases as 
high risk of aneuploidy 
Variable  cfDNA testing 
TP 36 
TN 213 
FP 9 (FP rate: 4%) 
FN 1 (FN rate: 2.7%) 
S 97.3 (86.2-99.5) 
Sp 95.9 (92.5-97.9) 
PPV 80.0 (66.2-89.1) 
NPV 99.5 (97.4-99.9) 
 
Considering no results cfDNA test cases 
as low risk of aneuploidy 
Variable  cfDNA testing 
TP 35 
TN 222 
FP 0 
FN 2 (FN rate: 5.4%) 
S 94.6 (82.3-98.5)  
Sp 100 (98.3-100) 
PPV 100 (90.1-100) 
NPV 99.1 (96.8-99.8) 
 
Diagnostic accuracy measures for T18 in pregnancies with 
outcome data, excluding test failures and miscarriages 
(calculated based on study results) 
Variable  cfDNAcfDNA testing 
TP 13 
TN 236 
FP 0 
FN 0 
S 100 (77.2-100) 
Sp 100 (98.4-100) 
PPV 100 (77.2-100) 
NPV 100 (98.4-100) 
. 
Diagnostic accuracy measures for T18 in pregnancies with outcome data, including test 
failures (calculated based on study results) 
Considering no results cfDNA test cases as 
high risk of aneuploidy 
Variable  cfDNAcfDNA testing 
TP 15 
TN 236 
FP 8 (FP rate: 3.28%) 
FN 0 
S 100 (79.6-100) 
Sp 96.7 (93.7-98.3) 
PPV 65.2 (44.9-81.2) 
NPV 100 (98.4-100) 
 
Considering no results cfDNAcfDNA test 
cases as low risk of aneuploidy 
Variable  cfDNAcfDNA testing 
TP 13  
TN 244 
FP 0 
FN 2 (FN rate: 13.3%) 
S 86.7 (62.1-96.3) 
Sp 100 (98.4-100) 
PPV 100 (77.2-100) 
NPV 99.2 (97.1-99.8) 
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Diagnostic accuracy measures for T13 in pregnancies with 
outcome data, excluding test failures and miscarriages 
(calculated based on study results) 
Variable  cfDNA testing 
TP 5 
TN 244 
FP 0 
FN 0 
S 100 (56.6-100) 
Sp 100 (98.4-100) 
PPV 100 (56.6-100) 
NPV 100 (98.4-100) 
 
Diagnostic accuracy measures for T13 in pregnancies with outcome data, including test 
failures (calculated based on study results)  
Considering no results cfDNA test cases as 
high risk of aneuploidy 
Variable  cfDNA testing 
TP 6 
TN 244 
FP 9 (FP rate: 3.6%) 
FN 0 
S 100 (61.0-100) 
Sp 96.4 (93.4-98.1) 
PPV 40.0 (19.8-64.3) 
NPV 100 (98.4-100) 
  
Considering no results cfDNA test cases as 
low risk of aneuploidy 
Variable  cfDNA testing 
TP 5 
TN 253 
FP 0 
FN 1 (FN rate: 16.7%) 
S 83.3 (43.6-97.0) 
Sp 100 (98.5-100) 
PPV 100 (56.6-100) 
NPV 99.6 (97.8-99.9) 
 
Additional patient relevant outcomes 
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: Invasive testing detected 8 anomalies not targeted by NIPT 
(11,3%) 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with unsignificant results: NA  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Oepkes et al [48] 
Study characteristics Study design: Observational, multicentre,prospective DTA study (TRIDENT study) 
Year of publication: 2016 
Study’s registration number in clinical trial database: not reported  
Country/ies of recruitment: The Netherlands 
Setting: routine prenatal screening 
Data collection period: April-September 2014 
Target population: high-risk pregnant population  
Target condition prevalence in the enrolled population: 1/48 for T21, 1/347 for each T18 and T13 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): Illumina HiSeq 2500 or Life Technologies 5500 W SOLiD 
Country where samples were analysed: The Netherlands 
Cut off for NIPT: Z-score>3.0 or WISECONDOR algorithm 
Population 
characteristics 
Maternal age in years (no [%]):  
<36= 603 [43] 
≥36= 703 [51] 
Unknown= 84 [6] 
Gestational age in weeks (median [169]): not reported 
Maternal weight (median [169]): not reported  
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: all pregnant women with high risk for T21, T18 or T13 based on FCT result (trisomy risk≥1:200)(n=1211) or medical history 
(previous child with such a trisomy or a balanced translocation in one of the parents)(n=179) 
Exclusion criteria: multiple pregnancies, vanishing twins, fetal nuchal translucency ≥3.5 mm or other structural anomalies, chromosome anomaly 
or history of maternal malignancy, gestational age <10+0 weeks, women <18 years old and inability to give informed consent. 
Study protocol Population enrollment flow 
Population enrolled: 1390 
Population excluded: 0 
Population included: 1390 
-with NIPT result: 1386 (one women underwent amniocentesis and four samples were indeterminate results) 
-with comparator result: no intervention 
-with reference standard result: 53 sample confirmed by invasive testing and 1376 confirmed by neonatal follow-up as well 
Reference standard (% pts): invasive testing (amniocentesis or CVS), ultrasound data, genetic testing in products of conception (cord blood, 
placenta), birth data and data of postnatal examination 
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Sample processing protocol 
Maternal blood samples were collected into EDTA or cfDNA BCT tubes at enrolment centres and sent to one of all eight University Hospital 
Genetics Laboratories where sequencing analysis was performed.  
It was not reported if NIPT and karyotyping analysis were performed in a blinded fashion. 
Study protocol Population enrollment flow 
Population enrolled: 1390 
Population excluded: 0 
Population included: 1390 
-with NIPT result: 1386 (one women underwent amniocentesis and four samples were indeterminate results) 
-with comparator result: no intervention 
-with reference standard result: 53 sample confirmed by invasive testing and 1376 confirmed by neonatal follow-up as well 
Reference standard (% pts): invasive testing (amniocentesis or CVS), ultrasound data, genetic testing in products of conception (cord blood, 
placenta), birth data and data of postnatal examination 
Sample processing protocol 
Maternal blood samples were collected into EDTA or cfDNA BCT tubes at enrolment centres and sent to one of all eight University Hospital Genetics 
Laboratories where sequencing analysis was performed.  
It was not reported if NIPT and karyotyping analysis were performed in a blinded fashion. 
Outcomes Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 4/1390 (0.3%) 
-Uncertain results rate (% samples): NA 
Diagnostic accuracy measures for T21 in 
pregnancies with outcome data, including test failures 
and miscarriages for abnormal results (calculated 
based on study results) 
Variable  cfDNA testing 
TP 29 
TN 1354 
FP 2 (FP rate: 0.15%) 
FN 1 (FN rate: 3.33%) 
S 96.7 (83.3-99.4) 
Sp 99.9 (99.5-100) 
PPV 93.5 (79.3-98.2) 
NPV 99.9 (99.6-100) 
  
Diagnostic accuracy measures for T18 in 
pregnancies with outcome data, including 
test failures and miscarriages for abnormal 
results (calculated based on study results) 
Variable  cfDNA testing 
TP 4 
TN 1381 
FP 1 (FP rate: 0.07%) 
FN 0 
S 100 (51-100) 
Sp 99.9 (99.6-100)  
PPV 80.0 (37.6-96.4) 
NPV 100 (99.7-100) 
 
Diagnostic accuracy measures for T13 in 
pregnancies with outcome data, including 
test failures and miscarriages for abnormal 
results (calculated based on study results) 
Variable  cfDNA testing 
TP 4 
TN 1380 
FP 2 (FP rate: 0.14%) 
FN 0 
S 100 (51-100) 
Sp 99.9 (99.5-100) 
PPV 66.7 (30-90.3) 
NPV 100 (99.7-100) 
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Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with unclear significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages related to invasive testing: NA 
-Reduction in uptake of invasive testing: Estimations based on figures of women with FCT who would elect to undergo invasive testing: 62% 
-Change in uptake of prenatal screening: NA 
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Author(s): Zhang et al [50] 
Study characteristics Study design: Observational prospective DTA study 
Year of publication: 2016 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China (Obstetrics and Gynecology Hospital of Fundan University) 
Setting: routine prenatal screening,  
Data collection period: January 2012- December 2013 
Target population: high-risk pregnant population  
Target condition prevalence in the enrolled population: 1/29 for T21, 1/87 for each T18 and Turner syndrome  
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): ): Verifi™™ Prenatal Test (Illumina HiSeq™ 2000) 
Country where samples were analysed: not reported 
Cut off for NIPT: cut-off point, Z=3 
Population 
characteristics 
Maternal age in years (mean [SD]): 37.48±2.17  
Gestational age in weeks (median [169]): 19.0 [12.4-32.5] 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: advanced maternal age pregnant women with aged≥35 years at the time of delivery, single birth, high-risk of DS or single 
abnormal multiple of the median, elevated fetal nuchal translucency in the early pregnancy, a soft marker in the genetic scan, or cardiac structural 
anomalies in the second-trimester genetic sonography or not suitable for invasive prenatal diagnosis (human immunodeficiency virus infection, 
placenta previa, low-set placenta, oligohydramnios, Rh-negative blood type, a history of abortion, threatened abortion or precious pregnancy) 
Exclusion criteria: pregnant women with chromosomal disease, received allogenic blood transfusion, organ transplantation, stem cell therapy or 
with a gestational age of <12 weeks 
Study protocol Population enrollment flow 
Population enrolled: 87 
Population excluded: 0 
Population included: 87 
-with NIPT result: 87 
-with comparator result: NA 
-with reference standard result: 87 
Reference standard (% pts): amniocentesis (24.1%), neonatal blood karyotyping (42.3%) or follow-up examination of newborn 
Sample processing protocol 
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Maternal blood samples were collected into EDTA and anticoagulant tubes.  
Sequencing analysis was performed by personnel who were blinded to the study. 
Outcomes Performance of NIPT for T21, T18 and other SCAs 
-Test failure (% samples): not reported 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for T21 in pregnancies with outcome 
data, excluding test failures and miscarriages (calculated based on 
study results) 
Variable  cfDNA testing 
TP 3 
TN 84 
FP 0 
FN 0 
S 100 (43.8-100) 
Sp 100 (95.6-100) 
PPV 100 (43.8-100) 
NPV 100 (95.6-100) 
  
Diagnostic accuracy measures for T18 in pregnancies with outcome data, 
excluding test failures and miscarriages (calculated based on study results) 
 
Variable  cfDNA testing 
TP 1 
TN 86 
FP 0 
FN 0 
S 100 (20.7-100) 
Sp 100 (95.7-100) 
PPV 100 (20.7-100) 
NPV 100 95.7-100) 
 
Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Ma et al [47] 
Study characteristics Study design: multicentre DTA study (only prospective samples considered for analysis)  
Year of publication: 2016 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China (18 centres) 
Setting: routine prenatal care 
Data collection period: February to May 2014 
Target population: high-risk population 
Target condition prevalence in the enrolled population: 1/64 for T21, 1/305 for T18 and 1/2,439 for T13 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): BGISEQ-1000/combinatorial probe-anchor ligation sequencing-cPAL platform-based NIPT testing 
Country where samples were analysed: clinical laboratory of BGI-China 
Cut off for NIPT: If Z-score>3 or <3, the sample was classified as high-risk of aneuploidy and if Z-score=-3 to 3, the sample was considered as low-
risk. 
Population 
characteristics 
Inclusion criteria: pregnant women who meet at least one high-risk factor, i.e. advanced maternal age, high risk of biochemical screening result, 
abnormal ultrasound markers and previous adverse pregnant history. 
Exclusion criteria: cases without karyotyping confirmation or follow-up results. 
Study protocol -NIPT test failure: 4 samples  
Population included: 2,425 samples 
-with NIPT result: 2,425 samples 
-with comparator result: no intervention 
-with reference standard result: 2,425 samples 
Referenece standard (% pts): karyotype testing (G-banding)(amniocentesis, CVS or percutaneous umbilical cord blood sampling) or postnatal follow-
up 
Sample processing protocol 
Blood samples were collected into EDTA tubes at each recruitment centre and sent to reference laboratory for its analysis.  
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Sequencing analysis was performed in a blinded fashion to respect medical information or previous testing results. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 0.60% (0.00%-2.70%) (14 samples) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated based 
on study results)  
Variable  cfDNA testing 
TP 38 
TN 2,387 
FP 0 
FN 0 
S 100 (90.8-100) 
Sp 99.8 (99.4-100) 
PPV 100 (90.8-100) 
NPV 100 (99.4-100) 
  
Diagnostic accuracy measures for Trisomy 18 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 8 
TN 2,378 
FP 0 
FN 0 
S 100 (60.3-100) 
Sp 100 (99.9-100) 
PPV 100 (60.3-100) 
NPV 100 (99.9-100) 
 
Diagnostic accuracy measures for Trisomy 
13 in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA Testing 
TP 1 
TN 2,378 
FP 0 
FN 0 
S 100 (2.5-100) 
Sp 100 (99.9-100) 
PPV 100 (2.5-100) 
NPV 100 (99.9-100) 
 
Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Kim et al [46] 
Study characteristics Study design: Prospective observationalDTA study 
Year of publication: 2016 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: Republic of Korea  
Setting: routine prenatal care 
Data collection period: December 2014- April 2015 
Target population: high-risk pregnant population 
Target condition prevalence in the enrolled population: 1/20 for T21 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): not reported/ion semiconductor-based sequencing i.e. Ion Torrent PGM or Proton platforms 
Country where samples were analysed: not reported 
Cut off for NIPT: Z-score>2.07 indicates a high risk of trisomy for the PGM system and >2.10 for Proton  
Population 
characteristics 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: singleton pregnant women underwent invasive testing based on first trimester serum screening (PAPP-A and hGC) and or 
ultrasonography (NT). The second-trimester serum screening (quadruple screening) was used to evaluate and define aneuploidy risk.  
Exclusion criteria: not reported 
Study protocol -with comparator result: no intervention 
-with reference standard result: 101  
Reference standard (% pts): amniocentesis (100%) 
Sample processing protocol 
Maternal blood samples were collected at each enrolment centers previously karyotyping testing and stored into BCT™ tubes. One mL of plasma 
was used to extract cfDNA using QIAmp Circulating Nucleic Acid Kit. 
The karyotyping results were blinded 
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Outcomes Diagnostic accuracy measures for Trisomy 21 in pregnancies with outcome data, excluding test failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 5 
TN 96 
FP 0 
FN 0 
S 100 (47.8-100) 
Sp 100 (96.2-100) 
PPV* 100 (47.8-100) 
NPV* 100 (96.2-100)  
*Although authors’ study identified sequencing quality difference between both platforms, these did not affect the final Z-score results and therefore accuracy of each 
one platform 
Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Song et al [57] 
Study characteristics Study design: DTA study (prospective cohort) 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China (Pekin Union Medical College Hospital) 
Setting: routine prenatal care 
Data collection period: May 2012-August 2013 
Target population: high-risk population 
Target condition prevalence in the enrolled population: 1/106 for T21, 1/213 for T18, T13, 47,XXY and 45,x/47,XXX  
Comparator: no intervention  
Cut off point comparator: no intervention 
Index test (trademark/technique type): Illumina HiSeq 2000 platform/ 
Country where samples were analysed: Berry Genomics, China 
Cut off for NIPT: normal Z-score range=-3<Z<3 
Population 
characteristics 
Maternal age in years (median [169]): 37.25 (35-45) 
85.8% women were <40 years of age  
Gestational age in weeks (median [169]): 9+6 (8+0 to 12+6) 
52% samples were collected between 8+0 to 9+6 week 
Maternal weight (mean [SD]): 60.02±8.83  
Pregnancy by ART (% pts): 6.1 
Previous miscarriage (% pts): 19.8 
Inclusion criteria: advanced maternal age (≥35 years) and singleton pregnancy 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 213 
Population excluded: 1 
Reason for exclusion: 
-not meet quality control standard due to hemolysis  
Population included: 212 
-with NIPT result: 212 
-with comparator result: no intervention 
-with reference standard result: 178 
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References standard (% pts): CVS or amniocentesis. Negative NIPT test results were confirmed by karyotyping and followed to birth and neonates 
were assessed clinically by pediatrician. 
Sample processing protocol 
Blood samples were collected into Streck tubes at enrolment institution and sent to Berry Genomics for its analysis. NIPT testing and karyotyping 
were performed in a double-blinded manner. 
Outcomes 
 
Performance of NIPT for T21, T18, T13 and SCA 
-Test failure (% samples): 1 sample (0.5%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
(n=178) in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 2 
TN 176 
FP 0 
FN 0 
S 100 (19.79-100) 
Sp 100 (97.35-100) 
PPV 100 (19.79-100) 
NPV 100 (97.35-100) 
  
Diagnostic accuracy measures for Trisomy 18 
(n=178) in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 1 
TN 179 
FP 0 
FN 0 
S 100 (5.46-100) 
Sp 100 (97.35-100) 
PPV 100 (5.46-100) 
NPV 100 97.35-100) 
 
Diagnostic accuracy measures for Trisomy 
13 in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA Testing 
TP 1 
TN 179 
FP 0 
FN 0 
S 100 (5.46-100) 
Sp 100 (97.35-100) 
PPV 100 (5.46-100) 
NPV 100 (97.35-100) 
 
Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other unconfirmed major chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Wang et al [58] 
Study characteristics Study design: Prospective observational DTA study 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China (Lyanyungang Maternal and Child Hospital) 
Setting: routine prenatal care 
Data collection period: January 2013- December 2013 
Target population: high-risk population 
Target condition prevalence in the enrolled population: 1/38 for T21 and 1/306 for T18 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): Illumina HiSeq2000 
Country where samples were analysed: China 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean no[%]): 
-18 to 25 years, 299 [22.86] 
-26 to 35 years, 318 [40] 
-36 to 46 years, 300 [37.14] 
Gestational age in weeks (median [169]):  
Maternal weight in Kg (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: abnormal result on FCT (alfa-fetoprotein and beta-human chorionic gonadotropin)(n=521, 56.82%), advanced maternal age (≥35 
years)(n=300, 32.72%), abnormal ultrasound findings (n=6, 0.65%) and others (abnormal amniotic fluid volume, adverse pregnancy history 
obtained from medical records and single umbilical artery)(n= 90, 9.81%)  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 917 
Population excluded: 0 
Population included: 917 
-with NIPT result: 917 
-with comparator result: no intervention 
-with reference standard result: 917 
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Reference standard (% pts): conventional karyotyping analysis or FISH and neonatal follow-up 
Sample processing protocol 
Maternal blood samples were collected into EDTA tubes at enrolment institution and sent to Berry Genomics for its analysis.  
It was not reported if sequencing or karyotyping analysis were performed in a blinded fashion. 
Outcomes 
 
Performance of NIPT for T21 and T18  
-Test failure (% samples): NA 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in pregnancies with 
outcome data, excluding test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 24 
TN 882 
FP 0 
FN 0 
S 100 (86.2-100) 
Sp 100 (99.6-100) 
PPV 100 (86.2-100) 
NPV 100 (99.6-100) 
  
Diagnostic accuracy measures for Trisomy 18 in pregnancies with outcome 
data, excluding test failures and miscarriages (calculated based on study 
results)  
Variable  cfDNA testing 
TP 3 
TN 882 
FP 1 (FP rate: 0.11%) 
FN 0 
S 100 (43.8-100) 
Sp 99.88 (99.4-100) 
PPV 75 (30.1-95.4) 
NPV 100 (99.6-100) 
 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Sánchez-Usabiaga et al [56] 
Study characteristics Study design: Prospective observational DTA study 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: México 
Setting: routine prenatal care 
Data collection period: March 2013-February 2015 
Target population: high-risk population 
Target condition prevalence in the enrolled population: 1/67 for T21, 1/270 for T18 and 1/270 for T13 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): not reported/SNPs 
Country where samples were analysed: Natera, San Carlos, USA  
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 35 (21-45) 
Gestational age in weeks (median [169]): 11.85 (9-26.3) 
Maternal weight in Kg (median [169]): 60.9 (45-78) 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: singleton pregnant women at least 9 week of gestation with advanced maternal age (≥35 years old)(n=114), positive FCT 
(biochemical and ultrasonographic markers)(n=72) and maternal anxiety (n=84). 
Exclusion criteria: women with multiple pregnancies by donor oocytes or surrogate mother, previous bone marrow transplant or did not give written 
consent informed 
Study protocol Population enrollment flow 
Population enrolled: 270 
Population excluded: 4 
Reason for exclusion: 
-absence of a result on cfDNA: 4  
Population included: 266 
-with NIPT result: 266 
-with comparator result: no intervention 
-with reference standard result: 214 
Reference standard (% pts): CVS, amniocentesis (n=6) or neonatal examination at birth (n=208) 
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Sample processing protocol 
Maternal blood samples were collected at enrolment institution and sent to Natera for its analysis 
Outcomes 
 
Performance of NIPT for T21, T18 and T13  
-Test failure (% samples): 4 samples (1%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 4 
TN 256 
FP 0 
FN 0 
S 100 (51.0-100) 
Sp 100 (98.5-100) 
PPV 100 (51.0-100) 
NPV 100 (98.5-100) 
  
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 1 
TN 256 
FP 0 
FN 0 
S 100 (20.7-100) 
Sp 100 (98.5-100) 
PPV 100 (20.7-100) 
NPV 100 (98.5-100) 
 
Diagnostic accuracy measures for Trisomy 13 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA Testing 
TP 1 
TN 256 
FP 0 
FN 0 
S 100 (20.7-100) 
Sp 100 (98.5-100) 
PPV 100 (20.7-100) 
NPV 100 (98.5-100) 
 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Benachi et al [51] 
Study characteristics Study design: multicentre DTA study (prospective cohort)(29 centres) 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: France 
Setting: routine prenatal care 
Data collection period: December 2012 to October 2013 
Target population: high-risk population 
Target condition prevalence in the enrolled population: 1/17 for T21, 1/40 for T18 and 1/74 for T13  
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): HiSeq1500/MPS 
Country where samples were analysed: not reported 
Cut off for NIPT: Z-score for T21=3 and Z-score for T18 and T13=3.95 
Population 
characteristics 
Maternal age in years (mean [SD]): 35 [30-39]  
Gestational age in weeks (median [SD]): 15.1 [10.2-34.6] 
BMI in Kg/m2 (median [169]): 23 [21-27] 
Pregnancy by ART(% pts): not reported 
Inclusion criteria: 
-Pregnant women were more 10 weeks of gestation and had a singleton or twin 
-With or without fetal ultrasound findings 
-Maternal age>38 years 
-Maternal serum screening or history of pregnancy with trisomy and who were willing to undergo invasive procedures  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 900 (893 singleton and 7 twin) 
Population excluded: 8 
Reason for exclusion: 
-Definitive karyotype not available: 8 
Population included: 892 
-with NIPT result: 886 
-with comparator result: no intervention  
-with reference standard result: 892 
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Reference standard (% pts): amniocentesis or CVS 
Sample processing protocol 
Maternal blood samples were collected into EDTA tubes at each enrolment institution and sent to the clinical laboratory.  
CfDNA was extracted from plasma samples by QIAamp DSP Circulating Nucleic Acid Kit. 
NIPT was performed in a blinded fashion respect to the fetal karyotype. It was not reported if karyotype analysis was blinded. 
Outcomes 
 
Performance of NIPT for T21  
-Test failure (% samples): 6 samples (0.7%) (fetal fraction<4% or atypical result, i.e. positive Z-score for more than one chromosome). By CVS 
were confirmed two cases of triploidy and one cases of monosomy X.  
-Uncertain results rate (% samples): not reported 
Forty-five cases with negative NIPT result, were classified as pathogenic (42 cases with 14 sex chromosomal anomalies and 3 cases of 18 
trisomy). 
Diagnostic accuracy measures for Trisomy 21 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 76 
TN 815 
FP 1 
FN 0 
S 100 (95.3-100) 
Sp 99.9 (99.3-100) 
PPV 98.7 (93.0-99.8) 
NPV 100 (99.5-100) 
  
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated based 
on study results)  
Variable  cfDNA testing 
TP 22 
TN 860 
FP 1 
FN 3 
S 88.0 (68.8-97.5) 
Sp 99.9 (99.4-100) 
PPV 95.6 (79.0-99.2) 
NPV 99.6 (99.0-99.9) 
 
Diagnostic accuracy measures for Trisomy 13 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 12 
TN 873 
FP 1 
FN 0 
S 100 (73.5-100) 
Sp 99.9 (99.4-100) 
PPV 92.3 (66.7-98.6) 
NPV 100 (99.6-100) 
 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with major other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
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-Change in uptake of prenatal screening: NA 
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Author(s): Ke et al [53] 
Study characteristics Study design: DTA study (prospective cohort) 
Year of publication: 2015 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: China 
Setting: routine prenatal care 
Data collection period: March 2012- May 2013 
Target population: high-risk pregnant population 
Target condition prevalence in the enrolled population: 1/138 for T21, 1/390 for T18 and 1/2340 for T13 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): not reported 
Country where samples were analysed:  
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 2061 women were <35 years and 279 were ≥35 years 
Gestational age in weeks (median [169]): 80 women at 12-14 week of gestation, 2239 at 15-20 week and 21 at ≥24 week 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported  
Inclusion criteria: singleton pregnant women at 12-14 week of gestation with high-risk of aneuploidies due to the following reasons, i.e. over age 
35 (n=147), history of abnormal pregnancy including children with DS and repeated spontaneous abortion, stillbirth in pregnancy periods, 
abnormal serological screening for DS at early and mid-pregnancy (n=1189) or abnormal screening for fetal NT (n=72). 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 2340 
Population excluded: 0 
Population included: 2340 
-with NIPT result: 2340  
-with comparator result: no intervention  
-with reference standard result: 2340 (24 samples by karyotyping and 2316 by follow-up) 
Reference standard (% pts): amniocentesis or neonatal follow-up 
Sample processing protocol 
Maternal blood samples were collected into an EDTA tubes at the enrolment institution. Fetal DNA in maternal plasma was extracted by QIAamp 
Circulation Nucleic Acid Kit (Qiagen).  
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Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 0 samples 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
in all pregnancies (calculated based on study 
results)  
Variable  cfDNA testing 
TP 17 
TN 2316 
FP 0 
FN 0 
S 100 (81.6-100) 
Sp 100 (99.8-100) 
PPV 100 (81.6-100) 
NPV 100 (99.8-100) 
  
Diagnostic accuracy measures for Trisomy 18 in 
all included pregnancies (calculated based on 
study results)  
Variable  cfDNA testing 
TP 6 
TN 2316 
FP 0 
FN 0 
S 100 (61-100) 
Sp 100 (99.8-100) 
PPV 100 (61.0-100) 
NPV 100 (99.8-100) 
 
Diagnostic accuracy measures for Trisomy 
13 in all included pregnancies(calculated 
based on study results)  
Variable  cfDNA Testing 
TP 1 
TN 2316 
FP 0 
FN 0 
S 100 (20.7-100) 
Sp 100 (99.8-100) 
NPV 100 (20.7-100) 
NPV 100 (99.8-100) 
 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Lee et al [54] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
Year of publication: 2015 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Korea (Asan Medical Center, Seoul, Ko-rea) 
Setting: routine prenatal screening 
Data collection period: August 2014-February 2015  
Target population: high-risk preg-nant population  
Target condition prevalence in the enrolled population: 1/19 for T21, 1/46 for T18 and 1/93 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): MiSeq and NextSeq, Illumi-na/random massively parallel shotgun sequencing-Momguard protocol 
Country where samples were ana-lysed: LabGenomics Clinical La-boratory, Korea 
Cut off for NIPT: Z-score>4 for a chromosome indicates a higher risk of aneuploidy than standard set. If Z-score is between 2.5 and 4, it was 
considered as intermediate risk for T21 and T18. For T13, cut-off for high risk was Z-score=2.8 and 1.9 for intermediate risk. 
Population 
characteristics 
Maternal age in years (mean [169]): 32 (21-43) 
Gestational age in weeks (median [169]): 21.2 (8.2-31.1) 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: women with sin-gleton or twin pregnancy who were >18 years old, gestational age >8 weeks and who met at least one of the 
following additional criteria: advanced maternal age (≥35 years), a positive serum biochemical screening test, the presence of fetal anomalies 
detected by ultrasound, or a personal/family history of fetal aneuploidy. It were also included multiple gestation (n: 2 twin preg-nancies) 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 93 
Population excluded: 1 
Reason for exclusion: 
-absence of a result on cfDNA  
Population included: 92 
-with NIPT result: 92 
-with comparator result: no inter-vention 
-with reference standard result: 93 
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Reference standard (% pts): amni-ocentesis, CVS, cordocentesis, neonatal peripheral blood or prod-ucts of conception. It was not re-ported 
sampled percentage ana-lysed with each method. 
Sample processing protocol 
Maternal blood samples were col-lected into Streck DNA BCT tubes and sent to LabGenomics Clinical Laboratory. 
All clinical data and NIPT results were blinded to the laboratory in-vestigators. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 1.07% (1 sample) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
in all pregnancies with karyotyping (calculated 
based on study results)  
Variable  cfDNA testing 
TP 5 
TN 87 
FP 0 
FN 0 
S 100 (56.6-100) 
Sp 100 (95.8-100) 
PPV 100 (56.6-100) 
NPV 100 (95.8-100) 
 
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with karyotyping (calculated 
based on study results)  
Variable  cfDNA testing 
TP 2 
TN 90 
FP 0 
FN 0 
S 100 (34.2-100) 
Sp 100 (95.9-100) 
PPV 100 (34.2-100) 
NPV 100 (95.9-100) 
 
Diagnostic accuracy measures for Trisomy 13 
in all pregnancies with karyotyping (calculated 
based on study results)  
Variable  cfDNA Testing 
TP 1 
TN 91 
FP 0 
FN 0 
S 100 (20.7-100) 
Sp 100 (95.9-100) 
PPV 100 (20.7-100) 
NPV 100 (95.9-100) 
 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: An additional 10 chromosome anomalies were de-
tected by cytogenetic analysis (10.8%) 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA  
-Change in uptake of prenatal screening: NA 
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Author(s): Sago et al [55] 
Study characteristics Study design: multicentre DTA study (prospective cohort) 
Year of publication: 2015 
Study’s registration number in clini-cal trial database: University Medi-cal Information Network clinical trials, UMIN000009338 
Country/ies of recruitment: Japan 
Setting: routine prenatal-screening 
Data collection period: April 2013-March 2014 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/110 for T21, 1/0228 for T18 and 1/860 for T13 
Comparator: no intervention 
Cut off point comparator: NA 
Index test (trademark/technique type): MaternityT Plus/MPS 
Country where samples were ana-lysed: USA (Sequenom, Inc.) 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 38.3 [21-48] 
Gestational age in weeks (median [169]): 13.3 [10.0-19.9]  
BMI (median [169]): 20.9 [14.1-37.0]  
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: women with sin-gleton pregnancy at least 10 weeks of gestation with increased risk of aneuploidy, i.e. maternal age≥35 years of 
age, foetuses with ultraso-nographic or maternal serum mark-er findings indicating an increased risk of aneuploidy, history of children affected by 
trisomy, or a parent car-rying a balanced Robertsonian translocation with an increased risk of trisomy 13 or trisomy 21.  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 7740 
Population excluded: 0 
Reason for exclusion: 
-absence of a result on cfDNA (n=4)  
Population included: 7736 
-with NIPT result: 7736 
-with comparator result: NA 
-with reference standard result: 131 
Reference standard (% pts): CVS or amniocentesis 
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Sample processing protocol 
Blood samples were collected at each institution and sent to Se-quenom, Inc. for its analysis.  
It was not reported if sequencing and karyotyping analysis was per-formed in a blinded fashion respect to ultrasonographic and standard 
screening results.  
Outcomes 
 
Performance of NIPT for T21, T18 and T13  
-Test failure (% samples): 0.05 (4 samples) 
-Uncertain results rate (% samples): NA 
PPV for Trisomy 21 in women who have undergone invasive testing: 95.9% (70/73) 
PPV for Trisomy 18 in women who have undergone invasive testing: 81% (34/42) 
PPV for Trisomy 13 in women who have undergone invasive testing: 81.8% (9/11) 
In 1638 women followed after birth, it was detected one false-negative case of T18. 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: not reported cases with other anomalies  
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with uncertain significance: not reported cases with 
other anomalies  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Hernandez-Gomez et al [52] 
Study characteristics Study design: DTA study (prospec-tive observational cohort) 
Year of publication: 2015 
Study’s registration number in clini-cal trial database: not reported  
Country/ies of recruitment: Mexico (Hospital Ángeles Loma) 
Setting: routine prenatal care 
Data collection period: August 2013-January 2015 
Target population: high-risk popula-tion  
Target condition prevalence in the enrolled population: 1/21 for T18 and 1/21 for monosomy 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Harmony® Prenatal Test 
Country where samples were ana-lysed: Ariosa Diagnostic, USA 
Cut off for NIPT: risk score for 13, 18 and 21 trisomy>99% or <1/10000 
Population 
characteristics 
Maternal age in years (mean [169]): 37.1 [23-46] 
Gestational age in weeks (median [169]): 13.3 [10.0-18.6] 
Maternal age (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: singleton pregnant women who meet any of the follow-ing indications, i.e. advanced mater-nal age (n=30), positive FCT (n=3), 
recurrent previous miscarriage (n=3), clinical decision (n=6) or ma-ternal anxiety due to X chromo-some-linked recessive disorder (n=1) 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 42 
Population excluded: 0 
Population included: 42 
-with NIPT result: 41 (1 case of failure test because of low fetal fraction) 
-with comparator result: no inter-vention 
-with reference standard result: 41 
Reference standard (% pts): amni-ocentesis (n=4) or neonatal follow-up (n=37) 
Sample processing protocol 
Blood samples were collected at enrolment center and sent to Ariosa Diagnostic for its analysis.  
The cfDNA of each sample was isolated and quantified using the DANSR assay and the FORTE algo-rithm was used to estimate the risk or OR of 
13, 18 and 21 trisomy in each sample. 
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Outcomes 
 
Performance of NIPT for T18 and Monosomy X  
-Test failure (% samples): 1 sample (2.8%) 
-Uncertain results rate (% samples): not reported  
Diagnostic accuracy measures for Trisomy 18 in pregnancies with outcome data, excluding test failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP* 2 
TN 37 
FP 0 
FN 0 
S 100 (34.2-100) 
Sp 100 (90.6-100) 
PPV 100 (34.2-100) 
NPV 100 (90.6-100) 
* One T18 case was not confirmed by karyotyping because of miscarriage but ultrasonography findings FCT were concordant with presence of NIPT result. Another 
T18 case was confirmed by amniocentesis (47, XX,+18).  
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Korostelev et al [60] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Russia 
Setting: routine prenatal care 
Data collection period: 2012-2014 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/37 for T21, 1/864 for T18 and 1/576 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): not reported/SNPs using NATUS algorithm 
Country where samples were ana-lysed: Natera laboratories, USA 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 34.4 (26-45) 
Gestational age in weeks (median [169]): 14 (3-33) 
Maternal weight (median [169]): not reported 
Pregnancy by ART (% pts): not re-ported 
Inclusion criteria: singleton pregnant women who had high-risk of aneu-ploidies according to the FCT results (risk score<1/250, 53.8%), age of the 
women (≥35 years, 27.9%) or the woman’s wish with results of the screening being normal (11%) and other reasons (bad reproductive history in 
3.6% of populations or undergone the IVF procedure in 2.4% of populations) 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 1968 
Population excluded: 240 
Reasons for exclusion: NA 
Population included: 1728 
-with NIPT result: 1728 
-with comparator result: no intervention 
-with reference standard result: 681 57 (invasive testing); 624 (follow up) 
Reference standard (% pts): karyo-typing, CMA (n=241) or neonatal examination at birth.  
Sample processing protocol 
Maternal blood samples were col-lected at enrolment institution and sent to Natera for its analysis. 
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Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 0 samples 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 47 
TN 682 
FP 0 
FN 0 
S 100 (92.4-100) 
Sp 100 (99.4-100) 
PPV 100 (92.4-100) 
NPV 100 (99.4-100) 
  
Diagnostic accuracy measures for Trisomy 
18 in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 2 
TN 680 
FP 0 
FN 0 
S 100 (34.2-100) 
Sp 100 (99.4-100) 
PPV 100 (34.2-100) 
NPV 100 99.4-100) 
 
Diagnostic accuracy measures for Trisomy 13 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA Testing 
TP 3 
TN 679 
FP 0 
FN 1 (FN rate: 25%) 
S 75 (30.1-95.4) 
Sp 100 (99.4-100) 
PPV 100 (43.8-100) 
NPV 99.9 (99.2-100) 
 
Additional patient relevant outcomes   
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: Using invasive testing one case of microdeletion 
22q13.31-q13.33 associated with PhelanMcDermid syndrome and two cases of small microdeletions associated dominant diseases were 
detected. None of them were identified by NIPT test. 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 214 
Author(s): Stumm et al [62] 
Study characteristics Study design: Blinded DTA study (prospective observational cohort) 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Germa-ny and Switzerland (5 centres) 
Setting: routine prenatal care  
Data collection period: not reported 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/13 for T21, 1/65 for T18 and 1/104 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): LifeCodexx (Illumina HiS-eq2000/random MPS) 
Country where samples were ana-lysed: LifeCodexx AG and GATC Biotech AG 
Cut off for NIPT: sample with Z-score≥3 was classified as high risk of T21. If Z-score<3, sample was considered as negative result for T21. The 
cut-off Z-score for T18 and T13 was 3.9 and 3.2 respec-tively 
Population 
characteristics 
Maternal age in years (mean [169]): 36.0 [19-47] 
Gestational age in weeks (mean [169]): 15.6 [11+0 – 32+1)  
Maternal weight (median [range]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported  
Inclusion criteria: singleton pregnant women at the age of at least 18 years who signed informed consent with indication for invasive testing due to 
any of following reasons: advanced maternal age (>35 years old)(n=363), positive maternal se-rum markers (n=58), ultrasound anomaly (n=205), 
positive family history for prenatally diagnosable disease (n=11), parental chromo-somal aberration (n=2) or other risk factors (n=78), performance 
of a conventional karyotyping procedure and blood drawn after the invasive procedure. 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 522 consecu-tive women 
Population excluded: 18 
Reason for exclusion: 
-no informed consent: 9 
-no karyotyping analysis: 8 
-previously analyzed: 1  
Population included: 504 
-with NIPT result: 472 (failed se-quencing quality criteria in 14 sam-ples and failed libraries in 18 sam-ples) 
-with comparator result: no inter-vention 
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-with reference standard result: 472  
Reference standard (% pts): amni-ocentesis (69.1), CVS (30.3) or cordocentesis (0.6) 
Sample processing protocol 
Blood samples were collected into either EDTA (n=166) or cell-free DNA BCT™ (n=306) tubes at each study center prior to invasive pro-cedure 
and sent to LifeCodexx AG or GATC Biotech AG for its analy-sis, which was blinded to popula-tion clinical information including karyotyping. 
CfDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (Qi-agen). Sequencing data analysis was performed using two 
bioinformatics algorithm DAP.21 focused on de-tection T21 only and DAP.plus which detects T18 and T13 in addi-tion to T21 and is based on 
guano-sine-cytosine (GC) normalization. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 32 samples (6.3%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 
21 in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 40 
TN 430 
FP 0 
FN 2 (FN rate: 4.8%) 
S 95.2 (84.2-95.7) 
Sp 100 (99.1-100) 
PPV 100 (91.2-100) 
NPV 99.5 (98.3-99.9) 
 
Diagnostic accuracy measures for Trisomy 18 
(only algorithm DAP.plus) in pregnancies with 
outcome data, excluding test failures and 
miscarriages (calculated based on study 
results)  
Variable  cfDNA testing 
TP 8 
TN 463 
FP 1 (FP rate: 0.21%) 
FN 0 
S 100 (67.7-100) 
Sp 99.8 (98.8-100) 
PPV 88.9 (56.5-98) 
NPV 100 (99.2-100) 
  
Diagnostic accuracy measures for Trisomy 13 
(only algorithm DAP.plus) in pregnancies with 
outcome data, excluding test failures and 
miscarriages (calculated based on study 
results)  
Variable  cfDNA Testing 
TP 5 
TN 467 
FP 0 
FN 0 
S 100 (56.6-100) 
Sp 100 (99.2-100) 
PPV 100 (56.6-100) 
NPV 100 (99.2-100) 
 
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-clear significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
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-Change in uptake of prenatal screening: NA 
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Author(s): Jeon et al [59] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: China (Xiamen Maternal & Child Health Care Hospital) 
Setting: routine prenatal care 
Data collection period: March 2012-October 2013 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/14 for T21 and 1/39 for T18 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Ion Proton™ System 
Country where samples were ana-lysed: not reported 
Cut off for NIPT: Sample Z-score>2.459 was considered indic-ative of T18 and sample Z-score>2.566 was classified as high-risk of T21 
Population 
characteristics 
Maternal age in years (mean [SD]): 30.73±4.99  
42% of women were ≥35 years old 
Gestational age in weeks (% popula-tions): 
12-21 weeks: 73.6% 
≥22 weeks: 26.5 %  
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported  
Inclusion criteria: women who were ≥19 years old, had a singleton preg-nancy with at least 12 weeks’ gesta-tion and classified as high-risk of 
aneuploidies by FCT screening in combination with nuchal translucen-cy measurement or second trimester serum screening alone or in combi-
nation with FTS results. 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 155 
Population excluded: 0 
Population included:155 
-with NIPT result: 155 
-with comparator result: no inter-vention 
-with reference standard result: 155 
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Reference standard (% pts): amni-ocentesis 
Sample processing protocol 
Maternal blood samples were col-lected into cfDNA BCT™ tubes at each enrolment institution.  
Plasma cfDNA was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen). 
Outcomes Performance of NIPT for T21 and T18 
Test failure (% samples): 0 samples 
Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in 
pregnancies with outcome data, excluding test failures 
and miscarriages (calculated based on study results)  
Variable  cfDNA testing 
TP 11 
TN 139 
FP 0 
FN 0 
S 100 (71.5-100) 
Sp 100 (97.5-100) 
PPV 100 (71.5-100) 
NPV 100 (97.5-100) 
  
Diagnostic accuracy measures for Trisomy 18 in pregnancies with 
outcome data, excluding test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 5 
TN 139 
FP 0 
FN 0 
S 100 (47.8-100) 
Sp 100 (97.6-100) 
PPV 100 (47.8-100) 
NPV 100 (97.6-100) 
 
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Porreco et al [61] 
Study characteristics Study design: Multicentre, blinded DTA study (prospective cohort) 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: NCT00847990 
Country/ies of recruitment: USA 
Setting: routine prenatal care 
Data collection period: September 2009-April 2011 
Target population: high-risk popula-tion 
Target condition prevalence in the enrolled population: 1/30 for T21, 1/107 for T18 and 1/260 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): HiSeq 2000, Illumina Inc. 
Country where samples were ana-lysed: USA 
Cut off for NIPT: Z-scores at or above 3 were considered indicative of trisomy 21 and Z-scores of at or above 3.95 were considered in-dicative of 
trisomies 18 and 13  
Population 
characteristics 
Maternal age in years (mean [SD]): 35.1 [5.6] 
Gestational age in weeks (mean [SD]): 16.3 [3.5]  
Maternal weight (median [169]): 156.9 [36.7] 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: singleton pregnant women were at least 18 years of age and had made the decision to pursue invasive prenatal diagnosis by 
CVS or amniocentesis due to high risk of aneuploidies because of met at least one of the following conditions: advanced maternal age (≥35 years 
of age), positive result on first or second trimester serum screening test, presence of fetal anomaly on ultrasound or per-sonal or familiar history of 
a chro-mosome anomaly  
Exclusion criteria: inability to give written informed consent, multiple gestation or fetal demise of an addi-tional embryo during the current 
pregnancy at ≥8 weeks of gestation 
Study protocol Population enrollment flow 
Population enrolled: 4170 
Population excluded: 740 
Reason for exclusion: 
-insufficient sample volume: 320 
-outside laboratory processing window: 120 
-laboratory quality control set: 270 
-incomplete report forms: 24 
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-no invasive procedure performed: 6 
Population included: 3430 
-with NIPT result: 3376 (54 samples with insufficient quality criteria due to low fetal DNA fraction, insuffi-cient library concentration/total accounts 
or amplification bias). 
-with comparator result: no inter-vention 
-with reference standard result: 3322 (56 samples with complex karyotypes) 
Reference standard (% pts): CVS (25%) or amniocentesis (75%) 
Sample processing protocol 
Maternal blood samples were col-lected into EDTA tubes at each participant institution and sent to external laboratory of study spon-sor 
(Sequenom Inc.) for its analy-sis.  
Karyotyping analysis was per-formed by an independent com-mercial laboratory. 
All database including NIPT test results, karyotyping analysis results and populations demographic information were stored separately until its 
statistical analysis 
Outcomes 
 
Performance of NIPT for T21, T18, T13 
-Test failure (% samples): 54 samples (1.29%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 
21 (n=3322) in pregnancies with outcome 
data, excluding test failures and 
miscarriages (calculated based on study 
results)  
Variable  cfDNA testing 
TP 137 
TN 3182 
FP 3 (FP rate: 0.09%) 
FN 0 
S 100 (97.34-100) 
Sp 99.9 (99.72-99.98) 
PPV 97.9 (93.8-99.56) 
NPV 100 (99.98-100) 
  
Diagnostic accuracy measures for Trisomy 18 
(n=3322) in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 36 
TN 3283 
FP 0 
FN 3 (FN rate: 7.7%) 
S 92.3 (79.13-98.38) 
Sp 100 (99.89-100) 
PPV 100 (90.26-100) 
NPV 99.9 (99.73-99.9) 
 
Diagnostic accuracy measures for Trisomy 13 
(n=3322) in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA Testing 
TP 14 
TN 3306 
FP 0 
FN 2 (FN rate: 12.3%) 
S 87.5 (61.65-98.45) 
Sp 100 (99.89-100) 
PPV 100 (76.84-100) 
NPV 99.9 (99.78-99.9) 
 
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
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-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Zhou et al [64]  
Study characteristics Study design: Blinded DTA study (prospective cohort) 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: China 
Setting: routine prenatal care 
Data collection period: September- July 2013  
Target population: high-risk preg-nant population  
Target condition prevalence in the enrolled population: 1/214 for T21, 1/770 for T18 and 1/3852 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): not reported 
Country where samples were ana-lysed: clinical laboratory at BGI-Shenzhen 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 40.4% or 3108/7701 wom-en with advanced age, ≥35 years and 59.6% or 4596/7701 women with <35 years 
Gestational age in weeks (median [169]): not reported 
Maternal weight (median [169]): not reported  
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: women with sin-gleton pregnancies at 12 to 14 week of gestation who met the following indications: advanced age, high risk for 
Down syndrome based on screening results (32.1%, 2472/7701) and presence de ab-normal ultrasonographic soft mark-ers or ultrasound 
anomalies, as well as women with no prior DS screen-ings (56.6%, 4361/7701).  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 7705 
Population excluded: 4 
Reason for exclusion: 
- absence of a result on cfDNA  
Population included: 7701 
-with NIPT result: 7701 
-with comparator result: no inter-vention 
-with reference standard result: 54 amniocentesis and 3894 follow-ups  
Reference standard (% pts): amni-ocentesis or neonatal follow-up 
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Sample processing protocol 
Sample collection, molecular test and trisomy analysis were per-formed in a clinical laboratory at BGI-Shenzhen. 
Fetal karyotyping was performed blindly following NIPT. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 0,05% (4 samples))  
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 36 
TN 3918 
FP 2 (FP rate: 0.05% [0.02-0.10 ]) 
FN 0 
S 100 (72.2-100) 
Sp 99.9 [99.8-100] 
PPV 94.7 [82.7-98.5] 
NPV 100 (99.9-100) 
  
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 10 
TN 3926 
FP 2 (FP rate: 0.05% [0.02-0.10]) 
FN 0 
S 100 (72.1-100) 
Sp 99.9 [99.8-100] 
PPV 83.3 [55.2-95.3] 
NPV 100 (99.9-100) 
 
Diagnostic accuracy for Trisomy 13 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA Testing 
TP 2 
TN 3944 
FP 2 (FP rate: 0.05% [0.02-0.10]) 
FN 0 
S 100 (34.2-100) 
Sp 99.9 [99.8-100] 
PPV 50.0 [15.0-100] 
NPV 100 (99.9-100) 
 
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA  
-Change in uptake of prenatal screening: NA 
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Author(s): Willems et al [63] 
Study characteristics Study design: Blinded DTA study (prospective cohort) 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Belgium and The Netherlands 
Setting: routine prenatal screening 
Data collection period: March to December 2013 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/59 for T21, 1/750 for T18 and 1/1500 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Harmony™ Prenatal Test/CSS 
Country where samples were ana-lysed: USA (Ariosa Diagnostic) 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [SD]): 36±3  
Gestational age in weeks (mean [SD]): 13±2 
Maternal weight (median [169]): not reported  
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: pregnant women who had indication for NIPT testing i.e. an elevated FCT risk (>1/200 in the Netherlands and >1/300 in Bel-
gium) (22%), advanced maternal age (>37 years at expected day of delivery) without increased risk on FTS or no FTS done (40.06%), other 
indications (previous pregnancies with chromosome anomalies in one or both parents or family)(3.27%) or none of these indications (34.73%)  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 3000 consecu-tive women 
Population excluded: 32  
Reason for exclusion: 
-absence of a result on cfDNA: 32 samples 
Population included: 2968 
-with NIPT result: 2968 
-with comparator result: NA 
-with reference standard result: 47  
Reference standard (% pts): amni-ocentesis or CVS 
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Sample processing protocol 
Maternal blood samples were col-lected into Streck DNA BCT tubes and sent to Ariosa Diagnostics for its analysis.  
It was not reported if sequencing and karyotyping analysis was per-formed in a blinded fashion respect to ultrasonographic and standard 
screening results.  
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 1.06% or 32 samples (27 2nd/3rd analysis samples and 5 no 2nd sample) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for 
Trisomy 21 in pregnancies with outcome 
data, excluding test failures and 
miscarriages (calculated based on study 
results)  
Variable  cfDNA testing 
TP 51 
TN 2911 
FP 0 
FN 1 (FN rate: 1.92%) 
S 98 (89.9-99.7) 
Sp 100 (99.9-100) 
PPV 100 (93.0-100) 
NPV 99.9 (99.8-100) 
  
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 4 
TN 2911 
FP 0 
FN 1 (FN rate: 20%) 
S 80 (37.6-96.4) 
Sp 100 (99.9-100) 
PPV 100 (51.0-100) 
NPV 99.9 (99.8-100) 
 
Diagnostic accuracy measures for Trisomy 13 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA Testing 
TP 3 
TN 2911 
FP 0 
FN 0 
S 100 (43.8-100) 
Sp 100 (99.9-100) 
PPV 100 (51.0-100) 
NPV 100 (99.8-100) 
 
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Liang et al [65] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
Year of publication: 2013 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: China 
Setting: routine prenatal care 
Data collection period: March 2009-June 2011 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/11 for T21, 1/31 for T18, 1/109 for T13, 1/435 for T13 and 1/54 for SCA 
Comparator: no intervention  
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): HiSeq2000, Illumina/MPS.  
For DNA library preparation was used the modified ChIP seq proto-col and data analysis was per-formed by guanosine-citosine (GC) correction 
algorithm. 
Country where samples were ana-lysed: Berry Genomics, China 
Cut off point for NIPT:  
T21, Z score=3 
T18, Z score= 5,91 
T13, Z score= 5,72 
T9, Z score= 7,45 
Sex chromosomal aneuploidy, Z score= -2,91 to 2,91/<3 
Population 
characteristics 
Maternal age in years (mean [SD]): 31±5.9 
31% women were ≥35 years of age 
Gestational age in weeks (median [169]): 21+3 (11+3 to 39+3) 
11+0 to 14+6=0.23% 
15+0 to 20+6=40% 
21+0 to 39+6=59.77% 
Maternal weight (median [169]): not reported 
Pregnancy by ART (% pts): not re-ported  
Inclusion criteria: pregnant women who had indication for invasive di-agnostic procedure, i.e. advanced maternal age (≥35 years old) (19.31%), 
positive serum screening (49.89%), ultrasound anomaly (14.48%), prior aneuploid pregnancy (0.92%) and more than one indica-tion (15.40%) 
Exclusion criteria: not reported 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 227 
Study protocol Population enrollment flow 
Population enrolled: 435 
Population excluded: 23 
Reason for exclusion: 
-failed sequencing quality control: 12 
-missing karyotyping: 11  
Population included: 412 
-with NIPT result: 412 
-with comparator result: no inter-vention 
-with reference standard result: 412 
Reference standard (% pts): amni-ocentesis and other method not specified  
Sample processing protocol 
Maternal blood samples were col-lected into EDTA tubes at each enrolment institution and sent to Berry Genomics for its analysis. Plasma was 
extracted using the QIAamp Circulating Nucleic Acid kit (Qiagen). The karyotyping was conducted in the participant cen-tres. 
Karyotyping information were con-ducted in a blinded fashion and Berry Genomics obtained sequenc-ing results independently. 
Outcomes 
 
Performance of NIPT for T21, T18, T13 
-Test failure (% samples): 12 samples (2.76%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 40 
TN 372 
FP 0 
FN 0 
S 100 (91.2-100) 
Sp 100 (99.0-100) 
PPV 100 (91.2-100) 
NPV 100 (99.9-100) 
 
Diagnostic accuracy for Trisomy 18 in 
pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 14 
TN 398 
FP 0 
FN 0 
S 100 (78.5-100) 
Sp 100 (99.0-100) 
PPV 100 (78.5-100) 
NPV 100 (99.0-100)  
 
Diagnostic accuracy measures for Trisomy 13* 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated based 
on study results)  
Variable  cfDNA Testing 
TP 4 
TN 407 
FP 1 (FP rate: 0.24%) 
FN 0 
S 100 (51.0-100) 
Sp 99.75 (98.6-100) 
PPV 80 (37.6-96.4) 
NPV 100 (99.1-100) 
*Including a twin sample 
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Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA  
-Change in uptake of prenatal screening: NA 
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Author(s): Verweij et al [67] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
European Non-Invasive Trisomy Evaluation, EU-NITE study 
Year of publication: 2013 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Norway, Sweden and Netherlands 
Setting: routine prenatal care 
Data collection period: May 2011 to March 2012 
Target population: high-risk popula-tion 
Target condition prevalence in the enrolled population: 1/33 for T21 
Comparator: no intervention 
Cut off point comparator: no inter-vention  
Index test (trademark/technique type): not reported 
Country where samples were ana-lysed: Ariosa Diagnostic, USA 
Cut off for NIPT: 1/100 (1%) was fixed as the threshold for classify-ing a sample as high-risk versus low risk 
Population 
characteristics 
Maternal age in years (median [169]): 36.4 [20-47] 
Gestational age in weeks (median [169]): 14.0 [10-28] 
Maternal weight (median [169]): not reported  
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: pregnant women ≥18 years of age with an increased risk for T21 based on first trimester screening (serum screening, nuchal 
translucency measurement and/or maternal age), choosing to undergo invasive testing due to presence of ultrasound fetal anomalies or requiring 
invasive testing for psy-chosocial or anxiety reasons. 
Exclusion criteria: women with >1 foetus, an invasive testing per-formed prior of the blood sampling, history or active significant malig-nancy 
requiring major surgery or systemic chemotherapy or language restriction with failure to understand the study information. 
Study protocol Population enrollment flow 
Population enrolled: 595 consecutive women 
Population excluded: 75 
Reason for exclusion: 
-no meet inclusion criteria: 21 
-insufficient plasma volume: 19 
-logistic problems: 11 
-other chromosome anomalies besides T21: 24 
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Population included: 520 
-with NIPT result: 504 (absence of a result on cfDNA due to low fetal fraction in 7 samples, 9 with assays failure and one additional samples with 
no accurate result)  
-with comparator result: no intervention 
-with reference standard result: 503 
Reference standard (% pts): CVS (n=280) or amniocentesis (n=240)  
Sample processing protocol 
Blood samples were collected into two cell-free DNA BCT™ tubes at each enrolment centers just prior to the invasive testing and sent to Ariosa 
Diagnostic, Inc. for its analysis.  
The cfDNA of each sample was isolated and quantified using the DANSR assay and the FORTE algorithm was used to estimate the risk of T21 in 
each sample (OR of T21). 
The laboratory personnel were blinded to the clinical information. 
Invasive analysis was performed by respective certified genetic laboratories of the participating centers. 
Outcomes 
 
Performance of NIPT for T21 
-Test failure (% samples): 16 samples (3.07%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in pregnancies with outcome data, excluding test failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 17 
TN 486 
FP 0 
FN 1 (FN rate: 5.6%) 
S 94.4 (72.7-99.9) 
Sp 100 (99.4-100) 
PPV 100 (81.6-100)  
NPV 99.8 (99.8-100) 
  
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other major unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies with un-certain significance: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
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-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Nicolaides et al [66] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
Year of publication: 2013 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: United Kingdom 
Setting: routine prenatal care 
Data collection period: not reported 
Target population: high-risk popula-tion 
Target condition prevalence in the enrolled population: 1/10 for T21, 1/81 for T18, 1/121 for Turner syn-drome and 1/242 for each T13 and triploid 
(69,XXX) 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): not reported/targeted se-quencing of SNPs with NATUS (Next-generation Aneuploidy Test Using SNPs) 
algorithm  
Country where samples were ana-lysed: Natera Inc. USA 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean [169]): 35.7 [18.5-46.5] 
Gestational age in weeks (median [169]): 13.1 [11.3-13.9] 
Maternal weight (median [169]): not reported  
Pregnancy by ART (% pts): not re-ported  
Inclusion criteria: singleton pregnant women at 11-13 week of gestation were undergoing fetal karyotyping because positive FCT result (risk for 
T13, T18 or T21>1/300)(n=227) or previous aneuploidy pregnancy (n=6) and advanced maternal age (n=5), or women were undergoing invasive 
testing for sickle cell dis-ease. 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 242 
Population excluded: 13 
Reason for exclusion: 
-absence of a result on cfDNA (insufficient total DNA, insufficient cfDNA fraction or high noise level) 
Population included: 229 
-with NIPT result: 229 
-with comparator result: no intervention 
-with reference standard result: 229 
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Reference standard (% pts): CVS 
Sample processing protocol 
Maternal blood samples were collected previously CVS, into Streck cell-free DNA BCT™ tubes from enrolment center and sent to the laboratory of 
Natera Inc. for its analysis.  
Sequencing analysis was blinded to the fetal karyotype information. 
Outcomes 
 
Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 13 samples (5.4%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 25 
TN 204 
FP 0 
FN NA 
S 100 [86.7-100] 
Sp 100 [98.2-100] 
PPV 100 (86.7-100) 
NPV 100 (98.2-100) 
  
Diagnostic accuracy measures for Trisomy 18 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 3 
TN 226 
FP 0 
FN 0 
S 100 (43.8-100) 
Sp 100 (98.3-100) 
PPV 100 (43.8-100) 
NPV 100 (98.3-100) 
 
Diagnostic accuracy measures for Trisomy 13 
in pregnancies with outcome data, excluding 
test failures and miscarriages (calculated 
based on study results)  
Variable  cfDNA testing 
TP 1 
TN 228 
FP 0 
FN 0 
S 100 (20.7-100) 
Sp 100 (98.3-100) 
PPV 100 (20.7-100) 
NPV 100 (98.3-100) 
 
Additional patient relevant outcomes    
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Norton et al [69] 
Study characteristics Study design: multicentre blinded DTA study 
Year of publication: 2012 
Study’s registration number in clinical trial database: not reported 
Country/ies of recruitment: United States of America (USA), The Netherlands and Sweden 
Setting: routine prenatal care 
Data collection period: August 2010 to November 2011 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/49 for T21 and 1/108 for 1/108 
Comparator: no intervention 
Cut off point comparator: no intervention 
Index test (trademark/technique type): trademark was not speci-fied/it was used Digital Analysis of Selected Regions-DANRS sequencing method 
and Fetal-fraction Optimized Risk of Trisomy Evaluation-FORTE analysis algorithm 
Country where samples were analysed: not reported 
Cut off for NIPT: 1/100 (1%) [99/100 or 99% to 1/10,000 or 0.01%] 
Population 
characteristics 
Maternal age in years (mean [169]): 34.3 [18-50] 
Gestational age in weeks (median [169]): 16.9 [10.0-38.7] 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): not reported 
Inclusion criteria: pregnant women aged ≥18 years, at gestational age≥10 weeks, with singleton preg-nancy and who were planned to undergo 
invasive prenatal diagnosis for any indication (not specified). 
Exclusion criteria: women with >1 foetus, presence of known aneuploidy, active malignancy or a history of metastatic cancer or who had already 
received CVS or amniocentesis during current pregnancy. 
Study protocol Population enrollment flow 
Population enrolled: 4002 
Population excluded: 774 
Reason for exclusion: 
-samples used for assay development: 433  
-failed inclusion/exclusion criteria: 237 
-insufficient sample volume: 84 
-incorrect sample labeling: 20 
Population included: 3228 
-with NIPT result: 3080 (148 samples were excluded due to low fetal fraction (n=57) and assay failure (n=91)) 
-with comparator result: no intervention 
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-with reference standard result: 3080 
Reference standard (% pts): CVS (25.3%) or amniocentesis (74.7%) 
Sample processing protocol 
Maternal blood samples were collected into Cell-free BCT tubes at each institution and sent to laboratory for its analysis. The laboratory personnel 
who performed the analyses were blinded to the clinical information associated with each sample. 
Outcomes 
 
Performance of NIPT for T21 and T18 
-Test failure (% samples): 148 samples (4.8%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 
21 in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 81 
TN 2887 
FP 1 (FP rate: 0.03% [0.002-
0.20]) 
FN 0 
S 100 (95.5-100) 
Sp 99.97 (99.8-99.99) 
PPV 98.8 (93.4-99.8) 
NPV 100 (99.9-100) 
 
Diagnostic accuracy measures for 
Trisomy 18 in pregnancies with outcome 
data, excluding test failures and 
miscarriages (calculated based on study 
results)  
Variable  cfDNA testing 
TP 37 
TN 2888 
FP 2 (FP rate: 0.07% [0.02-0.25]) 
FN 1 (FN rate: 2.6%) 
S 97.4 (86.5-99.9) 
Sp 99.9 (99.7-99.9) 
PPV 94.9 (83.1-96.6) 
NPV 99.9 (99.8-100) 
 
NIPT testing performance at other cut-off points (main 
changes in comparison to 1/100 cut-off point used 
previously) 
-Cut-off point=1/1000 (0.1%) 
S for T21 or T18 did not change but Sp decreased (99.90% and 
99.79% respectively) and therefore FP rate increased, i.e. 
added two FP cases more for T21 and four FP cases more for 
T18.  
-Cut-off point=1/300 (0.33%) 
S for T21 or T18 did not change but Sp decreased (99.90% and 
99.86% respectively) and therefore positive false rate increased 
two FP cases more for each trisomy.  
- Cut-off point=1/10 (10%) 
S for T21 did not change. However, S for T18 decreased 
(94.7%) and therefore there was one FN case more. Sp for T18 
did not change, whereas Sp for T21 increased and there were 
not FP cases. 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Lau et al [68] 
Study characteristics Study design: Blinded DTA study (prospective cohort) 
Year of publication: 2012 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Japan 
Setting: routine prenatal screening  
Data collection period: not reported 
Target population: high-risk preg-nant population 
Target condition prevalence in the enrolled population: 1/9 for T21, 1/11 for T18, 1/54 for T13, 1/13 for Turner syndrome and 1/108 for Klinefelter 
syndrome 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Verifi™™ Prenatal Test (Illu-mina HiSeq™ 2000) 
Country where samples were ana-lysed: Japan (enrolment center) 
Cut off for NIPT: sample with z-score>3 was classified as having at increased risk for assessed trisomy 
Population 
characteristics 
Maternal age in years (mean [SD]): 37±4.3  
Gestational age in weeks (median [169]): 12+5 [11+4 to 28+0] 
Maternal weight (median [169]): not reported 
Pregnancy by ART (% pts): not re-ported 
Inclusion criteria: singleton pregnant women with indication for diagnostic procedures i.e. high-risk for FCT (47.2%), positive first trimester so-
nographic markers (22.2%), other structural anomalies (18.5%), ma-ternal anxiety (11.1%) or previous trisomy 21 (0.9%). 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 108 
Population excluded: 0 
Population included: 108 
-with NIPT result: 108 
-with comparator result: NA  
-with reference standard result: 108  
Reference standard (% pts): CVS (94.4%) or amniocentesis (5.6%) 
Sample processing protocol 
Maternal blood samples were col-lected into EDTA tubes. DNA se-quencing and data analysis was performed in the enrolment center. 
Investigators who carried out the DNA extraction, sequencing and data analysis were blinded to the karyotyping information 
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Outcomes Performance of NIPT for T21, T18, T13 
-Test failure (% samples): 0 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for Trisomy 21 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA testing 
TP 11 
TN 97 
FP 0 
FN 0 
S* 100 (20.7-100) 
Sp 100 (96.2-100) 
PPV 100 (20.7-100) 
NPV 100 (96.2-100) 
*Using the z-score method with adjustment by GC 
correction, PPV=100%; using the Z-score method 
with adjustment by internal reference in this study, 
PPV= 100% 
Diagnostic accuracy measures for Trisomy 
18 in pregnancies with outcome data, 
excluding test failures and miscarriages 
(calculated based on study results)  
Variable  cfDNA testing 
TP 10 
TN 98 
FP 0 
FN 6 (FN rate: 37.5%) 
S* 62.5 (38.6-81.5) 
Sp 100 (96.2-100) 
PPV 100 (72.2-100) 
NPV 94.2 (88.0-97.3) 
*Using the z-score method with adjustment by GC 
correction, PPV=100%; using the Z-score method 
with adjustment by internal reference in this study, 
PPV= 90% 
Diagnostic accuracy for Trisomy 13 in 
pregnancies with outcome data, excluding test 
failures and miscarriages (calculated based on 
study results)  
Variable  cfDNA Testing 
TP 0 
TN 106 
FP 0 
FN 2 (FN rate: 100%) 
S* 0 
Sp 100 
PPV 0 
NPV 98.1 
*Using the z-score method with adjustment by GC 
correction, PPV=100%; using the Z-score method with 
adjustment by internal reference in this study, PPV= 
100% 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Ehrich et al [70] 
Study characteristics Study design: DTA study 
Year of publication: 2011 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: United States of America 
Setting: routine prenatal care 
Data collection period: August 2009- May 2009 
Target population: high-risk popula-tion 
Target condition prevalence in the enrolled population: 1/12 for T21 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): GAIIx sequencer by Ilumi-na/MPSS in combination with anal-ysis software CASAVA version 1.6 
Country where samples were ana-lysed: USA 
Cut off for NIPT: Z-score=2.5 
Population 
characteristics 
Maternal age in years (mean [169])(n=448): 37 [18-47] 
Gestational age in weeks (median [169])(n=448): 16 [8-36]  
Maternal weight in lbs (median [169])(n=425): 153 (96-314)  
Pregnancy by assisted reproductive techniques (% pts): not reported  
Inclusion criteria: pregnant women who were at high risk for fetal trisomy 21 or DS based on positive serum biochemical screening test 
(n=133/441), advanced maternal age (≥35 years at the estimated date of delivery)(n=306/448), fetal ultrasound finding suggestive of DS 
(n=57/441), a personal/family history of DS (n=23/441) or not specified (n=45/441) 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 480 
Population excluded: 31 
Reason for exclusion: 
-plasma volume<3.5 ml=9 
-processing error=4 
-failed quality control=18  
Population included: 449 
-with NIPT result: 449  
-with comparator result: no inter-vention 
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-with reference standard result: 449 
Reference standard (% pts): CVS (19%) or amniocentesis (80.9%) 
Sample processing protocol 
Maternal blood samples were col-lected into EDTA-K2 spray-dried Vacutainer at enrolment institution and sent to Sequenom Inc. for its analysis. 
Plasma DNA was extract-ed by QIAamp Circulating Nucleic Acid Kit from Qiagen and amount of extracted DNA was determinated by fetal 
quantifier assay (FQA).  
Sample, demographics and karyo-type results were unknown to the laboratory investigators and data analysts until after completion of all sample 
testing and submission for review. 
Outcomes 
 
Test performance 
-Test failure (% samples): 18 samples (3.75%)(failed quality control) 
-Uncertain results rate (% samples): not reported 
Performance for Trisomy 21 in pregnancies with outcome data, excluding test failures and miscarriages (calculated based on study results)  
Variable  cfDNA testing 
TP 39 
TN 409 
FP 1 (FP rate: 0.24%) 
FN 0 
S 100 (89-100) 
Sp 99.7 (98.5-100) 
PPV 100 (87.1-99.6) 
NPV 100 (99.1-100) 
The study’s authors reassessed accuracy NIPT test previous performing of quality control (QC) in 467 samples, excluding only the 13 samples 
with analytic failure with the aim of assessing value of QC. Therefore, S=97% (86-100), Sp=99.8 (98.5-100) and one FN case. 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
Abbreviations: NA: not available; S: sensitivity; Sp: specificity; TP: true positive; TN: true negative; FP: false positive; FN: false negative; PPV: positive predictive value; NPV: negative predictive value. 
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Table A4: Characteristics of included studies on high-intermediate pregnant population 
Author(s): Gil et al [71] 
Study characteristics Study design: prospective DTA study  
Year of publication: 2016 
Study’s registration number in clini-cal trial database: not reported  
Country/ies of recruitment: United Kingdom (UK) 
Setting: routine prenatal screening 
Data collection period: October 2013 to February 2015 
Target population: high-risk preg-nant population  
Target condition prevalence in the enrolled population: 1/282 for T21, 1/577 for T18 and 1/6067 for T13 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Harmony™ Prenatal Test/targeted free DNA based technology 
Country where samples were ana-lysed: USA  
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (median [in-terquartile range]):  
-High-risk: 36.1 (32.1-39.5) 
-Intermediate-risk: 34.8 (30.8-38.4) 
-Low-risk: 29.9 (25.8-33.2) 
Gestational age in weeks (median [169]): not reported 
Maternal weight in Kg (median [169]): not reported 
Pregnancy by ART (no [% pts]):  
-High-risk: 16 (3.5) 
-Intermediate-risk: 135 (3.8) 
-Low-risk: 172 (2.2) 
Inclusion criteria: women with sin-gleton pregnancy at 11-13 week of gestation classified as high (≥1/100) or intermediate (between 1/101 and 
1/2500) risk of aneuploidies by first-trimester combined test who NIPT was offered and opted for it. 
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 12134 
Population excluded: 512  
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Reason for exclusion: 
-not provided informed consent: 213 
-Pregnant termination, miscarriage or stillbirth without karyotyping result: 169 
-Lost follow-up: 60 
Population included: 11692 (as-sessed by FCT, 460 samples (3.9%) classified as high risk, 3552 samples (30.4%) classified as intermediate risk 
and 7680 sam-ples (64.7%) classified as low risk 
-with NIPT result: 3633 (3698 sam-ples with high- or intermediate risk).  
-with comparator result: no inter-vention 
-with reference standard result: 3633 
Reference standard (% pts): CVS 
Sample processing protocol 
Maternal blood samples were col-lected into EDTA or Cell-Free DNA BCT tubes at enrolment centres and sent to Ariosa Diagnostic, Inc. where 
sequencing analysis was performed.  
It was not reported if karyotyping and sequencing analysis were performed in a blinded fashion 
Outcomes 
 
Test performance 
Excluding samples without cfDNA results, NIPT accuracy test were analysed in 3633 samples. NIPT test detected 41 cases of T21, 21 cases of 
T18 and 2 cases of T13. By invasive testing, it was confirmed 47 cases of T21, 24 cases of T18, 4 cases of T13 and 11617 cases non-trisomy.  
Safety and effectiveness of NIPT for T21, T18 and T13 
-Test failure (% samples): 65 samples (1.75%) 
-Uncertain results rate (% samples): NA 
Performance for T21 in pregnancies with 
outcome data, excluding test failures and 
miscarriages (calculated based on study 
results) 
Variable  cfDNA testing 
TP 43* 
TN 3588 
FP 1 (FP rate: 0.027) 
FN 1 (FN rate: 2.3%) 
S 97.7 (88.2-99.6) 
Sp 99.9 (99.8-100) 
PPV 97.7 (88.2-99.6) 
NPV 99.9 (99.8-100) 
*There were three cases the parents elected no 
further testing option 
Performance for T18 in pregnancies with 
outcome data, excluding test failures and 
miscarriages (calculated based on study 
results) 
Variable  cfDNA testing 
TP 21 
TN 3608 
FP 4 (FP rate: 0.11%) 
FN 3 (FN rate: 12.5%)* 
S 87.5 (69.0-95.7) 
Sp 99.8 (99.7-100) 
PPV 84 (65.3-93.6) 
NPV 100 (99.9-100) 
*The test did not provided result for three samples 
Performance for T13 in pregnancies with 
outcome data, excluding test failures and 
miscarriages (calculated based on study 
results) 
Variable  cfDNA testing 
TP 2 
TN 3625 
FP 4 (FP rate: 0.11%) 
FN 2 (FN rate: 50%) 
S 50 (15.0-85.0) 
Sp 99.8 (99.7-100) 
PPV 33.3 (9.7-70.0) 
NPV 99.9 (99.8-100) 
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Additional patient relevant outcomes  
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Table A5: Characteristics of included studies on twin pregnant population 
Author(s): Fosler et al [72] 
Study characteristics Study design: Prospective DTA study (only Cohort B included) 
Year of publication: 2015 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: USA 
Setting: routine prenatal-screening 
Data collection period: not reported 
Target population: twin pregnancies 
Target condition prevalence in the enrolled population: 1/81 for T21 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Verifi® Prenatal Test/SNPs 
Country where samples were ana-lysed: USA (Clinical Laboratory Improvement Act (CLIA)-certified Illumina Laboratory 
Cut off for NIPT: not reported 
Population 
characteristics 
Maternal age in years (mean±SD): 35.5±4.9 
Gestational age in weeks (mean±SD): 13.7±3.9 
Maternal weight (mean [169]): not reported 
Pregnancy by ART (% pts): not reported 
Chorionicity (%): not reported 
Inclusion criteria: women at least 18 years of age and at least 8 weeks’ gestation carrying twins who meet the following criteria: advance ma-ternal 
age, abnormal ultrasound, previous affected pregnancy or positive serum screen 
Exclusion criteria: not reported 
Study protocol Patient enrollment flow 
Patient enrolled: 487 
Patient included: 487 (there was 8 cancellations but not for technical reasons) 
-with NIPT result: 479 
-with comparator result: no inter-vention 
-with reference standard result: 171  
Reference standard (% pts): kary-otyping (amniocentesis or CVS) or ultrasound findings. It was not reported the patients percentage in which it 
was be used each standard reference  
Sample processing protocol 
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Maternal blood samples were collected in Streck cfDNA BCT™ tubes and processed at Illumina Laboratory. Demographic infor-mation i.e. 
maternal age, gesta-tional age and clinical indication for testing was provided to labora-tory. 
It was not reported whether karyo-typing analysis was performed in a blinded fashion respect to ultra-sonographic results.  
Outcomes Performance of NIPT for T21 
-Test failure (% samples): 0 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy for T21 in confirmed and unconfirmed cases (n=479) 
Variable  cfDNA 
TP 6 
TN 472 
FP 1 (FP rate: 0.20%) 
FN 0 
S 100 (61.0-100) 
Sp 99.7 (99.8-100) 
PPV 85.7 (48.7-97.4) 
NPV 100 (99.2-100) 
Two cases were not confirmed (they were considered suspected to be concordant based on ultrasound findings). If these two cases were 
considered positive results, accuracy NIPT test would change as follows: S=100, E=99.7, PPV=88.9 and NPV=100. If these two cases were 
considered FP results (3/479, 0.6%), accuracy NIPT test would change as follows: S=100, E=99.3, PPV=66.7 and NPV=100. 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other un-confirmed chromosomal anomalies: not reported cases with other anomalies  
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: not report-ed cases with other anomalies  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA  
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Sarno et al [39] 
Study characteristics In this table only were summarised population characterisctics and accuracy test results regarding to twin pregnancies 
Study design: prospective DTA study  
Year of publication: 2016 
Study’s registration number in clini-cal trial database: not reported  
Country/ies of recruitment: UK 
Setting: routine prenatal screening 
Data collection period: October 2012 to August 2015 
Target population: high-risk pregnant population (singleton or twin pregnancies).  
Target condition prevalence in the enrolled population:  
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Harmony™ Prenatal Test/CSS 
Country where samples were analysed: USA  
Cut off for NIPT: risk score for T21, 18 and T13 was ranged between >99% to <0.01% 
Population 
characteristics 
Maternal age in years (median [169]): 37.3 [34.6-40.0] 
Gestational age in weeks (median [169]): 11.7 [10.4-12.9] 
BMI in Kg/m2 (median [169]): 23.5 [21.0-26.9] 
Pregnancy by ART (no [% pts]): 246 [56.2] 
Chorionicity (%): 373 (85.2%) were dichorionic and 65 (14.8%) were monochorionic 
Inclusion criteria: singleton or twin pregnant women at 11+0 to 13+6 weeks’ gestation who received NIPT as an option following FCT or as part of 
routine screening. All pregnant women were undergone FCT.  
Exclusion criteria: not reported 
Study protocol Population enrollment flow 
Population enrolled: 467 
Population excluded: 29 
Reason for exclusion: 
-Pregnancy ended in termination, miscarriage or stillbirth without karyotype results (n=23) 
-Lost to follow up (n=4) 
-Chromosomal anomalies other than trisomies 21, 18 or 13 (n=2) 
Population included: 438 
-with NIPT result: 417 
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-with comparator result: no inter-vention 
-with reference standard result: not reported 
Reference standard (% pts): fetal karyotype (not specified method used) 
Sample processing protocol 
Maternal blood samples were collected at enrolment centres and sent to laboratory for its anal-ysis. 
Outcomes Performance of NIPT for T21, T18 and T13 
-Test failure (% samples): 9.4% (41/438) after first NIPT testing. In a second testing, it was provided re-sults in 20 (51.3%) cases (test failure after 
2nd test-ing=4.8% or 21/438).  
-Uncertain results rate (% samples): NA 
Performance for all trisomies (n=417) in pregnancies with outcome data, excluding test failures and miscarriages (calculated based on study 
results)  
Variable  cfDNA 
TP 11 
TN 403 
FP 1 (FP rate= 0.25%) 
FN* 2 (FN rate= 15.4%) 
S* 84.6 (57.8-95.7) 
Sp 99.7 (98.6-100) 
PPV 91.7 (64.6-98.5) 
NPV 99.5 (98.2-99.9) 
*FN rate T21=0%, FN rate T18=25% and FN rate T13=100%; S T21= 100%, S T18= 75% and S T13= 0% 
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Author(s): Tan et al [73] 
Study characteristics Study design: DTA study (prospec-tive cohort) 
Year of publication: 2016 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: China 
Setting: routine prenatal-screening 
Data collection period: January 2012-December 2013 
Target population: twin pregnancy population after the treatment of assisted reproductive technology (ART)(in vitro fertilization embryo transfer 
(IVF-ET), ICSI or frozen embryo transfer (FET)) 
Target condition prevalence in the enrolled population: 1/141 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): not reported/MPS 
Country where samples were ana-lysed: China (Clinical Laboratories of BGI-Shenzhen) 
Cut off for NIPT:  
-If both t-score were >2.5 and the L-score was >1, the sample was in the high-risk zone 
-If either the t-score was >2.5 or the L-score was >1, the sample was in the warning zones 
-If the t-score was <2.5 and the L-score was <1, the sample was in the low-risk zone 
Cases falling in the “warning zone 1” were classified as affected but usually because of the presence of mosaicism or partial trisomy. Cases in 
“warning zone 2” were likely affected pregnancies but with inadequate fetal DNA concentration 
Population 
characteristics 
Maternal age in years (median [169]): 31 [20-43]  
Gestational age in weeks (median [169]): 12 [11-28] 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): 100 
ART treatment (% pts): FET (25.5), ICSI (21.2), IVF-ET (52.0) and un-known (1.2) 
Chorionicity (% pts): dichorionic diamniotic, 96.3; monochorionic diamniotic, 1.9; monochorionic monoamniotic, 1.2; other (monochorionic 
monoamni-otic+ monochorionic diamniotic, tri-chorionic tri-amniotic): 0.7  
Inclusion criteria:  
-pregnant women with twin preg-nancies after ART,  
-over 18 years old,  
-for one to two embryo transfer, confirmation of live twin pregnancy by ultrasound scan before enrolling in the study; for three embryo trans-fer, 
confirmation of live twin preg-nancy and no demise foetus by ultrasound scan before enrolling in the study, 
-voluntary received NIPT screening for fetal trisomy 21, trisomy 18 and trisomy 13, with or without prior DS screening result, 
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-gestational age>10 weeks. 
Exclusion criteria: not reported 
Study protocol Patient enrollment flow 
Patient enrolled: 565 
Patient excluded: 5 DCDA cases 
Reason for exclusion: low fetal fraction 
Patient included: 560 
-with NIPT result: 560 
-with comparator result: no intervention 
-with reference standard result: 560 
Reference standard (% pts): amniocentesis (NIPT positive cases)(3.1) or follow-up (NIPT negative cases)(96.9) 
Sample processing protocol 
Maternal blood was collected in an EDTA tube from each participant and sent to the accredited clinical laboratory of BGI-Shenzhen. 
It was not reported if sequencing karyotyping analysis was performed in a blinded fashion respect to ultrasonographic and standard screening results.  
Outcomes Performance of NIPT for T21 
-Test failure (n,% samples): 5 (0.9%) 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy for T21 in pregnancies with 
outcome data, excluding test failures and 
miscarriages (calculated basppped on study 
results 
Variable  cfDNA 
TP 4 
TN 556 
FP 0 (FP rate: 0 [0-0.70) 
FN 0 
S 100 (51.0-100) 
Sp 100 (99.3-100) 
PPV 100 (51.0-100) 
NPV 100 (99.3-100) 
 
Performance for T21 in pregnancies with outcome data, including test failures 
Considering cases with indeterminate results 
as high risk of aneuploidies 
Variable  cfDNA 
TP 4 
TN 556 
FP 5 (add +5 indeterminate results) 
FN 0 
S 100 (51.0-100) 
Sp 99.1 (97.9-99.6) 
PPV 44.4 (18.9-73.3) 
NPV 100 (99.3-100) 
 
Considering cases with indeterminate results 
as low risk of aneuploidies 
Variable  cfDNA 
TP 4 
TN 561 (add +5 indeterminate results) 
FP 0 
FN 0 
S 100 (51.0-100) 
Sp 100 (99.3-100) 
PPV 100 (51.0-100) 
NPV 100 (99.3-100) 
 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other un-confirmed chromosomal anomalies: not reported cases with other anomalies  
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-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: not report-ed cases with other anomalies  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Bevilacqua et al [74] 
Study characteristics Study design: DTA study 
Year of publication: 2015 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: Belgium, United Kingdom and Spain 
Setting: routine prenatal-screening 
Data collection period: May 2013-September 2014 
Target population: twin pregnant population 
Target condition prevalence in the enrolled population: 1/43 for T21 and 1/103 for T18 
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): Harmony™ Prenatal Test/MPS 
Country where samples were ana-lysed: USA (Ariosa Diagnostic, Inc.) 
Cut off for NIPT: risk score of each trisomy with range >99% and <0.01% 
Population 
characteristics 
Maternal age in years (median [169]): 36.8 [19.0-50.3]  
Gestational age in weeks (median [169]): 13.6 [10.0-34.7] 
Maternal weight (median [169]): 64.4 [42.0-148.0]  
Pregnancy by ART (% pts): 52.8 
Chorionicity (% pts): not reported 
Inclusion criteria: woman with twin pregnant at 10-28 weeks’ gestation underwent to cfDNA testing either because prior high-risk of aneu-ploidies 
(first-trimester screening combined test or second-trimester triple/quadruple test or ultrasound examination) or as a primary screening test. 
Exclusion criteria: not reported 
Study protocol Patient enrollment flow 
Patient enrolled: 515 
Patient excluded: 175 
Reason for exclusion (any sam-ples had more than one exclu-sions reason):  
-low fetal fraction (n=16),  
-unknown karyotype because of pregnancy resulted in miscarriag-es or stillbirth (n=7),  
-outcome unknown because the pregnancies were continuing (n=19), 
-were lost to follow-up (n=138). 
Patient included: 340 
-with NIPT result: 340 
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-with comparator result: no inter-vention 
-with reference standard result: 351  
Reference standard (% pts): CVS, amniocentesis, neonatal blood or neonatal examination. It was not reported patient percent.  
Sample processing protocol 
Maternal blood was collected (Streck cfDNA BCT™ tubes) and sent to via courier to the Ariosa Diagnostic laboratory. The infor-mation provided to 
the laboratory was patient-unique identifier, maternal age, method of concep-tion and date of blood collection. 
It was not reported if karyotyping analysis was performed in a blinded fashion respect to ultra-sonographic and standard screen-ing results. 
Outcomes Performance of NIPT for T21 and T18 
-Test failure (n,% samples): 3.1% 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for T21 in pregnancies with outcome 
data, excluding test failures and miscarriages (calculated based on 
study results) 
Variable  cfDNA testing 
TP 12 
TN 323 
FP 4 (FP rate: 1.22%) 
FN 1 (FN rate: 7.7%) 
S 92.3 (66.7-98.6) 
Sp 98.7 (96.9-99.5) 
PPV 75.0 (50.5-89.8) 
NPV 99.6 (98.3-99.9) 
  
Diagnostic accuracy measures for T18 in pregnancies with outcome data, 
excluding test failures and miscarriages (calculated based on study results) 
Variable  cfDNA testing 
TP 5 
TN 323 
FP 12 (FP rate: 3.58%) 
FN 0 
S 100 (56.6-100) 
Sp 96.4 (93.8-97.9) 
PPV 29.4 (13.3-53.1) 
NPV 100 (98.8-100) 
 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other un-confirmed chromosomal anomalies: not reported cases with other anomalies.  
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: not report-ed cases with other anomalies.  
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Huang et al [75] 
Study characteristics Study design: Prospective DTA study 
Year of publication: 2014 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: China 
Setting: routine prenatal-screening 
Data collection period: not reported 
Target population: twin pregnancy population 
Target condition prevalence in the enrolled population: 1/23 for T21 and 1/94 for T18  
Comparator: no intervention 
Cut off point comparator: no inter-vention 
Index test (trademark/technique type): not reported/MPS 
Country where samples were ana-lysed: China 
Cut off for NIPT:  
-If both t-score were >2.5 and the L-score was >1, the sample was in the high-risk zone 
-If either the t-score was >2.5 or the L-score was >1, the sample was in the warning zones 
-If the t-score was <2.5 and the L-score was <1, the sample was in the low-risk zone 
Cases falling in the “warning zone 1” were classified as affected but usually because of the presence of mosaicism or partial trisomy 
Cases in “warning zone 2” were likely affected pregnancies but with inadequate fetal DNA concentration 
Population 
characteristics 
Maternal age in years (median [169]): 31 [22-44] 
Gestational age in weeks (median [169]): 19 [11-36] 
Maternal weight (median [169]): not reported  
Pregnancy by ART (% pts): 59.8 
Chorionicity (% pts):  
-Monochorionic diamniotic: 16.4 
-Monochrorionic monoamniotic: 1.1 
-Dichrorionic diamniotic: 80.4 
-Unknown: 2.1 
Inclusion criteria: twin pregnancies that required invasive testing due to abnormal maternal serum screen-ing, abnormal sonographic signs or 
maternal anxiety. 
Exclusion criteria: women with intrauterine fetal demise at the time of sampling or without fetal karyo-type results. 
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Study protocol Patient enrollment flow 
Patient enrolled: 189 
Patient excluded: 0 
Reason for exclusion: 
Patient included: 189 
-with NIPT result: 189 
-with comparator result: no inter-vention 
-with reference standard result: 189  
Reference standard (% pts): CVS (2.1), amniocentesis (94.2) and cordocentesis (3.7) 
Sample processing protocol 
Maternal blood was sampled before invasive procedures and sent to the independent clinical laboratory BGI Health, Shenzhen (ISO/IEC 17025) to 
its analysis. Invasive testing was performed in medical centres. Both analysis were simultaneously performed. The karyotyping and sequencing 
results were kept confidential until final analysis. 
Outcomes Test performance of NIPT for T21 and T18 
-Test failure (% samples): not reported 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy measures for T21 in pregnancies with outcome 
data, excluding test failures and miscarriages (calculated based on 
study results) 
Variable  cfDNA 
TP 9 
TN 180 
FP 0 
FN 0 
S 100 (70.1-100) 
Sp 100 (97.9-100) 
PPV 100 (70.1-100) 
NPV 100 97.9-100) 
  
Diagnostic accuracy measures for T18 in pregnancies with outcome data, 
excluding test failures and miscarriages (calculated based on study results) 
Variable  cfDNA Testing 
TP 1 
TN 187 
FP 0 
FN 1 (FN rate: 50%) 
S 50 (9.5-90.5) 
Sp 100 (98.0-100) 
PPV 100 (20.7-100) 
NPV 99.4 (97.0-99.9) 
 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other unconfirmed chromosomal anomalies: not reported cases with other anomalies  
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: not reported cases with other anomalies  
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Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): NA 
-Change in uptake of prenatal screening: NA 
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Author(s): Lau et al [76] 
Study characteristics Study design: Prospective DTA study 
Year of publication: 2013 
Study’s registration number in clini-cal trial database: not reported 
Country/ies of recruitment: China  
Setting: routine prenatal-screening 
Data collection period: August 2011-April 2012 
Target population: twin pregnancy population 
Target condition prevalence in the enrolled population: 1/12 for T21  
Comparator: first or second tri-mester screening and/or first tri-mester ultrasound markers screen-ing, i.e. nuchal translucency, fetal nasal bone 
and Doppler assess-ment of the tricuspid valve and ductus venous 
Cut off point comparator: standard screening 
Index test (trademark/technique type): NIFTY test/MPS 
Country where samples were ana-lysed: laboratory where samples were analysis was previously re-ported (Lau TK, Chan MK, Lo PS, Chan HY, 
Chan WS, Koo TY, Ng HY, Pooh RK. Clinical utility of noninva-sive fetal trisomy (NIFTY) test--early experience. J Matern Fetal Neonatal Med. 
2012 Oct;25(10):1856-9) 
Clinical Laboratory of BGI-Shenzhen 
Cut off for NIPT: 
-If both t-score were >2.5 and the L-score was >1, the sample was in the high-risk zone 
-If either the t-score was >2.5 or the L-score was >1, the sample was in the warning zones 
-If the t-score was <2.5 and the L-score was <1, the sample was in the low-risk zone 
Cases falling in the “warning zone 1” were classified as affected but usually because of the presence of mosaicism or partial trisomy 
Cases in “warning zone 2” were likely affected pregnancies but with inadequate fetal DNA concentration 
Population 
characteristics 
Maternal age in years (mean [169]): 36.5 [28-41] 
Gestational age in weeks (median [169]): 13+1 [11+6 to 20+1] 
Maternal weight (median [169]): not reported 
Pregnancy by assisted reproductive techniques (% pts): 66.7% 
Chorionicity (% pts): 83.3% dichrorionic and 16.7% monochrorionic 
Inclusion criteria: women with twin pregnancies who fulfilled the following conditions: based on standard screening they have decided not to have 
invasive test, request NIFTY test, fully understand that NIFTY test efficacy had not been proven, accept that this test was performed on a research 
base, and only a research report would be issued, and signed an informed consent  
Exclusion criteria: not reported 
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Study protocol Patient enrollment flow 
Patient enrolled: 12 
Patient excluded: 0 
Patient included: 12 
-with NIPT result: 12 
-with comparator result: 12 
-with reference standard result: 12 
Reference standard (% pts): pre-natal karyotyping or clinical exam-ination of the newborn. 
Sample processing protocol 
Clinical and laboratory aspects were previously reported (Lau TK, Chan MK, Lo PS, Chan HY, Chan WS, Koo TY, Ng HY, Pooh RK. Clinical utility 
of noninvasive fetal trisomy (NIFTY) test--early experi-ence. J Matern Fetal Neonatal Med. 2012 Oct;25(10):1856-9) 
Blood samples were collected into EDTA tubes and sent to certified clinical laboratory BGI-Shenzhen (ISO/IEC 17025). 
It was not reported if sequencing karyotyping analysis was per-formed in a blinded fashion re-spect to ultrasonographic and standard screening 
results 
Outcomes Test performance of NIPT for T21  
-Test failure (% samples): not reported 
-Uncertain results rate (% samples): not reported 
Diagnostic accuracy for T21 in pregnancies with outcome data, excluding test failures and miscarriages (calculated based on study results) 
Variable  Standard screening cfDNA 
TP 1 1 
TN 9 11 
FP 2 (FP rate: 18.2%) 0 
FN 0 0 
S 100 100 (20.7-100) 
Sp 81.8 100 (52.3-94.9) 
PPV 33 33.3 (6.1-79.2) 
NPV 100 100 (70.1-100) 
 
Additional patient relevant outcomes     
Safety 
-Increase the number of children born with other un-confirmed chromosomal anomalies: NA 
-Increase in elective pregnancy termination for other unconfirmed chromosomal anomalies: NA 
Effectiveness 
-Reduction in children born with undiagnosed 13, 18 and 21 trisomies: all cases of main fetal aneuplodies were detected 
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-Reduction in the number of miscarriages or still birth of subject affected by 13, 18 and 21 trisomies: NA 
-Reduction in the number of miscarriage related to invasive testing: NA 
-Reduction in uptake of invasive testing (calculated from FP cfDNA vs. standard screening, %): two less invasive testing cases in NIPT group or a 
reduction of 16.7% 
-Change in uptake of prenatal screening: NA 
Abbreviations: NA: not available; S: sensitivity; Sp: specificity; TP: true positive; TN: true negative; FP: false positive; FN: false negative; PPV: positive predictive value; NPV: negative predictive value. 
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List of ongoing and planned studies 
 
Table A6: List of ongoing studies with NIPT 
Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Comparison of false 
positive rates in 
prenatal combined 
screening and cell 
free DNA screening 
for trisomy 21 
 
ISRCTN11174071  
Estimated completion date  
October 2017 
 
Study status 
Recruitment completed 
 
Study type 
Single-center randomised 
controlled trial  
Number of patients 
1400 
 
Intervention 
CfDNA screening 
 
Comparator 
Combined screening (maternal 
age, fetal NT, PAPP-A and free 
beta hCG) 
Inclusion criteria 
1. Patients coming for prenatal screening for 
trisomy at 11-13 weeks’ gestation 
2. Singleton pregnancies 
3. Normal ultrasound examination without 
increased nuchal translucency thickness 
>3.5mm and without fetal defects 
4. Informed consent 
Exclusion criteria 
1. Increased NT thickness 
2. Fetal defects 
3. Multiple gestations 
Primary outcome:  
Number and proportion of false 
positive cases in each arm 
Secondary outcomes: 
1. Number of cases that cannot 
be randomized (due to fetal 
defects, increased NT, multiple 
gestations). 
2. Time interval between 
randomization and return of the 
blood results 
3. Number of cases without 
results in each study arm.  
4. Number of women who opt for 
invasive testing.  
5. Acceptance of each screening 
test.  
SNP-based 
Microdeletion and 
Aneuploidy RegisTry 
(SMART)  
 
NCT02381457  
Estimated completion date  
November 2017 
 
Study status 
Ongoing recruitment 
 
Number of patients 
10000 
 
Intervention 
22q11.2 SNP-based non-
invasive prenatal screening 
Inclusion Criteria 
Singleton pregnancy 
Receiving Panorama prenatal screening test for 
both microdeletions (at least 22q11.2) and 
aneuploidy 
Planned hospital delivery 
Primary outcomes: test 
performance, including PPV, Sp 
and S 
Secondary outcomes: combined 
microdeletion syndrome 
screening test performance, 
failure ('no call') rate for the 
NATUS method for 22q11.2 
detection, as well as for 
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Study type 
Observational cohort study  
 
 
 
Comparator 
NA 
 
Gestational age of ≥ 9 weeks, 0 days based on 
clinical information and evaluation. 
Able to provide informed consent 
Exclusion Criteria 
Received results of the Panorama test prior to 
enrollment 
Organ transplant recipient 
Egg donor used 
aneuploidy, low fetal fraction 
aneuploidy risk refinement, 
placental mosaicism exploration 
and placental complications 
exploration 
Development of a 
Non-invasive Prenatal 
Test 
 
NCT01451684  
Estimated completion date  
December 2017 
 
Study status 
Ongoing recruitment 
 
Study type 
Observational cohort study  
Number of patients 
10000 
 
Intervention 
 
Comparator 
NA 
Inclusion Criteria 
Subject has singleton pregnancy confirmed via 
evaluation by a healthcare provider 
Subject is able to provide informed consent 
Subject is ≥ 18 years of age 
Exclusion Criteria 
Subject is pregnant with more than one foetus 
Subject is unwilling to undergo a blood draw 
Primary Outcome: 
Absence of chromosomal 
anomaly 
Development of a 
Prenatal Test for Fetal 
Aneuploidy Detection 
  
NCT01451671 
Estimated completion date  
November 2017 
 
Study status 
Ongoing recruitment 
 
Study type 
Observational cohort study  
Number of patients 
1500 
Intervention 
Non-invasive prenatal test 
 
Comparator 
NA 
 
Inclusion Criteria 
Subject has singleton pregnancy 
Subject is confirmed via invasive testing to be 
carrying a foetus with a chromosomal anomaly 
Subject is able to provide informed consent 
Subject is ≥ 18 years of age 
Exclusion Criteria 
Subject is pregnant with more than one foetus 
Primary Outcome: Identification 
of aneuploidy 
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Subject (mother) has a known aneuploidy 
Development of Non-
invasive Prenatal Test 
for Microdeletion and 
Other Genetic 
Syndromes Based on 
Cell Free DNA 
(Microdel Triad)  
 
NCT02109770  
Estimated completion date  
December 2018 
 
Study status 
Ongoing recruitment 
 
Study type 
Observational cohort study  
Number of patients 
200 
Intervention 
Non-invasive prenatal test 
 
Comparator 
NA 
 
Inclusion Criteria 
Couples who have a child diagnosed with an 
autosomal chromosome anomaly (e.g. DS, ES, 
Patau syndrome). 
Couples who have a child diagnosed with a sex 
chromosome anomaly (e.g. Turner syndrome, 
Klinefelter syndrome, Triple X syndrome, 47, 
XYY). 
Couples who have a child diagnosed with a 
microdeletion/duplication syndrome (a positive 
microarray test). 
Exclusion criteria 
Not an English language or Spanish language 
speaker 
Genetics report is not available 
S and Sp of the test to diagnose 
chromosomal microdeletions and 
aneuploidy in a foetus  
Development of Non-
invasive Prenatal 
Screening Test for 
Microdeletions Based 
on Fetal DNA Isolated 
From Maternal Blood 
 
NCT01852708  
Estimated completion date  
November 2018 
 
Study status 
Ongoing recruitment 
 
Study type 
Observational cohort study  
Number of patients 
100 
Intervention 
Non-invasive prenatal test 
 
Comparator 
NA 
 
Inclusion Criteria 
Age 18 or older at enrollment 
Singleton pregnancy 
Foetus with confirmed diagnosis of 
chromosomal anomaly or genetic disorder 
through karyotype, FISH or positive microarray 
results after amniocentesis or CVS 
The biological father of the foetus at least 18 
years of age 
Able to provide informed consent 
Exclusion Criteria 
Women carrying multiples 
S and Sp of the test to diagnose 
microdeletions (eg. 22q and 5p-) 
and aneuploidy in a foetus at 
chromosomes 13, 18, 21, X and 
Y  
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Pregnancy is a result of IVF with pre-
implantation genetic diagnosis 
Surrogate/egg or sperm donor used 
Previous participation in this study during a 
previous pregnancy 
Specimen Collection 
From Pregnant 
Women at Increased 
Risk for Fetal 
Aneuploidy 
 
NCT01429389  
Estimated completion date  
March 2017 
 
Study status 
Ongoing recruitment 
 
Study type 
Observational cohort study  
 
Number of patients 
2000 
 
Intervention 
Non-invasive prenatal test 
 
Comparator 
NA 
 
Inclusion Criteria 
pregnant between 10 and 22 weeks gestation 
18 years of age or older 
provides signed and dated informed consent 
subject is at increased risk for fetal aneuploidy 
subject is willing to undergo a CVS and/or 
amniocentesis procedure for the purpose of 
genetic analysis 
subject agrees to provide the genetic results of 
the invasive procedure 
Exclusion Criteria 
Fetal demise at time of specimen sampling 
Previous sample donation under this protocol 
Not reported 
A Safer Pre-Natal 
Diagnosis Using Free 
DNA in Maternal 
Blood 
 
NCT01472523  
Estimated completion date  
July 2019 
 
Study status 
Ongoing recruitment 
 
Study type 
Number of patients 
600 
 
Intervention 
IONA test 
 
Comparator 
Inclusion Criteria 
Patient/subject is willing and able to give 
informed consent for participation in the study. 
Female, aged 16 years or above. 
Currently pregnant at time of entry to the study. 
Pregnancy having been identified as 'high-risk' 
by screening test. 
Exclusion Criteria 
Primary Outcome: 
Validation of method of novel 
analysis for Aneuploidy 
Secondary Outcome: 
Optimization of existing methods 
for maximising cfDNA  
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Observational cohort study  
 
NA 
 
The patient/subject may not enter the study if 
any of the following apply: 
The participant herself has DS or other 
chromosomal anomaly. 
Children under 16 
Adults with learning disabilities, who are 
unconscious or very severely ill, have a 
terminal illness, in emergency situations, 
suffering from a mental illness or with dementia 
Prisoners 
Young offenders 
Adults who are unable to consent for 
themselves 
Any person considered to have a particularly 
dependent relationship with investigators 
Patients to be followed up for 1 
year. 
A Prospective Clinical 
Study to Evaluate a 
Novel Non-invasive 
Prenatal Screening 
Method for 
Characterizing Fetal 
Whole Chromosome 
Aberrations and Other 
Major Defects and 
Deletions Found in 
the Maternal Blood 
 
NCT02317965 
Estimated completion date  
January 2018 
 
Study status 
Ongoing recruitment 
 
Study type 
Observational cohort study 
 
Number of patients 
340 
 
Intervention 
Prenatal aneuploidy laboratory 
developed test (LDT) 
 
Comparator 
NA 
 
Inclusion Criteria 
Subject is a pregnant woman 18-54 years of 
age at 8-22 weeks' gestation inclusive; 
Subject has additional risk indicators for fetal 
chromosome aneuploidy, including one or more 
of the following: 
Maternal age > 34 years at the estimated date 
of delivery; 
Positive serum screening test suggesting fetal 
aneuploidy; 
Previous positive noninvasive cfDNA test is 
acceptable 
S, Sp, PPV and NPV of the 
laboratory developed test 
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Fetal ultrasound anomaly suggesting fetal 
chromosomal anomaly; 
Personal or family history DS or other 
chromosomal aneuploidy. 
Willing to provide written informed consent 
Willing to be re-contacted subsequently for 
additional information and/or testing if 
necessary. 
Exclusion Criteria 
Subjects will not be entered into this study if 
they meet the following criteria: 
Fetal demise at the time of the blood draw; 
Previous specimen donation under this 
protocol; 
Unwilling or lacks the capacity to provide 
informed consent or to comply with study 
procedures; 
Currently under treatment for cancer 
Any history of autoimmune disease 
Any pelvic mass 
Previous history of radiation to pelvis 
Any history or current evidence of a twin 
demise at any gestational age. 
Expanded 
Noninvasive Genomic 
Medical Assessment: 
The Enigma Study 
 
Estimated completion date  
June 2018 
 
Study status 
Number of patients 
2500 
 
Intervention 
Inclusion Criteria 
Subject is willing to provide informed consent 
and comply with study procedures 
Primary Outcome: 
Point estimates and 95% CIs for 
S, Sp, PPV, and NPV versus birth 
outcome (trisomy or 
Unaffected/non-trisomy) for the 
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
NCT02787486  Ongoing recruitment 
 
Study type 
Observational cohort study 
 
Noninvasive laboratory-
developed tests (LDTs)  
Two arms: 
-Aneuploidy arm 
-TORCH arm (infectious 
disease arm) 
 
Comparator 
NA 
 
 
Pregnant female, 18 to 54 years of age carrying 
a singleton foetus of 8 to 22 weeks gestational 
age 
Willing to provide a study blood sample in 
accordance with the protocol 
Willing to allow access to her medical records 
to collect pregnancy outcome information 
Willing to provide consent for release of fetal 
karyotype if an invasive procedure (CVS or 
amniocentesis) is performed during the 
pregnancy 
Subject is known to be at risk for one or more of 
the following: 
fetal gene and chromosome anomalies (e.g., 
T21, T18, T13, microdeletion syndromes, sex 
chromosome anomalies) 
congenital fetal infection (e.g. toxoplasmosis, 
syphilis, HIV, rubella, CMV, HSV) 
irregular blood group antigens (subject or father 
of the baby) 
other condition amenable to noninvasive 
prenatal testing such as a single gene disorder 
(e.g., CF, sickle cell, Fragile X) 
Exclusion Criteria 
No fetal heart activity detected 
Mother or father have known chromosomal 
anomalies (including known balanced 
translocations) 
Women with active or history of malignancy 
LDT in the population of 
pregnancies at mixed-risk for 
chromosomal anomalies  
 
Secondary Outcome: 
To estimate FP rate of the LDT 
versus birth outcome (trisomy or 
Unaffected/non-trisomy) in a low-
risk sub-population of pregnant 
women undergoing serum 
biochemical screening for fetal 
aneuploidy 
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Prenatal Non-invasive 
Aneuploidy Test 
Utilizing SNPs Trial 
(PreNATUS) 
 
NCT01545674  
Estimated completion date  
December 2017 
 
Study status 
Recruitment completed 
 
Study type 
Observational cohort study 
 
 
Number of patients 
1000 
 
Intervention 
Non-invasive prenatal test 
based on SNPs 
 
Comparator 
NA 
 
 
Inclusion Criteria 
Singleton pregnancy 
Gestational age between 8 weeks 0 days and 
23 weeks, 6 days by best obstetrical estimate 
Mother has a high or moderate risk for trisomy 
Mother is planning to have or has had an 
amniocentesis or CVS procedure 
Exclusion Criteria 
Unavailability of the father to provide a genetic 
sample (e.g. sperm donor, non-paternity) 
Egg donor used 
Mother or father have known chromosomal 
anomalies (including known balanced 
translocations) 
Participation in the study in a previous 
pregnancy 
Pregnancy is a result of IVF with pre-
implantation genetic diagnosis 
Primary Outcome: 
S and Sp of the test to diagnose 
aneuploidy in a foetus at 
chromosomes 13, 18, 21, X and 
Y 
Study of the Efficacy 
of New Non-invasive 
Prenatal Tests for 
Screening for Fetal 
Trisomies Using 
Maternal Blood 
(PEGASUS) 
NCT01925742  
Estimated completion date  
December 2017 
 
Study status 
Recruitment completed 
 
Study type 
Number of patients 
3819 
 
Intervention 
Different screening modalities: 
Integrated prenatal screening 
for Down's syndrome 
Serum QUAD Assay for 
aneuploidy screening 
Inclusion Criteria (High risk arm) 
Women 19 years or older between 10 weeks 
and 23 weeks 6 days gestation undergoing 
amniocentesis or CVS for positive prenatal 
screen; abnormal ultrasound; previous 
pregnancy with trisomy; patient or partner 
carrier of Robertsonian translocation involving 
chr 21; positive NIPT result; maternal age 40 or 
more 
Inclusion Criteria (Low risk arm) 
Primary Outcome: 
Number of cases with Fetal 
trisomy 21, 18 or 13  
Secondary Outcome: 
Number of women with assay 
failure  
 
Other Outcome: 
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Study title and 
identifier 
Estimated completion date  
Study status 
Study type 
Number of patients 
Intervention 
Comparator 
Patient population Endpoints 
Open label non-randomized 
trial 
 
 
 
Semiconductor MPSS NIPT 
assay using cfDNA in maternal 
blood 
Optical-based MPSS NIPT 
assay using cfDNA in maternal 
blood 
Harmony™ Test (Ariosa 
Diagnostics) 
 
Two arms: low and high risk of 
aneuploidies 
 
Comparator 
NA 
Women 19 years and older who are 10 and 13 
weeks 6 days gestation based on dating 
ultrasound (CRL) and are undergoing screening 
for DS (FCT, SIPS or IPS) 
Exclusion Criteria 
Women with multiple gestations; women with 
twin demise (spontaneous or elective) at any 
gestational age; women with active or history of 
malignancy 
Overall costs of screening 
algorithm  
Abbreviations: NA – not available 
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Systematic review/meta-analysis and HTA reports  
 
Table A7: Overview of systematics reviews/meta-analysis and HTA reports  
Author(s) 
Year of publication 
Type of study 
Country 
Methodological issues 
Aim, study criteria selection,  
Description of included studies 
Outcomes assessed 
Summary of conclusion and/or recommendations 
related to NIPT 
Iwarson et al [170] 
2017 
Systematic review/meta-analysis 
Sweden 
To review the performance of NIPT for 
detection of trisomy 21, 18 and 13 in a 
general pregnant population as well as 
to update the data on high-risk 
pregnancies. 
Mainly, it was included primary studies 
in English or Scandinavian languages in 
singlenton pregnancies published in 
1998-2015 and reached moderate or 
high quality using QUADAS tool. 
Finally, it was included 32 studies, 
i.e. 23 prospective cohort studies 
and 9 case-control studies. Among 
these, five investigated a general 
preganant population, two included 
both high-risk and average-risk 
population and the remaining 25 
studies analysed a high-risk 
pregnant population 
Outcome measures were S, Sp, 
number of TP, FP, TN and FN 
For general pregnant population 
With a moderate level of evidence, 21 trisomy pooled 
S=0.993[95% CI 0.955-0.999] and Sp=0.999[95% CI 
0.998-0.999]. Pooled S and Sp for trisomy 18 and 13 was 
not calculated due to insufficient number of studies. 
For high-risk pregnant population 
With a moderate level of evidence, 21 and 18 trisomy 
pooled S=0.988[95% CI 0.981-0.999] and 0.977[95% CI 
0.958-0.987] respectively. For T13 with a low level of 
evidence, S=0.975[95% CI 0.819-0.997]. The pooled Sp 
for all trisomies was 0.999[95% CI 0.998-0.999] 
Authors concluded that NIPT perform well as a screen for 
trisomy 21 in a general population. Moreover due to false 
positive rate of NIPT, positive results should be confirmed 
by invasive testing. 
Mackie et al [171] 
2017 
Systematic review/meta-analysis 
UK 
Determine accuracy of cfDNA-based 
NIPT for main trisomies i.e. 21, 18 and 
13 and other conditions (fetal sex, 
monosomy, rhesus D/C/E, 47XXX, 
47XXY, 47XYY, trisomy 16, congenital 
adrenal hyperplasia, deletion-duplication 
syndromes, sickle cell anaemia, 
thalassaemia, human platelet antigen 1a 
and KEL1). Evaluate influence of other 
factors on test performance 
The authors only considered prospective 
studies in women with a singleton 
A total of 117 cohort studies were 
included that analysed 18 
conditions. 
Summary measures including S, 
Sp, DOR, LR+, LR- were 
calculated when there were more 
than five studies per condition 
(fetal sex, rhesus D, trisomy 21, 
trisomy 18, monosomy X and 
trisomy 13) 
For conditions meta-analysed, S and Sp reached 90-
100%. The included studies reported an inconclusive 
result rate of 0.32-5.30%. For fetal sex and rhesus D, NIPT 
can be considered diagnostic. However, for trisomy 21, 18 
and 13 due to its lower S, Sp and disease prevalence 
combined with the biological influence of confined 
placental mosaicism designates it a screening test. The 
authors concluded that this work demonstrates that there 
is a sufficient body of evidence for the accuracy and 
reproducibility of cfDNA-based NIPT to allow. its 
introduction into routine clinical practice within the UK 
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 268 
Author(s) 
Year of publication 
Type of study 
Country 
Methodological issues 
Aim, study criteria selection,  
Description of included studies 
Outcomes assessed 
Summary of conclusion and/or recommendations 
related to NIPT 
pregnancy and different level of 
aneuploidies risk; and therefore 
excluded pre-implantation testing, fetal 
cel testing, case-control studies and 
case series with fewer than five 
participants  
Taylor-Phillips et al [172] 
2016 
Systematic review/meta-anlysis  
UK 
To measure test accuracy of NIPT for 
Ds, ES and Patau syndromes using 
cfDNA and identify factors affecting 
accuracy. 
In this review, it was included english 
language journal articles describing 
case-control studies with ≥15 trisomy 
cases or cohort studies with ≥50 
pregnant women who had been given 
NIPT and a reference standard. 
According to study selection 
criteria, the authors selected 41 
studies for the meta-analysis 
 
Outcome measures were S, Sp, 
number of TP, FP, TN, FN, PPV 
and probability of FP 
Pooled sensitivity was 97-99% and specificity was 99% for 
three trisomies. Sensitivity was lower in twin than singleton 
pregnancies. 
The authors concluded that NIPT test has high sensitivity 
and specificity for T21 and slightly lower S for T18 and 
T13. Moreover, pooled sensitivity was lower in the first 
trimester of pregnancy evaluated in general obstetric 
population or cohort studies with consecutive enrolment. 
Due to NIPT accuracy is not 100%, it should not be used 
as a final diagnosis for positive cases and therefore an 
invasive diagnostic test would be recommended on these 
cases. 
Finally, the authors pointed out that test performance in 
clinical practice could differ from those results showed in 
the published evidence due to high risk of bias of studies 
of cfDNA and unexplained heterogenity 
García-Pérez et al [173] 
2016 
HTA report 
Spain 
To review the validity and cost-
effectiveness of NIPT for the detection of 
trisomy 21, 18 and 13 
To assess the cost-effectiveness of 
screening strategy that includes NIPT for 
the detection of trisomy 21, 18 and 13 
from the National Heath System (NHS) 
perpective in Spain 
To report aspects related to ethical, 
organizational, legal and other domains 
Finally it was retrieved 49 articles 
about diagnostic accuracy of NIPT 
and 12 full economic evaluations 
 
Outcome measures were S, Sp, 
PPV, NPV, cost of each alternative 
and ICER 
According to meta-analysis performed, S and Sp of NIPT 
was over 95% for all trisomies. The systematic review of 
economic evaluations found contradictory results. 
In the economic evaluation, the authors calculated a 
estimated ICER of €234.596 per correctly diagnosed case. 
The prenatal screening with contingent NIPT has the 
advantage of a reduced number of invasive test related 
fetal losses. 
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related to NIPT 
with the aim of the informing the 
decision making 
For NIPT validity assessment it was 
included case-control studies with more 
than 15 cases and cohort studies with 
more than 500 cases all of these 
published in Spanish or English. In the 
systematic review of cost-effectiveness 
were considered full economic 
evaluations that compared a screening 
strategy that included NIPT to detect 
T21, T18 and T13 in the foetus with a 
screening strategy not including NIPT or 
the alternative “no screening” 
In the economic analysis were 
compared detection rate of trisomy 21, 
18 and 13 and cost of two screening 
strategies: first or second-trimester 
screening versus contingent NIPT 
strategy 
Juvet et al [174] 
2016 
HTA report 
Norway 
To analyze the diagnostic test accuracy 
of NIPT and health economic 
implications and highlight ethical 
consequences related to the national 
introduction of NIPT for detection of 
trisomy (21, 18 and 13) in pregnant 
women 
In this HTA report searched systematic 
reviews published 2010 to 2015. For 
health economic analysis it was 
considered three scenarios involving 
NIPT as both primary or secondary test 
Finally, it was included two 
systematic reviews, one from 
Sweden and one from UK.  
For test accuracy analysis were 
investigated outcomes as 
diagnostic test accuracy, predictive 
values, likehood ratios and 
inconclusive results. 
For health economic analysis 
number of correctly identified 
cases of trisomy 21, 18 and 13, 
number of undetected cases (FN), 
number of invasive test performed, 
total programme costs, costs per 
Acccording to two systematic reviews identified, S and Sp 
of NIPT for trisomy is near to 100% and therefore it was 
not recommended as a replacement for an invasive 
diagnostic test.  
The reports authors concluded that NIPT is a more 
accurate test for detecting trisomy than combination of 
blood test and ultrasound (CUB). Moreover, the number of 
invasive test is considerably reduced in all alternative 
health economic scenarios involving NIPT compared with 
CUB screening practice 
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related to NIPT 
diagnosis and incremental costs 
per additional case of trisomy 
detected compared with current 
screening practice 
Taylor-Phillip et al [175] 
2015 
HTA report 
UK 
See above 
Moreover systematic review and meta-
analysis, the authors made an economic 
model to compare three options for 
implementation of NIPT in the NHS:  
-current NHS screening programme 
using combined test and invasive testing 
offered to women with risk greater than 
1/150  
-combined test and cfDNA offered to 
women with risk greater than 1/150 and 
if they tested positive offered an invasive 
test use cfDNA test as first-line instead 
of the combined test  
See above See above 
By economic analysis, the authors reported that the 
second option resulted in similar numbers of trisomies 
detected, 43 fewer miscarriages of healthy pregnancies 
and may cost approximately the same as currently. The 
third option would cost an extra £105 million to the NHS 
and result in more invasive tests than the second option 
 
Yang et al [176] 
2015 
Systematic review 
China 
To evaluate the system accuracy of 
noninvasive prenatal diagnosis for 
abnormal chromosome genetic diseases 
using cfDNA in maternal plasma 
In this review, it were included studies 
published in English or Chinese which 
determine the accuracy of noninvasive 
prenatal diagnosis and/or compare it to 
traditional standards, i.e. karyotyping or 
FISH. 
In this review were included four 
studies that analysed accuracy test 
for T21 and T18 
Outcomes measures were S and 
Sp 
S for T21 was 100% and 97.4% for T18. Sp was similar for 
both trisomies (99%). Therefore, the authors concluded 
that noninvasive prenatal diagnosis can be used to identify 
abnormal chromosomes with high accuracy using free fetal 
DNA in the maternal plasma. The method used to 
diagnose T21 has become more advanced, while the 
application for T18 diagnosis requires additional research 
Hulstaert et al [157] 
2014 
HTA report 
To evaluate the economic impact of 
introducing NIPT in the prenatal testing 
process for DS whereby a systematic 
By systematic review, it was 
identified 7 full economic 
evaluations on the cost-
effectiveness of NIPT. 
According to modelling exercise, average cost for 
detection of a case of trisomy 21 was about €87 000. 
The authors concluded that use NIPT after a positive 
current screening was cost saving but limiting its use to the 
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Summary of conclusion and/or recommendations 
related to NIPT 
Belgium review and modelling exercise for the 
introduction of NIPT in Belgium. 
For systematic review, it were included 
full economic evaluations that compared 
at least two alternative treatments in 
terms of costs and outcomes for 
diagnosis of DS in singleton pregnant 
women. 
For economic evaluation, it was 
modelled two scenarios: NIPT as 
primary screening test and NIPT as 
second line test for triage after the 
current test. 
It was reported different economic 
outcomes as ICER, cost of 
screening, cost of DS, average 
cost for detection of a case of 
trisomy 21, etc. 
 
5% screen positives (risk cut-off 1:300). Moreover, a 
possible introduction of NIPT into the health insurance 
should be accompanied by an obligatory registration of the 
NIPT result and the final diagnosis after invasive testing 
and the pregnancy outcomes. 
Gil et al [177] 
2015 
Systematic review/meta-analysis 
UK 
To review clinical validation or 
implementation studies of maternal 
blood cfDNA analysis in screening for 
aneuploidies (trisomy 21/18/13, 
monosomy X and SCAs other than 
monosomy X) and to explore the 
potential use of this method in clinical 
practice. 
The inclusion criteria were studies 
reporting on clinical validation or 
implementation of maternal cfDNA 
testing in screening for aneuploidies, in 
which the laboratory scientists carrying 
out the test were not aware of the fetal 
karyotype or pregnancy outcomes. 
A total of 33 studies were included 
in the review. Among these, 28 
studies were used for meta-
analysis of test performance (only 
two in general population) and the 
remaining five were assessed in 
order to evaluate clinical 
implementation of NIPT in 
aneuploidies screening.  
Outcome measures were detection 
rate (DR) FP rate for each trisomy 
and SCA.  
For singleton pregnancies group, DR was over 90% for all 
trisomies, except for monosomy X that only reached 
88.6%. And for twin pregnancies, the DR was 94.4% for 
T21. The overall FP rate for three trisomies was 0.4%, 
although for T21 showed the lowest FP rate (0.08%) in 
comparison to trimosy 18 and 13 (0.15-0.20%) 
The authors concluded that cfDNA in maternal plasma 
blood provides effective screening for trisomies. 
Moreover in this review were proposed two options for the 
clinical implementation of cfDNA, i.e. as routine screening 
of th whole population (first-line method) or as contingent 
screening based on results of first-line screening by 
another method (first or second-trimester serum test). This 
last option retains the major advantages of cfDNA testing 
in increasing DR and decreasing FP rate, but at 
considerably lower cost than offering the test to the whole 
population 
Baños et al [178] 
2012 
To evaluate test accuracy of NIPT test 
based on cfDNA for diagnosis of 
aneuploidies. 
By bibliographic search, it were 
identified 3 primary studies, i.e. two 
DTA studies and one case-control 
The main conclusion of report were: 
-S was 79-100% and Sp 97.9-99.7% 
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related to NIPT 
HTA report 
Spain 
In this review were considered studies 
which reported NIPT test accuracy in 
comparison with invasive diagnostic test 
(amniocentesis or CVS). Only it were 
excluded letters to director, editorials or 
narrative reviews. 
study that reported pregnant 
women at high risk of trisomy 21.  
Outcome measures were S, Sp, 
PPV and NPV. 
-In pregnancies at high-risk, NIPT could avoid invasive 
diagnostic testing reducing the discomfort and the anxiety 
they generate and the possible birth complications caused 
by instrumentation and even the rsik of fetal loss 
Abbreviations: S-sensitivity, Sp-Specificity, TP-true positive, FP-false positive, TN-true negative, FN-false negative, LR+ positive likehood ratio, LR- negative likehood ratio, DOR-diagnostic odds ratio, 
DR-detection rate, FPR-false positive rate, PPV-positive predictive value, NPV-negative predictive value, CVS-chorionic villus sampling 
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Risk of bias tables 
 
Table A8: Risk of bias – study level (DTA study or cross-sectional study) 
NIPT in replacement of combined test: General pregnant population 
Author/year: Sarno et al. [39], 2016 Judgment Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial  
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Insufficient information to establish if 
the study includes unselected 
population 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT was carried out prior to 
invasive testing 
If a threshold was used, was it pre-specified? YES Cut-off point reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from the 
review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH According to following signalling 
questions, reference standard 
condunct could have introduced bias  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Fetal karyotype method was not 
reported 
Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Interpretation or conduction of 
reference standard matched the 
review question 
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH According to following signalling 
questions, there is high probability of 
bias 
Was there an appropriate interval between 
index test(s) and reference standard? 
YES Interval between index test and 
reference standard was appropriate 
Did all patients receive a reference standard? NO  
Did patients receive the same reference 
standard? 
UNCLEAR Reference standard method was not 
reported 
Were all patients included in the analysis? NO 168/10698 cases were excluded 
from the analysis 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Author/year: Norton et al. [31], 2015 Judgment Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
LOW  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial  
Did the study avoid inappropriate exclusion? YES Exclusion aligned with indications 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
LOW Unselected pregnant population 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the re sults of the reference 
standard? 
YES The analyses and interpretation of 
cfDNA data were performed in a 
blinded fashion  
If a threshold was used, was it pre-specified? YES 1/100 or higher was classified as 
high risk 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from the 
review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Newborn outcomes determined by 
medical record review of the physical 
examination at birth and any genetic 
testing 
Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW The target condition defined by the 
reference standard did match the 
review question 
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Miscarriage and termination results 
not always confirmed 
Did patients receive the same reference 
standard? 
NO Positive NIPT cases were confirmed 
by invasive testing and negative 
cases by neonatal examination 
Were all patients included in the analysis? NO Exclusion of 16% of cases (women 
without standard screening, 
reference standard results, NIPT 
failures and missed cases, including 
miscarriages and stillbirths without 
verification results 
OVERALL JUDGMENT At risk of bias 
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Author/year: Pérez-Pedregosa et al. [41], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Insufficient information to establish if 
the study includes a general 
unselected obstetric populatio 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
UNCLEAR  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
UNCLEAR It was not reported if result 
interpretation was performed in a 
blinded fashion 
If a threshold was used, was it pre-specified? YES Cut-off point for NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from the 
review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Follow up carried out by clinical 
examination or telephone contact  
Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW The target condition defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES It was reported that 100% cases 
received a reference standard 
Did patients receive the same reference 
standard? 
NO CVS or amniocentesis for positive 
NIPT or standard screening cases 
and telephome contact for rest of 
cases 
Were all patients included in the analysis? NO There were three cases excluded 
due to test failure  
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Author/year: Quezada et al. [42], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Lack of information regarding 
inclusion/exclusion criteria 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Insufficient information to establish if 
the study includes general 
unselected obstetric population 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT performed prior to invasive 
testing 
If a threshold was used, was it pre-specified? YES Cut-off point reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from the 
review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Insufficient information regarding 
verification of negative cases 
(information obtained from 
obstetrician, general practitioner or 
patient) 
Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
UNCLEAR Target condition as defined by the 
reference standard does not differ 
from the review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT performed prior to invasive 
testing 
Did all patients receive a reference standard? NO No fetal karyotyping in miscarriages 
or stillbirths 
Did patients receive the same reference 
standard? 
NO Karyotyping was used only in 
positive cases 
Were all patients included in the analysis? NO Women without reference standard 
results, miscarriages and stillbirths 
were excluded from the analysis 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Zhang et al. [43], 2015 Judgment Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Unclear inclusion/exclusion criteria 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH Study included participants offered 
primary or secondary screening 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES Cell free DNA analysis was blinded 
to sample karyotype 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT was not 
reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from the 
review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Telephone interviews were 
performed to obtain information on 
clinical outcomes 
Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
HIGH Important uncertainty regarding the 
classification of the target population 
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT was prior to reference standard 
Did all patients receive a reference standard? NO Outcome data was only available for 
77% of the population 
Did patients receive the same reference 
standard? 
NO Information was obtained by 
neonatal outcome, physical 
examination or cytogenetic testing 
Were all patients included in the analysis? NO Inappropriate samples, test failures 
and samples with no results on 
clinical outcomes (elective 
terinations and pregnancies) were 
excluded from the analyiss  
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Comas et al. [40], 2015 Judgment  Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO The study excluded cases of 
ultrasound anomalies and those at 
high risk of other genetic conditions 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH Study did not include general 
unselected population  
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or interpretation 
of the index test have introduced bias? 
UNCLEAR  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT was performed before invasive 
testing 
If a threshold was used, was it pre-specified? NO Test cut off values were not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from the 
review question 
LOW NIPT conduct and interpretation is in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Insufficient information regarding on 
neonatal examination of negative 
cases 
Were the reference standard results interpreted 
without knowledge of the results of the index 
test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard did match the 
review question 
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT performed prior invasive 
testing 
Did all patients receive a reference standard? NO All patients included present 
complete follow up but information is 
lacking regarding miscarriages and 
stillbirths 
Did patients receive the same reference 
standard? 
NO Positive NIPT cases were confirmed 
by invasive testing and negative 
cases by neonatal examination 
Were all patients included in the analysis? NO Information regarding test failures, 
lost cases, miscarriages and 
stillbirths is missing 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Author/year: Bianchi et al. [30], 2014 Judgment  Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Lack of information regarding 
population enrollment 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Exclusion of women without 
accessibility to pregnancy and delivery 
records 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Unclear if the study includes a general 
unselected obstetric population 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have 
introduced bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
LOW Authors report that all personnel were 
unaware of clinical data and outcomes  
If a threshold was used, was it pre-specified? YES Cut-off point reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, 
its conduct, or its interpretation have 
introduced bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Outcome determined on the basis of 
the newborn physical examination in 
97% of cases  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Cytogeneticists were unaware of the 
results of cfDNA testing  
Applicability: Is there concern that the target 
condition as defined by the reference 
standard does not match the review 
question? 
LOW Target condition as defined by 
reference standard did match the 
review question  
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES Invasive testing performed after NIPT 
or at least 2 weeks before plasma 
sampling 
Did all patients receive a reference standard? NO Patients without clinical outcomes or 
karyotyping results excluded 
Did patients receive the same reference 
standard? 
NO Both karyotyping or neonatal 
examination was used as reference 
standard  
Were all patients included in the analysis? NO 128 patients were excluded of analysis 
OVERALL JUDGMENT At risk of bias  
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Author/year: Pergament et al. [44], 2014 Judgment Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
HIGH  
Was a consecutive or random sample of 
patients enrolled? 
NO Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Lack of information regarding 
inclusion/exclusion criteria 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
YES Study did not include general non 
unselected population 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES Algorithm blinded to sample 
karyotype 
If a threshold was used, was it pre-specified? YES Cut off-point reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing was used for 
confirmation in all cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported but considered 
irelevant as invasive testing is an 
objective test) 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW No concern regarding the target 
condition 
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
UNCLEAR  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard in 
majority of cases; in few cases at 
least 4 days after invasive 
procedure 
Did all patients receive a reference standard? YES All verified by standard invasive 
testing 
Did patients receive the same reference 
standard? 
YES All verified by standard invasive 
testing 
Were all patients included in the analysis? NO Exclusion of patients with sex 
chromosome anomalies, confirmed 
triploidy, fetal mosaicism  
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Song et al. [45], 2013 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH Only women < 35 yrs 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES Results analysis was performed in a 
blinded fashion. 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT was provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding the 
follow up of birth outcomes 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Results analysis was performed in a 
blinded fashion.  
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW The target condition defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Cases excluded did not receive 
reference standard 
Did patients receive the same reference 
standard? 
NO Pregnant women received 
karyotyping (amniocentesis or CVS) 
or neonatal follow-up 
Were all patients included in the analysis? NO 175 cases were excluded from the 
analysis 
OVERALL JUDGMENT At risk of bias  
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NIPT in add-on to combined test: High-risk pregnant population 
Persico et al. [49], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
HIGH  
Was a consecutive or random sample of 
patients enrolled? 
YES Consecutive enrolment of pregnant 
women 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Inclusion of women undergoing 
invasive testing 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not only defined by a FCT 
threshold) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT was provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered 
adequate for classifying target 
condition  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES 
 
NIPT prior to reference standard 
Did all patients receive a reference standard? YES All pregnant women had results 
confirmed 
Did patients receive the same reference 
standard? 
YES Pregnant women received 
amniocentesis or CVS as refere 
rence standard 
Were all patients included in the analysis? NO Lack of information regarding 
miscarriages, still births 
OVERALL JUDGMENT Unclear risk of 
bias 
Concern 
regarding 
applicability 
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Author/year: Oepkes et al. [48], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
LOW  
Was a consecutive or random sample of 
patients enrolled? 
YES All pregnant women who chose 
NIPT involved 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? YES Exclusion criteria aligned with 
indications 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
LOW Inclusion aligned with review 
question (high risk women based on 
FCT or medical history), though risk 
threshold was not defined 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES This information was reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Follow up of consisted in a return 
form filled out by the women after 
pregnancy/birth 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES Complete follow up in 99% 
pregnancies 
Did patients receive the same reference 
standard? 
NO 53 samples confirmed by invasive 
testing and 1376 confirmed by 
neonatal follow-up 
Were all patients included in the analysis? YES No cases were excluded from the 
analysis 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 285 
Author/year: Zhang et al. [50], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? YES Exclusion criteria aligned with 
indications 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is not 
defined by FCT) 
Pregnant women received NIPT test 
from the first to third trimester 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES This information was provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding the 
neonatal examination 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All results confirmed by karyotyping, 
follow up examination by 
neonatologists or blood karyotyping  
Did patients receive the same reference 
standard? 
NO  Pregnant women received 
amniocentesis (24.1%), neonatal 
blood karyotyping (42.3%) or follow-
up examination of newborn. 
Were all patients included in the analysis? UNCLEAR Lack of information regarding the 
exclusion of patients 
OVERALL JUDGMENT At risk of bias 
Unclear concern 
regarding 
applicability 
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Author/year: Ma et al. [47], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not clearly 
reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by FCT) 
NIPT test was provided to 19 weeks 
of gestation  
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
UNCLEAR  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
UNCLEAR Sequencing analysis was performed 
in a blinded fashion 
If a threshold was used, was it pre-specified? YES Cut-off point reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding 
postnatal follow up  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? UNCLEAR Unclear information 
Did patients receive the same reference 
standard? 
NO Pregnant women received 
karyotype testing or postnatal 
follow-up as reference standard 
Were all patients included in the analysis? NO Exclusion of patients without 
karyotyping confirmation or follow 
up results 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Author/year: Kim et al. [46], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR No information regarding exclusion 
criteria 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Inclusion aligned with review 
question (high risk women based on 
FCT or medical history), though risk 
threshold was not defined. Around 
30% cases received NIPT test at 
second trimester of pregnancy 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT results interpretation was 
blinded to karyotyping information 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Reference standard used i.e. 
amniocentesis, CVS and newborn 
examination are considered 
adequate for classifying the target 
condition  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
LOW  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference 
standard i.e. amniocentesis 
Did patients receive the same reference 
standard? 
YES All cases received reference 
standard i.e. amniocentesis 
Were all patients included in the analysis? YES All cases were included in the 
analysis 
OVERALL JUDGMENT Unclear concern 
regarding 
applicability 
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Author/year: Wang et al. [58], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Consecutive women 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is not 
defined by FCT) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
HIGH  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO This information was not provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
UNCLEAR Unclear information regarding the 
conduct and interpretation of NIPT  
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
YES The clinical follow up (once/month) 
from birth to 6 months of negative 
cases was considered appropriate 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
LOW  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference standard 
Did patients receive the same reference 
standard? 
NO Positive cases verified by 
conventional karyotyping analysis or 
fluorescence in situ hybridization-
FISH and negative cases by neonatal 
follow-up 
Were all patients included in the analysis? YES No cases were excluded from the 
analysis 
OVERALL JUDGMENT At risk of bias  
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Author/year: Sánchez-Usabiaga et al. [56], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? YES Exclusion criteria aligned with 
indications 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding follow 
up of negative cases  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO NIPT failure cases did not receive 
reference standard 
Did patients receive the same reference 
standard? 
NO Cases received CVS, 
amniocentesis or follow up as 
reference standard 
Were all patients included in the analysis? NO Exclusion of test failures and lack of 
information on miscarriages amd 
stilL births 
OVERALL JUDGMENT At risk of bias  
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Author/year: Benachi et al. [51], 2015  Judgment  Explanation 
DOMAIN 1: PATIENT SELECTION 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold) 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT was performed in a blinded 
fashion respect to the fetal 
karyotype.  
If a threshold was used, was it pre-specified? YES NIPT cut-off point reported. 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Reference standard used i.e. 
amniocentesis or CVS are 
considered adequate for classifying 
the target condition  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question.  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Lack of information of women who 
did not undergoe invasive testing 
Did patients receive the same reference 
standard? 
YES All received invasive testing 
(amniocentesis or CVS) 
Were all patients included in the analysis? NO Only cases with a karyotype and 
cell-free DNA included in the 
analysis 
OVERALL JUDGMENT At risk of bias  
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Author/year: Ke et al. [53], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold). 
Women received NIPT test mainly 
in second trimester 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
HIGH  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
UNCLEAR NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut off point not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
UNCLEAR Unclear information regarding 
conduct and interpretation 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding follow 
up of negative cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
LOW  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference 
standard 
Did patients receive the same reference 
standard? 
NO Positive NIPT cases received 
amniocentesis and negative test 
cases received neonatal follow-up 
Were all patients included in the analysis? YES All cases were included in the 
analysis 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 292 
Author/year: Lee et al. [54], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold). 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES All clinical data and NIPT results 
were blinded to the laboratory 
investigators. 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Cordocentesis was used to confirm 
NIPT results in some cases 
(number not reported) 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES All clinical data and NIPT results 
were blinded to the laboratory 
investigators  
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All included cases received invasive 
testing 
Did patients receive the same reference 
standard? 
NO Different reference standard i.e. 
amniocentesis, CVS, cordocentesis 
or neonatal peripheral blood or 
products of conception 
Were all patients included in the analysis? NO Analysis was restricted to pregnant 
women who underwent invasive 
testing 
OVERALL JUDGMENT At risk of bias  
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 293 
Author/year: Song et al. [57], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (inclusion 
criteria:≥ 35 yrs). 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT testing was performed in a 
double-blinded manner 
If a threshold was used, was it pre-specified? YES Cut-off point provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Neonatal examination by patient´s 
pediatricians 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Karyotyping analysis was performed 
in a double-blinded manner 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Non verification of quality control 
failures, miscarriages or still births  
Did patients receive the same reference 
standard? 
NO Pregnant women received 
karyotyping testing (CVS or 
amniocentesis) in positive NIPT 
cases and were followed to birth 
and assessed clinically by 
paediatrician in negative NIPT test  
Were all patients included in the analysis? NO Exclusion of women who presented 
quality control failures, miscarriages 
or still births 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 294 
Author/year: Sago et al. [55], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold). 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
UNCLEAR NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT not provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR .  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding follow 
up of negative cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported  
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Data exists for only 1638 of the 
7740 negative cases. Most of 
miscarriages and still births did not 
receive a reference standard 
Did patients receive the same reference 
standard? 
NO Positive cases underwent invasive 
testing (chorionic villus sampling or 
amniocentesis) and negative cases 
were followed up 
Were all patients included in the analysis? NO Exclusion of test failures and 
patients without outcomes 
OVERALL JUDGMENT At risk of bias  
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 295 
Author/year: Hernández-Gómez et al. [52], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold). 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Unclear information regarding 
verification of negative cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? UNCLEAR Unclear information regarding 
verification of negative cases 
Did patients receive the same reference 
standard? 
NO Four cases received 
amnioncentesis and 37 cases 
neonatal follow-up 
Were all patients included in the analysis? YES All cases included 
OVERALL JUDGMENT At risk of bias . 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 296 
Author/year: Korostelev et al. [60], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Inclusion criteria aligned with review 
question (high risk women based on 
FCT or medical history), though risk 
threshold was not defined. Around 
30% cases received NIPT test at 
second trimester of pregnancy 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
UNCLEAR NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding follow 
up of negative cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR It was not reported if reference 
standard was performed in a 
blinded fashion 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matched the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO 423/1968 cases did not receive a 
reference standard 
Did patients receive the same reference 
standard? 
NO  Positive NIPT cases received 
karyotyping or chromosomal 
microarray analysis and negative 
NIPT cases were followed up 
Were all patients included in the analysis? NO Cases without reference standard 
result were excluded from analysis 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 297 
Author/year: Stumm et al. [62], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Consecutive enrolled women 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold). 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT test was blinded to patient 
clinical information including 
karyotyping. 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW The conduct or interpretation of 
NIPT did not refer from the review 
question 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered the 
gold standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matched the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Samples which failed quality control 
or did not undergoe invasive testing 
did not receive a reference standard 
Did patients receive the same reference 
standard? 
NO Pregnant women received 
amniocentesis (69.1), chorionic 
villus sampling (30.3) or 
cordocentesis (0.6) 
Were all patients included in the analysis? NO Patients with no outcome results 
were excluded from the analysis 
OVERALL JUDGMENT At risk of bias  
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 298 
Author/year: Jeon et al. [59], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
HIGH  
Was a consecutive or random sample of 
patients enrolled? 
YES Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Study only included pregnant 
women who were scheduled for 
invasive testing 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT 
threshold).First and second 
trimester pregnancies included. 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered the 
gold standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR It is unknown if reference standard 
results were analysed in a blinded 
fashion 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
LOW  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference 
standard 
Did patients receive the same reference 
standard? 
YES All cases received amniocentesis 
Were all patients included in the analysis? YES All cases were included in the 
analysis 
OVERALL JUDGMENT At risk of bias  
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 299 
Author/year: Porreco et al. [61], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
HIGH  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Only women who had decided to 
undergone invasive testing 
considered 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold). 
First and second trimester 
pregnancies included. 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES Blinded analysis 
If a threshold was used, was it pre-specified? YES Cut off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered the 
gold standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Blinded analysis 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All patients received invasive testing 
Did patients receive the same reference 
standard? 
YES Pregnant women received CVS 
(25%) or amniocentesis (75%) 
Were all patients included in the analysis? NO Exclusion of cases which failed 
quality control, did not undergoe 
invasive testing or were fetal 
demises (740/4170 cases excluded) 
OVERALL JUDGMENT At risk of bias  
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 300 
Zhou et al. [64], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
LOW  
Was a consecutive or random sample of 
patients enrolled? 
YES Offered to all women integrated in the 
workflow 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is not 
defined by a FCT threshold 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
HIGH  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT not provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
UNCLEAR Unclear information regarding the 
conduct and interpretation of NIPT 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding 
neonatal follow up 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Fetal karyotyping was performed 
blindly following NIPT 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Outcome data only available for 
3894/7705 pregnancies 
Did patients receive the same reference 
standard? 
NO Pregnant women received 
amniocentesis (n=54) or neonatal 
follow-up (n=3894) 
Were all patients included in the analysis? NO Only patients with outcome data 
included in the analysis 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 301 
Author/year: Willems et al. [63], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
LOW  
Was a consecutive or random sample of 
patients enrolled? 
YES Consecutive sampling 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH Only 660/994 who had FCT showed 
elevated risk 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Lack of information on follow up of 
negative cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matched the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO Terminations and miscarriages did 
not receive a reference standard 
Did patients receive the same reference 
standard? 
NO Only positive cases received 
amniocentesis or chorionic villus 
sampling  
Were all patients included in the analysis? NO Exclusion of test failures, terminations 
and miscarriages 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
 
 
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 302 
Author/year: Liang et al. [65], 2013 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold. 
Mostcases received NIPT test in the 
2º trimester of pregnancy 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT test was performed in a 
blinded fashion 
If a threshold was used, was it pre-specified? YES Cut off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered the 
gold standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Karyotyping information were 
conducted in a blinded fashion  
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
UNCLEAR  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received a reference 
standard 
Did patients receive the same reference 
standard? 
YES All women underwent invasive 
diagnosis 
Were all patients included in the analysis? NO Exclusion of samples that failed 
quality control 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Auhtor/year: Verweij et al. [67], 2013 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
YES Consecutive sampling 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Exclusion of failed samples, women 
with other trisomies, amongst others 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (women 
requesting NIPT for anxiety reasons 
also included) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES The laboratory personnel were 
blinded to the clinical information. 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW The conduct or interpretation have not 
introduced bias 
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered the gold 
standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Independent analysis 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases included received invasive 
testing 
Did patients receive the same reference 
standard? 
YES All cases received CVS (n=280) or 
amniocentesis (n=240) 
Were all patients included in the analysis? NO Exclusion of subjects with low fetal 
fraction and test failures. 
OVERALL JUDGMENT At risk of bias  
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Author/year: Nicolaides et al. [66], 2013 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
LOW Most of the included patients matched 
the review question (high risk based 
on FCT) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is consided the gold 
standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Blinded to karyotype 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received CVS 
Did patients receive the same reference 
standard? 
UNCLEAR This information was not clearly 
reported  
Were all patients included in the analysis? NO Exclusion of cases which failed 
quality controls. No information 
regarding miscarriages and still births. 
OVERALL JUDGMENT At risk of bias  
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Author/year: Norton et al. [69], 2012 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
HIGH  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Unclear elegibility criteria 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH All women planning to undergoe 
invasive testing included for any 
indication 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES Cut off point of NIPT not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing considered the gold 
standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference test 
Did all patients receive a reference standard? YES All cases received invasive testing 
Did patients receive the same reference 
standard? 
YES All received invasive testing 
(amniocentesis or CVS) 
Were all patients included in the analysis? NO Exclusion of subjects with fetal 
fraction and assay failures 
(774/4002). Lack of information on 
miiscarriages and still births 
OVERALL JUDGMENT At risk of bias  
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Author/year: Lau et al. [68], 2012 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria do not exactly 
match the review question (only 
47% were due to positive FCT) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES Blinded to karyotyping information 
If a threshold was used, was it pre-specified? YES Cut-off point NIPT was reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW Risk of bias related to reference 
standard performance was not 
considered relevant.  
Is the reference standard likely to correctly 
classify the target condition? 
YES Reference standard are considered 
adequate for classifying the target 
condition  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
LOW There is low risk of bias due to 
patient flow  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference 
standard 
Did patients receive the same reference 
standard? 
NO 94.4% cases received chorionic 
villus sampling and amniocentesis 
was used in 5.6% of cases  
Were all patients included in the analysis? YES All cases were included in the 
analysis 
OVERALL JUDGMENT Unclear risk of 
bias and concern 
regarding 
applicability 
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Author/year: Ehrich et al. [70], 2011 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
LOW  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
LOW The inclusion criteria do not exactly 
match the review question (risk is 
not defined by a FCT threshold 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES Blinded to reference standard 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Invasive testing is considered the 
gold standard 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES Independent analysis 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference 
standard 
Did patients receive the same reference 
standard? 
YES 80.9% cases received 
amniocentesis and 19% CVS 
Were all patients included in the analysis? NO Cases with sampling or quality test 
failure were excluded from analysis 
(n=31) 
OVERALL JUDGMENT Low risk of bias 
and concern 
regarding 
applicability 
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NIPT add-on to combined test: High or intermediate risk pregnant population 
Author/year: Gil et al. [71], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not reported 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? NO Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR The inclusion criteria match the 
review question, though a slightly 
higher FCT risk threshold is used 
(1:100)  
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT not reported  
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Unclear information regarding the 
follow up of negative cases 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR It was not reported if karyotyping was 
performed in a blinded fashion 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? UNCLEAR Unclear whether reference standard 
was used in all pregnant women  
Did patients receive the same reference 
standard? 
NO Invasive testing for positive NIPT 
cases and follow up for negative 
cases 
Were all patients included in the analysis? NO Exclusion of miscarriages, stillbirths 
and women lost to follow up (1.78%)  
OVERALL JUDGMENT At risk of bias  
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NIPT add-on to combined test: Twin pregnant population 
Author/year: Fosler et al. [72], 2017 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
UNCLEAR Unclear information regarding the 
enrolment of pregnant women 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW The interpretation of NIPT results 
could have introduced bias 
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? NO Cut-off point of NIPT not provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Ultrasound findings is not 
considered a reference standard for 
diagnosing prenatal aneuploidies.  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported  
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by 
ultrasound findings matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
NO Interval between index test and 
reference standard might not have 
been appropriate in all cases 
Did all patients receive a reference standard? NO Aneuploidy outcome information 
was only available for 35.7% of 
patients 
Did patients receive the same reference 
standard? 
NO Pregnant women received 
karyotyping (amniocentesis or CVS) 
or ultrasound findings 
Were all patients included in the analysis? NO Exclusion of patients without 
outcomes 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Author/year: Tan et al. [73], 2016 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
LOW  
Was a consecutive or random sample of 
patients enrolled? 
YES All women receiving NIPT included 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported  
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH 100% women included had a 
pregnant by ART (double or multiple 
pregnancies)  
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT not reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
HIGH  
Is the reference standard likely to correctly 
classify the target condition? 
NO Pregnant outcome was surveyed by 
telephone interview 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? NO No information regarding 
miscarriages or stillbirths 
Did patients receive the same reference 
standard? 
NO Pregnant women received 
amniocentesis (NIPT positive 
cases) (3.1%) or follow-up (NIPT 
negative cases) (96.9%) 
Were all patients included in the analysis? NO Exclusion of cases of miscarriages 
and stillbirths 
OVERALL JUDGMENT At risk of bias 
Concern 
regarding 
applicability 
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Author/year: Bevilacqua et al. [74], 2015 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported  
Applicability: Is there concern that the 
included patients do not match the review 
question? 
LOW The inclusion criteria match the 
review question, although FCT risk 
threshold was not specified 
DOMAIN 2: INDEX TEST(S) 
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to reference standard 
If a threshold was used, was it pre-specified? YES NIPT cut off point reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD 
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Lack of information regarding 
neonatal examination 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard does not differ 
the review question 
DOMAIN 4: FLOW AND TIMING 
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to referene standard 
Did all patients receive a reference standard? NO Lack of information regarding 
miscarriages and stillbirths 
Did patients receive the same reference 
standard? 
NO Pregnant women CVS, 
amniocentesis, neonatal blood or 
neonatal examination.  
Were all patients included in the analysis? NO 175/515 cases were excluded from 
the analysis 
OVERALL JUDGMENT At risk of bias  
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Author/year: Huang et al. [75], 2014 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
UNCLEAR  
Was a consecutive or random sample of 
patients enrolled? 
UNCLEAR Not specified 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH Patients who opted to have invasive 
testing included (abnormal 
screening, sonographic signs aswell 
as anxiety) 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES The sequencing results were kept 
confidential until final analysis.  
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT provided 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
LOW  
Is the reference standard likely to correctly 
classify the target condition? 
YES Reference standard used are 
considered adequate for classifying 
the target condition  
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
YES The karyotyping results were kept 
confidential until final analysis.  
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question  
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
LOW  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received invasive testing 
Did patients receive the same reference 
standard? 
YES All received invasive testing as 
reference standard 
Were all patients included in the analysis? YES All cases included in the analysis 
OVERALL JUDGMENT Low risk of bias or 
concern regarding 
applicability 
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Author/year: Lau et al. [76], 2013 
DOMAIN 1: PATIENT SELECTION Judgment  Explanation 
Risk of bias: Could the selection of patients 
have introduced bias? 
HIGH  
Was a consecutive or random sample of 
patients enrolled? 
NO Only some twin pregnancies 
considered 
Was a case-control design avoided? YES Prospective DTA trial 
Did the study avoid inappropriate exclusion? UNCLEAR Exclusion criteria not reported 
Applicability: Is there concern that the 
included patients do not match the review 
question? 
HIGH NIPT indications do not match the 
review question 
DOMAIN 2: INDEX TEST(S)   
Risk of bias: Could the conduct or 
interpretation of the index test have introduced 
bias? 
LOW  
Were the index test results interpreted without 
knowledge of the results of the reference 
standard? 
YES NIPT prior to FCT 
If a threshold was used, was it pre-specified? YES Cut-off point of NIPT reported 
Applicability: Is there concern that the index 
test, its conduct, or interpretation differ from 
the review question 
LOW NIPT conduct and interpretation in 
accordance with standard 
procedure 
DOMAIN 3: REFERENCE STANDARD   
Risk of bias: Could the reference standard, its 
conduct, or its interpretation have introduced 
bias? 
UNCLEAR  
Is the reference standard likely to correctly 
classify the target condition? 
UNCLEAR Unclear information regarding 
clinical examination of the newborn 
Were the reference standard results 
interpreted without knowledge of the results of 
the index test? 
UNCLEAR Not reported 
Applicability: Is there concern that the target 
condition as defined by the reference standard 
does not match the review question? 
LOW Target condition as defined by the 
reference standard matches the 
review question 
DOMAIN 4: FLOW AND TIMING   
Risk of bias: Could the patient flow have 
introduced bias? 
HIGH  
Was there an appropriate interval between 
index test(s) and reference standard? 
YES NIPT prior to reference standard 
Did all patients receive a reference standard? YES All cases received reference 
standard 
Did patients receive the same reference 
standard? 
NO Pregnant women received prenatal 
karyotyping or clinical examination 
of the newborn 
Were all patients included in the analysis? YES All cases included 
OVERALL JUDGMENT At risk of bias  
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Table A9: GRADE assessment of diagnostic test accuracy outcomes. NIPT as an add-on to combined testing in general pregnant population  
Outcome Nº of 
studies (Nº 
of patients 
Study design Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
21 trisomy 
True positives 
(patients with 21 
trisomy)  
8 studies 
136544 
pregnant 
women 
 
DTA studies  
(5 comparative) 
  
Seriousa 
 
Not seriousb 
 
Not serious 
 
Not serious 
 
Unlikelyc 
 
⨁⨁⨁◯ 
MODERATE 
 
Critical  
 
False negatives 
(patients incorrectly 
classified as not 
having 21 trisomy) 
True negative 
(patients without 21 
trisomy) 
8 studies 
136544 
pregnant 
women 
 
DTA studies  
(5 comparative) 
  
Very seriousa 
 
Not seriousb 
 
Not serious 
 
Not serious 
 
Unlikelyc 
 
⨁⨁◯◯ 
LOW 
 
Critical  
 
False positive 
(patients incorrectly 
classified as having 
21 trisomy) 
18 trisomy 
True positives 
(patients with 21 
trisomy) 
7 studies 
135639 
pregnant 
women 
 
DTA studies  
(5 comparative) 
 
Seriousd 
 
Not seriousb 
 
Not serious 
 
Very seriouse 
 
Unlikelyc 
 
⨁◯◯◯ 
VERY LOW 
 
Critical  
 
False negatives 
(patients incorrectly 
classified as not 
having 21 trisomy) 
True negative 
(patients without 21 
trisomy) 
7 studies 
135639 
pregnant 
women 
 
DTA studies  
(5 comparative) 
 
Very seriousd 
 
Not seriousb 
 
Not serious  
 
Not serious 
 
Unlikelyc 
 
⨁⨁◯◯  
LOW 
 
Critical  
 
False positive 
(patients incorrectly 
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Outcome Nº of 
studies (Nº 
of patients 
Study design Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
classified as having 
21 trisomy) 
13 trisomy 
True positives 
(patients with 21 
trisomy) 
6 studies 
130203 
pregnant 
women 
 
DTA studies  
(4 comparative) 
 
Seriousf  
 
Not seriousb 
 
Not serious 
 
Very seriousg  
 
Unlikelyc 
 
⨁◯◯◯ 
VERY LOW 
 
Critical 
 
False negatives 
(patients incorrectly 
classified as not 
having 21 trisomy) 
True negative 
(patients without 21 
trisomy) 
6 studies 
130203 
pregnant 
women 
 
DTA studies  
(4 comparative) 
  
Very seriousf 
 
Not seriousb 
 
Not serious 
 
Not serious 
 
Unlikelyc 
 
⨁⨁◯◯ 
LOW 
 
Critical 
 
False positive 
(patients incorrectly 
classified as having 
21 trisomy) 
a. Many studies presented a high or unclear risk of bias regarding reference standard and index test due to performance of both test could have not blinded; for sentivity estimations, RoB is very serious as some studies did not confirm 
negative NIPT cases.  
b. Although included studies used different NIPT platform, it is considered that it is not relevant to rate down quality of evidence for indirectness.  
c. Possibility of publication bias not excluded but not considered sufficient to downgrade quality of evidence. 
d. Many studies presented a high or unclear risk of bias regarding reference standard and index test due to performance of both test could have not blinded; moreover some of them did not confirm negative NIPT cases.  
e. Four studies (Bianchi et al 2014, Norton et al 2015, Quezada et al 2015 and Song et al 2013) showed wide confidence intervals of sensitivity.  
f. Many studies presented a high or unclear risk of bias regarding reference standard and index test due to performance of both test could have not blinded; moreover some of them did not confirm negative NIPT cases. 
g. Four studies (Bianchi et al 2014, Norton et al 2015, Song et al 2013 and Pérez-Pedregosa et al 2015) showed wide confidence intervals of sensitivity 
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Table A10: GRADE assessment of diagnostic test accuracy outcomes. NIPT as an add-on to combined testing in high-risk pregnant population 
Outcome Nº of 
studies (Nº 
of patients 
Study design Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
21 trisomy 
True positives 
(patients with 21 
trisomy)  
23 studies 
28188 
pregnant 
women 
 
DTA studies  
 
Seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikelyb 
 
⨁⨁⨁◯ 
MODERATE 
  
Critical  
 
False negatives 
(patients incorrectly 
classified as not 
having 21 trisomy) 
True negative 
(patients without 21 
trisomy) 
23 studies 
28188 
pregnant 
women 
  
DTA studies 
 
Very seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikelyb 
 
⨁⨁◯◯ 
LOW 
 
Critical  
 
False positive 
(patients incorrectly 
classified as having 
21 trisomy) 
18 trisomy 
True positives 
(patients with 21 
trisomy) 
20 studies 
25972 
pregnant 
women 
 
DTA studies 
 
Seriousa 
 
Not serious 
 
Not serious 
 
Very seriousc 
 
Unlikelyb 
 
⨁◯◯◯ 
VERY LOW 
 
Critical  
 
False negatives 
(patients incorrectly 
classified as not 
having 21 trisomy) 
True negative 
(patients without 21 
trisomy) 
20 studies 
25972 
pregnant 
women 
 
DTA studies 
 
Very seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikelyb 
 
⨁⨁◯◯ 
LOW 
 
Critical  
 
False positive 
(patients incorrectly 
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Outcome Nº of 
studies (Nº 
of patients 
Study design Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
classified as having 
21 trisomy) 
13 trisomy 
True positives 
(patients with 21 
trisomy) 
15 studies 
22650 
pregnant 
women 
 
DTA studies 
 
Seriousa 
 
Not serious 
 
Not serious 
 
Very seriousc 
 
Unlikelyb 
 
⨁◯◯◯ 
VERY LOW 
 
Critical 
 
False negatives 
(patients incorrectly 
classified as not 
having 21 trisomy) 
True negative 
(patients without 21 
trisomy) 
15 studies 
22650 
pregnant 
women 
  
DTA studies 
 
Very seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikelyb 
 
⨁⨁◯◯ 
LOW 
  
Critical 
 
False positive 
(patients incorrectly 
classified as having 
21 trisomy) 
a. 44% of studies presented a high risk of bias regarding flow and timing domain; 50-60% of studies showed a high or unclear risk of bias regarding reference standard or index test domains; moreover for sensitivity estimations, RoB is 
very low as some studies did not confirm negative NIPT cases.  
b. Although Deeks's Funnel Plot Asymmetry Test reached statistical significance (p=0.00) for publication bias, it is considered that it is not relevant to downgrade quality of evidence. 
c. 17/20 studies reported wide confidence intervals around estimates of sensitivity.  
  
Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing 
Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 318 
Table A11: GRADE assessment of diagnostic test accuracy outcomes. NIPT as an add-on to combined testing in high  
or intermediate risk pregnant population 
Outcome Nº of studies 
(Nº of 
patients 
Study 
design 
Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
21 trisomy 
True positives 
(patients with 21 
trisomy)  
1 study 
3633 
pregnant 
women 
 
DTA study 
 
Seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikely 
 
⨁⨁⨁◯ 
MODERATE  
 
Critical  
 
False negatives 
(patients 
incorrectly 
classified as not 
having 21 
trisomy) 
True negative 
(patients without 
21 trisomy) 
1 study 
3633 
pregnant 
women 
  
DTA study 
 
Seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikely 
 
⨁⨁⨁◯ 
MODERATE 
 
Critical  
 
False positive 
(patients 
incorrectly 
classified as 
having 21 
trisomy) 
18 trisomy 
True positives 
(patients with 21 
trisomy) 
1 study 
3633 
pregnant 
women 
 
DTA study 
 
Seriousa 
 
Not serious 
 
Not serious 
 
Very seriousb 
 
Unlikely 
 
⨁⨁◯◯ 
LOW  
 
Critical  
  
False negatives 
(patients 
incorrectly 
classified as not 
having 21 
trisomy) 
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Outcome Nº of studies 
(Nº of 
patients 
Study 
design 
Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
True negative 
(patients without 
21 trisomy) 
1 study 
3633 
pregnant 
women 
 
DTA study 
 
Seriousa 
 
Not serious Not serious 
 
Not serious 
 
Unlikely 
 
⨁⨁⨁◯ 
MODERATE 
 
Critical  
 
False positive 
(patients 
incorrectly 
classified as 
having 21 
trisomy) 
13 trisomy 
True positives 
(patients with 21 
trisomy) 
1 study 
3633 
pregnant 
women 
 
DTA study  
 
Seriousa 
 
Not serious 
 
Not serious 
 
Veryb serious 
 
Unlikely 
 
⨁⨁◯◯ 
LOW 
 
Critical 
 
False negatives 
(patients 
incorrectly 
classified as not 
having 21 
trisomy) 
True negative 
(patients without 
21 trisomy) 
1 study 
3633 
pregnant 
women 
  
DTA study  
 
Seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikely 
 
⨁⨁⨁◯ 
MODERATE 
  
Critical 
 
False positive 
(patients 
incorrectly 
classified as 
having 21 
trisomy) 
a. This study showed a high risk of bias regarding of flow and timing domain and there was an unclear risk due to reference standard and index test domains as both test was not performed in a blinded fashion.  
b. Study reported wide confidence intervals around estimates of sensitivity. 
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Table A12: GRADE assessment of diagnostic test accuracy outcomes. NIPT as an add-on to combined testing in twin pregnant population 
Outcome Nº of studies 
(Nº of 
patients 
Study 
design 
Factors that may decrease quality of evidence Test accuracy 
QoE 
Importance 
Risk of bias Inconsistency Indirectness Imprecision Publication 
bias 
21 trisomy 
True positives 
(patients with 21 
trisomy)  
6 studies 
1985 patients 
 
DTA studies 
 
Seriousa 
 
Not serious 
 
Not serious 
 
Seriousb 
 
Unlikely 
 
⨁◯◯◯ 
VERY LOW  
  
Critical  
 
False negatives 
(patients 
incorrectly 
classified as not 
having 21 
trisomy) 
True negative 
(patients without 
21 trisomy) 
6 studies 
1985 patients 
  
DTA studies 
 
Very 
seriousa 
 
Not serious 
 
Not serious 
 
Not serious 
 
Unlikely 
 
⨁⨁◯◯ 
LOW 
 
Critical  
 
False positive 
(patients 
incorrectly 
classified as 
having 21 
trisomy) 
a. 60-80% of studies showed a high or unclear risk of bias regarding of some of the domains.  
b. All studies performed in twin pregnant population reported wide confidence intervals around estimates of sensitivity.  
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Applicability tables 
 
Table A13: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population As mentioned in the PICO question, three target populations were considered i.e. general 
pregnant population, that is without any pre-defined fetal aneuploidy risk factor, high-risk 
population (>1:300 from first or second serum combined testing) and intermediate risk 
population (1:300-1:1000 from first or second serum combined testing) which all included 
pregnant women at least 8-9 weeks’ gestation. 
With regards to general pregnant population, although all retrieved studies enrolled women 
who were undergoing routine screening, some of them included patients defined as high 
risk by first or second combined test (16.5-64%) or used a narrow patient selection criteria, 
that is women who had elegibility to health records, with known results, NIPT results 
verified by invasive testing, only included women <35 years old or excluded twin 
pregnancies or in vitro fertilisations with user donor oocytes. Moreover, the prevalence of 
most common trisomies reported in these studies is quite higher than values described in 
literature.  
Therefore, pregnant women included in these studies do not match completely the general 
population and reducing the applicability of evidence. 
The studies performed in high risk pregnant womenalso present important applicability 
concerns as included population do not match to the review question. Twenty-five percent 
of studies on high risk women reported that advanced maternal age was the main or only 
indication for NIPT or included ≤15% of women with no risk indication, that is due to 
anxiety, not suitable for invasive testing or other reasons not specified. The only DTA study 
on intermediate-risk population included women with risk ≥2500. 
Finally, the evidence reported in the studies performed in twin pregnant women could 
maybe be applicable to the review question raised. However, it should be taken into 
account that one study exclusively enrolled women who conceived after assisted 
reproductive technology.  
Intervention With regard to the five types of intervention proposed, the retrieved evidence only 
assessed NIPT as a primary testing method in general pregnant population and studies 
on NIPT as an add-on to combined test and other factors for women estimated to be at 
high/intermediate risk by combined screening. Therefore, there is no evidence available 
regarding the second and fifth type of intervention (NIPT as a part of combined test and 
NIPT in replacement of invasive testing respectively).  
Reference 
standard 
The appropriate reference standard of NIPT would have to be a confirmation method of 
screening results, i.e. fetal karyoptype for positive NIPT results or clinical examination for 
negative NIPT results. All studies used these reference standards as appropiate, so there 
is no concern about the applicability of evidence regarding this aspect. 
Comparators The comparator of NIPT is a standard screening based on first or second serum combined 
testing followed by invasive diagnostic test. Although only four studies performed on 
general population compared NIPT vs. standard screening, all of these used an 
appropriate comparator. Therefore, retrieved evidence would seem to match the review 
question in relation to this aspect. 
Outcomes Effectiveness of NIPT was evaluated not only in terms of accuracy of test, that is FP, FN, 
S, Sp, PPV and PNV but also in terms of assessing the impact of NIPT in a prenatal 
screening pathway, i.e. reduction of miscarriages related to invasive testing or reduction 
of children born with undiagnosed trisomy. However, most studies only reported the 
accuracy of NIPT. Therefore, it was not possible to provide conclusions about safety or 
effectiveness of prenatal screening with NIPT.  
Setting Mainly, retrieved studies were performed at routine prenatal-screening in medical centers 
from different European countries, USA, China, Republic of Korea, Japan, México and 
Russia. Thus, it is considered that there is no concern about the applicability of evidence 
related to this aspect. 
Abbreviations: NIPT, Non-Invasive, Prenatal Test; DTA, Diagnostic Test Accuracy; USA, United States of America; FP, 
False Positive, FN, False Negative, S, Sensitivity; Sp, Specificity, PPV, Predictive Positive Value; PNV, Predictive 
Negative Value. 
Sources: Evidence retrieved for effectiveness and safety domains 
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
Table A14: Regulatory status 
Country Institution issuing 
approval 
Authorisation status 
yes/no/ongoing 
Verbatim wording of the 
(anticipated) indication(s) 
Specified 
contra-
indications 
Date of 
approval 
(include 
expiry date 
for country 
of 
assessment) 
Launched 
yes/no 
If no 
include 
date of 
launch 
Approval 
number 
(if 
available) 
USA1 Food and Drug 
Administration (FDA) 
Not applicable 
NIPT is considered LDTs 
(laboratory developed tests), a 
subset of IVDs devices that 
have not to comply FDA 
requirements for IVDs 
- - - Yes - 
Australia2 Australian Therapeutic 
Good Administration 
(TGA) 
Not applicable 
If NIPT are IVDs developed “in 
house”, these only required to 
have approval and yearly 
validation 
If sequencing analysis is 
performed in overseas 
countries, only equipment to 
collect and transport samples 
have to be registered 
- - - Yes (nearly 
established) 
- 
Canada3 Ministry of Health and 
Long-Term Care 
(MOHLTC) in Ontario 
region  
British Columbia (BC) 
Ministry of Health in 
British Columbia 
region 
Yes (reimbursement only for 
women who fullfil indications in 
Ontario and British Columbia)  
NIPT is available for trisomy 
21, 18, 13 and sex aneuploidy 
These test are approved for 
women with: 
-a positive prenatal screening 
and ultrasound results 
Microdelection 
testing is not 
funded 
NIPT is not 
recommended 
for multiple 
gestations 
- - Yes - 
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Country Institution issuing 
approval 
Authorisation status 
yes/no/ongoing 
Verbatim wording of the 
(anticipated) indication(s) 
Specified 
contra-
indications 
Date of 
approval 
(include 
expiry date 
for country 
of 
assessment) 
Launched 
yes/no 
If no 
include 
date of 
launch 
Approval 
number 
(if 
available) 
-a previous trisomic pregnancy 
or history of aneuploidy 
-advanced age (≥40 years) 
-other reasons i.e. fetal 
congenital anomalies or risk of 
a sex-limited disorder 
 
European 
countries4,5 
Organization in charge 
of giving CE mark in 
each country 
Yes 
EC-IVD certification (annexe 
III- IV) for different NIPT 
trademark (VeriSeq, 
MaterniT21 PLUS, IONA Test, 
Panorama, Harmony, etc. see 
Tables 3-4, TEC domain) 
This information is not clearly 
reported in EC-IVD certification 
According to manufacturers 
information, NIPT test detected 
trisomy 21, 18, 13 and sex 
chromosome aneuploidies. And 
moreover, some of them could 
be used to identify 
microdeletions in all pregnant 
women (single or twin 
pregnancies)(see Table 3, TEC 
domain)  
Information not 
available in EC-
IVD certification 
2013-2017 Yes - 
China6 China Food and Drug 
Administration (CFDA) 
Yes 
BGISEQ-100, NextSeq CN500, 
NFTY 
Pregnant women with high risk 
of aneuploidies (Trisomy 21, 18 
and 13) 
- - - - 
Abbreviations: NIPT, Non-Invasive Prenatal Test; IVDs, “in vitro” diagnostic; LDTs, Laboratory Diagnostic Tests; CE, Conformité Européenne.  
Sources: 1Oversight of Laboratory Developed Test, Food and Drug Administration (FDA), available from: https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM472777.pdf; 
2Non-invasive prenatal testing (NIPT), HealthPACT, available from: https://www.health.qld.gov.au/_data/assets/pdf_file/0033/426993/wp142.pdf; 3Non-invasive prenatal testing, GECKO, available 
from: http://geneticseducation.ca/educational-resources/gec-ko-on-the-run/non-invasive-prenatal-testing/; 4Companies web pages; 5Submission file/information provided by company; 6China Food 
and Drug Administration webpage (http://eng.sfda.gov.cn/WS03/CL0755/). 
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Table A15: Summary of recommendations and level of reimbursement of NIPT in European countries  
Country and issuing 
organisation e.g. G-
BA, NICE 
Summary of reimbursement recommendations and restrictions Level of reimbursement 
UK, National 
Screening Commitee 
Evaluative implementation of NIPT to assess the impact on the existing NHS fetal anomaly screening 
programms (combined test risk score for T21 greater than 1 in 150 and combined test risk score for T18 
and T13 greater than or equal to 1 in 15) 
UK National Screening Committee – GOV.UK 
Implementation starting 2018 for a 2 
year study. Fully reimbursed on con-
tingent with risk >1:150 with FCT.  
 
France, HAS   Recommended for T21 in women with trisomy high and intermediate risk by contingent screening approach”  
https://www.has-sante.fr/portail/jcms/c_2768510/fr/place-des-tests-adn-libre-circulant-dans-le-sang-
maternel-dans-le-depistage-de-la-trisomie-21-foetale 
Fully reimbursed on contingent with 
risk >1:1000 with FCT 
Belgium, Ministry of 
Health 
Recommended for T21 as first line screening test for all pregnant women”. 
http://www.deblock.belgium.be/fr/maggie-de-block-rembourse-le-test-dpni-pour-le-syndrome-de-down-
%C3%A0-toutes-les-femmes-enceintes-qui 
Implementation started 2017. All 
women, 8 euro out of pocket 
payment 
Germany, G-BA Ongoing No reimbursement at present 
Offered Privately 
Spain, Ministry of 
Health 
Ongoing Reimbursed in some regions  
Offered Privately 
Netherlands, Health 
Council 
Recommended as a first line screening test for T21, T18 and T13 instead of the combined test” (ref. Prenatale 
screening, Health Council of the Netherlands, December 2016 
https://www.gezondheidsraad.nl/nl/taak-werkwijze/werkterrein/preventie/prenatale-screening) 
Implementation started 2017 for a 3 
year study for all women, choice be-
tween primary FCT or primary NIPT 
(for T21, 13 and 18 or for all auto-
somes).  
Fully reimbursed for women with risk 
>1:200 with FCT, 170 euro out of 
pocket for risk < 1:200.  
Denmark NIPT is recommended for screening of fetal aneuploidies in women with high risk (1:300) by contingent 
screening strategy 
Fully reimbursed on contingent with 
risk >1:300 from FCT 
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Country and issuing 
organisation e.g. G-
BA, NICE 
Summary of reimbursement recommendations and restrictions Level of reimbursement 
Norway, Health 
Directorate 
No reimbursement recommendation available Not yet released 
Sweden, Swedish 
National Health Board 
Investigation 
application of NIPT 
SBU published a recommendation on NIPT in 2015 and endorsed NIPT offering for high risk (Analys av 
foster-DNA i kvinnans blod: icke-invasiv fosterdiagnostik (NIPT) for trisomy 21, 18 and 13 
http://www.sbu.se/sv/publikationer/SBU-utvarderar/analys-av-foster-dna-i-kvinnans-blod-icke-invasiv-
fosterdiagnostik-nipt-for-trisomi-13-18-och-21/ 
Offered privately, no reimbursement  
Italy, 
Ministry of Health 
(Consiglio Superiore 
di Sanitá) 
NIPT introduction recommended as a first or second line test. 
(http://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2381) 
No reimbursement at present 
Offered Privately 
Greece No national prenatal screening program 
NIPT offered privately 
Private 
Poland No national prenatal screening program 
NIPT offered privately  
Private 
Ireland No national prenatal screening program 
NIPT offered privately 
Private 
Switzerland, BAG  NIPT is recommended for women with intermediate or high risk of aneuploidies (>1:1000) assessed by 
FCT  
https://www.bag.admin.ch/bag/de/home/themen/versicherungen/krankenversicherung/krankenversicherung-
leistungen-tarife/Analysenliste.html 
Fully reimbursed on contingent with 
risk>1:1000 from FCT with NGS 
based technologies only 
(Analysenliste 1.7.2017 BAG) 
Abbreviations: FCT, first-trimester combined test 
Sources: Companies web pages, Submission file/information provided by company. 
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APPENDIX 3: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, PATIENT AND SOCIAL AND LEGAL ASPECTS 
1 Ethical  
1.1 Does the introduction of the new technology and its potential use/non-use instead of the defined, existing comparator(s) give rise to 
any new ethical issues? 
Yes 
Routine introduction of NIPT for prenatal genetic screening could lead to changes in the risk managing approach of pregnant women, which may cause ethical issues for 
the couple as well as for the health-care provider, as benefits/risks could be substantially different and must be carefully explained.  
1.2 Does comparing the new technology to the defined, existing comparators point to any differences that may be ethically relevant? Yes 
Prenatal genetic screening NIPT testing can be offered to women with different risks of developing fetal aneuploides, leading to important ethical considerations, NIPT 
testing could create a great demand that is probably not justified on health grounds in some risk groups. 
2 Organisational  
2.1 Does the introduction of the new technology and its potential use/non-use instead of the defined, existing comparator(s) require 
organisational changes? 
Yes 
The new intervention could require important organisational changes if NIPT is implemented in hospital premises and centralised to tertiary care units. Even if the 
samples are sent to external clinical labs, organisational changes might be required to ensure that there are no delays and an important budget impact can be expected.  
2.2 Does comparing the new technology to the defined, existing comparator(s) point to any differences that may be organisationally 
relevant? 
Yes 
NIPT could replace other screening tests and lead to a change in the current pathways of care, affecting the work load at different levels (reduce imaging, 
amniocentesis, etc.). 
3 Social  
3.1 Does the introduction of the new technology and its potential use/non-use instead of the defined, existing comparator(s) give rise to 
any new social issues? 
Yes 
NIPT are being offered as accurate tests which could avoid invasive testing, and this could have led to great expectations regarding their application, leading to a non-
justified demand in some groups. Pressure can also be imposed on parents to avoid a child with anormalities and lead to possible discrimination of people with 
anomalities. 
3.2 Does comparing the new technology to the defined, existing comparator(s) point to any differences that may be socially relevant? No 
4 Legal  
4.1 Does the introduction of the new technology and its potential use/non-use instead of the defined, existing comparator(s) give rise to 
any legal issues? 
No 
4.2 Does comparing the new technology to the defined, existing comparator(s) point to any differences that may be legally relevant? No 
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APPENDIX 4: ADDITIONAL TABLES AND FIGURES 
Table A16: Alternative measures of diagnostic accuracy: positive and negative likelihood ratios (LR+/LR-) and diagnostic odds ratio (DOR)* 
Condition Population Measure Mean 95% confidence interval (CI) 
Lower bound Upper bound 
21 trisomy General risk LR+ 1521.47 698.79 3312.69 
LR- 0.0066 0.0019 0.0219 
DOR 229941.4 76247.02 693443.9 
High risk LR+ 2021.187 1418.76 2879.4 
LR- 0.0078 0.0023 0.2149 
DOR 258584.9 134179.3 498334.2 
Twin pregnant LR+ 399.54 95.04 1679.54 
LR- 0.0080 0.00005 1.1817 
DOR 49358.04 187.94 1.30 e+07 
18 trisomy General risk LR+ 1853.03 787.01 4362.97 
LR- 0.0256 0.0116 0.0565 
DOR 72245.4 22213.85 234961.4 
High risk LR+ 3319.87 1583.59 6959.85 
LR- 0.0313 0.0080 0.1221 
DOR 106012.2 23475.54 478736.2 
13 trisomy General risk LR+ 2448.46 1788.67 3351.64 
LR- 0.0018 5.01 e-08 68.2318 
DOR 1324686 32.9292 5.33 e+10 
High risk LR+ 5530.72 1347.24 22074.7 
LR- 0.0232 0.0008 0.6104 
DOR 238300.4 7852.63 7231599 
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Figure A1: Hierarchical summary ROC for general pregnant population 
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Figure A2: Hierarchical summary ROC for high risk pregnant population 
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Figure A3: Hierarchical summary ROC for twin pregnant population 
 
 
 
 
